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Abstract 
The Y-Box-binding protein-1 (YB-1) is a ubiquitous and multifunctional 
protein involved in several cellular processes such as transcription, mRNA splicing, 
and translation. YB-1 has been shown to be of significance to the area of cancer 
research, where it has been observed to be expressed at elevated levels in ~40% of 
invasive breast carcinomas and a number of other malignancies. Within the nucleus, it 
has been reported to induce the transcription of a variety of genes, including 
oncogenes that upregulate cell proliferation, migration, and invasion. The 
phosphorylation of YB-1 at serine 102 has been reported to be necessary for its 
nuclear translocation and transcriptional activities. In most cases, the majority of the 
cell’s YB-1 is present within the cytoplasm, where it is involved in processes such as 
mRNA translation. YB-1 translationally upregulates several EMT associated and 
promoting genes, potentially contributing to metastasis. Its phosphorylation at serine 
102 was also reported to allow the translation of latent oncogenic transcripts that 
upregulate cell proliferation.  
The general goal of this study was to functionally characterise YB-1 
phosphorylation and determine its significance on tumour malignancy. However, the 
specific aims of this project were: (1) To purify and characterise the phosphorylation 
status of cytoplasmic and nuclear YB-1 by mass spectrometry; (2) To characterise 
their phosphorylation profiles under normal conditions, and after treatment with a 
variety of genotoxic agents; (3) To determine the significance of phosphorylation on 
YB-1 localisation and YB-1 driven cell proliferation and migration (hallmarks of 
cancer), using phosphorylation-defective mutants. As detailed in this thesis, a total of 
7 distinct YB-1 phosphorylation residues have now been identified from A549 lung 
cancer cell lysate. The contribution of these phosphorylation sites to the regulation of 
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YB-1 localisation and functions remain unknown. Nuclear and cytoplasmic YB-1 
were both individually purified and identified by mass spectrometry, and a total of 7 
phosphorylation sites were identified under normal conditions, and 6 under genotoxic 
stress (doxorubicin, cisplatin). Experiments with the phosphorylation-defective 
mutants suggest that dephosphorylation in general increases YB-1 nuclear localisation 
in colorectal and lung cancers, with the most nuclear localisation observed with NLS-
proximal phosphorylation mutants. The data also suggests that phosphorylation at the 
NLS proximal serine 167, 174, and 176 sites are necessary for lung cancer cells to 
proliferate at an accelerated rate. On the other hand, phosphorylation-defective serine 
165 and serine 174 & 176 double-mutants appear to act as oncoproteins that 
upregulate proliferation. Migration speed was also observed to increase with the 
serine 174-176 double and the threonine 271 phosphorylation-defective mutants, 
suggesting dephosphorylation at those residues increase bone cancer cell migration. 
Phosphorylation-defective mutants were also found to generally increase migration 
persistence (i.e. towards a gradient) in bone cancer cells. These studies implicate 
additional YB-1 phosphorylation residues in the regulation of two major hallmarks of 
cancer, proliferation and metastasis, and can potentially be of valuable prognostic 
value in future therapeutic endeavours in cancer research.  	 	
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Chapter One: Literature review 									
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 1.0. Introduction 
Cancer is a condition characterised by abnormal cell growth and proliferation 
(reviewed by Fearnhead, 2002). The causes of cancer include environmental 
influences (e.g. UV radiation, carcinogens), infectious agents (e.g. Human 
Papillomavirus in cervical cancer), as well as other factors such as ageing and genetic 
predisposition (Dix, 1989; Ohbayashi et al, 2007; Perez de Castro et al, 2007). Cancer 
is an increasing problem in developed nations with quality health care; the incidence 
of cancer increases with age, and as populations live longer more people are at risk 
than ever before (reviewed by Irigaray et al, 2007). 
Cancer cells can also invade neighbouring tissue, as well as lymphatic and 
blood vessels, which allows them to mobilise to secondary organs where they can 
form secondary tumours (Yachida et al, 2010). This phenomenon is known as 
‘metastasis’, and may be more accurately defined as the dissemination and growth of 
neoplastic cells in an organ distinct from the organ of origin (Yachida et al, 2010). 
Metastasis is a leading cause of cancer death (Weigelt et al, 2005), and along with 
accelerated proliferation, is considered a major hallmark of cancer (Hanahan and 
Weinberg, 2011).  
Cancer cells have acquired capabilities known as the ‘hallmarks of cancer’, 
which include sustained proliferative signaling, evasion of growth suppressors, 
resistance to cell death (apoptosis resistance), enabled replicative immortality, 
sustained angiogenesis (formation of new blood vessels that bring in nutrients), as 
well as activated invasion of neighbouring tissue and metastasis (Hanahan and 
Weinberg, 2011). However, only activated invasion and metastasis are unique to 
malignant tumours, in contrast to benign non-cancerous tumours (Lazebnik, 2010; 
Rubin et al, 2008). Nevertheless, cancer is more accurately viewed as an umbrella of 
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diseases of many different classes with common manifestations, most notably 
accelerated growth and unlimited proliferation, as well as activated cell invasion and 
metastasis, rather than a specific disease attributed to a specific cause (Golub et al, 
1999; Hanahan and Weinberg, 2000; Hanahan and Weinberg, 2011; Lazebnik, 2010; 
Rubin et al, 2008). It is more commonly known as a “disease of the genes”, as the 
dysregulated expression, mutation, loss, or duplication of certain genes is usually 
required for tumours to develop (Perez de Castro et al, 2007; Vogelstein and Kinzler, 
2004).  
1.1. Genetic instability and cancer 
Cancer arises through multiple somatic mutations, which give cancerous cells 
a selective growth advantage over normal cells, resulting in their outgrowth and 
tumour formation (Perez de Castro et al, 2007; Vogelstein and Kinzler, 2004). These 
multiple somatic mutations arise through genetic instability, a state where cells lose 
their genetic integrity at an accelerated rate (Cardoso et al, 2006). Mutations at the 
level of single nucleotides, to whole chromosome regions (chromosome instability) 
have been observed in a variety of cancers. A common form of genetic instability is 
chromosome instability, evident in cells with abnormal karyotypes and chromosomal 
aberrations such as translocations, amplifications, and deletions of specific loci 
(Gollin, 2001; Lengauer et al, 1997; Thirthagiri et al, 2007). Chromosome instability 
appears in the early stages of tumorigenesis, and is thought to derail the cells 
regulatory mechanisms, which would result in aberrant mitotic events (Buffart et al, 
2007; Lengauer et al, 1997; Nowak et al, 2002). These events in turn allow further 
progression of chromosome instability as well as the promotion of aneuploidy 
(abnormal chromosome number), a typical characteristic of cancer (Ehlers et al, 2008; 
Wilkens et al, 2004). Aneuploidy, a product of chromosome mis-segregation, is one 
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of the most common abnormalities associated with cancer and is usually found in 
malignant tumours. (eg. Chiang et al, 1998; Duesberg et al, 2000; Ehlers et al, 2008; 
Jiang et al, 2003). Tumour cells have been known to become aneuploid as a result of 
irregular mitotic divisions caused by previous defects in cell division, centrosome 
amplification, or impaired mitotic regulatory responses (Hass et al, 2008). 
It is widely accepted that alterations in three types of genes are responsible for 
tumorigenesis. These genes are: oncogenes (e.g. MET, PDGFRA, RET), tumour-
suppressor genes (e.g. APC, TP53, CDKN2A), and stability genes (e.g. ATM, NBS1, 
WRN), where any alteration that affects the final gene product may contribute to 
cancer (reviewed by Vogelstein and Kinzler, 2004). Oncogene activation usually 
results from chromosomal translocations, gene amplifications, or mutations at 
nucleotide(s) that affect the activity of the gene product. Inactivation in tumour 
suppressor and stabiliser genes may occur from missense mutations, mutations that 
result in truncated proteins, deletions or insertions of various sizes, and epigenetic 
silencing (e.g. methylation) (reviewed by Vogelstein and Kinzler, 2004). These three 
gene types will be discussed in detail in the following subsections. Although all 
discussed gene functions are in fact functions of the expressed gene product and not 
the gene itself, for ease of discussion, throughout this thesis a single label will be used 
to specify a gene, or its transcribed mRNA, or expressed protein product, to which all 
discussed functions are attributed to. However, the context of the text will clarify 
what is being discussed.  
 1.1.1. Oncogenes 
Oncogenes are genes that, once activated by mutations that allow them to be 
ectopically or constitutively expressed, result in an increased rate of cell growth or 
proliferation (or both), contributing to tumorigenesis (Vogelstein and Kinzler, 2004). 
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They may include genes that code for: transcription factors that activate growth and 
proliferation genes; chromatin remodelers (i.e. can silence tumour suppressors or 
activate growth and proliferation genes); growth factors; growth factor receptors; 
signal transducers; or apoptosis regulators (reviewed by Croce, 2008). A list of some 
established oncogenes is presented in Table 1.1. 
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Table 1.1. A list of some established oncogenes and their commonly observed 
changes in cancer (Adapted from, Kopnin et al, 2000). 
Oncogene 
(abbreviated) 
Function of expressed 
protein 
Changes in cancer 
RET (GDNFR) Receptor tyrosine kinase -Point activating mutations  
-Recombination that forms a 
chimeric RET gene, which 
permanently activates the RET 
receptor 
ERBB1 (EGFR) Receptor tyrosine kinase -Gene amplification and 
overexpression 
ERBB2 (HER2) Receptor tyrosine kinase -Gene amplification and 
overexpression 
PDGF-Rβ Receptor tyrosine kinase -Chromosome translocations 
forming a chimeric PDGFRβ gene, 
which permanently activates the 
PDGFRβ receptor  
SRC Non-receptor tyrosine kinase -Mutations in codon 531 which 
abolishes the negative regulation of 
SRC kinase activity 
RAS (K-RAS, N-
RAS, H-RAS) 
Mitogen signal transduction 
and morphogenetic reactions 
-Mutations in codons 12, 13, and 
61, which permanently activate 
RAS 
PRAD1/cyclin D1 Cell cycle regulator -Gene amplification and 
overexpression 
c-MYC Transcription factor that 
regulates cell cycle and 
telomerase activity 
-Chromosome translocation that 
positions the c-MYC gene under 
control of regulatory elements of 
immunoglobulin genes 
- Gene amplification and 
overexpression 
-Mutations that stabilise the protein 
CTNNB1 (β-catenin) A transcription factor that 
regulates c-MYC and cyclin 
D1, and an adhesion protein 
that participates in the 
formation of contacts via 
cadherin binding. 
-Mutations leading to increased E-
cadherin-unbound β-catenin which 
allows it to function as a 
transcription factor 
BCL2 Inhibits apoptosis -Chromosome translocation 
positioning the BCL2 gene under 
control of regulatory elements of 
immunoglobulin genes 
ABL Regulates the cell cycle and 
apoptosis 
- Chromosome translocations 
forming a chimeric ABL gene, 
which stimulates cell proliferation 
and inhibits apoptosis 
MDM2 Inactivates tumor suppressors 
p53 and pRb 
-Gene amplification and 
overexpression 
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As listed in Table 1.1, Cyclin D1 is an example of a well-established oncogene 
that is frequently overexpressed and deregulated in a variety of cancers (Barbash et al, 
2004; Benzeno et al, 2006; Buckley et al, 1993; Hinds et al, 1994; Matsushime et al, 
1991; Jiang et al, 1992). Its overexpression can largely be attributed to its gene locus 
amplification (Buckley et al, 1993; Jiang et al, 1993). However, Cyclin D1 
overexpression alone is insufficient for oncogenic transformation, where it requires an 
altered proteolysis and nuclear trafficking in favour of nuclear retention to manifest its 
oncogenecity (Barbash et al, 2004; Benzeno et al, 2006; Kim and Diehl et al, 2010). 
Cyclin D1 functions by forming a complex with the cell cycle regulating CDK4 and 
CDK6 kinases and permitting their cell cycle promoting activities, and resulting in an 
overall increase in cell growth and proliferation (reviewed by Fu et al, 2004). CDKs 
and cyclins are discussed further in section 1.2. 
B-Cell Lymphoma 2 (BCL2) is another well-established oncogene (Table 1.1), 
originally identified in lymphoma cells after a specific chromosome translocation that 
resulted in its constitutive expression (Ngan et al, 1988; Tsujimoto et al, 1984). In 
contrast to cyclin D1, rather than directly promoting cell growth and proliferation, 
BCL2 promotes cell growth and proliferation indirectly by inhibiting apoptosis and 
enabling cell survival (Vaux et al, 1988). BCL2, the founding member of the BCL2 
family of apoptosis regulating proteins, is an inner mitochondrial membrane protein 
that directly inhibits effectors of apoptosis (Cory et al, 2003; Hockenbery et al, 1990). 
It is constitutively expressed or overexpressed in a variety of cancers including 
leukemia, colorectal, and prostate cancers (Mcdonnell et al, 1992; Placzek et al, 2010; 
Sinicorpe et al, 1995), and has been implicated in drug resistance to apoptosis 
inducing chemotherapeutic agents (Niture and Jaiswal, 2012; Singh and Saini, 2012; 
Srivastava et al, 1999).  
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MDM2 is another example of an oncogene that promotes growth and 
proliferation through the inhibition of apoptosis (Table 1.1). This protein will be 
discussed in section 1.1.2.1. Also listed in Table 1.1, and of direct relevance to this 
project, are several proteins of the RAt Sarcoma (RAS) GTPase pathway (Fig.1.1), 
which are all well-known oncogenes. As an example of an oncogenic pathway, the 
EGFR-RAS-MAPK pathway will be discussed next (Fig.1.1)  
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Fig.1.1. The RAS pathway. The EGFR is first activated by extracellular mitogens (e.g. 
EGF), which activates the tyrosine kinase activity of its cytoplasmic domain, and allows for 
the docking of the GRB2-SOS protein complex. The SOS guanine nucleotide exchange factor 
then catalyses the exchange of GDP for GTP on RAS, thus activating it. The activation of 
RAS sets off a cascade of phosphorylation, eventually phosphorylating c-Myc, which then 
activates the transcription of a variety of genes involved in processes such as the cell cycle, 
apoptosis, and DNA dynamics (Dang et al 2006; reviewed by Roberts and Der, 2007).  
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The Epithelial Growth Factor Receptor gene (EGFR), which codes for a 
transmembrane receptor-linked tyrosine kinase protein, is an example of a commonly 
mutated or constitutively expressed oncogene in a variety of cancers (Kosaka et al, 
2009; Marx et al, 2010; Miyanaga et al, 2008; Rego et al, 2010). EGFR gene 
mutations, amplifications, and overexpression are all implicated with a wide variety 
of cancers (Santarius et al, 2010). Its amplification and overexpression act as a 
predictive biomarker for cancer, and result in increased tumour proliferation (Andl et 
al, 2003; Simon and Roychowdhury, 2013) In a study of 277 lung cancer patients, 
EGFR mutations were observed in 40% of patient tumours, where 52 cases showed 
in-frame deletions, 54 patients had point mutations, and 5 showed 
duplications/insertions (Kosaka et al, 2009). Another study on lung cancer (Berrett’s 
adenocarinomas) showed that EGFR amplification was associated with a higher 
tumour size and level of metastasis, and poorer patient prognosis (Marx et al, 2010). 
In brain cancer (glioblastomas), a study of 109 patient tumours showed EGFR 
overexpression and amplification in 33% and 24% of patients, respectively (Miyanaga 
et al, 2008). The effects of EGFR overexpression were also observed in colon cancers 
(colon carcinomas), where the intensity of EGFR expression was found to correlate 
with tumour stage (Rego et al, 2010).  
The EGFR is activated by mitogens such as the Epithelial Growth Factor 
(EGF), Transforming Growth Factor-a (TGF-a), and the Heparin-Binding EGF-like 
growth factor (HB-EGF), which lead to the transcriptional activation of downstream 
genes including, growth, survival, proliferation, and differentiation associated genes. 
(Mahimainathan et al, 2005; Mehta and Besner, 2007; Oda et al, 2005; Oliver et al, 
1995). Due to the central nature of these mechanisms to tumorigenesis, these 
downstream pathways have been studied extensively in cancer research.  
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The RAS-MAPK pathway is one of these pathways, which acts as a stepwise 
kinase cascade downstream of the EGFR (Fig.1.1) (Wu et al, 1993). Once activated, 
the EGFR can lead to the activation of RAS GTPase enzymes, which in turn can 
trigger a cascade of downstream phosphorylation pathways such as the Mitogen 
Activated Protein Kinase (MAPK) pathway (Lowenstein et al, 1992; Schubbert et al, 
2007). 
Encoded by the K-RAS, N-RAS, and H-RAS genes, the RAS genes are well-
characterised oncogenes of the RAS superfamily of small GTPases, and are mutated 
in a variety of cancers (Bowen, 2005; Cortot, 2010; Marchetti, 2009). They act as 
downstream effectors of the EGFR, activating the oncogenic MAPK signaling 
cascade (Lowenstein et al, 1992). Activating RAS mutations occur in 30% of human 
cancers, and specific RAS mutations are prevalent in different cancer types 
(Schubbert et al, 2007). K-RAS mutations were found to be most prevalent in 
pancreatic cancers (60% of cases), whereas, H-RAS and N-RAS mutations were most 
prevalent in Bladder cancers (11% of cases), and Melanomas (18% of cases) 
respectively (reviewed by Schubbert et al, 2007).  
Activation of the RAS-MAPK pathway requires the binding of growth signals 
to tyrosine kinase receptors such as EGFR, which can then dimerise and cross-
phosphorylate their tyrosine residues within the cytosol (Yarden and Schlessinger, 
1987a; Yarden and Schlessinger, 1987b; Yu et al, 2002). The Sons Of Sevenless 
(SOS) protein can then dock at these phospho-tyrosine residues via Growth Factor 
Receptor Bound-2 (GRB2) adaptor proteins and subsequently interact with RAS at the 
cell membrane (Bowtell et al, 1992; Buday et al, 1993; Buday et al, 1994; Lowenstein 
et al, 1992; Reif et al, 1994). The SOS protein acts as a guanidine nucleotide 
exchange factor that exchanges RAS-bound GDP for GTP to activate it (Fig.1.1) 
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(Buday et al, 1994). The activation of RAS allows it to associate with RAF and 
phosphorylate it, which can then phosphorylate MEK and set off the MEK-ERK 
kinase cascade (reviewed by Rajasekharan and Raman, 2013; Williams et al, 1992).  
The intrinsic GTPase activity of RAS is catalysed by the GTPase-Activating 
Protein (GAP), which converts the GTP to GDP and prevents RAS from associating 
with RAF, therefore returning RAS to its deactivated form after signal transduction 
(Dominguez et al, 1991; Jelinek et al, 1996). However certain point mutations at 
codons G12, G13, and Q61 can render RAS impaired for GAP-mediated GTP 
hydrolysis, and as a result maintain RAS in a constitutively activated form (Prior et al, 
2012). This leads to the constant activation of the oncogenic RAS-MEK pathway, 
regardless of the presence or absence mitogens, which leads to tumorigenesis 
(Rajasekharan and Raman, 2013). Details explaining the RAS mechanism of 
activation are illustrated in Figure 1.1. 
One of the downstream targets of the RAS pathway is the cellular-
MYeloCytomatosis transcription factor (c-MYC), originally identified as the cellular 
homologue of the viral oncogene v-MYC (Sears et al, 2000; Vennstrom et al, 1982). 
The c-MYC transcription factor activates genes involved in cell survival, cell-cycle 
regulation, metabolism, ribosome biogenesis, protein synthesis, and mitochondrial 
function, all of which are processes relevant to tumorigenesis (reviewed by Dang et 
al, 2006). Consistent with its role as an oncogene, the ectopic or constitutive 
expression of c-MYC results in an increased rate of cell growth and proliferation, 
contributing to, or resulting in tumorigenesis (Hawksworth et al, 2010; Iritani and; 
Luo, 2005; Morrish et al, 2009).  
The EGFR, and the subsequent downstream RAS-MAPK pathway are 
examples of how a biochemical pathway can be derailed by oncogenes and driven 
		 15	
towards cancer. However, excessive growth and proliferation are not the only 
consequences of a derailed EGFR-RAS-MAPK pathway. This pathway has 
additionally been implicated with another hallmark of cancer, metastasis (Roberts and 
Der, 2007).  
1.1.1.a. Oncogenes implicated with metastasis 
RAS has been reported to be involved with cancer metastasis (Hoogwater et 
al, 2010; Mulholland et al, 2012; Uekita et al, 2014). Mutations that permanently 
activate RAS (Table 1.1), result in increased tumour migration and invasion along 
with growth and proliferation, driving malignancy and promoting metastasis 
(Campbell et al, 2007; Mora et al, 2007). Downstream targets of RAS such as c-MYC 
(Fig.1.1) have also been implicated with metastasis, where the downstream 
transcription signature has even been reported to be a prognostic marker for cancer 
metastasis through its regulated effects on tumour cell migration and invasion (Rapp 
et al, 2009; Wolfer and Ramaswamy, 2011). 
The EGFR-RAS-MAPK pathway has also been implicated in the upregulation 
of Epithelial to Mesenchymal Transformation (EMT) (Lamouille et al, 2014), a major 
contributor to tumour metastasis (Ocaña et al, 2012; Tsai et al, 2012). The initiation of 
metastasis requires tumour migration and invasion, which is mediated by EMT 
(reviewed by Yilmaz and Christofori, 2009). During EMT, epithelial cells lose 
polarity, cell-to-cell adhesion, and gain migratory and invasive properties of 
mesenchymal cells (Hay, 1995). This transformation allows benign tumours to 
become invasive and migrate to secondary organs and form secondary tumours (Tsai 
et al, 2012). Metastasis will be discussed further in chapter five and six.  
		 16	
1.1.2. Tumour suppressors 
Tumour suppressor genes are the converse of oncogenes, where it is the 
abolished or reduced activity of their encoded proteins that contributes to 
tumorigenesis (Chen et al, 2005; Dohner et al, 1995; Esteller et al, 2000; Gnarra et al, 
1994; Herman et al, 1994; Miyaki et al, 1994; Whang et al, 1998). They are important 
for suppressing uncontrolled cell growth and proliferation, as well as maintaining a 
balance between cell growth and proliferation, and cell death (apoptosis) and 
senescence (permanent arrest of proliferation) (An et al, 2002; Bennett et al, 1998; 
Schmitt et al, 2002; Yijun et al, 2004). In addition to their central role in controlling 
the balance of cell population dynamics, tumour suppressor proteins are also required 
for the prevention of tumour invasion, dissemination, and growth in organs distinct 
from that in which they originate (metastasis) (Streuli, 2002; Zia et al, 2007). A list of 
some common well-known tumour suppressor genes is illustrated in Table 1.2. As an 
example of a tumour suppressor gene, the p53 protein will be discussed next. Other 
examples of tumour suppressors will also be discussed in section 2.1. 
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Table 1.2. A list of some well-established tumour suppressors and their general 
functions (Adapted from Kopnin et al, 2000). 
Tumour 
suppressor gene 
(abbreviated) 
 
Function of expressed protein 
p53 -Transcription factor that regulates cell cycle and 
apoptosis 
-Controls genome integrity 
INKα/ARF -Inhibits Cdk4 
-Activates p53 
Rb -Controls transition into S-phase by regulating the 
E2F transcription factor 
E-cadherin -Involved in intercellular communications 
-Initiates signal transduction that activates p53 and 
p27KIP1 
APC -Binds and degrades cytoplasmic β-catenin 
-Prevents formation of the transcription complex 
β-catenin/Tcf 
VHL Suppresses expression of the Vascular 
endothelium growth factor gene 
-Suppresses hypoxia genes 
WT1 -Transcription factor that modulates the expression 
of p53-responsive genes by binding p53 
NF1 -Converts active RAS to an inactive form 
NF2 -Involved in membrane-cytoskeleton interactions 
 
Tumour suppressor protein 53 kilodaltons (p53), one of the earliest discovered 
tumour suppressor genes, and one of the most important, is mutated in ~50% of 
cancers (Hollstein et al, 1991; Lane and Crawford, 1979). Its protein product, p53, is 
the most studied protein in this field, with over 75,000 papers published to date 
(International Agency for Research on Cancer, 2015). This protein is discussed in 
detail in the following subsection. 
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1.1.2.1. Tumour suppressor protein: p53 
The tumour suppressor protein p53 can induce apoptosis, temporary cell 
cycle arrest, or cell senescence when certain conditions of the cell cycle are not met, 
ensuring only normal and healthy cells (genetically stable) continue to divide (see 
section 1.2 for more detail) (Agarwal et al, 1995; Manfe et al, 2012; Villalonga-
Planells et al, 2011). Present at low or undetectable levels within cells, p53 must reach 
a certain threshold to counteract its predominant negative regulator, the Mouse 
Double Minute 2 homolog  (MDM2) protein, so as to induce a measurable response 
(Canman et al, 1994; Honda et al, 1997; Honda and Yasuda, 1999; Isaacs et al, 1997; 
Kandel et al, 2000; Moro et al, 1995; Nadal et al, 1995; Ogden et al, 1992; Oliner et 
al, 1993). The MDM2 oncogene (Table 1.1) functions by forming a complex with the 
p53 protein to inhibit its activation domain (Oliner et al, 1993), and transports it to the 
cytoplasm to be degraded by proteosomes (Freedman and Levine, 1999; Haupt et al, 
1997). 
P53 is predominately a nuclear protein that acts as a transcription factor, and 
regulates the function of a variety of genes in response to cellular stress (Gu and 
Roeder, 1997; Hess, 1994). It can induce several cell cycle inhibiting genes to halt the 
progression of the cell cycle and trigger temporary cell cycle arrest (Table 1.3), which 
in turn allows for cells to repair any accumulated DNA damage (e.g. mutations).  
Table 1.3. p53-regulated cell cycle controlling genes (reviewed by 
Somasundaram and El-Deiry, 2000).   
Gene Transcriptional activity Outcome 
p21WAF1/CIP1 Activation G1 arrest 
Gadd45 Activation G2 arrest 
14-3-3 Activation G2 arrest 
Cyclin B Repression G2 arrest 
 
Alternatively, depending on a variety of factors and conditions (e.g. cellular 
context or cell type), p53 can transcriptionally induce apoptosis instead, eliminating 
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any defective cells from the general population (Finlay et al, 1989; Kuerbitz et al, 
1992; Polyak et al, 1997; Sugrue et al, 1997; Toledo and Wahl, 2006). This provides 
cells with a powerful tumour suppressive mechanism to overcome the outgrowth of 
potential tumours (Levine, 1997). P53 has also been reported to play a role in 
transcriptionally independent apoptosis from within the cytoplasm (reviewed by Moll, 
2005). Away from any target genes in the nucleus, it has been reported to induce 
apoptosis by directly binding the pro-apoptotic BCL-2 Associated X (BAX) and BCL-
2 Antagonist Killer (BAK) proteins (induction), as well as the anti-apoptotic B-cell 
Lymphoma-EXtra Large (BCLXL) and B-Cell Lymphoma 2 (BCL 2) proteins 
(inhibition) within the cytoplasm, therefore acting as a direct effector protein in the 
apoptotic process (Chipuk et al, 2004; Leu et al, 2004; Mihara et al, 2003; Park et al, 
2005). The choice between growth arrest and apoptosis was widely thought to mainly 
depend on the severity of stress signals (Menendez et al, 2009). However, it has 
become clearer in recent years that this choice probably depends on a variety of 
factors including the levels of p53, cell type, type and intensity of stimuli, presence or 
absence of certain co-activators, as well as the general conditions within the cell, and 
might well include other factors yet to be determined (Christophorou et al 2005; 
Flores et al, 2002; Toledo and Wahl, 2006). For example, in studies where ectopic 
p53 expression was induced in mice, treatment with ionizing radiation (results in 
DNA damage) induced apoptosis in the spleen and thymus (Christophorou et al, 
2005). The same study also reported that the ectopic expression of p53 in Mouse 
Embryo Fibroblasts (MEFs) activated cell senescence after RAS expression. In 
another study, it was reported that p53 required both the p63 and p73 proteins to 
induce apoptosis in MEFs after DNA damage (Flores et al, 2002). These studies 
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collectively stress the importance of cell type/context, type of stimuli, and the 
importance of protein co-factors in a p53 driven response. 
The functions of p53 are not only restricted to apoptosis and cell senescence. 
P53 can activate a variety of DNA repair and antioxidant genes, which maintain the 
overall integrity of the genome (Gatz and Wiesmuller, 2006; Matheu et al, 2007; 
Sablina et al, 2005). It can also induce the transcription of anti-angiogenic genes to 
inhibit angiogenesis (formation of new blood vessels) and uncontrolled cell growth 
(Ravi, 2000). P53 has also been observed to possess transcription-independent 
functions in DNA repair and recombination (Gatz and Wiesmuller, 2006). These 
properties collectively show why p53 is one of the most studied proteins in the field 
of cancer research. Its many functions make it a powerful tumour suppressor protein 
(Fig.1.2), with some functions similar to that of a stability gene (i.e. DNA repair) 
(Gatz and Wiesmuller, 2006). Stability genes will be discussed next. 
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Fig.1.2. The p53 pathway. After genotoxic stress, oncogene activation, ribosomal stress, 
hypoxia, or uncontrolled cell growth, a variety of effector proteins (in red) can activate p53. 
Ataxia-Telangiectasia and Rad 3 related (ATR) and Ataxia-Telangiectasia Mutated (ATM) 
kinase detect DNA damage and phosphorylate CHEK1 and 2, leading to a DNA damage 
response and p53 activation. Alternatively, oncogene expression can lead to the activation of 
p14ARF, which inhibits the p53 inhibitor MDM2, and allows p53 to build-up and function 
freely. The ribosomal proteins L5, L11, and L23 can also inhibit MDM2 after ribosomal 
stress in the nucleolus. On the other hand, the von Hippel-Lindau (VHL) tumour suppressor 
can activate p53 after hypoxia, and along with p53, inhibit the oncogenic VHL inhibitor 
Hypoxia-Inducible Factor 1 α (HIF1α). Depending on cell type, external stimuli, and cellular 
context, the p53 protein once activated can then upregulate a variety of anti-oncogenic and 
protective pathways in the cell in a transcriptionally dependent and independent manner 
(Chipuk et al, 2004; Leu et al, 2004; Mihara et al, 2003; Park et al, 2005). P53 can 
transcriptionally activate a variety of genes involved in (from left to right) cell senescence, 
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Reactive Oxygen Species (ROS) protection (antioxidant genes), and angiogenesis inhibition. It 
was also reported to inhibit error prone DNA Double Strand Break (DSB) repairs (e.g. 
RAD51 dependent Homologous Recombination) and is actively involved in error free DSB 
repair (e.g. sequence specific Homologous Recombination), Nuclear Exchange Repair 
(NER), and Base Exchange Repair (BER) of DNA. The p53 protein can also upregulate genes 
involved in Apoptosis (Far right), and act as a direct effector in the process (For more 
information refer to: Brady and Attardi, 2010; Gatz and Wiesmuller, 2006; Holmberg et al, 
2012; Roe et al, 2006; Sermus and Michiels, 2011; Zilfou and Lowe, 2009) (é=Activation or 
upregulation; Τ=Inhibition; MGMT: Methyl Guanine Methyl Transferase; MMR: MissMatch 
Repair; HR: Homologous Recombination; NHEJ: Non-Homologous End-Joining).  
		 23	
 1.1.3. Stability genes 
Stability genes are genes that encode proteins that maintain genomic integrity 
by sustaining the DNA repair of mutations (Vogelstein and Kinzler, 2004). Like 
tumour suppressor genes, it is the abolished or reduced activity of the encoded 
proteins that usually contributes to cancer (Gorski et al, 2003; Zhang et al, 2003). 
However, unlike tumour suppressor and oncogenes, mutations in stability genes do 
not usually lead to uncontrolled cell growth and proliferation (Vogelstein and Kinzler, 
2004); rather, they result in the accumulation of unrepaired mutations and the 
promotion/acceleration of genetic instability that contributes to tumorigenesis (Jardim 
et al, 2009; Roberts et, 2012; Vogel et al, 1999). 
Ataxia-Telangiectasia Mutated (ATM) kinase is a well-characterised key 
stability gene, essential in the maintenance of genomic stability (Banin et al, 1998; 
Shin et al, 2012). It acts primarily as a key “sensor” of double-stranded DNA breaks, 
and activates a variety of downstream targets leading to DNA repair, senescence, or 
apoptosis (Cortez et al, 1999; Shieh et, 1997). In response to double stranded DNA 
breaks, the Mre11/Rad50/Nbs1 (MRN) protein complex activates ATM kinase, which 
in turn phosphorylates several downstream targets including p53, CHEcKpoint kinase 
2 (CHEK 2), Histone 2A Family member X (H2AFX), and BReast CAncer 1 early 
onset (BRCA1) among others (Burma et al, 2001; Cortez et al, 1999; Lee and Paull, 
2004; Matsuoka et al, 2000; Shieh el al, 1997). The phosphorylation of p53 (at serine 
15) and the cell cycle associated CHEK2 protein by ATM promote the stabilisation 
and activation of p53, followed by cell-cycle arrest and DNA repair, or, depending on 
the cell type and conditions, apoptosis (Fig.1.2) (Banin et al, 1998; Finlay et al, 1989; 
Kuerbitzet et al, 1992; Polyak et al, 1997; Shieh et al, 1997; Sugrue et al, 1997) 
(Fig.1.2). The activation of CHEK2 allows for it to phosphorylate any untargeted p53 
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proteins at serine 15, and at serine 20 among other sites, which further stabilises p53 
from targeted degradation and influences the activation of downstream target 
promoters (Hirao et al, 2000; Ou et al, 2005; Shieh et al, 2000). ATM kinase also 
phosphorylates MDM2, the predominant p53 negative inhibitor, preventing its 
association with and targeted degradation of p53 (Fig.1.3) (Maya et al, 2001). The 
other targets of ATM kinase such as H2AFX and BRCA1, play essential roles in 
DNA repair (Burma et al, 2001; Cortez et al, 1999). Phosphorylated H2AFX (referred 
to as γ-H2AX after phosphorylation) is known as a hallmark of DNA repair, which 
localises to DNA damage foci early in the damage response process, and has been 
reported to recruit DNA repair factors (Paull et al, 2000). On the other hand BRCA1, 
a well-known stability gene, has been reported to co-localise with γ-H2AX at DNA 
damage foci, and repair double-stranded DNA breaks, as well as maintain global 
genomic repair (Cortez et al, 1999; Hartman and Ford, 2002; Moynahan et al, 1999; 
Paull et al, 2000). Mutations in BRCA1, and the functionally related stability protein, 
BReast CAncer 2 early onset  (BRCA2) (repairs double strand breaks) have been 
associated with cancer susceptibility (Palomba et al, 2009). It has been reported that 
ATM kinase additionally phosphorylates BRCA2 in vitro (Kim et al, 2008). 
Another well-characterised stability gene, Ataxia-Telangiectasia and Rad 3 
related (ATR) kinase, is a serine-threonine kinase which belongs to the same 
PhosphatidyInositol 3’ Kinase-like Kinase (PIKK) family as ATM kinase; like ATM, 
ATR acts as an important regulator of genome stability (Casper et al, 2002; Foster et 
al, 2003). ATR kinase is also a downstream target of the ATM kinase pathway; after 
double-stranded DNA breaks, ATM activates ATR and allows it to activate many of 
the same target genes (Agarwal et al, 1995; Myers and Cortez, 2006; Nghiem et al, 
2002; Shinozaki et al, 2003; Stiff et al, 2006). Nonetheless, ATR is also triggered by a 
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variety of other DNA damage events (e.g. DNA cross-links, base modifications, and 
stalled replication forks) (Pabla et al, 2011; Shell et al, 2009; Ward and Chen, 2001). 
However, it is mainly known to be involved in the replication stress DNA damage 
response. 
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Figure	1.	1.	DNA	damage	induced	cell	cycle	inhibition	by	ATM	and	ATR	kinase. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1.3. DNA damage induced cell cycle inhibition by ATM and ATR kinase. Upon 
genotoxic stress, ATM and ATR kinase phosphorylate CHEK1 and CHEK2 respectively, 
which correspondingly activate CDC25 and p53 mediated cell cycle arrest. Inhibiting DNA 
damaged cells from proceeding with the cell cycle during G1 and G2 phase, ensure a sound 
genome before DNA replication (S phase) and mitosis (M phase). ATM kinase also 
phosphorylates MDM2, the predominant p53 negative inhibitor, preventing its association 
with, and targeted degradation of, p53 (Abraham, 2014; Bartek and Lukas, 2003). 
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In response to a variety of genotoxic stress events, ATR kinase phosphorylates 
proteins such as p53, MDM2, CHEcKpoint kinase 1 (CHEK 1), H2AFX, and BRCA1 
among others, which allow it to generate its DNA damage response (Casper et al, 
2002; Liu et al, 2000; Nghiem et al, 2001; Nghiem et al, 2002; Shinozaki et al, 2003; 
Tibbetts et al, 2000; Ward and Chen, 2001). Although it activates some of the same 
targets as ATM, it does this in a different manner (Canman et al, 1994; Lu and Lane, 
1993; Shinozaki et al, 2003); it phosphorylates proteins like p53 at serine 15 at a 
much slower kinetic rate than ATM kinase, inducing a prolonged p53 induction 
(Canman et al, 1994; Lu et al, 1993). ATR also phosphorylates MDM2 at an alternate 
position (serine 407), inhibiting the MDM2 dependent export of p53 to the cytoplasm 
for degradation (Shinozaki et al, 2003). Additionally, unlike ATM kinase, ATR is a 
stability protein indispensible for survival (Brown and Baltimore, 2000; de Klein et al, 
2000). 
In general, the loss of DNA repair genes usually leads to microsatellite 
instability (Oki et al, 1999). Microsatellites are variable short tandem repeats of 
repetitive DNA sequences that are widespread throughout the genome (Ellegren et al, 
2004). Microsatellite instability is a state where error-prone repetitive repeat regions 
of DNA (non-coding microsatellite genes) accumulate mutations at an accelerated 
rate, and the overall length of the microsatellite repeat genes may be shortened or 
extended, leading to frameshift mutations in nearby coding genes (e.g. tumour 
suppressor genes), and eventually overall genetic instability (reviewed by Soreide et 
al, 2006). Genetic instability provides insight into how tumours may first develop. 
However, to fully comprehend the mechanisms in which tumours arise, it is necessary 
to first understand the underlying mechanisms that regulate normal cell growth and 
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proliferation (cell cycle), and how they become deregulated (i.e. manifestations of 
genetic instability). 
1.2. Cell cycle and cell cycle “checkpoints” 
The cell cycle consists of four tightly maintained sequential events known as 
the Gap1 (G1), Synthesis (S), Gap 2 (G2), and Mitosis (M), phases (Fig.1.4). 
Succession into each cell cycle phase is carefully regulated by several types of 
cellular proteins, one class of which are the Cyclin-Dependent Kinases (CDKs) (Lees, 
1995; Morgan, 1995). CDKs play a major role in the regulation of the cell cycle, 
where they induce its progression at each phase by phosphorylating key regulatory 
cell cycle associated proteins. However, CDKs do not work on their own, and must 
first associate with cyclin proteins to be activated and elicit their regulatory action 
(reviewed by Lees, 1995; Morgan, 1995).  
There are specific cyclins expressed in different phases of the cell cycle that 
can form complexes with various CDKS to allow phase-specific tasks to be completed 
and entry into the next phase (reviewed by Satyanarayana and Kaldis, 2009). G1 phase 
requires the presence of D-type cyclins, which partner with CDK 4 and 6 to 
phosphorylate target proteins required for cell cycle progression (Fig.1.5) (Baldin et 
al, 1996; Harbour et al, 1999; Pan et al, 2001; Satyanarayana and Kaldis, 2009; 
Veiga-Fernandes and Rocha, 2004). On the other hand, cyclin E-CDK 2 is required 
for the transition from G1 phase into S phase, where type A cyclins are synthesised 
(Harbour et al, 1999; Satyanarayana and Kaldis, 2009). Cyclin A-CDK 2 complexes 
can then phosphorylate proteins required for the completion of S phase (Coverley et al 
2000; Petersen et al, 1999). In G2 phase, Cyclin A-CDK 1 complexes can then 
phosphorylate target proteins that allow the transition into M phase (Furuno et al, 
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1999). Finally, cyclin B-CDK1 complexes accumulated in G2 phase allow for the 
progression and completion of M phase (Gavet and Pines, 2010; Lidqvist et al, 2007). 
In addition to CDKs and cyclins, the cell cycle is also regulated by 
mechanisms that ensure each phase is completed correctly; these mechanisms are 
known as cell cycle “checkpoints” (reviewed by Kastan, 2004; Russell, 1998) 
(Fig.1.4). There are two major classes of cell cycle checkpoints: the DNA damage 
checkpoints (Fig.1.4 & 5), which delay cell cycle transition from the G and S phases 
(G1, G2, & S) to allow DNA repair, and the dependency checkpoints, such as the 
spindle damage checkpoint at M phase (see section 1.2.2 for more detail) (Brondello 
et al, 1999; Doherty et al, 2003). These checkpoints delay cell cycle phase transitions 
until essential cell cycle events have been completed (Doherty et al, 2003). Cell cycle 
checkpoints, along with several other mechanisms of regulation ensure a smooth 
transition into each phase, and a proper order of events. 
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Figure	1.	2.	The	cell	cycle	checkpoints 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1.4. The cell cycle and checkpoints. The cell cycle starts at G1, where cell growth 
occurs. It then proceeds on to S phase where DNA replication occurs, before entry into the G2 
phase, where it prepares to divide. Finally, upon completion of the G2 phase, the cell 
undergoes mitosis at M phase, where it divides into two daughter cells. Commitment of the 
cell to completing the cell cycle is regulated at the Restriction point (R), which only allows 
the cell to continue the cycle if the cellular environment is sustainable for survival. At this 
point, if conditions are not optimal for the cell cycle to continue (e.g. absence of 
growth factor signals), the cell may pause in a state of reversible growth arrest known 
as the Gap 0 phase (G0). Otherwise, cells can then progress through the cell cycle 
unhindered, providing fidelity “checkpoints” are not activated (e.g. G2 and M phase 
checkpoints). Each phase of the cell cycle is regulated by cyclin-CDK complexes, which also 
allow entry and exit from each cycle phase (reviewed by Lees, 1995; Morgan, 1995).  
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When a new cell is formed, it initially undergoes a period of growth, which 
occurs in the G1 phase. An important feature of this phase is the cell’s regulatory 
mechanism known as the restriction point (Fig.1.5), which is the cell’s point of 
commitment, where it no longer requires growth factors to complete the cell cycle 
(Pardee, 1974). At this point, if conditions are not optimal for the cell cycle to 
continue (e.g. absence of growth factor signals), the cell may pause in a state of 
reversible growth arrest known as the Gap 0 phase (G0) (reviewed by Cooper, 2003; 
Zetterberg et al, 1995). The accumulation of cyclin D overcomes this restriction, and 
is maintained by continued extracellular growth signals, which subsequently allow for 
the formation of cyclin D-CDK 4 complexes (Ben-Porath and Weinberg, 2005; Yao et 
al, 2008; reviewed by Parry et al 1995). The cyclin D-CDK 4 complex can then 
phosphorylate the Retinoblastoma (Rb) tumour suppressor protein, an inhibitor of the 
growth promoting E2F transcription factor; as a result the Rb protein is then released 
from restricting E2F activity (Fig.1.5). The E2F transcription factor is then free to 
transcriptionally upregulate cyclin E, which forms a complex with CDK 2, and further 
phosphorylates the Rb protein in a positive feedback loop (Fig.1.5). The accumulation 
of Cyclin D also inhibits the p16 tumour suppressor protein, preventing it from 
binding and inhibiting CDK 4, thus further promoting cell cycle progression. Once the 
restriction point has been passed (under normal conditions), the cell can then commit 
to completing the cell cycle and will continue on to other phases. Providing there is no 
DNA damage, the cell cycle then proceeds on to the S phase followed by the G2 
phase, where DNA replication and preparations for mitosis occur respectively, before 
entry into the final stage of the cell cycle, the M phase (Ben-Porath and Weinberg, 
2005; Yao et al, 2008; reviewed by Parry et al 1995). 
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The final stage of the cell’s cycle is at the Mitotic phase, where the 
chromosomes segregate to opposite poles of the cell (Fig.1.6), and the cell undergoes 
cytokinesis (reviewed by O'Connell and Khodjakov, 2007; Rieder and Khodjakov, 
2003). Mitosis is a critical stage in the cell cycle, as chromosomes segregate 
irreversibly into their daughter cells. During this process, accurate chromosome 
segregation and cell division is maintained by a variety of cellular regulatory 
mechanisms that ensure the daughter cells are euploid (the normal state of 
chromosome numbers, which is diploid in humans). 
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Fig.1.5. The cell cycle restriction point and DNA damage checkpoint. Cells may pause in 
a state of reversible growth arrest known as the Gap 0 phase (G0) during unfavourable 
conditions (e.g. absence of growth factors). The accumulation of cyclin D overcomes this 
restriction, and is maintained by continued extracellular growth signals. The cyclin D-CDK 4 
complex then phosphorylates the E2F protein inhibitor, Retinoblastoma (Rb), therefore 
releasing it from the growth promoting E2F transcription factor. This in turn upregulates 
cyclin E, which forms a complex with CDK 2 and further phosphorylates the Rb protein, 
acting as a positive feedback loop. Cyclin D also inhibits the p16 tumour suppressor protein, 
preventing it from binding and inhibiting CDK 4. Once the restriction point is successfully 
overcome, providing no genotoxic stress is detected, cells are then allowed to progress 
through the cell cycle on to S phase (For further information: Ben-Porath and Weinberg, 
2005; Parry et al 1995; Yao et al, 2008). 
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Fig.1.6. Chromosome segregation in mitosis. During mitosis, microtubules emanating from 
centrosomes project towards condensed chromosomes to attach to kinetochore proteins 
located at the centromeres of chromosomes. At metaphase the microtubule spindles align the 
chromosomes along the metaphase plate and generate tension. Once the chromosomes are 
aligned, and tension is generated, sister-chromatid cohesion is released and the microtubule 
spindle pulls the sister chromatids apart and directs the sister chromatids to segregate into 
their respected daughter cells. 
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1.2.1. Mechanisms that regulate chromosome structure and segregation 
The regulation of chromosome segregation is an intricate process that requires 
a high level of regulatory input from the cell. Various forms of regulation exist, where 
processes such as the reversible phosphorylation of proteins implicated in mitosis 
allow for the careful segregation of chromosomes into daughter cells (Amon, 1999; 
Francisco et al, 1994; Verde et al, 1990). The Aurora/Ipl1p kinase family is such a 
group, where they regulate mechanisms such as centrosome separation, formation of 
the bipolar spindle, and the binding of microtubules to kinetochores (Biggins et al, 
1999; Glover et al, 1995). Polo-Like Kinases (PLK) are another group of kinases 
involved in the regulation of chromosome segregation and stability, where PLK1 for 
example, has been found to regulate kinetochore-microtubule interactions (Kang et al, 
2006). To ensure sister chromatids segregate to their daughter cells at the onset of 
anaphase, it is necessary that chromosomes have a bipolar attachment to the mitotic 
spindle, and that cohesion is maintained between sister chromatids until the onset of 
anaphase (Fig.1.6). An early or delayed release of the sister chromatids would result 
in aneuploidy, a state of abnormal chromosome numbers. It is therefore necessary for 
chromosome segregation and sister chromatid cohesion to be maintained and 
regulated precisely for the proper segregation of chromosomes, and to ensure this 
occurs in a timely manner. This process is regulated by the spindle checkpoint 
proteins and the chromosome cohesion protein known as cohesin (discussed in detail 
below). 
1.2.2. The spindle cell-cycle checkpoint 
The activation of sister chromatid separation is mediated by the Anaphase 
Promoting Complex/Cyclosome (APC/C) at the onset of anaphase	 (Chen, 2007; 
Chung and Chen, 2003). The APC/C is an E3-ubiquitin ligase that targets specific 
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proteins for degradation and allows chromosome segregation and mitotic exit (Chen, 
2007; Peters, 2006; Reddy et al, 2007). Its regulation is mediated in part by the 
spindle checkpoint family of seven proteins (Brady and Hardwick, 2000; Castillo et 
al, 2002; Chen et al, 1998; Chen et al, 1999). These proteins were originally identified 
and characterised in Saccharomyces cerevisiae, and homologues were subsequently 
identified in all eukaryotes examined to date (Castillo et al, 2002; Hoyt et al, 1991; Li 
and Murray, 1991).  
During prometaphase, the mitotic spindle attaches to kinetochores present at 
chromosome centromeres and aligns them along the metaphase plate. The spindle 
checkpoint detects the bio-orientation of those chromosomes as a whole, where it 
ensures the bilateral attachment of mitotic spindles to the kinetochores and the proper 
alignment of the chromosomes along the metaphase plate (reviewed by Amon, 1999; 
Gardner and Burke, 2000) (Fig.1.6). In the event where a chromosome might attach to 
the microtubule spindles in a uni-polar fashion (Fig.1.7), or where no tension is 
established from one or more of the spindles, the spindle checkpoint proteins would 
detect the improper attachment or lack of tension, and halt the progression of mitosis 
at metaphase until proper attachment is established (Encalada et al, 2005). The spindle 
checkpoint remains activated until it is disabled by the APC/C-dependent multi-
ubiquitination of target proteins, which leads to the dissociation of the Mitotic Arrest-
Deficient 2 (MAD2) and MAx Dimerisation protein 3 /BUB1 Related Kinase 
(MAD3/BUBR1) checkpoint proteins from the cdc20 component of the APC/C 
(Reddy et al, 2007).  
Once all kinetochores are under tension, the spindle checkpoint is 
subsequently inactivated, and the APC/C can then resume its action and degrade its 
targeted proteins, which is necessary for the progress of mitosis. The APC/C targets 
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securin, a protein that maintains sister chromatid cohesion by inhibiting the protease 
activity of another protein known as separase (Uhlmann et al, 1999). The ubiquitin-
dependent degradation of securin allows for the release of separase, which is then free 
to degrade the sister-chromatid cohesion maintaining cohesin protein (Hoque and 
Ishikawa et al, 2002; Uhlmann et al, 1999). As result, sister chromatids are free to 
separate unhindered and segregate into their respective daughter cells. 
Maintaining proper chromosome segregation is important for normal cellular 
function, and the prevention of chromosome instability and cancer. Nevertheless, 
there is much more to the maintenance of chromosome stability than proper 
segregation.  Eukaryotic linear chromosomes pose a fundamental biological 
challenge, where their ends must be distinguished from internal chromosome breaks 
to avoid being recognised as sites of DNA damage. DNA ‘repair processes’ at the 
ends of linear chromosomes would result in deleterious chromosome end-to-end 
fusions and chromosome instability (Cesare and Reddel, 2010; Soler et al, 2005; 
Wenner et al, 2003). Fused chromosome ends lead to chromosomes with amplified 
centromeres, potentially leading to chromosome shearing at anaphase and genetic 
instability (Boukamp et al, 2005; Soler et al, 2005; Wenner et al, 2003). To 
distinguish a chromosome end from an internal DNA break, eukaryotic organisms 
have evolved telomeres: repetitive DNA-protein complexes at the ends of linear 
chromosomes. Telomeres prevent chromosome end-joining, and protect chromosome 
ends from a DNA damage response (Cosme-Blanco et al, 2007; Moyzis et al, 1988). 
However, this topic is beyond the scope of this review. 
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Fig.1.7. The mitotic spindle checkpoint at metaphase. a) A unipolar microtubule spindle 
attachment is detected by the spindle checkpoint proteins, which activate the MAD2, 
MAD3/BUBR1, and BUB3 checkpoint proteins. These proteins then phosphorylate the 
Cdc20 subunit of the APC/C and deactivate it. This results in mitotic arrest due to the 
inactivity of the APC/C, which is required for progression to anaphase. b) Once the spindle 
checkpoint is satisfied, the Cdc20 component of the APC/C is then released and the APC/C is 
then free to promote sister-chromatid segregation. It ubiquitinates the securin protein (PSD1) 
and enables the liberation of separase (ESP1), which then cleaves the cohesin protein by 
proteolysis within the RAD21 subunit (Uhlmann et al, 1999). The cleavage of cohesin then 
allows sister-chromatids to separate during mitosis (adapted from Peters, 2006). 
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 Whether it is whole chromosomes, telomeres, individual genes, or single base 
pairs, the field of cancer research requires a deeper understanding of a variety of 
interconnected phenomena and mechanisms to develop better therapeutic agents. One 
of the most important fields of cancer therapy research is the development of tumour 
biomarkers for early detection. The above subsections provided a general overview of 
cancer, covering a variety of topics either directly or indirectly related to this project. 
The next subsection will discuss the prognostic value of tumour biomarkers, an 
essential component to cancer therapy and research, before moving on to the main 
topic of this thesis, which will cover the biology and biochemistry of the prognostic 
oncoprotein YB-1. 
1.3. Tumour biomarkers 
The main concern regarding the survival of most cancer patients is early 
detection, before the progression of the disease to later stages (Byers et al, 1997; 
Etzioni et al, 2003). Once more prognostic tools are available to detect malignant 
tumours early and before the onset of metastasis, which is a leading cause of death 
and remission among cancer patients, chances of patient survival will improve 
dramatically (Etzioni et al, 2003).  
Malignant tumours are characterised mainly by cells exhibiting an unlimited 
proliferative capacity, as well as invasiveness and metastatic potential (Golub et al, 
1999; Hanahan and Weinberg, 2000; Hanahan and Weinberg, 2011; Lazebnik, 2010; 
Rubin et al, 2008). Detecting malignant tumours early in the progression of cancer has 
been the focus of many research labs worldwide. A promising venture in this field has 
been the use of tumour biomarkers as prognostic tools for the proliferative potential 
and invasiveness of malignant tumours (Gradilone et al, 2003; Hur et al, 2012; 
Nicolson et al, 2003; Tuan et al, 2012). Tumour biomarkers are defined by the 
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National Cancer Institute (NCI), USA as: “substances that are produced by cancer 
cells, or by other cells of the body in response to cancer or certain benign conditions”. 
These “substances” can be obtained from biopsies of tumours, blood samples, as well 
as many other sources (Smith et al, 2010).  
In recent years, the expression pattern and status of many genes (e.g. 
oncogenes, tumour suppressors, and stability genes) have been used as tumour 
biomarkers (Minamida et al, 2011; Sigal et al, 2012; Wu et al, 2011). Some biomarker 
genes already widely studied include: the EGFR, the Estrogen Receptor (ER), the 
Progesterone Receptor (PR), and the Human Epidermal Growth Factor Receptor 2 
(HER-2), all of which are well-known oncogenes (Castaneda et al, 2012; Liu et al, 
2010; Monteiro et al, 2012). The status and expression levels of these genes have a 
high prognostic value for tumour malignancy and patient outcome in breast cancers, 
and are widely utilised in the field (Castaneda et al, 2012; Liu et al, 2010; Monteiro et 
al, 2012; Subik et al, 2010).  
With the advent of tumour migration and invasion assays, other genes and 
proteins associated with tumour invasion have been identified as potential markers for 
metastasis (Bandyopadhyay et al, 2003; Cho et al, 2009; Ma and Weinberg, 2007). 
YB-1 is a protein that has been reported to promote cell proliferation (Lasham et al, 
2012), and metastasis (Wang et al, 2015). It is an emerging biomarker protein with a 
reported substantial potential as a prognostic marker of tumour malignancy, drug 
resistance (resistance to chemotherapeutic agents), and poor patient outcome (Lasham 
et al, 2013 and reviewed by Kohno et al, 2003). Through its overexpression, 
localisation, and phosphorylation at serine 102, YB-1 has been implicated with the 
tumorigenesis of a variety of cancers (discussed in detail in the subsections below). 
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The general aim of this thesis is to functionally characterise YB-1 
phosphorylation and explore its significance on localisation and tumour malignancy, 
mainly on the two characteristic hallmarks of cancer: unlimited proliferation and 
metastasis. As detailed in this thesis, a total of 7 distinct YB-1 phosphorylation 
residues have been identified. The contribution of each of these phosphorylation sites 
to YB-1 driven tumorigenesis remain unknown. This project will look to explore YB-
1’s phosphorylation (Chapter three), localisation (Chapter four), and their impact on 
tumour malignancy (Chapter four, five, and six), which may potentially lead to a 
better understanding of YB-1 as a prognostic biomarker, and potentially contribute to 
the advancement of targeted cancer therapy. The biology of this protein and its 
prognostic value for cancer is discussed in detail in the following subsections.   
1.4. YB-1:  an overview 
The Y-Box binding proteins comprise a family of proteins that possess a 
common Cold Shock Domain (CSD) (Fig.1.8), that were initially reported to bind a 
conserved sequence known as the Y-Box sequence (5’-CTGATTGGCCAA-3’), 
present within the promoters of a variety genes throughout the genome (reviewed by 
Wolffe et al, 1994). The CSD is highly conserved, showing structural similarities with 
the bacterial Cold Shock Proteins (CSPs), indicating its essential biological role 
across species (Kloks et al, 2002).  
In Humans, the Y-Box Binding protein-1 (YB-1), a member of the Y-Box 
binding protein family, is a nucleic acid binding protein that binds both DNA and 
RNA via its conserved cold shock domain (reviewed by Kloks, et al, 2002). YB-1 is 
ubiquitous, multifunctional, and is involved in several cellular processes such as DNA 
repair, transcription, mRNA splicing, and translation (discussed further below). Over 
the past decade, YB-1 has been shown to be of significance to the area of cancer 
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research (reviewed by Kosnopfel et al, 2014). It has been observed to be present at 
elevated levels in ~40% of invasive breast carcinomas, and in a number of other 
malignancies (Gluz et al, 2009; Habibi et al, 2008; Oda et al, 2003;Wachowiak et al, 
2010). 
The biological functions of YB-1 appear to be directly associated with its 
cellular localisation status (Bader and Vogt, 2005; Basaki et al, 2010; Evdokimova et 
al, 2009). In most cases, the majority of the cell’s YB-1 is present within the 
cytoplasm, where it is involved in processes such as mRNA translation (reviewed by 
Kosnopfel et al, 2014). Within the nucleus, YB-1 has been observed to induce the 
transcription of genes such as the EGFR, avian ERythroBlastic leukemia viral 
oncogene homolog 2 (ERBB2/HER2), Matrix MetalloProteinase-2 (MMP-2), Matrix 
MetalloProteinase-12 (MMP-12), and Matrix MetalloProteinase-13 (MMP-13), 
implicating YB-1 in a variety of pathways involved with cancer (Mertens et al, 1997; 
Sakura et al, 1988; Samuel et al, 2007; Shapiro, 1999; Shibata et al, 2013; Stratford et 
al, 2007). However, there still remains much to be learnt about YB-1, as the literature 
concerning its sub-cellular location, abundance across different tissue types, and 
within different cancers, have been riddled with inconsistencies (Funakoshi et al, 
2003; Jurchott et al, 2003; Oda et al, 1998; Shibahara et al, 2001). Thus, the broader 
goal of this thesis is to explore one factor – YB-1 phosphorylation – that may affect 
the protein’s localisation, activity as an oncogene, and other biological properties. 
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Fig.1.8. A Schematic diagram of the human Y-Box-binding proteins. Y-Box-binding 
protein-1 (YB-1), also known as DNA-binding protein B (DbpB), carries both a Nuclear 
Localisation Signal (NLS) and a Cytoplasmic Retention Signal (CRS) within its C-terminal 
domain. Marked within the C-terminal domain of YB-1 is the proposed 20S proteosome 
cleavage site located between the NLS (amino acids 185-205) and the CRS (amino acids 247-
267). Also represented in this figure are YB-2/DbpC and YB-3/DbpA, which are members of 
the human Y-Box-binding protein family. AP= Alanine and Proline rich region (N-terminal 
domain). CSD = Cold Shock Domain. Basic/Acidic repeat = Basic and Acidic amino acid 
repeats (C-terminal domain) (Wolffe et al, 1994; reviewed by Eliseeva et al, 2011). 
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1.5. YB-1 structure and domain function 
The YB-1 gene (known as YBX1) is located on human chromosome 1p 34, 
and consists of 8 exons spanning approximately 19 kb of genomic DNA (Makino et 
al, 1996; Toh et al, 1998).  The YB-1 gene promoter spans from bp -920 to +85, and 
carries two E-box sequences, E-box 1 (-868 to -863 bp) and E-box 2 (-814 to -809 
bp), both of which were found to be necessary for effective Twist1 induced YB-1 
expression (Shiota et al, 2008). 
Expressed as a protein, YB-1 consists of 324 amino acids, and has a predicted 
molecular mass of 35.9 kDa. It has, however been shown to have an aberrant 
electrophoretic mobility of ~49 kDa (Cohen et al, 2010; Sorokin et al, 2005). The YB-
1 protein consists of three main domains: the N-terminal domain, followed by the 
central Cold Shock Domain (CSD), and the C-terminal domain  (Fig.1.8) (reviewed 
by Wolffe et al, 1994). The N-terminal domain (amino acids: 1-55) consists of an 
alanine/proline rich region (AP), and is of uncharacterised functional significance. 
Unlike the CSD, the functions of the N-terminus have not been characterised 
extensively. However, it has been reported to be involved in protein-protein 
interactions (Table 1.4), and has been implicated in the nuclear translocation of YB-1 
through its interaction with the SRp30c protein (Raffetseder et al, 2003). 
Almost all protein interactions listed in Table 1.4 were identified by yeast two-
hybrid screens, GST-pulldown, or co-immunoprecipitation experiments. To reinforce 
their claims, several studies investigated putative protein-protein interactions using 
more than one of these experimental procedures (Ashizuka et al, 2002; Chibi et al, 
2008; Shnyreva et al, 2000). For example, several YB-1 interacting partners were 
identified through yeast two-hybrid screens, and investigated further by co-
immunoprecipitation experiments (e.g. IRP2, RBBP6, hnRNP K). There were 
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exceptions however, where for example the interactions between YB-1 and the 
ribosomal proteins S3A, L18A, L5, L23A, and S5 were not reinforced by any follow up 
experiments (Ashizuka et al, 2002). There have also been experiments where the 
antibodies used for YB-1 immunoprecipitations were not specified, as was the case 
with the YB-1-IRP2 and YB-1-p300 co-immunoprecipitations (Ashizuka et al, 2002; 
Higashi et al, 2003). This is a major concern, given the cross-reactivity of many 
commercially available anti-YB-1 antibodies (see section 1.6). On the other hand, in 
other studies the immunoprecipitation results were strengthened with mass 
spectrometry after pulldown, which unequivocally identified YB-1 as a binding 
partner (e.g. α-/β- tubulin and Ankrd2) (Chernov et al, 2008; Kojic et al, 2004). 
Finally, not all experiments were conducted using human proteins, or in a human cell-
line. The YBAP1 protein for example, is the chicken homolog of the human splicing 
factor SRp30a, which was studied in a DT40 chicken cell-line (Matsumoto et al, 
2005).  
Nevertheless, the YB-1 protein can bind a variety of proteins (Table 1.4); the 
majority of which are involved in its established functions (see section 1.7) as a 
transcription, splicing, and translation factor (e.g. AP2, CTCF, hnRNP K, SRp30c) 
(Chernukhin et al, 2000; Mertens et al, 1998; Raffetseder et al, 2003; Shnyreva et al, 
2000). YB-1 can also bind several viral proteins such as the HIV-1-Tat protein and 
the JC virus agnoprotein (Ansari et al, 1999; Safak et al, 2002), which is not 
unexpected given YB-1’s involvement in transcription and translation, and the 
common dependence of viruses on host ‘machinery’ for these processes (Baric et al, 
1983; Everett, 1984; Gale et al, 2000; Janda and Ahlquist, 1993; Moraleda and 
Taylor, 2001). 
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Table 1.4. Some of the known YB-1 binding proteins. 
Protein name YB-1 domain of interaction Reference 
α- and ß- Tubulin Unknown Chernov et al, 2008 
Actin N-terminal domain Ruzanov et al, 1999 
Activating Protein 2 (AP2) Unknown Mertens et al, 1998 
 
AKR mouse Thymoma (AKT) 
Kinase 
CSD Basaki et al, 2007, 
Sutherland et al, 2005 
ANkyrin Repeat Domain-
containing protein 2 
(ANKRD2) 
Unknown Kojic et al, 2004 
Casein kinase II Unknown (Phosphorylates) Minich et al, 1993; 
Skabkin et al, 2001 
CCCTC-Binding Factor 
(CTCF) 
Unknown Chernukhin et al, 2000 
Endonuclease III Unknown Marenstein et al, 2001 
EWing’s Sarcoma protein 
(EWS) 
C-terminal domain Chansky et al, 2001 
heterogeneous 
RiboNucleoProtein particle 
K (hnRNP K) 
Two independent sites within 
the C-terminal domain (aa: 
124-150 and 271-320) 
Shnyreva et al, 2000 
Human Immunodeficiency 
Virus type-1-transactivating 
(HIV-1-Tat) protein 
N- terminal domain and CSD 
(aa: 75-203) 
Ansari et al, 1999 
Iron-Regulatory Protein 2 
(IRP2) 
C-terminal domain (aa: 129-
205) 
Ashizuka et al, 2002 
John Cunningham (JC) virus 
late regulatory agnoprotein 
CSD and C-terminal domain 
(aa: 125-318) 
Safak et al, 2002 
Nuclear Factor Kappa Beta 
(NFκB) subunit: Re1A 
Unknown Raj et al, 1996 
Proliferating Cell Nuclear 
Antigen (PCNA) 
C-terminal domain (aa: 128-
317) 
Ise et al, 1999 
Purine-rich element-binding 
protein α (Pur α) 
CSD and C-terminal domain 
(aa: 75-203) 
Safak et al, 1999 
E1A-Binding protein, 300- 
kilodaltons  (p300) 
Unknown Higashi et al, 2003 
Tumour suppressor 
protein 53 kilodaltons 
(p53) 
 
N- and C-terminal domains 
(N-terminus aa: 1-51, C-
terminus aa: 129-205; 272-
324). 
Okamoto et al, 2000 
RetinoBlastoma Binding 
Protein 6 (RBBP6) Ring 
finger domain 
Unknown (Ubiquinates YB-
1) 
Chibi et al, 2008 
Ribosomal proteins (S3A, 
L18A, L5, L23A, S5) 
Unknown Ashizuka et al, 2002 
Serine/arginine-Rich protein 
30c (SRp30c) 
N-terminal domain and CSD 
(Strong interaction aa: 21-
147) C- terminal domain 
(Weak interaction aa: 260-
317) 
Raffetseder et al, 2003 
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In line with its pleiotropic nature, YB-1 can also bind proteins such as the 
DNA repair Endonuclease III protein and several cytoskeletal proteins (α-/β- tubulin, 
actin, γ-tubulin) (Chernov et al, 2008; Davies et al 2011; Ruzanov et al, 1999); all of 
which are observations consistent with the described functions of YB-1 (see section 
1.7).  
As evident from Table 1.4, the many YB-1 protein-protein interactions more 
commonly involve the CSD and C-terminal domains of YB-1. The CSD (amino acids: 
56-128) consists of a five-stranded anti-parallel ß-barrel capped by a long flexible 
loop, and carries two conserved RNA binding motifs (RNP-1 and -2), which are 
known to be involved in specific and non-specific RNA binding (Izumi et al, 2001; 
Kloks et al, 2002). A structural study of the YB-1 CSD domain by Kloks et al (2002), 
determined using NMR spectrometry, suggested a possible DNA-binding site 
consisting of a region of positively charged and aromatic residues on the surface of 
the CSD ß-barrel (including residues within RNP-1 and -2) (Fig.1.9). However, they 
also observed that the CSD alone (excluding other YB-1 domains) bound weakly and 
with poor specificity to the Y-Box DNA sequence, suggesting the involvement of 
domains other than the CSD in binding the Y-Box DNA sequence (Kloks et al, 2002). 
Using several YB-1 deletion mutants, Izumi et al, (2002) found that the CSD was 
necessary but not sufficient (i.e. CSD alone) for double-stranded DNA binding, and 
SMA-Mothers Against 
Decapentaplegic 3 (SMAD3) 
CSD and C-terminal domain Higashi et al, 2003 
TATA box Binding Protein 
(TBP) 
Two independent sites within 
the C-terminal domain (aa: 
124-150 and 271-320) 
Shnyreva et al, 2000 
Translocation LipoSarcoma 
protein (TLS) 
C-terminal domain (aa: 170-
258) 
Chansky et al, 2001 
Y-Box protein-associated 
Acidic Protein 1 (YBAP1) 
C-terminal domain Matsumoto et al, 2005 
Centrosomes (Pericentrin and 
γ-tubulin 
Unknown Davies et al 2011 
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that it was rather the CSD and the C-terminal domain together that were required for 
sufficient double-stranded DNA binding.  In addition, the C-terminal domain was also 
found to interact with both single-stranded DNA and RNA independently of the CSD. 
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Fig.1.9. The ß-barrel structure of the Cold Shock Domain (CSD) of YB-1. A structural 
study of the YB-1 CSD domain by NMR spectrometry, suggested a possible DNA-binding 
site consisting of a region of positively charged and aromatic residues on the surface of the 
CSD ß-barrel (CSD indicated in blue). Flexible loops are indicated in red, orange, and yellow. 
The N- and C-termini are in light green and white respectively (image source: Kloks et al 
2002). 
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The C-terminal domain (amino acids: 129-324) consists of basic and acidic 
amino acid clusters, each approximately 30 amino acid residues in length (Kloks et al, 
2002; Wolffe et al, 1994). This region was found to be involved in several protein-
protein interactions (Table 1.4), where deletion analyses have indicated the C-terminal 
domain as necessary for YB-1 homodimerisation (Izumi et al, 2001). In addition to 
nucleic acid binding and protein-protein interactions, the C-terminal domain is 
thought to play a role in the regulation of YB-1 cellular localisation status (Bader and 
Vogt, 2005; Didier et al, 1988; Evdokimova et al, 2001; Koike et al, 1997; Okamoto 
et al, 2000; Raffetseder et al, 2003). Contained within the C-terminal domain are both 
the Nuclear Localisation Signal (NLS) and the Cytoplasmic Retention Signal (CRS); 
these signals are regulated by undefined mechanisms to ensure a predominantly 
cytosolic localisation of YB-1, and are possibly involved in its nuclear translocation 
(Bader and Vogt, 2005; Didier et al, 1988; Koike et al, 1997). However, the CSD was 
also found to play a role in YB-1’s nuclear translocation (Bader et al, 2003; Jurchott 
et al, 2003; Sutherland et al, 2005). Bader et al (2003), observed using 
immunofluorescence that a mutant YB-1 protein bearing two point mutations within 
the RNA-binding motif RNP-1 translocated to the nucleus, in contrast with wild-type 
YB-1 which remained in the cytoplasm. Additionally, YB-1 carrying a serine-to-
alanine mutation at amino acid 102 within the CSD was found to be inhibited for 
cytoplasmic retention, and was observed to translocate to the nucleus (Sutherland et 
al, 2005). On the other hand, Jurchott et al (2003), reported that the C-terminal and 
CSD domains together were both involved in the regulation of this process, where 
several deletion mutants fused to GFP were used to demonstrate that both the C-
terminal domain and CSD were responsible for nuclear translocation. Although, GFP 
is a large protein that might interfere with the proper function and localisation of YB-
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1, the involvement of both the CSD and the C-terminus in the regulation YB-1 
localisation remains likely, given the variety of studies indicating their importance 
(Bader et al, 2003; Bader and Vogt, 2005; Jurchott et al, 2003; Sutherland et al, 2005). 
The localisation status of YB-1 is still a controversial area of research. Earlier 
immunohistochemical studies are in question, mainly due to the cross-reactivity of 
many commercially available anti-YB-1 antibodies, and poor antibody validation 
(Cohen et al, 2010; Woolley et al, 2011). These issues will be discussed in the 
following subsection. 
1.6. Poor antibody validation in earlier YB-1 immunohistochemical studies 
Most of the earlier studies on YB-1 relied on the immunohistochemical 
analysis of endogenous, or tagged recombinant YB-1 (Table 1.5). However, much of 
this data was dependent on un-validated (for specificity) or improperly characterised 
antibodies, which greatly contributed to the inconsistencies observed within the 
literature (Cohen et al, 2010). A variety of different antibodies have been used to 
identify (Western blot) or locate (immunohistochemical) YB-1 within cells (Table 
1.5), yet most of these studies gave very little, or no information regarding the 
antibody’s specific epitope or validity. 
Two of the most widely used anti-YB-1 antibodies were developed by Ohga et 
al (1996), and were generated against the N and C-terminal ends of YB-1 (Table 1.5: 
antibodies known as N1 and C1). Although the information regarding the specific N1 
and C1 epitopes have been properly documented in their paper, very little information 
regarding the validation of these particular antibodies was presented. They remain the 
most commonly used anti-YB-1 antibodies, and have been used in several earlier 
studies with very little information regarding validation (Gimenez-Bonafe et al, 2004; 
Izumi et al, 2001; Oda et al, 1998; Oda et al, 2003; Shibahara et al, 2001; Sutherland 
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et al, 2005). There have been other cases, where studies have not specified which of 
the two commonly used N1 and C1 antibodies were used (Fujita et al, 2005; Habibi et 
al, 2008; Okamoto et al, 2000).  For example, Okamoto et al (2000), used anti-YB-1 
antibodies for western blots of a reciprocal GST/GST-p53 pull-down assay, and an in 
vitro p53 immunoprecipitation, but did not specify whether it was the N1 or C1 anti-
YB-1 antibody that was used. These studies stress the need for the proper 
documentation and validation of antibodies, which was widely lacking in many early 
studies the field. However, with studies such as Izumi et al (2001), YB-1 pulldown 
and co-immunoprecipitation experiments performed with the C1 antibody were 
confirmed using anti-FLAG and anti-HA antibodies against FLAG- and HA-tagged 
YB-1.  It was not until the study by Schittek et al (2007), that the C1 antibody was 
finally validated. Using an shRNA knockdown experiment, they showed that the 
blotted YB-1 protein detected with this antibody on a western, could be reduced in 
intensity after a knock down, thus confirming the specificity of the antibody for YB-1.  
There have also been several other YB-1 studies using tagged-antibodies 
against tagged YB-1. Raffetseder et al (2003), used an anti-FLAG antibody for 
western blotting and immunoprecipitation, whereas, Bader and Vogt (2008), used 
anti-FLAG antibodies for immunohistochemistry studies. On the other hand, 
Okamoto et al, (2000), used an anti-Thio antibody to detect recombinant GST-YB-1 
and its derivatives (deletion mutants) in p53 binding assays (western Blots). 
Combining data generated from antibodies against tagged YB-1 and antibodies 
against endogenous YB-1 may add validity to some studies. However, to be certain of 
observed trends from immunohistochemical studies, there is no substitute for proper 
antibody validation and documentation (i.e. specific epitope).  
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Table 1.5. A summary of YB-1 antibodies used in the literature. 
Antibody  Epitope Validated Application Reference 
Polyclonal 
rabbit anti-
YB-1 
Unpublished 
reference 
-No information Western blot, IHC, 
Immunoshift assay 
(data not shown) 
Bargou et al, 
1997 
Polyclonal 
rabbit anti-
YBC 
No information -No information Western blot, IHC Koike et al, 
1997 
Polyclonal 
rabbit N1 
(anti-YBN) 
and C1 
(anti-YBC) 
Generated against 
synthetic peptides 
corresponding to 
sequences within 
the YB-1 cold 
shock domain (aa 
101-119), and the 
C-terminal end 
(aa 299-313)  
-Insufficient 
information.  
-Detected 
increase in YB-
1 protein 
expression 
strengthened by 
Northern blot 
analysis. 
Western blot, IHC Ohga et al, 
1996 
Polyclonal 
rabbit anti-
dbpB 
antibody 
Generated against 
a synthetic 
peptide 
corresponding to 
the YB-1 C-
terminal end (aa 
310-324). 
-No information Western blot, 
Immunoshift assay. 
Protein purification 
was done using an 
anti-His antibody 
against His-tagged 
YB-1 
Shen et al, 
1998 
Polyclonal 
rabbit anti-
Xenopus  
FRGY2 
(αFRGY2) 
 
Generated against 
the conserved 
DNA-binding 
domain of 
FRGY2 (Xenopus 
Y-box family 
protein).  Has 
previously been 
shown to cross-
react with mouse 
YB-1 
-No information Immunoshift assay Lasham et al, 
2000 
Anti-dbp 
COOH-
terminus   
Generated against 
a synthetic 
peptide 
corresponding to 
the C-terminal 
end (aa 310-324) 
-No information Western blot, 
Immunoshift assay 
Sternina et al, 
2000 
Polyclonal 
rabbit anti-
YB-1 
Generated against 
full length YB-1 
(Davydova et al, 
1997) 
-No information Western blot, 
Immunoprecipitatio
n 
Evdokimova et 
al, 2001 
Polyclonal 
rabbit anti-
YB-1 
Generated against 
a synthetic 
peptide 
corresponding to 
the N-terminus 
(no specific 
epitope given) 
-No information Western blot, IHC, 
Immunoshift assay 
Jürchott et al, 
2003 
Polyclonal 
Chicken 
No information -No information 
 
Western blot Berquin et al, 
2005 
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anti-human 
YB-1  
 
 
 
 
Polyclonal 
rabbit C1 
(anti-YBC) 
and rabbit 
anti-CSD 
(polyclonal?
?) 
C1 antibody 
(Ohga et al, 
1997). Rabbit 
anti-CSD 
antibody epitope 
not specified 
(source 
referenced) 
-Some of the 
IHC data was 
confirmed by 
using anti-
FLAG 
antibodies 
against FLAG-
tagged YB-1 
Western blot, IHC, 
Immunoprecipitatio
n  
Sutherland et 
al, 2005 
Polyclonal 
rabbit anti-
YB-1 
Generated 
synthetic peptide 
corresponding to 
the N-terminus 
(aa 1-12) 
-Validated by 
siRNA 
knockdown of 
wild-type YB-1. 
-siRNA 
specificity also 
tested against 
mutant YB-1 
(siRNA negative 
control) 
-Antibody 
preincubated 
with inhibitory 
peptide that 
prevented YB-1 
staining during 
IHC analysis 
(IHC -ve 
control). 
-Immunoblot 
data also 
confirmed by 
anti-Ha 
antibodies 
against HA-
tagged YB-1. 
 
 
Western blot, IHC Chatterjee et 
al, 2008 
Polyclonal 
rabbit anti-
YB-1 
Generated against 
full-length YB-1 
-Validated by 
siRNA 
knockdown 
-Immunoblot 
data confirmed 
by anti-Ha 
antibodies 
against HA-
tagged YB-1. 
 
Western blot, IHC Evdokimova et 
al, 2009 
All antibodies were labelled according to the published literature, or according to 
specificity. IHC: Immunohistochemmical   
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1.7. Functions of YB-1 
YB-1 appears to be involved in a variety of functions depending, in part, on its 
cellular localisation status (Asakuno et al, 1994; Bader and Vogt, 2005; Basaki et al, 
2010; Evdokimova et al, 2009; Raffetseder et al, 2003). In the cytoplasm YB-1 is 
involved in microtubule formation and translation, whereas in the nucleus it behaves 
as a transcription and splicing factor (Bargou et al, 1997; Chernov et al, 2008; 
Evdokimova et al, 2001; Wu et al, 2007). However, YB-1 is not limited to these 
functions in the cytoplasm and nucleus (e.g. de Souza-Pinto et al, 2009 and Izumi et 
al, 2001). The cellular functions of YB-1 are discussed in further detail below 
(reviewed by Lyabin et al, 2014). 
1.7.1. Translation 
YB-1 is a major component of messenger ribonucleoprotein particles 
(mRNPs) in the cytosol of somatic cells (Evdokimova, et al 2001). It associates with 
mRNA in a non-sequence-specific manner, and under certain conditions has been 
observed to inhibit cap-dependant translation (Bader and Vogt, 2005; Evdokimova et 
al, 2001; Matsumoto et al, 2005). Evdokimova et al (2001), hypothesised that YB-1 is 
usually anchored to mRNA by non-specific RNA binding, and is prevented from 
interacting with the mRNA cap region by the eukaryotic initiation factor eIF4F 
(necessary for the initiation of cap-dependant translation). Under certain conditions, 
such as during early embryogenesis or stress, an increase in YB-1 levels, or an 
increased sequestration of the eIF4E protein (part of the eIF4F protein complex) from 
the mRNA cap, results in an increase in cap-bound YB-1. As a result, YB-1 then 
inhibits the 5’ mRNA cap from interacting with ribosomes during translation, and 
therefore inhibits cap-dependant translation.  
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YB-1 can translationally inhibit several growth and proliferation-associated 
genes (Evdokimova et al, 2009). However, its translational inhibition of proliferation 
can be reversed by its phosphorylation at serine 102, which allows for the translation 
of latent oncogenic mRNA transcripts that upregulate cell proliferation (Evdokimova 
et al, 2006). YB-1 was even observed to autoregulate its own mRNA translation via a 
hypothesised 3’- UTR regulatory element (Skabinka et al, 2005). This autoregulation 
was inhibited by the Poly (A)-Binding Protein (PABP), which restored the translation 
of YB-1 mRNA. The YB-1 protein can also promote 5’ cap-independent translation 
of mesenchymal-associated genes such as HIF1α (El-Naggar et al, 2015; Evdokimova 
et al, 2009), which will discussed further in the review (see section 1.10).  
1.7.2. Alternative RNA splicing 
Among its nuclear functions, YB-1 acts as regulator of alternative RNA 
splicing (Raffetseder et al, 2003; Rapp et al, 2002; Stickeler al, 2001). It can 
specifically regulate alternative splice site selection of a viral E1A minigene in vivo 
(Rapp et al, 2002; Stickeler et al, 2001), and is able interact with the splicing factor 
protein Serine/arginine-Rich protein 30c (SRp30c), and the TransLocated in Sarcoma 
(TLS) protein, which are involved in RNA processing and YB-1 recruitment to RNA 
polymerase II splicing machinery (Table 1.4) (Rapp et al, 2002; Stickeler et al, 2001).  
YB-1 was initially reported to bind A/C-rich exon enhancers to stimulate the 
alternative splicing of exon v4 of the CD44 gene in vivo (Fig.1.10) (Stickeler et al, 
2001). More recently, two high affinity YB-1 binding mRNA motifs (CAUC and 
CACC) that function as splicing enhancers were identified using Systematic Evolution 
of Ligands by EXponential enrichment (SELEX) (Wei et al, 2012). YB-1 was able to 
activate exon v5 inclusion of the CD44 gene via multiple CAUC motifs within the 
alternative exon and its upstream polypyramidine tract (Wei et al, 2012). It was also 
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able to facilitate the recruitment of U2AF65 (essential for spliceosome assembly) to 
weak polypyramidine tracts via direct protein-protein interactions (through YB-1’s C-
terminal domain), which allows for the inclusion of weak 3’ splice sites (Wei et al, 
2012).  
In another study, YB-1 was found to be involved in exon skipping of the 
Muscle Specific receptor tyrosine Kinase (MuSK) gene, which codes for a 
postsynaptic transmembrane molecule that mediates the clustering of AcetylCholine 
Receptors (AChR) (Nasrin et al, 2014). MuSK requires the alternatively spliced exon 
10 for Wnt-mediated AChR clustering, which was observed to be mediated by the 
hnRNP C, hnRNP L, and YB-1 protein. 
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Fig.1.10. The alternative splicing assembly of CD44 showing alternative exon inclusion 
mediated partly by YB-1. Presented, is a schematic diagram of the transcription initiation 
complex showing protein-protein and protein-RNA interactions around the CD44 
transcription unit, where YB-1 binds an alternate exon to promote its inclusion in the final 
mRNA transcript. The C-terminal domain of the RNA Polymerase II protein (RNAPII), 
following phosphorylation, mediates the assembly of the snRNP proteins (U1, U2), and 
splicing factors on the pre-mRNA sequence (pre-mRNA indicated by red line). Through the 
recognition of splice sites on the emerging CD44 pre-mRNA during transcription, 
spliceosome assembly takes place, where splicing factors (marked in yellow and white) 
recognise exon enhancers (ESE, ISE) on the alternative exon (marked as blue box) and 
stimulate splicing. These splicing regulators are known as Serine-arginine-Rich proteins (SR) 
in yellow, or non-SR-like proteins in white. YB-1, a non-SR-like protein binds the A/C-rich 
exon enhancer (ACE element) on the alternative exon to stimulate exon inclusion (Stickeler et 
al, 2001). Other proteins in this diagram are components of the spliceosome (Figure source: 
Prochazka et al, 2014). 
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1.7.3. DNA repair 
YB-1 has been reported to be involved in DNA repair in the nucleus and 
mitochondria (de Souza-Pinto et al 2009). RNA knockdown experiments with YB-1 
showed an increased sensitivity to ciplatin, mitomycin C, and UV radiation in drug 
resistant cell-lines, suggesting YB-1 may protect cells from the cytotoxic effects of 
agents that induce DNA cross-linking (Ohga et al, 1996). YB-1 was also observed to 
preferentially bind cisplatin-modified double-stranded DNA, rather than untreated 
double stranded DNA (Izumi et al, 2001). To assess the binding affinity of YB-1 to 
nucleic acids under genotoxic drugs, double-stranded (25mer) and single-stranded (32 
mer) DNA oligonucleotides including the Multi-Drug Resistance-1 (MDR-1) gene Y-
Box sequence, with or without cisplatin treatment, were incubated with YB-1 in a gel-
shift assay. The cisplatin-modified double stranded DNA showed the highest 
retardation of mobility in this assay, indicating a higher level of bound YB-1 than the 
other DNA probes. YB-1 was also shown to exhibit intrinsic 3’ to 5’ DNA 
exonuclease activity (Izumi et al, 2001), and was able to promote strand separation of 
duplex DNA containing mispaired bases or cisplatin modifications in vitro.  
In addition to its observed exonuclease activity, YB-1 exhibits in vitro 
endonucleolytic activities (Gaudreault et al, 2004). It was also observed to bind 
several proteins involved in DNA repair, where it co-localised with Ku80 or MSH2 in 
the nucleus after cisplatin treatment, implicating YB-1 in the base excision and 
mismatch DNA repair pathways (Gaudreault et al, 2004). Moreover, YB-1 was 
reported to bind Proliferating Cell Nuclear Antigen (PCNA) in vitro and in vivo 
(Table 1.4), which is an essential protein in DNA repair, and a component necessary 
for nucleotide excision repairs (Yoshimatsu et al, 2005). Its expression expression 
was also correlated with PCNA expression (Yoshimatsu et al, 2005).  
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More recently, de Souza-Pinto et al (2009), observed in thymidine-stressed 
HeLa cells that 80% of the cytosolic YB-1 localised to the mitochondria, where it was 
reported to be involved in a DNA mismatch-repair pathway, distinct from the 
conventional nuclear mismatch repair pathway. These protective functions of YB-1 in 
the nucleus/mitochondria are in contrast with its proposed role as an oncogenic 
transcription factor, indicating the importance of understanding YB-1 regulation to 
comprehend its contribution to the pathology of cancer. 
1.7.4. Transcription 
YB-1 has been observed to reside predominantly in the cytoplasm (Cohen et 
al, 2010; Kosnopfel et al, 2014). Once in the nucleus, YB-1 can act as an oncogenic 
transcription factor, where it induces the transcription of several growth and 
proliferation promoting genes (Wu et al, 2007).  However, its role in cancer is not 
limited to its functions as an oncogenic transcription factor. Next, the broad role of 
YB-1 in cancer will be discussed in detail.  
1.8. YB-1 is involved with cancer 
YB-1 was reported to be overexpressed in several common malignancies, and 
is seen as a hallmark of malignant and drug resistant tumours (Chatterjee, et al, 2008; 
Huang et al, 2005; Janz et al, 2002). Habibi et al (2008), observed that YB-1 was a 
highly predictive biomarker of tumour relapse and poor patient survival across all 
breast cancer subtypes studied (including the entire cohort when taken together). This 
study also reported that patients with node +/- cancer showed a lower survival rate if 
YB-1 was expressed. Analysis with a Cox regression model showed that YB-1 was 
significantly associated with relapse and poor patient survival in a subtype 
independent manner, further substantiating YB-1 as prognostic marker. This analysis 
revealed that YB-1 was a superior predictor of relapse and patient survival compared 
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to the ER and HER-2 prognostic markers. In patients diagnosed as low-risk (no 
chemotherapy), YB-1 was found to be an indicator of poor patient survival, as was the 
case in tamoxifen-treated ER+ patients, where Breast Cancer Specific Survival (BCS) 
was decreased. Using the Cox regression model in this setting, YB-1 was shown to be 
an independent biomarker for poor patient survival.  
YB-1 has also been implicated in the development of a wide a range of 
different malignancies including breast cancer (Bargou et al, 1997; Bergmann et al, 
2005; Habibi et al, 2008; Gluz et al, 2009), cervical adenocarcinomas (Asakuno et al, 
1994), multiple myelomas (Chatterjee et al, 2008), neuroblastomas (Wachowiak et al, 
2010), non-small cell lung cancer (Shibahara et al, 2001), osteosarcomas (Oda et al, 
1998), ovarian cancer (Kamura et al, 1999; Yahata et al, 2002), pediatric 
glioblastomas, prostate adenocarcinomas (Gimenez-Bonafe et al, 2004), synovial 
sarcomas (Oda et al, 2003), and thyroid neoplasms (Ito et al, 2003). The role of YB-1 
in tumor malignancy and drug-resistance is discussed further in the following 
subsections. 
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1.8.1. YB-1 and tumourigenesis 
Earlier studies implicated YB-1 with tumorigenesis on the basis of its nuclear 
localisation. For example, in patients with NSCLC (Non-Small Cell Lung Cancer), 
nuclear YB-1 was found to be present in 49% of a total of 196 tumours examined, 
whereas in human prostate cancer tissue samples, YB-1 showed an increased nuclear 
expression (using an unspecified antibody) with tumour progression (Gleason 
grading) (Gimenez-Bonafe, 2004; Shibahara, 2001). Additionally, 
immunohistochemical studies in synovial sarcomas revealed that cases with nuclear 
YB-1 expression correlated with poor patient survival and showed high levels of 
topoisomerase II α and Ki-67 expression (proliferation markers) (Oda et al, 2003). 
Nuclear YB-1 and tumorigenesis was also the focus of a number of other studies 
(Schittek et al, 2007; Shibahara et al, 2001; Sutherland et al, 2005). However, a 
variety of studies have also reported that it was in fact both nuclear and cytoplasmic 
YB-1 that were implicated in tumorigenesis (e.g. Wang et al, 2015), with many 
reports of increased cytoplasmic YB-1 in a number of cancers (Janz et al, 2002; Kolk 
et al, 2011; Szczuraszek et al, 2011).  
Although cytoplasmic YB-1 has been implicated in the inhibition of 5’ cap-
dependant translation, it was also observed to increase the expression of 5’ cap-
independent translation, upregulating a variety of EMT promoting genes (precursor to 
metastasis). Akt-mediated YB-1 phosphorylation at S102 was also reported to 
increase the translation of proteins regulating cell proliferation and oncogenic 
transformation (Evdokimova et al 2006). Additionally, YB-1 binding to a high 
affinity 5’- untranslated mRNA region of the growth promoting TGF-β protein-ligand 
was reported to be necessary for the translation of the protein in kidney proximal 
tubule cells (Fraser et al, 2008). Furthermore, Habibi et al (2008), reported that YB-1 
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was a highly predictive biomarker of tumour relapse and poor patient survival across 
all breast cancer subtypes studied, but also found that only  ~ 3% of the tumours 
examined had nuclear YB-1. 
More recently, it has become clear that it is in fact overall YB-1 expression, 
whether nuclear or cytoplasmic, that is associated with tumorigenesis (Bergmann et 
al, 2005; Davies et al, 2014; Hipfel et al, 2000; Lasham et al, 2012; Lee et al, 2008; 
Schittek et al, 2007; Shiota et al, 2008; Wang et al, 2015). For example, one study in 
melanoma cells demonstrated that a reduced overall YB-1 expression was 
accompanied by the downregulation of several genes involved in proliferation, 
survival, migration, and invasion (e.g. MMP-2, Bcl-2, Cyclin D1, p53, and 
p16INK4A) (Schittek et al, 2007). Another study in mice breast carcinomas by 
Bergmann et al (2005) revealed that YB-1 overexpression was accompanied with 
chromosome instability. Targeting YB-1 expression by knockdown was even 
observed to induce apoptosis and reduce tumour growth in mice (Lee et al, 2008). On 
the other hand, Lasham et al (2012) observed in breast cancer that an elevated overall 
expression of YB-1 was associated with aggressive tumours, and strongly associated 
with poor disease-free patient survival and poor distant metastasis-free patient 
survival.  
The literature implicates both nuclear and cytoplasmic YB-1 in tumorigenesis 
(discussed further in chapter six). These studies indicate the importance of the broader 
goal of this thesis research: to contribute to the understanding of how YB-1’s 
localisation relates to its functions within the cell, and to further explore its role as an 
oncogene and driver of tumorigenesis.  
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1.8.2. YB-1 and drug-resistance 
YB-1 has been reported to convey drug resistance to tumours through the 
transactivation of the MDR-1 gene (Asakuno et al, 1994). The MDR-1 gene, 
expressed as a 170 kDa transmembrane P-glycoprotein (P-gp), is a member of the 
ATP binding cassette transporter superfamily, and acts as an ATP-dependent efflux-
pump against a variety of structurally unrelated cytotoxic drugs (reviewed by Zhou et 
al, 2008). Genotoxic drugs such as actinomycin D and paclitaxel result in the 
upregulation of the activity of the MDR-1 gene promoter in reporter gene assays 
(Asakuno et al, 1994; Fujita et al, 2005). Asakuno et al (1994) observed that the 
inverted CCAAT box of the MDR-1 promoter, a proposed YB-1 target-sequence, was 
necessary for the transactivation activity in response to actinomycin D. Additionally, 
actinomycin D augmented YB-1 binding to the MDR1 gene promoter, and increased 
the steady state levels of MDR-1 and YB-1 mRNA. 
Nuclear YB-1 expression was also observed to correlate significantly with P-
glycoprotein expression (Bargou et al, 1997; Oda et al, 2003; Oda et al, 1998). In 
multidrug-resistant MCF-7 breast cancer cells, YB-1 localised to the nucleus and was 
associated with MDR-1 gene expression (Bargou et al, 1997). Oda et al (1998) 
observed using immunohistochemical expression studies in untreated osteosarcomas 
that YB-1 was localised in the nucleus of 46% of cases (32 cases). The expression of 
P-gp was evident in 23 of these 32 cases, and a highly significant correlation was 
found between YB-1 nuclear localisation and P-gp expression (P < 0.0001). 
Chondroblastic osteasarcomas were observed to express YB-1 in the nucleus more 
frequently than other types of osteosarcomas (8/9 cases), and P-gp was frequently 
expressed in this tumour subtype.  Additionally, Fujita et al (2001) reported that 33% 
(9 of 27) of breast cancer tissues treated with paclitaxel showed YB-1 translocation to 
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the nucleus, together with increased expression of P-glycoprotein during the course of 
treatment. The increased expression of P-glycoprotein was also found to correlate 
significantly with YB-1 nuclear translocation (p = 0.0037). It is noteworthy, however, 
that this data represented only a small subset of cells showing nuclear localisation. 
Whether these studies can reliably determine YB-1 as nuclear, and not perinuclear, is 
debatable, as no confocal images were taken. This is also the case with most of the 
immunohistochemical studies that focused on nuclear YB-1. Confocal images easily 
distinguish between perinuclear and nuclear localisation via Z-stacking (see chapter 
four). However, Fujita et al (2005), did observe using confocal microscopy that 
paclitaxel induced the nuclear translocation of YB-1-GFP fusion proteins in MCF7 
cells (Fujita et al, 2005). Nevertheless, none of the immunohistochemical images were 
confocal. 
On the other hand, Giménéz-Bonafé et al (2004) demonstrated in androgen-
sensitive human prostate adenocarcinoma tumour model cells (LNCaP cells) in vivo 
(mouse xenografts), and in vitro (YB-1 overexpression studies), that YB-1 and P-gp 
both increased in expression with increasing time after castration (i.e. androgen 
ablation). This implicates YB-1 and its putative downstream target gene MDR-1 as 
possible initiators of tumour Androgen Independence (AI: the ability of malignant 
prostate cancer cells to survive in the absence of androgens). Further YB-1 
overexpression studies in vitro also showed an overall decrease in vinblastine (a P-gp 
substrate) in YB-1 overexpressing cells, compared to controls. DiHydroTestosterone 
(DHT) efflux by P-gp was also assayed by observing the expression of a luciferase-
linked downstream target gene of DHT, where YB-1 overexpression indicated an 
overall decrease in DHT. Furthermore, P-gp was found to be overexpressed during 
prostate cancer tumour progression to AI stage.  
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Moreover, YB-1 levels were observed at higher concentrations in cisplatin-
resistant cell-lines (indirect immunofluorescence microscopy), and the overall 
downregulation of YB-1 expression was observed to increase sensitivity to cisplatin, 
mitomycin C, and etopside (Ohga et al, 1996; Schittek et al, 2007). 
Immunohistochemical analysis of YB-1 expression in situ also showed that the 
overall overexpression of YB-1 resulted in resistance towards doxorubicin-mediated 
apoptosis (Chatterjee et al, 2008). Collectively the data suggest that through drug 
resistance and other oncogenic properties of YB-1, cancer patients exhibiting an 
elevated total expression of YB-1 (nuclear and cytoplasmic) show a poor prognosis.   
1.9. YB-1 promotes cell proliferation 
YB-1 has been implicated with increased cell proliferation (reviewed by, 
Lasham et al, 2013). Earlier studies revealed that YB-1 conferred a selective 
proliferative advantage to tumours of several cancer types, indicated by the Ki-67 
(MIB-1 L1) proliferation marker (Chatterjee et al, 2008; Oda et al, 1998; Oda et al, 
2003). Reduced YB-1 expression has been reported to induce apoptosis or reduce cell 
proliferation in a number of in vitro (Basaki et al, 2010; Chatterjee et al, 2008; 
Cobbold et al, 2010; Dhillon et al, 2010; Gao et al, 2009; Lasham et al, 2003; Lasham 
et al, 2012; Lee et al, 2008; Shiota et al, 2011; Wu et al, 2006) and in vivo studies 
(Basaki et al, 2010; Gao et al, 2009; Jurchott et al, 2010; Lasham et al, 2012; Shiota et 
al, 2011; Yu et al, 2010). YB-1 has been observed to promote cell proliferation 
through its activities as a transcription factor, where it induces the expression of 
several growth and proliferation promoting genes (Wu et al 2007).  
The transcriptional activity of YB-1 has been attributed in part to its 
phosphorylation at the S102 residue, which was observed to increase the production 
of proteins regulating cell proliferation and oncogenic transformation (Evdokimova et 
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al, 2006; Sinnberg et al, 2012). YB-1 is thought to induce the expression of several 
growth and proliferation-associated genes such as Protein-Tyrosine Phoshpatase 1B 
(PTP1B), DNA topoisomerase II α, DNA polymerase α, and PCNA (Asakuno et al, 
1994; En-Nia et al, 2005;Fukada and Tonks, 2003;Mertens et al, 1997;Mertens et al, 
1997;Mertens et al, 1999;Oda et al, 2003;Yoshimatsu et al, 2005). It can also 
upregulate the expression of proliferation promoting genes such as the EGFR gene, 
the mitosis regulating factor Cell Division Cycle 6 (CDC6) gene, and the cell cycle 
promoting cyclin A and B1 genes (Basaki et al, 2010; Berquin et al, 2005; Jurchott et 
al, 2003; Stratford et al, 2007).  
More recently, YB-1 was observed to be involved in the transcription of 
several genes of the E2F pathway, co-regulating target E2F genes and upregulating 
cell growth and proliferation (Lasham et al, 2012). Microarray data suggest YB-1 
upregulates the E2F1, E2F2, and E2F3 proliferation promoting transcription factors, 
and inhibits the E2F5 and E2F7 proliferation repressors, in a cell type specific manner 
(reviewed by Lasham et al, 2013). YB-1 can upregulate the expression of E2F1 
(proliferation activator) in A549 lung cancer cells, and can bind the promoters of the 
E2F2 (proliferation activator) and E2F5 (proliferation repressor) genes in MCF7 
breast cancer cells (Lasham et al, 2012). It can bind the promoters of the E2F2 and 
E2F3 proliferation activators in SUM149 breast cancer cells, as well as the promoter 
of the E2F7 proliferation repressor (Finkbeiner et al, 2009). Moreover, YB-1 
knockdown was observed to increase E2F7 expression in SKOV-3 ovarian cells 
(Basaki et al, 2007).  
YB-1 is also involved with the PI3K-AKT-mTOR cell growth and division 
pathway (Lyabin et al, 2012), and is reported to require phosphorylation by 
downstream kinases of this pathway such as AKT kinase or Ribosomal S6 Kinase 
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(RSK), to translocate to the nucleus and become transcriptionally active (Davies et al, 
2014; Imada et al, 2013; Stratford et al, 2007). Additionally, phosphorylation by AKT 
reduces YB-1’s cap-dependent translational repression of proliferation (Evdokimova 
et al, 2006). The YB-1 protein can downregulate, through cap-dependent translational 
inhibition, several growth and proliferation promoting genes including G1/S and 
mitotic cyclins such as cyclins A2, B1, D1, D3, and E1 (Evdokimova et al, 2009). 
This translational inhibition is inhibited by S102 phosphorylation (Evdokimova et al, 
2006), revealing the importance of post-translational regulation on YB-1 function. 
Studies have also shown the interdependence of YB-1 and the PI3K-AKT-mTOR 
pathway, where YB-1 was found to upregulate Phosphatidyl Inositol 3-Kinase 
Catalytic Alpha (PI3KCA) expression, acting as a positive feedback mechanism for 
the pathway (Astanehe et al, 2009). On the other hand, a reduction in PI3K expression 
was observed to reduce expression from a cloned YB-1 gene (Sinnberg et al, 2012). 
Furthermore, a reduced expression of YB-1 has also been observed to result in a 
reduction of mammalian Target Of Rapamycin (mTOR) expression (Lee et al, 2008). 
YB-1 is also involved with the RAS-RAF-MEK-ERK pathway, a PI3K-AKT-mTOR 
interrelated and interactive pathway that promotes cell proliferation and migration (as 
discussed earlier) (reviewed by Lasham et al, 2013). This pathway will be discussed 
further in chapter six. 
In addition to the effects YB-1 induces on proliferation, reduced YB-1 
expression was accompanied by the downregulation of genes involved in cell 
proliferation and survival (e.g. Cyclin D1, Bcl-2) and resulted in an upregulation of 
apoptosis (Schittek et al, 2007). YB-1 can also promote cell proliferation indirectly by 
evading the tumour-suppressing activities of the cell, therefore allowing unrestricted 
proliferation (reviewed by Lasham et al, 2013, and Lyabin et al, 2012). By 
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transcriptionally activating cyclin D1, and controlling the transcription of CDK1 and 
CDK2 (Basaki et al, 2010; Harada et al, 2014), YB-1 indirectly results in RB 
hyperphosphorylation through cyclin-CDK kinase activity, and additionally drives the 
expression of S-phase genes by upregulating the E2F1 transcription factor (Lasham et 
al, 2012), thus allowing proliferation to continue. YB-1 also inhibits p53 transcription 
of its p21 target gene (Okamoto et al, 2000), thus inhibiting cell senescence while 
promoting cell survival, and allowing further proliferation.  
The proliferation promoting properties of YB-1, coupled with its evasion of 
tumour-suppressors, drive tumour proliferation further with important consequences 
to tumorigenesis.  
1.10. YB-1 is implicated in metastasis 
YB-1 has been implicated in the development of another hallmark of cancer, 
metastasis (Wang et al, 2015). It has been described as a driver of cell migration and 
invasion, two major processes required for metastasis (Evdokimova et al, 2009; 
Schittek et al, 2007; van Zijl et al, 2011). A recent study reported that YB-1 and the 
GOLgi PHosphoprotein 3 (GOLPH3) protein were elevated in glioblastomas, where 
GOLPH3 increased cell migration and invasion via the mTOR-YB-1 pathway (Zhou 
et al, 2014). Another study revealed that an siRNA knockdown of YB-1 in gastric 
cancer cells significantly inhibited migration and invasion in vitro (Guo et al, 2013).  
YB-1 has been observed to activate the transcription of several genes 
implicated with tumour invasion and metastasis, such as the Matrix Metalloproteinase 
genes MMP-2, MMP-12, and MMP-13 (Cheng et al, 2002; Sarkar et al, 2004; Samuel 
et al, 2007; Shapiro et al, 1999). The MMP proteins are key enzymes required for the 
degradation of the extracellular matrix during cell invasion (reviewed by Pengfei et al, 
2011). YB-1 can also bind gene promoters of the Wnt pathway, which are major 
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regulators of cell migration (Finkbeiner et al, 2009). For example, it has been reported 
to bind the Wnt11 gene, a known activator of the c-Jun N-terminal Kinase (JNK), 
which leads to the activation of migration regulators (Rho-family GTPase activation), 
cell polarisation, cytoskeletal remodelling, as well as cell migration (Nishita et al, 
2006; reviewed by Petrie et al, 2009). It was also found to upregulate the transcription 
of the CD44 adhesion molecule, which is implicated in metastasis, and additionally 
promotes its alternate splicing to include an exon (exon 4) that results in a gene 
variant (CD44v4) that further promotes tumour cell invasion (Hiraga et al, 2013; 
Spiegelberg et al, 2014; Stickeler et al, 2001; To et al, 2010; Zen et al, 2008).  
Along with its activities as a transcription and splice factor, YB-1 has also 
been shown to induce migration through its activities as a translation factor 
(Evdokimova et al 2009; Mertens et al, 1998). It has been observed to affect migration 
by influencing several EMT promoting genes (Evdokimova et al, 2009; Khan et al, 
2014). YB-1 can downregulate epithelial cell markers such as E-cadherin, Zona 
Occludens 1 (ZO-1), CytoKeratin 18 (CK18), and MUCin 1 (MUC1), and promote 
the upregulation of mesenchymal markers such as fibronectin, vimentin, α-Smooth 
Muscle Actin (SMA), CytoKeratin 14 (CK14), and tumour protein p63 (Evdokimova 
et al, 2009; Khan et al, 2014). It was also found to translationally upregulate several 
EMT promoting genes including SNAIL homolog 1 (SNAIL1), Twist homolog-1 
(Twist1), and Hypoxia-Inducible Factor 1-alpha (HIF1α), all of which are implicated 
in tumour invasion and metastasis (Evdokimova et al, 2009; Kudo-Saito et al, 2009; 
Yang and Wu, 2008; Yang et al, 2008).  
YB-1 has been described to affect several hallmarks of cancer (reviewed by 
Lasham et al, 2013), with cell proliferation and metastasis being the most proclaimed 
among the literature. The only form of YB-1 protein regulation widely-attributed to 
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the effects observed with these many pathways and processes is phosphorylation, 
which is reported to activate YB-1 nuclear localisation and drive the transcription of 
several oncogenes implicated with increased proliferation and migration (Wu et al, 
2007). This phosphorylation of YB-1 at serine 102 (p-YB01102) also remains the only 
characterised YB-1 phospho-modification reported to be involved with proliferation, 
migration, and invasion (Sinnberg et al, 2012; Wu et al, 2007). The possible 
involvement of other phosphorylation modifications in these processes is partly 
addressed in this thesis. 
Phosphorylation has also been implicated in YB-1 nuclear localisation 
(discussed below). Some of the known mechanisms of YB-1 nuclear localisation will 
be discussed in the following subsections. 
1.11. Mechanism of nuclear translocation 
YB-1 is hypothesised to translocate to the nucleus in response to genotoxic 
stress (Fujita et al, 2005). Cytotoxic drugs such as actinomycin D and paclitaxel (see 
section 1.8.2), and genotoxic stress-inducing agents such as UV radiation, have all 
been implicated in inducing the nuclear translocation of YB-1  (Bargou et al, 1997; 
Cohen et al, 2010; Fujita et al, 2005; Oda et al, 2003; Oda et al, 1998). Hypothermia 
was also described to induce YB-1’s nuclear translocation, indicating that other 
stressful events may also play a role (Stein et al, 2001). Nevertheless, nuclear 
translocation in response to cytotoxic drugs is of major concern to cancer therapy, as 
these drugs are commonly used as chemotherapy agents in the treatment of cancer 
(Luqmani et al, 2005). Treatment with some chemotherapy drugs may therefore 
increase the oncogenic transcriptional activity of YB-1. However, studies claiming to 
specifically observe nuclear YB-1 have come in to question, given the observed cross-
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reactivity of many commercially available anti-YB-1 antibodies with the protein 
hnRNP A1, which also resides in the nucleus (Cohen et al, 2010; Sorokin et al, 2005).  
It was previously proposed that the proteolytic cleavage of full-length YB-1 
induced the nuclear translocation of a truncated ‘activated’ nuclear form of YB-1 
(Sorokin et al, 2005). It has now been verified that the proposed cleaved nuclear form 
of YB-1 is in fact another protein, detected erroneously by many studies due to 
antibody cross-reactivity (Cohen et al, 2010). The proteolysis model is discussed in 
the following subsection.  
1.11.1. Proteolysis model 
In GFP-fused YB-1 deletion mutants, it was observed that only mutants with 
C-terminal deletions translocated to the nucleus with or without genotoxic stress (UV 
radiation), indicating the importance of the C-terminal region in the regulation of 
cytoplasmic retention (Fig.1.8) (Koike et al, 1997). Additionally, GFP-YB-1 fusion 
proteins were also reported to translocate to the nucleus of thrombin-stimulated 
endothelial cells after proteolytic cleavage within the C-terminal domain (Stenina et 
al, 2000). During thrombin activation, YB-1 was described to undergo cleavage, 
yielding a 30-kDa NH2-terminal fragment that recognised the thrombin-response 
element sequence, but not the Y-box consensus sequence. Incubation of these 
endothelial cells with Protein Tyrosine Phosphatase (PTP) inhibitors completely 
inhibited the formation of what was thought to be ‘activated’ nuclear YB-1 (i.e. 
truncated YB-1), along with the inhibition of promoter activation by thrombin. 
The proposed activation of nuclear YB-1 by protein cleavage was reported to 
be carried out by the 20S Proteosome, through the sequence-specific endoproteolytic 
cleavage between amino acids 219 and 220 of YB-1 (Sorokin et al, 2005). The 
cleavage was said to activate YB-1, and mediate its nuclear translocation by removing 
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the C-terminal fragment containing the CRS (Fig.1.8). Sorokin et al (2005) also 
reported that the association of YB-1 with mRNA prevented this cleavage, and that 
only unbound mRNA-free YB-1 was targeted. 
This proposed mechanism of YB-1 activation, where the cleavage of full-
length unbound YB-1 results in a distinct activated nuclear species of YB-1, is known 
as the proteolysis model. However, there have been inconsistencies associated with 
this model, such as the lack of a decrease of full length YB-1 expression with YB-1 
knockdown, or the lack of the proposed proteolytic cleavage after treatment with 
paclitaxel or cisplatin (Cohen et al, 2010). The discrepancies in the literature have 
been suggested to be partly due to the aberrant electrophoretic mobility of YB-1; its 
molecular mass is 35.9 kDa, but its observed electrophoretic mobility is ~48 kDa, and 
the proposed cleaved form migrates at ~37 kDa (Cohen et al, 2010; Sorokin et al, 
2005). 
However, Cohen et al (2010) showed using protein purification and mass 
spectrometry that the proposed cleaved YB-1 protein (i.e. ‘activated’ YB-1) was in 
fact another protein known as Heterogeneous Ribonucleoprotein Particle A1 (hnRNP 
A1). This was a consequence of antibody cross-reactivity, and a lack of proper 
antibody validation in many previous studies (see section 1.6). This issue has called 
into question many previous claims associating tumorigenesis strictly with a nuclear 
form of YB-1. The lack of confocal analysis of the immunofluorescence images may 
also play role. Regardless, the regulation of YB-1 cellular localisation remains an 
important issue in understanding YB-1 functions, and how it affects tumorigenesis.  
1.11.2. The regulation of YB-1 nuclear translocation 
Processes that regulate the localisation of YB-1 may have relevance to its 
behaviour as an oncogene. YB-1 was described to translocate to the nucleus during 
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the G1-S transition phase, in a cell cycle-dependent manner, indicating a cell cycle 
dependent regulation of the localisation status of YB-1 (Jurchott et al, 2003). 
Additionally, YB-1 has also been shown to repress p53 transcription in the nucleus, 
further implicating its localisation status with cell cycle progression (Okamoto et al, 
2000; Homer et al, 2005). Moreover, Zhang et al, (2003), observed that genotoxic 
stress induced the nuclear localisation of YB-1, but only in cells with wild-type p53. It 
was also reported that functional p53 was required for YB-1 to translocate to the 
nucleus, where p53 mutants were attenuated for the nuclear localisation of YB-1 
(Zhang et al, 2003). 
In another study, it was observed that the subcellular localisation of YB-1 was 
dependent on the SRp30c mRNA splicing protein (Raffetseder et al, 2003), 
suggesting YB-1’s nuclear translocation is associated with its mRNA alternative 
splicing function. Raffetseder et al (2003) showed, using confocal microscopy, that 
FLAG-tagged SRp30c induced the nuclear localisation of YB-1, whereas heat shock 
(i.e. recruitment of SRp30c to sam68 nuclear bodies) abrogated this co-localisation, 
where YB-1 would then translocate back to the cytoplasm. 
As described earlier, the phosphorylation status of YB-1 has also been 
implicated with its localisation status within the cell (Coles et al, 2005; Shabkin et al, 
2001; Stratford et al, 2008; Sutherland et al, 2005).  It was reported that the Protein 
Kinase C inhibitor H7 inhibited the nuclear translocation of YB-1 after treatment with 
UV radiation, suggesting its nuclear translocation could be mediated by protein kinase 
C (Koike et al, 1997). In addition, it was observed that a phosphorylation-defective 
mutation of YB-1 at Serine 102 inhibited its nuclear translocation (Sutherland et al, 
2005). However, this study lacked any confocal images, and more robust experiments 
would be needed to make such a claim (see chapter six discussion). YB-1 was also 
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found to be phosphorylated by AKT and RSK 1/2 kinase at the S102 residue, which 
was also described to be a requirement for its nuclear localisation and activation of 
transcription (Coles et al, 2005; Shabkin et al, 2001; Stratford et al, 2008; Sutherland 
et al, 2005). 
The localisation of YB-1 remains an issue in need of investigation. The 
reported involvement of phosphorylation in YB-1 localisation (Wu et al, 2007), as 
well as proliferation and migration (see sections 1.9 & 10), reveal the importance of 
this mode of regulation on YB-1 functions and on tumorigenesis. 
1.12. Scope of thesis 
Immunohistochemical analyses of a variety of drug-resistant cancers and cell-
lines have suggested a relationship between YB-1 and tumour malignancy and drug 
resistance (Dahl et al, 2009; Gluz et al, 2009; Janz et al, 2002; Oda et al, 2003; 
Shibahara et al, 2001). However, as discussed above, much remains to be resolved 
about the many conflicting observations reported from different studies (Woolley et 
al, 2011; reviewed by, Kosnopfel et al, 2014).  
As detailed in this thesis, seven distinct phosphorylation residues on YB-1 
derived from A549 lung cancer cells have been identified. Given the importance of 
YB-1 phosphorylation on its cellular localisation and functions (Coles et al, 2005; 
Shabkin et al, 2001; Stratford et al, 2008; Sutherland et al, 2005; Wu et al, 2007), the 
significance of these phosphorylation sites in the regulation of YB-1 driven-
tumorigenesis remains to be explored. The general goal of this study was to 
functionally characterise YB-1 phosphorylation and determine its significance on 
tumour malignancy. The specific aims of this project were: (1) To purify and 
characterise the phosphorylation status of cytoplasmic and nuclear YB-1 by mass 
spectrometry; (2) To characterise their phosphorylation profiles under normal 
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conditions and after treatment with a variety of genotoxic agents; (3) To determine the 
significance of phosphorylation on YB-1 localisation and YB-1 driven cell 
proliferation and migration (hallmarks of cancer), using phosphorylation-defective 
mutants. 
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2.0. Materials and methods 
2.1. General reagents 
Table 2.1. A list of general reagents used in this study 
Reagent Supplier Catalogue number 
10,000-1000 kb ladder 
Acetonitrile 
 
Acrylamide/bis solution (30%) 
Ammonium bicarbonate 
(NH4HCO3) 
Ammonium chloride (NH4Cl) 
Ammonium hydroxide (NH4OH) 
Ammonium PerSulfate (APS) 
Ampicillin 
Blue/Orange 6× loading dye 
Bromophenol blue 
Complete EDTA-free complete 
protease inhibitor cocktail 
Bovine Serum Albumin (BSA) 
1,4-DiAzaBiCyclo[2.2.2.]Octange 
(DABCO) 
4’,6-DiAmidino-2-PhenylIndole 
dihydrochloride (DAPI) 
DiMethyl SulfOxide (DMSO) 
DiThioThreitol (DTT) 
DpnI 10 U/µL 
Dulbecco's Modified Eagle 
GeneRuler 
Honeywell Burdick & 
Jackson 
Bio-Rad Laboratories, Inc. 
Sigma-Aldrich, Inc. 
 
Sigma-Aldrich, Inc. 
Sigma-Aldrich, Inc. 
Bio-Rad Laboratories, Inc. 
Sigma-Aldrich, Inc. 
Promega 
Bio-Rad Laboratories, Inc. 
Roche Applied Science 
 
Sigma-Aldrich, Inc. 
Sigma-Aldrich, Inc. 
 
Sigma-Aldrich, Inc. 
 
Sigma-Aldrich, Inc. 
MP Biomedicals LLC 
Promega 
Life technologies 
SM0331 
0154 
 
161-0518 
A6141 
 
A9434 
221228 
161-0700 
A9518 
G190A 
161-0404 
11873580001 
 
A2153 
D2522 
 
D9542 
 
D2650 
02100597 
R623A 
11965-092 
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Medium (DMEM) 
Ethylene DiamineTetra Acetate 
(EDTA) 
Ethanol (Absolute) 
Foetal Bovine Serum (FBS) 
Formic acid (88%) 
Formaldehyde (37%) 
Glycine 
Glycerol 
Hydrochloric acid (HCl) 
Isopropanol 
Kanamycin 
LB-medium, Lennox 
LB-agar, Lennox 
Lipofectamine RNAiMAX™ 
Transfection Reagent 
ß-mercaptoethanol 
Magnesium sulphate (MgSO4) 
Methanol 
Neon™ Transfection System 100 
µL kit 
Phosphate buffered saline (PBS) 
tablets 
KAPA HiFi PCR Kits 
Phenyl Methyl Sulfonyl Fluoride 
(PMSF) 
Porcine trypsin 
 
Amresco Inc. 
 
Merck Pty. Ltd. 
Life technologies 
Sigma-Aldrich, Inc. 
Chem-Supply 
Amresco Inc. 
Ajaz Finechem Pty. Ltd. 
Merck 
BDH Laboratory Supply 
Sigma-Aldrich, Inc. 
MP Biomedicals, LLC 
MP Biomedicals, LLC 
Life Technologies 
 
Sigma-Aldrich 
Sigma-Aldrich 
Merck Pty. Ltd. 
Life Technologies 
 
MP Biomedicals LLC 
 
KapaBiosystems 
Sigma-Aldrich 
 
Promega 
 
0105 
 
901449020 
26140-079 
399388 
FA010 
0167 
242 
6.10307.2511 
103456A 
K4000 
3002-132 
3002-332 
13778-100 
 
M7154 
M7506 
4102329020 
MPK10025 
 
92810305 
 
KK2102 
P7626 
 
V5111 
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Pre-stained SDS-PAGE standard 
(Broad range) 
QIAquick® gel extraction kit 
Roswell Park Memorial Institute 
medium (RPMI) 
Sodium chloride (NaCl) 
Sodium phosphate, dibasic 
(Na2HPO4) 
Sodium Dodecyl Sulphate (SDS) 
TetraMethylEthyleneDiamine 
(TEMED) 
TriFluoroAcetic acid (TFA) 
Tris(hydroxymethyl)aminomethane 
Triton X-100 
Trypsin-EDTA (0.05%) 
Tween 20 
Ptoassium phosphate, monobasic 
(KH2PO4) 
Wizard® Plus Midipreps DNA 
Purification System 
10× Tris/Glycine/SDS buffer 
Bio-Rad 
 
Qiagen 
Life Technologies 
 
Ajax Finechem Pty. Ltd. 
Sigma-Aldrich 
 
Bio-Rad Laboratories, Inc. 
Bio-Rad Laboratories, Inc. 
 
Sigma-Aldrich 
Bio-Rad Laboratories, Inc. 
Merch Pty. Ltd. 
Life Technologies 
Sigma-Aldrich 
Sigma-Aldrich 
 
Promega 
 
Bio-rad 
161-0318 
 
28706 
22400 
 
465 
71636 
 
161-0416 
161-0800 
 
299537 
161-0719 
1086031000 
25300120 
P1379 
P9791 
 
A7640 
 
161-0772 
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2.2. Cell-lines 
All cell-lines used in this study are outlined in Table 2.2. Cell lines were authenticated 
at Cell Bank Australia as soon as received, and re-authenticated if used for over six 
months. 
Table 2.2. Outline of cancer cell-lines used in this study including tissue of origin, 
cancer type, and cell morphology. 
Cell-line Organ of origin Cancer type Cell Morphology 
A549 Lungs Carcinoma Epithelial 
HCT116 Colon Carcinoma Epithelial 
Saos-2  Bone Sarcoma Epithelial 
 
2.3. Drugs 
All drugs used in this study are outlined in Table 2.3 & 4.  
Table 2.3. Antibiotics used to select for transformed bacteria 
Drug Mode of action Supplier 
Ampicillin Inhibits transpeptidase and 
prevents cell wall 
formation 
Sigma-Aldrich, Inc. 
Kanamycin Interacts with prokaryotic 
30S ribosome and 
interferes with protein 
synthesis 
Sigma-Aldrich, Inc. 
 
 
Table 2.4. Drugs used to induce apoptosis in human cell-lines 
Drug Mode of action Supplier 
Cisplatin Cross-links guanosine 
DNA bases on opposing 
strands and prevents DNA 
replication* 
Sigma-Aldrich, Inc. 
Doxorubicin Inhibits Topoisomerase II 
and prevents DNA 
replication* 
Sigma-Aldrich, Inc. 
MiTMAB Inhibits Dynamin II and 
prevents endocytosis 
Sigma-Aldrich, Inc. 
*Results in genotoxic stress 
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2.4. Antibodies 
Table 2.5. A list of antibodies utilised in this study. 
Antibody dilution always 1:1000 unless specified otherwise 
2.4.1. Purification of N-terminal anti-YB-1 polyclonal sheep antibody  
First, a 1 mL Affi-Gel 10 bead slurry solution (BioRad Affi-Gel 10 beads 
#1536046) was transferred into a 1.5 mL centrifuge tube on ice (0.5 mL slurry/0.5 mL 
beads = 7.5 mmol active ester), where the beads were allowed to settle to remove 
most of the storage alcohol. A chilled 2-mmol absolute peptide solution of ~2.5 mg 
dry YB-1 antigenic peptide/100 µL HEPES-KOH buffer (1 M, pH = 7.9)/1 mL H2O 
was then added to the beads on ice. The peptide corresponds to epitope a 
Antibody Primary or 
Secondary 
Use Supplier Catalogue no. 
Polyclonal 
rabbit anti-
NYB-1 
(epitope a) 
Primary Immunofluoresence 
and western blotting 
In-house (Weini 
Ma) (Cohen et al, 
2010) 
- 
Polyclonal 
sheep anti-
NYB-1 
(epitope a) 
Primary Immunopurification 
and western blotting 
In-house (Tariq 
Al Jabry) 
- 
Polyclonal 
rabbit anti-
HA  
Primary Immunofluoresence 
and western blotting 
Sigma-Aldrich, 
Inc. 
H6908-2ML 
Polyclonal 
rabbit anti-ß-
tubulin  
Primary Western blotting Life 
Technologies 
PA1-16947 
Monoclonal 
rabbit anti-
BrdU 
antibody 
Primary Immunofluoresence Sigma-Aldrich, 
Inc. 
B8434-200UL 
Polyclonal 
donkey anti-
rabbit (FITC 
conjugated) 
Secondary Immunofluoresence Jackson 
ImmunResearch 
711095152 
Polyclonal 
donkey anti-
rabbit (Texas 
Red 
conjugated) 
Secondary Immunofluoresence Jackson 
ImmunResearch 
711075152 
Polyclonal 
donkey anti-
mouse (FITC 
conjugated) 
Secondary Immunofluoresence Jackson 
ImmunResearch 
715095150 
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(MSSEAETQQPPA) of the YB-1 protein, which will be used to capture and purify 
the N-terminal specific anti-YB-1 antibodies (see chapter three). The suspension was 
rotated at 4 °C overnight, which slowed the rate of H2O hydrolysis more than the 
favoured reaction of amide formation. Following overnight rotation, 100 uL of Tris-
HCl (1 M, pH 7.5) was then added to the solution to deactivate any remaining NHS 
ester. 
The prepared bead slurry was then transferred to a 15 mm fritted glass column, 
and washed once at room temperature with 50 mL of 0.1 M glycine (pH 2.5), and 50 
mL of 50 mM Tris-HCl (pH 7.5).  
Following preparations of the modified beads, the anti-YB-1 antibody sheep 
serum was prepared. To the serum (40 mL), 20 mM Tris-HCl (1 M, pH 7.5)/0.02% 
NaN3 (3% w/v) preservative was first added, and the serum was allowed to incubate at 
55 °C for 1 hour to inactivate proteases, then centrifuged at ~4000 ×g at 2 °C for 20 
minutes to pellet debris. The serum supernatant was then added in two 20-mL 
portions to the fritted glass column with the modified beads. Each 20-mL aliquot was 
rotated at room temperature for 2 hours and drained, before the column was washed 
with chilled buffers.  
 The modified beads with the trapped anti-YB-1 antibody, were first washed 
with 50 mL of 50 mM Tris-HCl (pH 7.5)/0.1% Triton X-100, followed by 100 mL of 
50 mM Tris-HCl (pH 7.5)/0.5 M NaCl/0.1% Triton X-100, and finally with 50 mL of 
TE buffer. These washes sufficiently removed non-specific antibodies. The trapped 
antibody was then eluted in 1 mL fractions of 0.1 M glycine (pH 2.5). Upon the 
addition of each 1 mL aliquot of glycine, the column was allowed to sit at room 
temperature for 5 minutes before elution by gravity. A total of 8 fractions were 
collected into Eppendorf tubes, each already containing 250 µL of HEPES-KOH (1 
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M, pH 8). The fractions were then pooled into 100 mL (~10 volumes) of exchange 
buffer (20 mM HEPES-KOH [1 M, pH 8]/200 mM K-Cl/1 mM EDTA/0.02% NaN3). 
These steps were then repeated for a second 40 mL aliquot of serum. The purified 
antibody was then concentrated in fractions using an Amicon Ultra centrifugal filter 
(MWCO = 3,000, #UFC900308), and centrifuged at 1,000 ×g for 20 minutes at a 
time, to remove a total of ~15 mL of excess buffer.  The antibody was finally 
concentrated to two ~1.5 mL fractions. A sample of 2 µL was taken from each 
fraction to determine yields by UV spectrometry on NanoDrop, where 1 OD280 nm = 
~0.75 mg/mL antibody (Harlow and Lane, 1999). The A280 O.D. readings and 
concentrations of each fraction of recovered antibody are illustrated in Table.2.6. 
Table 2.6. NanoDrop A280 readings of purified antibody preparations.  
Purified antibody 
fraction 
A280 O.D. reading Concentration mg/mL 
I-2a 6.7 5 
I-2b 6.6 4.9 
 
2.5. Human cell culture methods 
2.5.1. Propagation and harvesting of cell-lines 
A549, HCT116, and Saos-2 cells were maintained in Dulbecco's Modified 
Eagle Medium (DMEM), supplemented with 10% Foetal Bovine Serum (FBS). All 
cells were grown at 37 °C in a humidified incubator with 5% CO2 with a humidified 
atmosphere. To transfer or harvest cells, the media was first removed, and the cells 
were washed once with Phosphate Buffered Saline (PBS) to eliminate excess media. 
Trypsin-EDTA was then added to the culture to allow the release (detachment) of 
cells from the culturing surface.  The cells were then resuspended in 5× volume of 
DMEM (10% FBS) in order to neutralise the trypsin, and the media carrying cells 
were transferred to a new culturing flask (BD Falcon®) or harvested. 
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2.5.2. Freezing and storage of cell-lines 
The required number of cells (~1 million) were harvested and resuspended in 
5 mL of [90% FBS v/v and 10% v/v DMSO]. Resuspended cells were then aliquoted 
into 5 cryovials (1 mL each). The vials were rapidly frozen in liquid nitrogen (-196 
°C), and stored at -80 °C. 
2.5.3. Thawing of cell-lines 
Frozen cryovials of cells were thawed at 37 °C in a water bath. Pre-warmed 
(37 °C) DMEM (1 mL) was then added to the thawed cells, and used to uptake the 
cells. The media containing cells were added to 10 mL of media (10% FBS) in a 50 
mL Falcon® tube. The cells were then spun down at 500 ×g for 10 minutes to remove 
traces DMSO.  The media containing the DMSO was aspirated off and the cell pellet 
was resuspended in 5 mL of fresh medium. The media containing cells were used to 
seed the appropriate tissue culture flask (depending on experiment) and allowed to 
grow in a 37 °C incubator (5% CO2). 
2.5.4. siRNA knockdown 
2.5 × 105 cells were seeded per well in a 6 well plate.  The cells were then 
transfected 24 hours later with the appropriate siRNA/Lipofectamine® complex (Life 
Technologies, catalogue #13778030), according to recommended manufacturer 
guidelines, as outlined in Table 2.7. Cells were harvested 96 hours (4 days) post 
transfection unless stated otherwise. For control knockdowns, cells were transfected 
with a control (“scrambled” sequence) standard siRNA (Life technologies AM4611). 
The manufacturer did not specify the nucleotide sequence. The anti-YB-1 siRNA 
sequence 5’-GGUCCUCCACGCAAUUACCAGCAAA-3’ was used for chapter three 
experiments. For chapter five experiments, the specific nucleotide sequences of 
siRNA-4 (Qiagen catalogue #SI04233684), siRNA-7 (Qiagen catalogue 
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#SI05060076), and siRNA-8 (Qiagen catalogue #SI05060083), were not specified by 
the manufacturer. 
Table 2.7. Lipofectamine® RNAiMAX transfection reagent preparation for the 
knockdown of YB-1 (10 mL plate). 
Per plate Amount 
DMEM Media (serum free) 2 mL 
siRNA duplex 150 pmoles 
Lipofectamine™ 2.5 µL siRNA/Lipofectamine	complex	incubated	for	20	minutes	before	added	to	cells		
2.5.5. Drug treatment of cell-lines 
Drugs used are listed in Table 2.4. All drugs were prepared in DMSO 
(working concentrations stated in the results section). 
2.6. Molecular methods 
All solutions were prepared using MilliQ® ultrapure deionised water and 
when required, sterilised by filtration or autoclaving.  
2.6.1. PCR amplification 
A general PCR mutagenesis protocol is outlined in Table 2.8. Phosphorylation 
mutants were generated from a wildtype YB-1-HA cDNA, using mutagenesis primers 
(Table 2.9). All plasmids including YB-1-HA were generated in pcDNA3.3 plasmids. 
Amplifications of mutants were performed using a KAPA HiFi DNA polymerase 
(KAPA HiFi PCR kit #KK2502). A list of mutagenesis primers used in this study is 
listed in Table 2.9.  
Table 2.8. YB-1 mutagenesis PCR protocol. 
Cycling step Duration and 
temperature 
Cycles 
Initial denaturation 2 minutes at 95˚C  ×1 
Denaturation 20 seconds at 98˚C  
×35 cycles Annealing 15 seconds at 55-60˚C 
Extension 3.15 minutes at 72˚C 
Final extension 1 minute at 72˚C ×1 
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Table 2.9. YB-1 mutagenesis primers*. 
Primer name Sequence 
S174-176A Fwd. 5’-GCGGAGGCTGCTCCCGAAGGCCAGGCCC-3’ 
S174-176A Rev. 5’- AGCCTCCGCTCCCTCGTTCTTTTCCCCACTCTCACT-3’ 
T271A Fwd 5’-GCCCAAGGTCAGCAGCCACCTCAA-3’ 
 T271A Rev. 5’-CCGTTACTTCTTCTATTTCTTTTAGTTCCTCTACTCC-3’ 
* S102A-HA, S165A-HA, S167A-HA, S174A-HA, and S176A-HA YB-1 mutant 
constructs generated by Rhodri Harfoot at the Braithwaite CTU laboratory, 
Pathology department, University of Otago.  
2.6.2. Restriction enzyme digestion and electrophoresis  
Standard restriction enzyme digestion methods were performed for all digests 
(Sambrook and Russell, 2001). All restriction enzymes and buffers used in digestions 
were obtained from either New England BioLabs or Promega. Restriction enzyme 
digestions of plasmid preparations, and all other DNA were also performed according 
to guidelines specified by the manufacturer (New England BioLabs or Promega). 
DNA fragments from digestions were separated and analysed by agarose gel 
electrophoresis. Gels were run in 1× Tris-Acetate-EDTA (TAE) running buffer at 400 
mA (100 V) for 60-120 minutes. All gels consisted of 1% agarose in 1× TBE buffer, 
with 2.5 uL of ethidium bromide per 50 mL of gel (10mg/mL).  
2.6.3. In-fusion recombination of PCR-amplified mutagenesis product 
10 µg of YB-1 mutagenesis PCR product was digested with DpnI to remove 
any non-PCR generated wildtype YB-1 template DNA. The DpnI restriction enzyme 
only digests and fragments methylated DNA. PCR generated DNA is unmethylated, 
whereas template DNA propagated in, and harvested from bacteria (midiprep), is 
heavily methylated. After the complete digestion of template DNA, the PCR 
generated mutants were set-up for in-fusion reactions (Clonetech In-fusion® HD 
Mutagenesis). In-fusion recombination was used to convert linearised PCR products 
into circularised plasmids. The reaction was set up according to manufacturer 
guidelines, with ~200 ng (1 or 2 µL) of the PCR product, 2 µL of the in-fusion 
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enzyme (concentration of enzyme not specified at the time by manufacturer), and was 
brought up to 10 µL total volume with MilliQ H2O. Samples were incubated for 15 
minutes at 50 ºC to allow the in-fusion reaction to take place. Recombinant mutant 
plasmids were then used to transform competent cells for plasmid-DNA propagation.  
From each reaction, 1 µL of the reaction DNA-mixture was taken up and 
added to a 14-mL polypropylene Falcon tube on ice (0˚C). 100 µL of Invitrogen 
DH5α-competent cells (Invitrogen 18265-017) was then added to the DNA from each 
reaction and mixed gently. Samples were incubated on ice for 30 minutes, and heat 
shocked for 30 seconds at 42 °C, followed by another incubation on ice for 2 minutes. 
1 mL of Luria Broth (LB) medium (Table 2.10) was then added to the transformed 
bacteria, and cultures were agitated at 200 rpm at 37 °C, for 1 hour. The cultures were 
then spread onto LB agar-ampicillin plates (100 µg/mL ampicillin) (Table 2.11), and 
incubated at 37 °C overnight. Approximately 24 hours later, single colonies were 
picked for every mutant and were expanded for midipreparations. 
Table 2.10. Constituents of 1 litre of Luria Broth medium. 
LB medium constituents 
Bacto tryptone (Amyl Media) 10 g 
Bacto yeast extract (Amresco) 5 g 
NaCl (Amresco)  10 g 
MilliQ® ultrapure deionised H2O 1 L 
 
 
Table 2.11. Constituents of 1 litre of Luria Broth agar. 
LB Agar 
Bacto agar (Spectrum) 12 g LB medium  12 g 
LB medium  1 L 			  
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2.6.4. Plasmid transformation 
As in section 2.6.3. 
2.6.5. Propagation and Preparation of plasmid DNA  
After plasmid DNA had been transformed into bacteria, single colonies grown 
on agar plates were picked and each used to inoculate 10 mL of LB-Amp/Kan (100 
µg/mL ampicillin or 50 µg/mL kanamycin depending on plasmid type). Samples were 
incubated at 37 °C with agitation at 250 rpm for 12-16 hours.  The 10 mL cultures 
were then used to seed 100 mL of LB-Amp/Kan (100 µg/mL ampicillin or 50 µg/mL 
kanamycin), which was incubated at 37 °C with agitation at 250 rpm for another 12-
16 hours. DNA was extracted and purified using the Wizard® Plus midiprep DNA 
purification system, Promega, WI, USA (based on an alkaline lysis principle). 
Purified DNA was then subjected to spectrophotometry to determine the 
concentration and purity (NanoDrop ND-1000, NanoDrop Technologies, Delaware, 
USA). DNA was stored at -20 °C until use. For long-term storage, 500 µL of the 
originally transformed bacteria in broth was mixed with 500 µL (or 50% v/v) sterile 
glycerol and stored at -80 °C. 
2.6.6. Quantification of DNA 
The concentration* of plasmid DNA was determined by testing samples on a 
NanoDrop spectrophotometer (ND-1000, NanoDrop	Technologies, Delaware, USA) 
for ultraviolet irradiation absorbance at wavelengths of 260 nm and 280 nm, 
according to the Christian-Warburg protocol. A260:A280 ratio of 1.8-2.0 indicated 
highly purified DNA with minimal protein contamination. 
 
*DNA concentration (ng/µL) = A260 reading × dilution factor × 50 ng/µL constant 
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2.6.7. DNA sequencing 
To confirm the identity of the wildtype YB-1-HA and HA-tagged YB-1 
mutant plasmids, 200 ng of the purified plasmid was sent to the Australian	Genome	Research	Facility	(AGRF,	Westmead Millinium Institute, Australia). The DNA was 
sequenced using an AB 3730xl capillary based sequencing machine, and the resulting 
chromatogram analysis files were analysed with CodonCode Aligner™. The primers 
used to sequence the YB-1-HA and HA-tagged mutant plasmids are outlined in Table 
2.12. 
Table 2.12. YB-1-HA and HA-tagged mutant sequencing primers.  
Primer name Sequence 
CMV fwd. 5’-CGCAAATGGGCGGTAGGCGTG-3’ 
TK polyA reverse 5’-CTTCCGTGTTTCAGTTAGC-3’ 
102-176 Fwd 5’-CAACAGGAATGACACCAAGGA-3’ 
314 Fwd 5’-AAGACAGCCTAGAGAGGACG-3’ 
176 Rev 5’-TGACCTTGGGTCTCATCTCC-3’ 
102 Rev 5’-AACTGGAACACCACCAGGAC-3’ 
5' Rev 5’-CTTCGTTGCGATGACCTTCT-3’ 	
2.6.8. Transient transfections 
The Fugene®6 transfection reagent was first diluted in serum free DMEM, 
according to the manufacturer’s instructions (3:1 Fugene 6 to DNA ratio), and 
allowed to incubate at room temperature for 5 minutes (Fugene 6 Transfection 
reagent, Roche Applied Science, Germany). The plasmid DNA was then added to the 
Fugene 6/serum free DMEM solution and diluted to the desired concentration.  After 
a 15-minute incubation at room temperature, the plasmid DNA/Fugene 6 transfection 
mixture was then added to cells to be transfected (volumes and concentrations 
dependent on culture size, outlined in manufacturer instructions). Transfected cells 
were then incubated at 37 °C/10% CO2 for 48 hours, before harvest or analysis.  
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2.7.0. Protein: preparations and analysis methods 
2.7.1. Cell lysis 
Prior to cell harvest, cell lysis buffer was chilled on ice (20 mM HEPES-
KOH/300 mM KCl/2 mM MgCl2/10% Glycerol/0.1% Triton X-100). DiThioThreitol 
(DTT) was added to the buffer on the day of the experiment, and brought to a 
concentration of 1 mM (Table 2.13). Additionally, a cOmplete protease inhibitor 
cocktail pellet (Roche Applied Science, Germany), was dissolved in the buffer prior 
to harvest (1 pellet per 25 mL).  
Table 2.13. Preparation of 500 mL cell lysis buffer. 
Stock solution Mass/Volume Final concentration 
1 M HEPES-KOH 10 mL 20 mM HEPES-KOH 
2 M KCl 75 mL 300 mM KCl 
1 M MgCl2 1 mL 2 mM MgCl2 
100% Glycerol 62.5 g 10% Glycerol 
10% Triton X-100 5 mL 0.1% Triton X-100 
MilliQ deionised H2O Brought upto 500 mL MilliQ deionised H2O 
+ 1mM DTT/1 cOmplete, EDTA-free protease inhibitor tablet added to cell lysis 
buffer prior to experiment 
 
 
Cells were detached from the tissue culture flask/plate by the addition of 
trypsin, or scraping directly into chilled PBS (both methods were used for this 
project). Total harvested cells were then spun down for 5 minutes at 500 ×g, and 
resuspended in the chilled cell lysis buffer. Cells were pipetted up and down to ensure 
complete suspension of the cell pellet. For pulldown experiments, cells were left in 
the cell lysis buffer for an hour, and then sonicated for 10 seconds on ice at 100 Watts 
using a Branson Sonifier 250, followed by incubation on ice for 30 minutes. (Output: 
3.5, 30% duty cycle, Timer: hold). Lysates were spun down at 13, 000 ×g for 20 
minutes at 4 °C to remove cell debris. 
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2.7.2. Cytoplasmic and nuclear extract preparations 
All reagents were placed on ice beforehand (including Beckman JS-13.1 rotor 
centrifuge and polycarbonate centrifuge tubes, catalogue #363664). 50 mL of 
hypotonic buffer was prepared and chilled on ice (Table 2.14). 1mM DTT (1 M 
stock), 120 nM okadaic acid (600 M stock), and 20 nM calyculin (100 M stock), were 
also added to the buffer on the day of the experiment.  
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Table 2.14. Preparation of Hypotonic buffer (500 mL). 
Stock solution Mass/Volume Final concentration 
1 M HEPES-KOH 2.5 mL 5 mM HEPES-KOH, pH 8 
1 M MgCl2 0.5 mL 1 mM MgCl2 
2 M KCl 1.25 mL 5 mM KCl 
100% Glycerol 62.5 g 10% Glycerol 
+ 1mM DTT/120 nM Okadaic acid/20 nM Calyculin A/1 cOmplete, EDTA-free 
protease inhibitor tablet added to hypotonic buffer prior to experiment 
  
 Cells were first detached from the T225 cm2 tissue culture flask by the 
addition of trypsin. The total harvested cells (~500 x 106 cells) were spun down at 180 
×g, and resuspended in the chilled hypotonic buffer (106 cells/mL,). Cells were then 
pipetted up and down to ensure the complete resuspension of the cell pellet. The 
suspension was then incubated at 37 ºC for 30 minutes to allow cell swelling, and then 
transferred to ice to rapidly cool down before adding 0.5% Triton X-100 detergent to 
the buffer  (10% Triton X-100 stock). The cell suspension was mixed by vortex once 
for ~30 seconds and then replaced on ice. For lysis with homogenisation, suspensions 
were incubated at room temperature for 5 minutes, and transferred to a 40-mL Dounce 
homogeniser (Kontes 885300-0040) with a tight pestle (0.025-0.076 mm). Cells were 
lysed with ~10-20 strokes, and lysis was monitored under a light microscope. 
The cell lysate was then centrifuged at 228 ×g in a Beckman JS-13.1 rotor for 
10 minutes at 4 ˚C to isolate (pellet) nuclei.  The supernatant containing the 
cytoplasmic extract was then stored in 10 mL aliquots and snap frozen in liquid 
nitrogen (100 µL of the cytoplasmic samples were always set aside for SDS-PAGE 
analysis).  
The isolated nuclei pellet was then suspended in 5 mL of low-sucrose buffer 
(0.25 M sucrose/10 mM MgCl2), and approximately half of the sample was gently 
layered (poured gently) on top of a 5-mL cushion of high-sucrose buffer (0.88 M 
sucrose/0.5 mM MgCl2). The other half poured onto another 5 mL high sucrose 
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buffer cushion. Samples were then centrifuged (2800 ×g) at 4 ˚C to isolate clear 
nuclei pellets (debris-free). The preparations of low and high sucrose buffers were 
prepared as outlined in Tables 2.15 and 2.16 respectively. 
Table 2.15. Preparation of low sucrose buffer (500 mL). 
Stock solution Volume Final concentration 
2.55 M sucrose 50 mL  0.25 M sucrose 
1 M MgCl2 5 mL 10 mM MgCl2 
 
 
Table 2.16. Preparation of high sucrose buffer (500 mL). 
Stock solution Volume Final concentration 
2.55 M sucrose 173 mL 0.88 M sucrose 
1 M MgCl2 2.5 µL 0.5 mM MgCl2 
 
The nuclei pellet suspension was then centrifuged at 2800 ×g for 10 minutes at 
4 ˚C and then resuspended in 10 mL nuclear extract buffer (Table 2.17). The nuclear 
extraction suspension was then rotated at 4 °C for 30 minutes in a 4˚C cold room. 100 
µL of the nuclear extract was taken out for a western blot analysis. The remainder of 
the nuclear preparation was snap frozen in liquid nitrogen. 
Table 2.17. Preparation of nuclear extract buffer (500 mL). 
Stock solution Mass/Volume Final concentration 
1 M HEPES-KOH 10 mL 20 mM HEPES-KOH 
2 M KCl 75 mL 300 mM KCl 
1 M MgCl2 1 mL 2 mM MgCl2 
100% Glycerol 62.5 g 10% Glycerol 
10% Triton X-100 5 mL 0.1% Triton X-100 
+ 1mM DTT/120 nM Okadaic acid/20 nM Calyculin A/1 cOmplete, EDTA-free 
protease inhibitor tablet added to nuclear extract buffer prior to experiment 
2.7.3. Quantification of protein in cell lysates 
Protein concentrations of cell lysates were determined directly using 
Nanodrop 2000 UV-VIS, or a Bio-Rad protein assay kit (#500-0006).  From each 
sample 2 µL of cell lysate was taken out and measured directly on the Nanodrop 
2000, or diluted into 800 µL of MilliQ ultrapure H2O and 200 µL of Bio-Rad dye for 
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the Bio-Rad protein assay. The optical density was then measured at 595 nm of 
visible light using a spectrophotometer. The optical densities of 1, 2, 5 and 10 µg/mL 
of BSA were measured to generate a standard of concentration versus optical density. 
The optical density of each experimental sample was then measured and its 
concentration was determined from the standard curve. 
2.7.4. Resolving proteins on an SDS-PAGE gel 
Protein concentrations of each sample were either based on the number of 
cells per sample, or the protein levels determined as outlined in section 2.7.3. For 
sample preparation 2 × 105 cells per well (for lysates), or the required amount of 
protein, were prepared in 5× loading buffer and made up to 20 µL with MilliQ 
ultrapure H2O when required. Samples were then heated at 75 °C for 10 minutes to 
denature proteins, and equal amounts of each sample were then loaded onto the wells 
of a precast 10% Sodium Dodecyl Sulphate - PolyAcrylamide Electrophoresis Gel 
(Novex® NuPAGE SDS-PAGE gel system). The precast gels were purchased from 
Life technologies, and were run in a Bio-Rad mini-protein gel apparatus. Samples 
were prepared in 4× NuPAGE™ running buffer, 2 µL of DTT (1M), and brought up 
to 20 µL with MilliQ H2O. The proteins were resolved for 1 hour in 1× running buffer 
(NuPAGE® MOPS SDS running buffer NP0001) at 200 V. A Pre-stained Magic 
Mark™ XP Western protein standard (Life technologies #LC5602) was used as 
molecular size standard. 
For large-scale protein preparations, large stacking gels were used. A 40 mL 
lower gel (bottom half) solution was prepared from a stock solution (Table 2.18-19), 
and was then poured into and cast between two glass slabs of a large-protein gel 
apparatus from Bio-Rad. To prevent the formation of bubbles, the gel was overlaid 
with 95% ethanol (Cat. no. 901449020). The gel was allowed to set for an hour, and 
		 96	
the alcohol was then removed. A 20 mL upper gel solution was set up (Tables 2.20-
21), and poured on top of the lower gel cast. A 15-well comb was then inserted, and 
the upper gel was then allowed 15 minutes to set, before the combs were later 
removed. Electrophoresis was run for ~5 hours at 200 V in a 1× Laemmli’s 
electrophoresis buffer (Table 2.22). Samples run on large gels were prepared in a pre-
prepared sample buffer (Table 2.23). Before loading, samples were first heated at 75 
ºC for 10 minutes and then spun down for 1 minute. Bench Mark™ protein ladder 
(Thermo Fisher Scientific #10747-012) was used as a molecular size standard. 
To visualise proteins, gels were stained with Coomassie Brilliant Blue G-250 
dye overnight, followed by gel de-staining for 24 hours to remove background 
staining. 
Table 2.18. Preparation of a 1L 10× lower gel buffer. 
10× Lower gel buffer (filtered) 
454.3 g Tris base 
50 mL 20% SDS 
HCl to pH 8.8 
H2O to 1 L 
 
 
Table 2.19. Preparation of a 40 mL 10% lower gel. 
10% lower gel constituents (40 mL) 
4 mL 10× Lower gel buffer 
13.3 mL 30% Acrylamide 
22.2 mL dd H2O 
0.5 mL 30% APS (APS added just before pouring and addition of 
TEMED) 
20 µL TEMED (swirled around and poured immediately) 		 	
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Table 2.20. Preparation of a 1L 10× upper gel buffer. 
  10× Upper gel buffer (filtered) 
151.5 g Tris base 
10 mL 20% SDS 
HCl to pH 6.8 
H2O to 1 L 
 
 
Table 2.21. Preparation of a 20 mL 4% upper stacking gel. 
4% upper gel (20 mL) 
2 mL 10× upper gel buffer 
2.7 mL 30% acrylamide 
14.8 mL dd H2O 
0.5 mL 30% APS (APS added just before pouring and addition of 
TEMED) 
20 µL TEMED (swirl around and pour immediately) 
 
 
Table 2.22. Preparation of a 2 L 10× Laemmli’s electrophoresis buffer. 
10× Laemmli’s electrophoresis buffer 
58 g Tris base 
288 g Glycine 
100 mL 20% SDS 
H2O to 2 L 
 
 
Table 2.23. Preparation of a 4× SDS Sample buffer. 
4× SDS Sample buffer (10 mL) 
4 mL Glycerol 
4 mL 20% SDS 
600 mg DTT 
Trace bromophenol blue 
2.7.5. Western blotting 
Proteins resolved by SDS-PAGE (section 2.7.4) were transferred by 
electroblotting to a PolyVinylidene DiFluoride (PVDF) membrane (Amersham, GE 
Healthcare, UK). An XCell™ Blot Module and XCell SureLock® Mini-Cell 
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(#EI0002) were used for electroblotting with 1× NuPAGE® transfer buffer (NP0006) 
at 30 V for 1 hour. A list of antibodies used to detect electrophoresed proteins is 
outlined in Table 2.5.  
Protein detection was carried with the WesternBreeze™ Chemiluminescent 
Western Blot Immunodetection kit according to manufacturer’s instructions (Life 
technologies, USA). Chemiluminescent signal was detected using Kodak BioMAX 
MR Film (Cat #870-1307, Eastman Kodak, USA) or Fuji Super RX Film (Cat#47410 
1923, Fujifilm, Japan), using a Konica Minolta SRX101A developer (Konica Minolta 
Medical Imaging, USA). Digital detection and quantification was done using a 
Fujifilm ImageQuant LAS-4000 luminescence imager (Fujifilm, Japan). 
2.7.6. Optimisation of YB-1 immunopurification with the N-terminal anti-YB-1 
polyclonal sheep antibody with pulldown titration  
The I-2a sheep antibody stock was first diluted to 1 µg/mL in extract buffer 
(20 mM HEPES-KOH/300 mM KCl/ 2 mM MgCl2/10% Glycerol/0.1% Triton X-
100), and added to lysate samples increasing increments of concentration (outline in 
chapter three). Samples were allowed to rotate at 4 °C for an hour before the addition 
of 40 uL of Protein G beads (50% slurry composition). An additional hour of rotation 
was allowed to facilitate binding of the protein G beads to the antibodies. 
Lysate/Protein G suspensions were then collected in micro-spin columns under 
vacuum. The leftover beads, with bound antibody/YB-1 complexes, were then washed 
with 5 mL cold of wash buffer (20 mM HEPES-KOH/300 mM KCl/2 mM 
MgCl2/10% Glycerol/0.1% Triton X-100/1mM DTT) under vacuum to remove excess 
bound material. 
Each pulldown sample was then centrifuged for 10 seconds at 1,000 g to 
remove excess wash buffer, and then resuspended in 100 uL of elution buffer (20 mM 
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HEPES-KOH/2 mM MgCl2/100 mM NaCl/10% Glycerol/0.1% Triton X-100). The 
elution buffer contains excess antigenic peptide (MSSEAETQQPPA; 1 mM in 0.02% 
NaN3 = 2 nM), which was used to trap the antibodies and free captured YB-1 
proteins. Samples were then incubated at room temperature for 1 hour and vortexed 
every 15 minutes to speed up the elution of YB-1 from the antibodies. Elutions were 
then collected and spun for 10 seconds at 1,000 ×g, before analysis by western blot. 
To quantitatively analyse the intensity of each pulldown blot, protein blots 
were scanned using an LAS-4000 luminescent image analyser, and quantitated 
digitally. 
2.7.7. YB-1 immunopurification with the N-terminal anti-YB-1 polyclonal sheep 
antibody 
A total of 200 µg of antibody was added to each lysate sample (10 µg/mL lysate), 
for optimum pulldown with the sheep antibody. Samples were then allowed to rotate 
for 30 minutes at 4 °C, before the addition of 400 µL of Protein G beads (50% slurry 
composition) to each sample (i.e. 20 µL/mL). Samples were then allowed to rotate for 
an additional hour at 4 °C to allow the beads to react with the antibodies. Half of the 
preparation lysate/Protein G suspensions were then collected in micro-spin columns 
under vacuum, and washed with 5 mL cold wash buffer (20 mM HEPES-KOH/300 
mM KCl/2 mM MgCl2/10% Glycerol/0.1% Triton X-100/1mM DTT). This step was 
then repeated for the second half of the preparation.  
Columns holding the collected beads/antibody/YB-1 complexes, were then 
centrifuged for 10 seconds at 1,000 ×g to remove any remaining wash buffer. 500 mL 
of elution buffer containing the YB-1 antigenic peptide (MSSEAETQQPPA) was then 
added to each column (488 µL buffer per column + 12.5 nmol antigenic peptide), to 
trap the anti-YB-1 antibodies, and release the bound YB-1 protein. Each suspension 
		 100	
was rotated at room temperature for an hour, and collected by centrifugation at 1,000 
×g for 10 seconds. Finally, the immunoprecipitate volume was brought down to ~70 
µL by centrifugation in a 3,000 MWCO Amicon® Ultra membrane column at 14,000 
×g for 30 minutes. Lowering the immunoprecipitate volume allowed for an entire 
preparation to be loaded into a single well of an SDS-PAGE gel, as an extra YB-1 
enrichment step for mass spectrometry analysis 
2.8. Mass spectrometry  
2.8.1. Destaining of protein-gel stains 
Gel stains showing putative proteins of interest, visualised by Coomassie 
Brilliant Blue G-250 dye staining, were cut out and added to separate low bind 
eppendorf tubes containing ~120 µL of destaining solution each (50% [v/v] 
acetonitrile, 25 mM NH4HCO3, pH 7.8). The gel bands were then incubated in wash 
solution (0.1 % TFA) for 10 minutes at 37 ˚C.  The wash solution was then drained, 
and the destaining procedure was repeated a maximum of 3 times (until complete 
destaining was achieved). Gel pieces were then put on speed-vacuum for 15 minutes 
to dry and prepare for digestion. 
2.8.2. In-gel digestion of proteins 
To each dried gel piece, 8 µL of sequencing grade trypsin (15 ng/µL Promega, 
Cat. no. V5111 in 25 mM NH4HCO3, pH 7.8) was then added, and the gel pieces were 
allowed to swell for ~10 minutes. After swelling, 20-40 µL of 25 mM NH4HCO3, pH 
7.8 was then added to ensure the gel pieces were completely covered under solution. 
Samples were then incubated at 37 ˚C for ~16 hours (overnight) for digestion. 
  
		 101	
2.8.3. Extraction of digested peptides 
After overnight in-gel digestions, gel samples were spun down to concentrate 
the liquid at the bottom of the tube, and 20-30 µL of extract solution (10% [v/v] 
acetonitrile, 0.5 % [v/v] TFA) was then added to each sample. Samples were 
incubated for 15 minutes in a water bath sonicator at room temperature. All Extracted 
peptides were then pipetted into new tubes. Approximately 30-40 µL of additional 
extract buffer was then added to each gel sample to extract any remaining peptides, 
and gel samples were then re-sonicated for 15 minutes. After the second peptide 
extraction, gel slices were disposed of and the extracted peptides were then each 
separately pooled together for each sample, and placed in a speed-vacuum to dry ~30 
minutes.  The dried down samples were then resuspended in 30 µL 0.5% (v/v) TFA in 
water and purified using a C18 filter membrane plug. The C18 membrane was first 
cut out and packed into an Eppendorf GELoader tip using an SGE syringe tip (Part 
No. 038250). This column was then packed with a 3M Empore C18 filter membrane 
(Cat #2215 Sigma Supelco Cat #66883-U).  The Column was first activated with 30 
µL of activate/elute solution and equilibrated with 30 µL of wash solution. The 
resuspended peptides were then loaded onto the column and washed with 30 µL of 
wash solution (each sample had a separate column prepared). The peptides were then 
eluted with 5 µL of activate/elute solution. 
For phosphopeptide purification, eluted samples were dried down in a speed-
vacuum and resuspend in TiO2 loading buffer (1 M glycolic acid/80% [v/v] 
acetonitrile/5% [v/v] TFA) in preparation for further purification steps (explained 
below). 
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2.8.4. TiO2 purification of phosphopeptides  
For phosphopeptides, an additional step of purification (stage-tip clean-up) 
was required.  First an Eppendorf GELoader tip (Cat #0030 001.222) column was 
packed with a C8 Empore disc (Cat #2214 Sigma Supelco Cat #66882-U). The C8 
filter membrane plug was cut out and packed into the Eppendorf GELoader tip using 
an SGE syringe tip (Part No. 038250). 
The C8 packed tip was then packed with 1-3 mm (~3-5 µL) TiO2 resin (70% 
[v/v] acetonitrile, 0.5% [v/v] TFA). The tip was then washed with 30 µL of loading 
solution and the samples were loaded onto each column in 30 µL of TiO2 loading 
buffer (a separate column was setup for each sample). The columns were washed with 
5 µL of loading solution (wash flow-through pooled with main flow-through). The 
columns were then washed with 20 µL of TiO2 wash buffer (80% [v/v] acetonitrile, 
1% [v/v] TFA) and pooled with the main flow-through sample. Washes were repeated 
three times, and all flowthrough of non-phosphopeptides were pooled for each 
sample. The Pooled flowthrough samples were placed on a speed-vacuum, and 
purified using a C18 filter membrane. These fractions were used for the initial 
identification of the proteins. 
Phosphopeptides were then eluted from TiO2 columns with 20 µL of elution 
solution. Samples were eluted into pre-loaded eppendorf tubes with 2 µL of 100% 
[v/v] TFA each. Phosphopeptides were then purified further, prior to analysis, using a 
C18 filter membrane. The C18 filter membrane plug was cut out and packed into an 
Eppendorf GELoader tip using an SGE syringe tip (Part No. 038250). This column 
was then packed with a 3M Empore C18 filter membrane (Cat #2215 Sigma Supelco 
Cat #66883-U).  Additionally 1-3 mm of the POROS Oligo R3 resin (Part No. 
1771990) was packed (pipetted) on top of the C18 filter for a clean-up of the TiO2 
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eluate (POROS resin made in 70% [v/v] acetonitrile, 0.5% [v/v] TFA). Each Column 
was first activated with 30 µL of activate/elute solution, and equilibrated with 30 µL 
of wash solution. The TiO2 eluates were then each loaded onto columns and washed 
with 30 µL of wash solution. Phosphopeptides were finally eluted with 5 µL of 
activate/elute solution.  
2.8.5. Solutions  
Table 2.24. Preparations of 100 mL 50mM NH4HCO3, pH 7.8.  
50mM NH4HCO3 
 
0.395 g of NH4HCO3 was made up to 100 mL with H2O 
 
 
Table 2.25. Preparation of Porcine trypsin (Promega, Cat V5111). 
Porcine Trypsin (15 ng/µL) 
 
20 µg of Trypsin (Promega, Cat. no. V5111) dissolved in 1335 µL of 25 mM 
NH4HCO3, pH 7.8 
 (Stored in aliquots [~200 µL] at -20 ˚C for upto 1 month) 
Table 2.26. Preparation of Destaining Solution (50% [v/v] acetonitrile, 25 mM 
NH4HCO3, pH7.8) 
Destaining Solution 
 
An equal volume of 50 mM NH4HCO3, pH 7.8 was added to 100% [v/v] acetonitrile 	 	
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Table 2.27. Preparation of 20 mL extract solution (10% [v/v] acetonitrile, 0.5 % 
[v/v] TFA). 
Extract solution 
 
                                            2 mL Acetonitrile 
                                         18 mL H2O water 
                                              100 µL TFA 
 
 
Table 2.28. Preparation of 20 mL loading solution (0.5% [v/v] TFA in water). 
Loading solution 
 
20 mL H2O 
100 µL TFA 
 
 
Table 2.29. Preparation of 20 mL activate/elute solution (70% [v/v] acetonitrile, 
0.5% TFA). 
Activate/elute solution 
 
                                         14 mL Acetonitrile 
                                                            6 mL H2O 
                                                          100 µL TFA 
 
 
Table 2.30. Preparation of 10 mL of wash solution (0.1 % TFA). 
Wash solution 
 
1000 µL TFA 
9 mL H2O 
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 Table 2.31. Preparation of 4 mL of TiO2 loading buffer (1 M glycolic acid, 80% 
[v/v] acetonitrile, 5% [v/v] TFA). 
TiO2 loading buffer 4 mL 
 
3.2 mL of Acetonitrile (100%) 
200 µL of TFA (100%) 
434 µL of 70% [w/v] Glycolic acid 
166 µL of H2O 
 70% [w/v] Glycolic acid (Sigma Cat #420581), MW 76.05, 70 g/100 mL, 9.2 M 
 
Table 2.32. Preparation of 20 mL TiO2 wash buffer (80% [v/v] acetonitrile, 1% 
[v/v] TFA). 
TiO2 wash buffer 
 
16 mL Acetonitrile 
200 µL TFA 
3.8 mL H2O 
 
 
Table 2.33. Preparation of TiO2 elution buffer (0.5% [v/v] ammonia in water, pH 
11 – made fresh). 
TiO2 elution buffer 
 
20 µL of a 25% [v/v] Ammonia solution   
980 µL H2O 
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Table 2.34. Preparation of POROS Oligo R3 (Part No. 1771990). 
POROS Oligo R3 
 
50 mg POROS Oligo R3 
1 mL 70% [v/v] Acetonitrile, 0.5% TFA 
 
 
Table 2.35. Preparation of 20 mL of Oligo R3 activate/elute solution (70% [v/v] 
acetonitrile, 0.5% TFA). 
Oligo R3 Activate/elute solution 
 
14 mL Acetonitrile 
6 mL H2O 
100 µL TFA 
 
Once purified phosphopeptides were analysed on a Thermo Velos Orbitrap 
mass spectrometer coupled to a Dionex Ultimate 3000 HPLC system. The peptides 
were loaded onto a pre-column (Dionex 300 um x 5 mm, C18, 5 um) and separated on 
a 12 cm x 100 µm column packed with a ReproSil-Pur 120 C18-AQ 3 µm resin (Dr. 
Maisch GmbH) running at 250 nL/min. Samples were loaded in 0.5% (v/v) formic 
acid in water and separated over a 35 minute linear gradient of 0-32% (v/v) 
acetonitrile. The percentage of acetonitrile was linearly increased to 55% (v/v) over 
the next 5 minutes, and then to 90% (v/v) over a one-minute period. The column was 
re-equilibrated prior to each sample analysis. 
The initial MS scan (350-2000 m/z) was performed in the Orbitrap with the 
resolution set to 60,000. Following this scan, MS MS of the top 20 peptides was 
performed in the linear ion trap with the normalised collision energy set to 35. Data 
was explored using Mascot 2.3.0 and the SWISS-PROT database (56.6) limited to 
human (20413 sequences), with the precursor mass set to 10 ppm and MS MS 
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tolerance at 0.6 Da. Modifications included deamidation (N, Q), methionine 
sulphoxide oxidation and phosphorylation (S, T, Y). The False Discovery Rate (FDR) 
for each peptide was set at 1% and all spectra were analysed manually to confirm 
assigned phosphorylation sites.  
2.9.  Functional assays 
2.9.1. Apoptosis assay 
To assess for apoptosis, media was first aspirated from cells. DMEM media 
containing a 1 in 200 dilution of NucView™ 488 (Biotium #30062) was then added to 
the cells and incubated for 30 minutes at room temperature. After this incubation, the 
cells were washed once gently with PBS (Mg2+ and Ca2+), and fixed with 4% 
Paraformaldehyde/PBS (Mg2+ and Ca2+) for 10 minutes at room temperature. After 
fixation, cells were rinsed twice with PBS (Mg2+ and Ca2+), and then stored in PBS 
(Mg2+ and Ca2+) until preparations for immunofluoresence were made (see section 
2.10.1). As a positive control, cells were treated with 3 µM MitMab to cause cell 
death. 
Other functional assays such as the proliferation and migration assays are 
explained within each chapter. 
2.10. Microscopy 
2.10.1. Immunofluorescence Microscopy 
Cells were grown on a coverslip within 6-well plates or in chambered slides 
(Thermo Scientific™ Nunc™ Lab-Tek II Chamber Slide™ System #154461). 
Following siRNA knockdown, plasmid transfection, or drug treatment, cells were 
washed once with PBS (with Mg2+ and Ca2+), and fixed with 4% 
Paraformaldehyde/PBS (with Mg2+ and Ca2+) and incubated for 10 minutes. After 
fixation, cells were rinsed twice with PBS (with Mg2+ and Ca2+), and permeabilised 
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by adding 0.5% Triton X-100/PBS. Samples were incubated for 10 minutes to allow 
permeablisation. Cells were then washed three times with PBS, and blocked for 30 
minutes with buffer B (10% Foetal Calf Serum [FCS]/PBS/0.02% NaN3). Blocking 
and all washes were conducted with agitation at room temperature. After blocking, the 
protein of interest was probed for with the primary antibody. A list of all the 
antibodies used for this project is outlined in section 2.4. Buffer B was diluted 1/5 in 
PBS to obtain a 2% FCS solution, and this dilution was used to dilute the primary 
antibody accordingly (usually 1:1000 unless specified). Samples were then incubated 
for 1 hour at room temperature in a humid chamber. 
After incubation with the primary antibody, cells were washed with 0.1% 
Tween-20/PBS three times (each wash incubated for 5 minutes), and the appropriate 
Texas-red or FITC conjugated secondary antibody was then added (1:1000 in 1/5 
buffer B). Samples were incubated for 30 minutes with the secondary antibody at 
room temperature in a humid chamber. The cells were then washed once with 0.1% 
Tween-20/PBS (wash incubated for 5 minutes), and where DAPI nuclear counter 
staining was required, cells were stained with a 1:10000 dilution of DAPI (incubated 
for 5 minutes).  The slides were each mounted with DABCO anti-fade and covered 
with 100 Deckglaser 22 × 50 mm #1 coverslips. The coverslip edges were sealed with 
see-through nail polish. The slides were stored at 4 °C for 24 hours before 
microscopic analysis by a fluorescence microscope. Fluorescence images were 
captured and processed using a Zeus Imager M.1 inverted microscope/ or Cell 
Voyager™ for confocal microscopy (Yokogawa, Japan). All chapter four microscopy 
images were MRP confocal images obtained from the Cell-Voyager (40× 
magnification; 21 Z-stack slices; 0.5 µm step height). Images were analysed using 
Metamorph®/Cell Voyager™ CV1000 software. All immunofluorescence 
		 109	
microscopy experiments were repeated three times in A549 (~5% transfection 
efficiency) or HCT116 (~20% transfection efficiency) cells, with 100 transfected cells 
analysed each time. 
2.10.2. Live cell imaging 
Live cell imaging was used for the cell proliferation and migration assays. To 
assess cell proliferation, these methods were modified as detailed in chapter four. For 
the migration assays, 100,000 HCT116 or Saos-2 cells were seeded in 35 mm glass 
plates with 1 mL of DMEM (10% FCS). Cells were then transfected with the plasmid 
of interest (YB-1-HA, HA-tagged mutant, or control), and treated as indicated in 
chapter five. To visualise transfected cells during live cell imaging, the cells were co-
transfected with a pN1-mcherry plasmid (Clontech, USA) at ~10% the amount of the 
plasmid of interest (i.e. YB-1-HA, HA-tagged mutant, or control). The mcherry-
positive cells were assumed to be carrying the 10-fold more abundant, co-transfected 
plasmid of interest (indirect conservative scoring), as chances of cells uptaking one 
plasmid (pN1-mcherry) without the other co-transfected plasmid was unlikely. Cells 
were observed with a Cell Voyager internal inverted microscope. A time-lapse series 
was acquired using a fully motorized stage, 10× objective and provided Cell Voyager 
CV1000 software using the time-lapse modules. The temperature was maintained at 
37 °C, and atmosphere at 5% CO2, which was humidified internally within the Cell 
Voyager microscope. Images were captured every 5 minutes for 48 hours (or as 
otherwise stated). Each plasmid transfection had 5 fixed fields to be photographed at 
every time point. The time-lapse series was analysed frame-by-frame using the 
provided Cell Voyager CV1000 software or Metamorph® software. For further 
details on each experiment, refer to chapters four and five. 
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Chapter Three: YB-1 protein 
purification and analysis 										
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3.0. Introduction 
 As discussed in chapter one, the general aim of this project was to investigate 
the phosphorylation status of YB-1 with respect to its cellular localisation, and its 
implications on YB-1 driven malignancy. Identifying YB-1’s phosphorylation sites 
would be key to understanding the role of phosphorylation in the regulation of its 
localisation and functions. For the unequivocal identification of YB-1 
phosphorylation sites by mass spectrometry, it was first necessary to develop a 
purification protocol for cytoplasmic and nuclear YB-1 fractions.  
 The initial step in this study involved the purification and validation of an 
accurate and specific anti-YB-1 antibody (Fig.3.1), suitable for large-scale protein 
purification. In this chapter, the development and validation of this antibody against 
YB-1 is first discussed. The steps involved in the purification of nuclear and 
cytoplasmic YB-1, with modifications to established methods are then discussed. 
 
  
 
 
 
 
 
  
 
 
 
 
Fig. 3.1. YB-1 and hnRNP A1 protein antibody cross-reactivity. Many studies on the YB-1 
protein were plagued with unvalidated anti-YB-1 antibodies that cross-reacted with the 
hnRNP A1 protein (Cohen et al, 2010). This in turn led to conflicting and inaccurate results.	
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Finally, the validity of antibody pulldowns are confirmed and validated directly by 
mass spectrometry with high-throughput MALDI analysis. An outline of the 
workflow in this chapter is illustrated in Figure 3.2. These methods are then utilised 
for the phosphopeptide analysis of YB-1 by LC-MS MS. This in turn allowed for 
further functional studies downstream of the project (see chapters four and five). 
 The high-throughput MALDI analysis was initially utilised for the 
phosphopeptide analysis. However, it was not sensitive enough to detect any 
phosphopeptides, and was thus only used to conclusively identify the YB-1 protein.  
LC-MS MS was also used to determine if genotoxic anti-cancer drugs had an effect 
on YB-1’s phosphorylation signature, where cells treated with 0.25 µg/mL 
doxorubicin and cisplatin (10 µg/mL) were also analysed alongside untreated cells. 
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Fig.3.2. Flowchart of workflow from protein purification to mass spectrometry analysis 
of YB-1. (a) YB-1 western blot of crude lysates from nuclear and cytoplasmic preparations. 
(b) Immunopurification of nuclear and cytoplasmic YB-1 with anti-YB-1 antibodies and 
Protein G beads. (c) Coomassie stained SDS-PAGE gel of immunopurified nuclear and 
cytoplasmic YB-1 identified via mass spectrometry analysis. Note: Preparative SDS-PAGE 
gels show some variance in protein mobility when compared to commercial pre-cast gels. 
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3.1. Purification of N-terminal anti-YB-1 polyclonal sheep antibody 
 In order to immunopurify YB-1 for large-scale protein preparations, 
polyclonal anti-YB-1 antibodies were prepared in sheep. The antibodies were 
generated against amino acids 1-12 of the YB-1 protein (epitope a: 
MSSEAETQQPPA), and the sheep serum was collected at IMVS pathology, 
Adelaide. Polyclonal antibodies against this epitope were already found to be specific 
to YB-1 when generated in rabbit (Cohen et al, 2010).  
 To purify the sheep antibodies from the serum, peptides corresponding to the 
antibody epitope, covalently bound to modified agarose beads (BioRad Affi-Gel 10 
beads) were used to capture them (Fig.3.3a). Affi-Gel beads are modified N-
hydroxysuccinimide esters, which are reactive with primary amines to a binding 
capacity of 15 mmol/mL of beads. This allowed for the beads to covalently bind the 
antibody’s peptide epitope, providing an affinity-reagent for the desired anti-YB-1 
antibodies.  The immunopurification process is summarised in Fig. 3.3 and outlined in 
chapter two. 
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a) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
c)  						
Fig.3.3. Affinity purification of N-terminal anti-YB-1 polyclonal sheep antibody. a) The 
YB-1 peptide: MSSEAETQQPPA, corresponding to amino acids 1-12  (epitope a) of the YB-
1 protein, was used to immunise sheep for the production of polyclonal anti-N-YB-1 antibody 
b) Modified agarose beads covalently attached to the target peptide of epitope a were used to 
trap the polyclonal anti-N-terminal antibody from the extracted sheep serum. c) The trapped 
polyclonal antibody was then separated from serum debris by washing in a high salt buffer, 
before elution with a low salt buffer solution.	
 	
Anti-YB-1 antibody 
trapped 
High salt wash to 
remove debris 
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3.2. The purified sheep polyclonal anti-N-YB-1 antibody is specific for YB-1 
 The specificity of each of the newly purified sheep antibodies, designated I-2a 
and I-2b, was assessed by western blotting (Fig.3.4). To ensure that detected protein 
blots were specifically YB-1, whole-cell lysates from A549 cells with normal and 
reduced expressions were compared. A reduction in the intensity of the putative 
blotted YB-1 protein would therefore confirm the specificity of the antibodies for YB-
1. The reduction of YB-1 expression was achieved through a knockdown of its 
mRNA levels by a gene specific siRNA (knockdowns were previously optimised in 
this cell-line by Cohen et al, 2010).  
 Approximately 2 × 106 A549 cells were seeded per 100 mm plate, and 
transfected 24 hours later with a YB-1 mRNA specific RNAi complex (as outlined in 
chapter 2). Control cells were left untreated for this experiment. 
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a) 
 
 
 
 
 
 
 
 
 
 
 	
 
 
 
 
 
 
 
 
 
 
 
 
b) 
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.4. Validating purified polyclonal anti-N-YB-1 sheep antibody. Antibody specificity 
was assessed in A549 cell lysates (with or without YB-1 knockdown) by western blot. a) YB-
1 was first probed using a previously validated rabbit anti-N-YB-1 antibody (2 ug/mL) 
against epitope a. b) YB-1 was then probed using the newly purified sheep anti-N-YB-1 
antibody (2 ug/mL) against epitope a. YB-1 is indicated in both blots with red arrows (KD= 
knockdown). Note: slight natural variation was occasionally observed with marker blot 
intensities.  
	
Ponceau-stained blot 
	
Ponceau-stained blot 
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 Cells from each plate were harvested in 4 mL of trypsin, 96 hours post 
transfection, and quenched with 20 mL of DMEM (10% FBS). Harvests from each 
YB-1 knockdown transfection plate (5 total = 120 mL) were then centrifuged at 500 
×g for 10 minutes (4 ˚C), resuspended and pooled into 50 mL DMEM (10% FBS), 
and 500 µL were taken out for a cell count (total cell no. = 13 x106). The same 
procedure was carried out for the control cells (total cell no. = 2.72 x108). The pooled 
samples were then harvested, lysed, and prepared for western blotting.  
3.2.1. Detecting the YB-1 protein with the newly purified sheep anti-YB-1 antibody 
The total harvested YB-1 siRNA knockdown and control A549 cells were 
resuspended in chilled cell lysis buffer on ice.  The two batches of pooled cells were 
brought to a concentration of ~ 106 cells/mL and were completely resuspended before 
the addition of freshly-made 1mM PhenylMethaneSulfonyl Fluoride (PMSF) protease 
inhibitor. The cell suspensions were then rotated for 30 minutes at 4 °C to allow for 
complete cell lysis, followed by centrifugation at 16,000 ×g for 20 minutes at 4 °C to 
pellet cellular debris. 
 Lysates were run on two 10-well 10% SDS-PAGE gels from Life 
Technologies simultaneously. From each sample lysate of 106 cells/mL, 15 µL was 
loaded onto each well. The gels were electrophoresed for 1 hour at 200 V, and then 
transferred to PVDF membranes by electrophoresis with 30 V for 1 hour.  The 
transferred lysates were then stained with Ponceau S solution (0.1% w/v in 5% acetic 
acid) to show equal well-loading, and then probed with either the previously validated 
rabbit anti-YB-1 antibody (2 ug/mL), or the newly purified sheep anti-YB-1 antibody 
(2 ug/mL). The rabbit anti-N-YB-1 antibody, specific to the same epitope as the 
newly purified sheep anti-N-YB-1 antibody (epitope a), acts as a model of an 
expected YB-1 protein blot (Fig.3.4.a.). Both antibodies were diluted in the primary 
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antibody diluent from the WesternBreeze™ Chemiluminescent Western Blot 
Immunodetection kit (Life technologies, USA), as outlined in chapter two. 
 A reduction in the intensity of the putative blotted YB-1 protein in the 
knockdown sample (runs at ~50 kDa), as seen in both blots (Fig.3.4.), confirms the 
specificity of the newly purified antibody for YB-1. Additionally, the appearance of a 
single band of the correct predicted YB-1 protein size in the newly purified sheep 
antibody blot, further suggests that the purified antibodies are indeed specific and 
suitable for protein purification (Fig.3.4.b.). For further details on the methods of 
knockdown, lysis, and western blotting, refer to chapter two. 
Following purification and validation of the sheep anti-N-YB-1 antibody, the 
optimum concentration of antibody for YB-1 protein purification was then determined 
(i.e. optimum binding capacity). This is discussed in the following subsection.   
3.3. The optimisation of YB-1 immunopurification 
The optimum sheep anti-N-YB-1 antibody concentration for YB-1 
immunoprecipitations (Fig.3.5) was determined through titrations of YB-1 pulldowns 
with increasing antibody concentrations (Fig.3.6. & 3.7.). First, the I-2a antibody was 
added to 1 mL aliquots of A549 lysate samples (106 cells/mL) in increasing antibody 
concentrations (as outlined in Fig.3.6.). Samples were then allowed to rotate for 1 
hour at 4 °C before the addition of 40 uL of Protein G beads (50% slurry 
composition). The Protein G beads covalently bound the heavy chain of the anti-N-
YB-1 antibody and was then used to immunopurify YB-1 (Fig.3.5.). 
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Fig.3.5. Immnouaffinity purification of YB-1 using the anti-N-YB-1 polyclonal sheep 
antibody. a) Protein G beads covalently bound to the heavy chain of anti-N-YB-1 polyclonal 
sheep antibody were used to immunopurify YB-1. b) Excess peptide antigen (epitope a) was 
then used to trap the antibody and elute the immunopurified YB-1 protein. 
  
YB-1 protein 
captured 
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The first YB-1 titration (Fig.3.6), with 0-50 µg/mL of antibody, showed a 
saturation of bound YB-1 protein at approximately 5-15 µg/mL of antibody. This 
indicated the need for another titration experiment with a wider increment and more 
data points within the 0-15 µg/mL concentration range of antibody, to allow for an 
optimum concentration for maximum YB-1 pulldown to be determined.  The second 
experiment narrowed the optimum concentration range down to 10-15 µg/mL of 
antibody (Fig.3.6.b.).  
From Figure 3.7, the optimum antibody concentration for YB-1 pulldowns 
was determined to be 10 µg/mL. Having determined the optimum conditions for YB-1 
immunopurification, nuclear and cytoplasmic preparations were then optimised to 
allow for the purification of nuclear and cytoplasmic YB-1 for mass spectrometry 
analysis (Fig.3.2.). 
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Fig.3.6. Titration to measure anti-N-YB-1 antibody affinity. (a) YB-1 from A549 lysates 
was pulled down using 0-50 µg/mL of sheep anti-N-YB-1 antibody. Saturation of maximum 
bound YB-1 was observed at around 5-15 µg/mL. Further optimization was therefore carried 
out between the 0-15 µg/mL range of antibody (b) YB-1 from A549 lysate was pulled down 
using 0-15 µg/mL of antibody, with the maximum fraction bound YB-1 at ~10 µg/mL. 
 
	
Fig 3.7. Titration to measure sheep anti-N-YB-1 antibody affinity and dissociation 
constant (Kd). Binding curve for the sheep anti-N-YB-1 antibody, measuring 
immunoprecipitation of YB-1 as a function of antibody concentration.  Maximum fraction 
bound YB-1 ~10 µg/mL.  
	 	
Max fraction bound 
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3.4. Optimisation of nuclear and cytoplasmic preparations from A549 cells 
Based on previous experiments in the laboratory, it was estimated that nuclear YB-1 
constitutes less than ~5% of the total cellular YB-1 (Cohen et al, 2010). Therefore, to 
immunopurify enough nuclear YB-1 for mass spectrometry, cell cultures were 
expanded to ~5 x108 cells total. Cells were harvested at ~90-95% confluency, and 
then placed in a low-salt hypotonic buffer to induce cell swelling. The cells were then 
lysed (Fig.3.8.), and centrifuged for 10 minutes at low speed (228 ×g) at 4 ˚C to pellet 
released intact nuclei and isolate them from the cytoplasmic content. The isolated 
nuclear pellets were then re-centrifuged at high speed (2800 ×g) at 4 ˚C in a sucrose 
gradient for 10 minutes to further remove cytoplasmic debris (Fig.3.9).  Following 
isolation, the nuclei were resuspended in a high-salt nuclear extract buffer, and rotated 
at 4 °C for 30 minutes to extract the nuclear contents. Nuclear and cytoplasmic 
extracts were then prepared for the immunoprecipitation of YB-1 with the newly 
purified polyclonal sheep anti-N-YB-1 antibody (Fig.3.2.b.) 
Given the lower quantity of nuclear YB-1 compared to the cytoplasmic 
component, the purity of each nuclear preparation was assessed for the presence of ß-
tubulin, a cytoplasmic marker (Fig.3.9.b.). This was to ensure that the small pool of 
nuclear YB-1 was not contaminated and diluted out, with the much larger pool of 
cytoplasmic YB-1. Through trial and error, it was determined that the cell lysis 
method was central to obtaining a clean nuclear preparation, free of cytoplasmic 
contamination. Optimisation of the nuclear preparations for maximum purity is 
discussed in the following subsection. 
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3.4.1. Optimisation of cell lysis for nuclear and cytoplasmic preparations  
Initially, Dounce homogenization was used to lyse cells after swelling in 
hypotonic buffer, based on a previous method optimised in the lab (Cohen et al, 
2010). However, upon assessment of the purity of the nuclear fraction (ß-tubulin 
western), it was observed that this method consistently afforded low levels of 
cytoplasmic contamination (Appendix 1: Fig.S1.). The nuclear preparation method 
was therefore optimised (Fig.3.8.). 
As an alternative to Dounce homogenization, the use of detergent (0.5% 
Trition-X-100) as a method of lysis was assessed. Upon treatment of the cells with 
detergent, lysates were immediately analysed under a light microscope and the state 
of the released nuclei were then compared preparations by Dounce homogenization. 
The detergent lysis was carried out in a 37-˚C waterbath to speed up lysis, which 
showed less cellular debris and more intact nuclei (Fig.3.8.a.). This method of lysis 
was used for all subsequent preparations, and proved consistent between preparations 
(Fig.3.9).  
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Fig.3.8. Optimisation of A549 cell lysis for nuclear and cytoplasmic extractions. Cells 
were harvested and placed in low salt hypotonic buffer to induce swelling, and were then 
lysed using either (a) 0.5% Triton-X.100 detergent  or, (b) a Dounce homogeniser. Lysis 
using detergent showed less cellular debris, less damage to nuclei, more intact nuclei, and 
most importantly consistent results between preparations (nuclei slightly out of focus to show 
debri). 
  
				Cells	harvested	
		Cell	swelling	
Lysis	
b)	Dounce	
homogeniser	a)	Detergent	
Debri	
Intact	nuclei	
Intact	nuclei	
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a)  														 	 	 	 					
b) 
		
Fig.3.9. Preparation of A549 cell nuclear and cytoplasmic extracts. (a) Cells were 
harvested and placed in low salt hypotonic buffer to induce swelling, and were then lysed by 
detergent. High-speed centrifugation of cell lysates in a sucrose gradient buffer results in clear 
nuclear pellets, isolated from the cytoplasmic extract in the supernatant. (b) A typical western 
blot of ß-tubulin, a cytoplasmic marker, which appears almost completely absent from the 
nuclear fraction. Taking into account the extract volumes of the nuclear and cytoplasmic 
preparations (cytoplasmic fraction is 5x the nuclear fraction) and the blot intensities of ß-
tubulin in both fractions, the blot indicates a nuclear enrichment of ≥ 95%. 
Centrifuged	nuclei	
pellets	in	sucrose	
gradient	
Harvested	cells	lysed	
with	0.5%	Triton-X.	
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3.5. Harvesting nuclear and cytoplasmic YB-1 
Following the optimisation of the nuclear and cytoplasmic preparations, 
nuclear and cytoplasmic lysates were prepared from 5 x108 freshly-harvested A549 
cells as detailed in the previous section. Lysate preparations were then centrifuged at 
26,500 ×g for 20 minutes at 4 ˚C to remove cellular debris, and then used for the 
immunoprecipitation of nuclear and cytoplasmic YB-1 (Fig.3.2.b & Fig.3.10) 
The detection of nuclear and cytoplasmic YB-1 by immunoprecipitation and 
mass spectrometry allowed for the unequivocal confirmation of the specificity of the 
newly purified polyclonal sheep anti-N-YB-1 antibody. 
 
		 128	
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b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3.10. Nuclear and cytoplasmic YB-1 protein levels in A549 cells after a nuclear and 
cytoplasmic preparation. (a) western blot showing the nuclear and cytoplasmic levels of 
YB-1 from crude lysate, with final preparation volumes noted at the bottom. Additionally, 
each nuclear preparation was assessed for purity by probing for ß-tubulin, a cytoplasmic 
specific protein. (b) Coomassie stained polyacrylamide gel showing the putative nuclear and 
cytoplasmic YB-1 proteins after pulldown from crude nuclear and cytoplasmic preparations. 
Note: Preparative SDS-PAGE gels show some variance in protein mobility when compared to 
commercial pre-cast gels. 
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3.6. Unequivocally identifying immunopurified nuclear and cytoplasmic YB-1  
Immunopurified nuclear and cytoplasmic YB-1 were resolved on a preparative 
4-10% gradient SDS-PAGE gel and stained with Coomassie Brilliant Blue.  Proteins 
running in the general region of YB-1 (~35-50 kDa) were collected for Matrix-
Assisted Laser Desorption/Ionisation (MALDI) mass spectrometry analysis with a 
MALDI TOF/TOF 5800 machine (Fig.3.11). The mass spectrometry analysis allowed 
for YB-1 to be identified unequivocally, given the observation of several proteins 
running within the 35-50 kDa region after immunopurification (Fig.3.10b). 
All proteins were trypsin-digested for the analysis, and were also enriched for 
phosphopeptides (C8/TiO2 purification), before the C18 purification step to detect any 
phosphorylated peptides (see chapter two for more information). Both nuclear and 
cytoplasmic YB-1 were successfully identified (Fig.3.11), with several peptides 
matched to the online SWISS-PROT database (Tables 3.1. & 3.2.); however, no 
phosphopeptides were detected with the MALDI TOF/TOF 5800 machine (Tables 
3.1. & 3.2.). The analysis of YB-1 phosphorylation using the much more sensitive 
LC-MS MS is discussed next.  
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a)     Cytoplasmic YB-1 spectrum 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b)    Nuclear YB-1 spectrum 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3.11. Mass spectra of identified sheep anti-N-YB-1 antibody pulldown products. 
Anti-N-YB-1 pulldowns corresponding to the YB-1 protein size on a Coomassie gel (35-50 
kDa) were cut out, extracted, and identified by mass spectrometry. (a-b) Mass spectrometry 
spectra of the trypsin-digested peptides with the mass over charge (m/z) ratio indicated on the 
x-axis, and the reading intensity indicated on the y-axis. The green dots indicate ions 
matching the YB-1 protein. The pulldown peptides from the cytoplasmic (a) and nuclear (b) 
preparations were confirmed unequivocally to be YB-1.  
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Table 3.1. Cytoplasmic YB-1 peptide sequence coverage identified by MALDI-
TOF/TOF analysis. 
Residues m/z Charge Peptide sequence 
Error 
(ppm) 
[70-77] 940.46 1 r.NGYGFINR.n -10.8 
[78-92] 1744.89 1 r.NDTKEDVFVHQTAIK.k -13.7 
[119-137] 1695.87 1 k.GAEAANVTGPGGVPVQGSK.y -15 
[138-146] 1165.55 1 k.YAADRNHYR.r -11.7 
[157-170] 1688.71 1 r.NYQQNYQNSESGEK.n -14.3 
[157-185] 3257.4 1 
r.NYQQNYQNSESGEKNEGSESAPE
GQAQQR.r -3.8 
[171-185] 1587.7 1 k.NEGSESAPEGQAQQR.r -11.8 
[257-279] 2628.1 1 
r.EDGNEEDKENQGDETQGQQPPQR.
r -5.9 
[265-279] 1711.76 1 k.ENQGDETQGQQPPQR.r -32.1 
[283-288] 869.44 1 r.RNFNYR.r -9.5 
[284-289] 869.44 1 r.NFNYRR.r -9.5 
[290-301] 1421.76 1 r.RRPENPKPQDGK.e -19 
[291-301] 1265.66 1 r.RPENPKPQDGK.e -10.2 
[291-304] 1623.84 1 r.RPENPKPQDGKETK.a -13.3 
[305-324] 1897.8 1 k.AADPPAENSSAPEAEQGGAE. -19.1 
   m/z: mass/charge; ppm: parts per million 
 
Table 3.2. Nuclear YB-1 peptide sequence coverage identified by MALDI-
TOF/TOF analysis. 
Residues m/z Charge 
 
Peptide sequence 
Error 
(ppm) 
[265-279] 1711.76 1 k.ENQGDETQGQQPPQR.r -41.8 
[82-93] 1414.77 1 k.EDVFVHQTAIKK.n -34.4 
[305-324] 1897.8 1 k.AADPPAENSSAPEAEQGGAE. -26 
[102-118] 1795.82 1 r.SVGDGETVEFDVVEGEK.g -22.2 
[78-92] 1744.89 1 r.NDTKEDVFVHQTAIK.k -19.9 
[157-170] 1688.71 1 r.NYQQNYQNSESGEK.n -17.9 
[291-304] 1623.84 1 r.RPENPKPQDGKETK.a -17.9 
[119-137] 1695.87 1 k.GAEAANVTGPGGVPVQGSK.y -17.8 
[171-185] 1587.7 1 k.NEGSESAPEGQAQQR.r -12.8 
[70-77] 940.46 1 r.NGYGFINR.n -12.4 
[291-301] 1265.66 1 r.RPENPKPQDGK.e -10.7 
[138-146] 1165.55 1 k.YAADRNHYR.r -9.5 
[257-279] 2628.1 1 
r.EDGNEEDKENQGDETQGQQPPQR.
r -9.2 
[283-288] 869.44 1 r.RNFNYR.r -8.1 
[284-289] 869.44 1 r.NFNYRR.r -8.1 
[157-185] 3257.4 1 
r.NYQQNYQNSESGEKNEGSESAPE
GQAQQR.r -4.6 
   m/z: mass/charge; ppm: parts per million 	  
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3.7. Purification and phosphopeptide analysis of YB-1 with LC-MS MS 
  Nuclear and cytoplasmic YB-1 were prepared from A549 lysates according to 
the methods optimised in this chapter (see Fig.3.2. for an overview), with the mass 
spectrometry analysis carried out using LC-MS MS instead of MALDI, to allow for a 
more sensitive phosphopeptide analysis. Additionally, treatments of 0.25 µg/mL of 
doxorubicin and 10 µg/mL of cisplatin were also carried out during the culturing 
phase, to determine if genotoxic anti-cancer drugs had an effect on YB-1’s 
phosphorylation signature. Previous work in the laboratory has found these 
concentrations to be sufficient to cause DNA damage (stress) without compromising 
the viability of the cells, therefore allowing them to be harvested for analysis. The 
drugs were added 18-24 hours prior to cell culture harvest, and were analysed 
alongside untreated A549 cells (Fig. 3.12).  
 No specific phosphorylation pattern, specific to drug-treated nuclear or 
cytoplasmic YB-1 was evident. However, in unstressed conditions (untreated), 
phosphorylation at the threonine 271 residue was only detected in the nuclear fraction 
(Fig.3.12). Regardless of phosphorylation signature, what is clearly evident is that 
YB-1 can be phosphorylated at various residues, with a total of 7 phosphorylation 
sites identified overall, spanning the CSD and C-terminal domain. At the present time, 
only the serine 102 phospho-residue has been studied extensively (reviewed by 
Lasham et al, 2013).  
		 133	
a)	
 
b) 
 
 
c) 
 
Fig.3.12. A Compilation of all identified phosphorylation sites, accumulated from A549 
cell lysates using LC-MS MS. (a) All YB-1 phosphorylation sites identified. (b) Status of 
each phosphorylation site in the literature at the time of this study, and their status in this 
study after its completion. No apparent phosphorylation pattern, specific to drug-treated 
nuclear or cytoplasmic YB-1 was evident. However, T271 phosphorylation was exclusive to 
the nucleus of unstressed cells. (c) LC-MS MS mass spectrum showing mass to charge ratio 
(x-axis) and relative intensity (y-axis) for the newly identified T271 phosphopeptide. All 
other phosphopeptide spectra are listed in Appendix 1. (a: Mayya et al, 2009; Oslen et al, 
2010; Rigbolt et al, 2011; Rush et al, 2005). 
Phosphorylation 
site 
Status Identification 
Serine 102 
 
Reported in literature and 
partially characterised; 
confirmed in this study. 
Identified in the 
nucleus and 
cytoplasm of stressed 
and unstressed cells 
Serine 165, 167, 
174, 176, 314 
Identified in high-throughput 
screensa (unconfirmed) and 
previously identified once in 
our laboratory. Functionally 
uncharacterised. 
Identified in the 
nucleus and 
cytoplasm of stressed 
and unstressed cells 
Threonine 271 First identification in this 
study. 
Only identified in the 
nucleus of unstressed 
cells 
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3.8. Discussion 
 The first goal of this study was to develop and purify a specific anti-YB-1 
antibody (Fig.3.1), suitable for large-scale protein purification and phosphopeptide 
analysis by mass spectrometry. This antibody was successfully validated for 
specificity by siRNA knockdown, where a single YB-1 blot that was responsive to 
YB-1 knockdown was detected on a western blot (Fig.3.4). Steps involved in the 
fractionation and purification of nuclear and cytoplasmic YB-1 were also explored. 
These methods revealed high levels of enrichment for the nuclear fractionation, and 
sufficient amounts for identification. However, the method of mass spectrometry 
analysis (MALDI-TOF/TOF) was not sensitive enough to detect any phosphopeptides 
(Tables 3.1 and 3.2), and LC-MS MS was used as a much more sensitive method of 
phosphopeptide analysis. Even more abundant phosphopeptides (Fig.3.12) were never 
detected with MALDI-TOF/TOF, regardless of the presence of phosphatase 
inhibitors, and phosphopeptide enrichment. The necessity for the more sensitive LC-
MS MS analysis suggests that the majority of the YB-1 pools in both the nucleus and 
cytoplasm are unphosphorylated. Nevertheless, a total of 7 phosphorylation sites were 
identified (Fig.3.12). These phosphorylation sites were identified in both the nucleus 
and cytoplasm of A549 cells, with the T271 site being the only exception, where out 
of six independent experiments it was identified twice only in the nucleus of untreated 
cells (no genotoxic stress). 
3.8.1. Sheep anti-N-YB-1 antibody specificity 
There was precedent for a YB-1 antibody against epitope a generated in rabbit 
(Bargou et al, 1997; Cohen et al, 2010). However, for large-scale protein purification, 
much larger quantities of antibody were required. Therefore, an antibody against the 
same epitope was generated in sheep. This antibody detected a single blot by western, 
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which was responsive to siRNA knockdown against YB-1, thus confirming the 
specificity of the antibody, and suggesting it was suitable for protein purification 
(Fig.3.4.b.).  
3.8.2 Nuclear and cytoplasmic YB-1 purification 
The method of lysis was found to be central to pure nuclear preparations, 
where lysis with detergent consistently provided highly-enriched nuclear fractions 
(Fig.3.9.b.). Lysis with the Dounce homogeniser was inconsistent, with many nuclear 
preparations showing cytoplasmic contamination and cellular debris (Fig.3.8; 
Fig.S1.).   
The purity of the cytoplasmic fractions was not assessed for this project. In 
principle, the nuclear fraction could contaminate the cytoplasmic fraction. However, 
given the difference in the distribution of the total cellular YB-1 (2-5% nuclear YB-1 
to 95-98% cytoplasmic YB-1), it was concluded that any nuclear contamination into 
the cytoplasmic fraction would be masked by the much greater quantity of 
cytoplasmic YB-1 during mass spectrometry analysis. Even with small pools of 
phosphorylated nuclear and cytoplasmic YB-1, phosphorylated cytoplasmic YB-1 is 
still probably several-fold more abundant than phosphorylated nuclear YB-1, given 
the known distribution of YB-1 across the nucleus and cytoplasm of A549 cells. 
Phosphorylated cytoplasmic YB-1 would therefore still conceal any contamination 
with phosphorylated nuclear YB-1. Nonetheless, this issue remains one of the 
limitations of this study. 
3.8.3. Mass spectrometry analysis of YB-1 
Mass spectrometry analysis with the MALDI TOF/TOF 5800 was effective in 
identifying both cytoplasmic and nuclear YB-1 (Fig.3.11). However, when used for 
phosphopeptide analysis, it was not sensitive enough to detect any phosphorylation 
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sites (Tables 3.1 & 3.3), indicating the limitations of this method of analysis. The 
results also suggest that the proportion of non-phosphorylated YB-1 peptides greatly 
outweigh the proportion of phosphorylated YB-1 peptides in the cell. This provides 
some insight into how phosphorylation might be regulated for the YB-1 protein, 
suggesting a high degree of control over phosphorylation. However, a repeat of these 
experiments with a positive phosphopeptide control would be required to be certain of 
this conclusion. The phosphopeptide analysis of YB-1 using the more sensitive LC-
MS MS mass spectrometry method, and its cellular distribution is discussed in the 
following section. 
3.8.4. LC-MS MS mass spectrometry analysis 
Despite the majority of cellular YB-1 protein existing in an unphosphorylated 
form, as seen from the MALDI analysis (i.e. all of detected protein 
unphosphorylated), it is evident from the LC-MS MS data that a small subset of the 
YB-1 pools in the nucleus and cytoplasm can be phosphorylated at various residues 
(Fig.3.12). There remains a possibility that these identified residues might only be 
phosphorylated as an artifact of cell lysis, where the YB-1 protein would be exposed 
to kinases upon the onset of lysis. This would inform us that YB-1 can at least be 
phosphorylated at the identified phospho-sites in vitro, but not necessarily in vivo. 
However, this phenomenon is unlikely, as all lysates were prepared on ice, limiting 
any kinase activity. The S102 phosphorylation site, being the only previously 
characterised site, was the only residue detected within the CSD. It was previously 
reported to be responsible for YB-1 nuclear localisation (Sutherland et al, 2005), but 
was identified in both the nucleus and cytoplasm in this analysis. Given the qualitative 
approach of the mass spectrometry analysis in this study, this result was not 
surprising, as it would require a quantitative approach to conclude overall 
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distributions of phosphopeptides (quantitative analysis of phosphopeptides). LC-MS 
MS is sensitive enough to detect even minute amounts of phosphopeptides within the 
nucleus or cytoplasm, and therefore give a positive result for an enriched 
phosphopeptide regardless of distribution.  
The highest density of phosphorylation sites was close to the NLS, suggesting 
the importance of this region in YB-1 regulation (Fig.3.12), and might therefore have 
important implications on YB-1’s subcellular localisation. The newly identified T271 
phosphorylation site’s close proximity to the CRS might also suggest a possible role 
of phosphorylation in the cytoplasmic retention of YB-1.  
Finally, the identified S314 phosphorylation site might have an important role 
in protein-protein interactions, given the importance of the C-terminus in protein 
interactions (see chapter one: Table 1.1). However, this phospho-site was not 
investigated further in this study, as the focus of this project shifted towards NLS and 
CRS proximal phosphorylation sites, due to the importance of those regions in the 
regulation of YB-1 localisation and probably, functions (Bader and Vogt, 2005). 
There were additional phosphorylation sites that were identified in high-
throughput screens, such as the Y162 phospho-site, that were not detected in this 
study (Rush et al, 2005). Given the small subset of proteins that may be 
phosphorylated at any one time, it’s a possibility that some less prevalent 
phosphorylation sites might have remained undetected (Delom and Chevet, 2006). 
This might especially hold true if the method of phosphopeptide enrichment is more 
selective for certain more abundant phosphopeptides. However, it is not uncommon to 
observe false positive phosphopeptide identification in large-scale high-throughput 
proteomic screens, where putative phosphopeptides usually require some form of 
further validation due to dataset errors (mainly errors in the software based 
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assignment of phosphorylation sites) (Beausoleil et al, 2006; Delom and Chevet, 
2006; Lin et al, 2010). Another possibility might be that YB-1 may shows different 
phosphorylation signatures in different cell and tissue types, as it has been known to 
act differently in different cell-lines (Lasham et al, 2013). It has certainly been 
observed that YB-1 can suppress or enhance the E2F pathway in a cell type specific 
manner (reviewed by, Lasham et al, 2013). This topic is discussed further in chapter 
six. 
Treatment with doxorubicin and cisplatin did not appear to have any clear 
effect on the majority of the phosphorylation sites (Fig.3.12). Again, the abundance or 
lack of certain phosphopeptides under genotoxic stress would have been better studied 
using a quantitative, rather than a qualitative approach, highlighting one of the 
limitations of this study. Nonetheless, phosphopeptide T271 was absent from drug-
treated cells, and was only confined to the nucleus of unstressed cells. To determine if 
dephosphorylation at T271 is indeed associated with YB-1’s ability to induce drug 
resistance would require further studies. However, its implications in the nuclear 
localisation of YB-1 were further explored in this project (chapter four). 
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Chapter Four: YB-1 phospho-protein 
analysis 										
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4.0. Introduction 
YB-1 has been described as an oncogenic transcription factor in the nucleus of 
cells, where it also binds mRNA, and is involved in the alternative splicing of genes 
(reviewed by, Wu et al, 2007). In the cytoplasm YB-1 acts as a translation factor, 
inhibiting 5’ cap-dependent translation, and promoting 5’cap-independent translation 
(Evdokimova et al, 2009). Central to its localisation, phosphorylation at S102 by AKT 
and RSK 1/2 kinase was reported to induce YB-1’s nuclear translocation and promote 
its activity as an oncogenic transcription factor (Davies et al, 2014; Imada et al, 2013; 
Stratford et al, 2007). However, there have been conflicting reports of the functional 
consequences of S102 phosphorylation (Bader and Vogt, 2008; Sinnberg et al, 2012).  
This chapter explores most the phosphorylation sites identified by LC-MS MS 
(chapter three). Phosphorylation mutants close to the NLS and CRS were generated to 
study the importance of these phosphorylation sites on YB-1’s localisation, and 
overall observed oncogenic properties (explored in this chapter and the next).  
In this chapter the effects of wildtype YB-1 and phosphorylation mutants on 
localisation, chromatin condensation, and proliferation (a main hallmark of cancer) 
will be explored. 
4.1. YB-1 phosphorylation and localisation 
  A total of 7 phosphorylation sites were identified overall, spanning the CSD 
and C-terminal domains. Our original hypothesis was that there could be a phospho-
YB-1 species specific to the nucleus of drug-treated cells (see chapter one). However, 
no specific phosphorylation pattern specific to drug-treated nuclear or cytoplasmic 
YB-1 was evident. However, phosphorylation at threonine 271 was only detected in 
the nuclear fraction of unstressed cells (see chapter three). Regardless of 
phosphorylation signature, what is clearly evident is that YB-1 can be phosphorylated 
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at various residues, where at the present time, only the serine 102 phospho-residue has 
been studied extensively (reviewed by, Lasham et al, 2013; Mayya et al, 2009; 
Sutherland et al, 2005).  
 To determine the effects of phosphorylation on YB-1’s localisation, HA-
tagged phosphodeficient (Ser → Ala) mutants were generated and used for 
immunofluorescence studies. The selected PCR-generated mutants cover all 
phosphorylation sites proximal to the Nuclear Localisation Signal (NLS) and the 
Cytoplasmic Retention Signal (CRS) (Fig.3.12), and were compared with an HA-
tagged wildtype YB-1 protein. A phosphodeficient mutant for the CSD serine 102 
residue was also generated. All examples of nuclear and cytoplasmic staining 
throughout this chapter, whether in HCT116 or A549 cells, show images taken from 
the same microscope slide for each transfection experiment, with no difference in 
treatment (e.g. Fig. 4.1 & 4.2). 
 Wildtype YB-1-HA and several serine-to-alanine HA-tagged YB-1 mutants 
(S102A-HA, S165A-HA, S167A-HA, S174A-HA, S176A-HA), mimicking a constant 
unphosphorylated state (Further information on mutants in Appendix 2), were used 
for immunofluorescence studies in another epithelial cell-line, HCT116. This cell-line 
was previously optimised for immunofluorescence experiments in the laboratory 
(showed a better transfection efficiency than A549 cells).  
 Wildtype YB-1-HA and HA-tagged YB-1 mutants were transfected into 
HCT116 cells, and probed for localisation using a primary rabbit anti-HA antibody 
and secondary donkey anti-rabbit. Both recombinant YB-1-HA and mutants were 
observed as either mainly cytoplasmic, or cytoplasmic with an increased nuclear 
localisation (Fig.4.1 & 4.2). As with all localisation studies in this chapter, all 
assessments of YB-1 distribution were analysed visually and tallied. Wildtype YB-1-
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HA was observed mainly in the cytoplasm (Fig.4.3), whereas, the S102A-HA mutant 
along with all the NLS-proximal phosphorylation mutants showed a significant shift 
in YB-1 distribution, with a dramatic increase in nuclear YB-1 (Fig.4.2 & 4.3). These 
results suggest the importance of dephosphorylation at the CSD and NLS regions on 
YB-1’s localisation.  
 The Localisation of YB-1-HA and its mutants were scored, and compared 
using a chi-squared significance test (Raw data in Appendix 2). The average observed 
values of the mutant localisation distributions were compared to values of the 
wildtype YB-1-HA transfection, therefore allowing for a significance value to be 
determined for any deviations from the wildtype distribution. All mutants 
significantly increased nuclear localisation (p < 0.05), with the S167A-HA, S174A-
HA, and S176A-HA mutants showing the highest levels of YB-1 nuclear localisation 
(i.e. mutations closest to the NLS) (Fig.4.3). 
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Fig.4.1. Examples of immunofluorescent staining of HA-tagged YB-1 and its serine-to-
alanine mutants showing a mainly cytoplasmic localisation. HA-tagged YB-1 and mutants 
were transfected into HCT116 cells and probed using a primary rabbit anti-HA antibody and 
secondary 488nm Alexa Fluor® donkey anti-rabbit antibody. All cells showed some degree 
of nuclear localisation. a-c) YB-1-HA. d-f) S102A-HA mutant. g-i) S165A-HA. J-l) S167A-
HA. m-o) S174A-HA. p-r) S176A-HA. All nuclei were stained with DAPI.  
DAPI  YB-1-HA  YB-1-HA + DAPI 
S102A-HA DAPI  S102A-HA + DAPI 
 S165A-HA + DAPI S165A-HA DAPI 
 S167A-HA + DAPI S167A-HA DAPI 
 S174A-HA + DAPI S174A-HA DAPI 
 S176A-HA + DAPI S176A-HA DAPI 
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Fig.4.2. Examples of immunofluorescent staining of HA-tagged YB-1 and its serine-to-
alanine mutants showing a dramatic increase in nuclear localisation (i.e. cytoplasmic 
and nuclear distribution). HA-tagged YB-1 and mutants were transfected into HCT116 cells 
and probed using a primary rabbit anti-HA antibody and secondary 488nm Alexa Fluor® 
donkey anti-rabbit antibody. a-c) YB-1-HA. d-f) S102A-HA mutant. g-i) S165A-HA. J-l) 
S167A-HA. m-o) S174A-HA. p-r) S176A-HA. All nuclei were stained with DAPI.   
DAPI  YB-1-HA  YB-1-HA + DAPI 
S102A-HA DAPI  S102A-HA + DAPI 
 S165A-HA + DAPI S165A-HA DAPI 
 S167A-HA + DAPI S167A-HA DAPI 
 S174A-HA + DAPI S174A-HA DAPI 
 S176A-HA + DAPI S176A-HA DAPI 
		 145	
 
 
 
 
Fig.4.3. Phosphorylation-defective mutants increase YB-1 nuclear localisation. HA-
tagged YB-1 and its serine-to-alanine mutants were transfected into HCT116 cells and probed 
using a primary rabbit anti-HA antibody and secondary 488nm Alexa Fluor® donkey anti-
rabbit secondary antibody. Cells were scored as either nuclear and cytoplasmic, or mainly 
cytoplasmic, with the S167A-HA, S174A-HA, and S176A-HA mutants showing the highest 
levels of nuclear localisation. Each transfection experiment was repeated three times (n=3), 
where 100 transfected cells were analysed for each experiment. Distributions were compared 
between transfections using chi-squared tests (*p < 0.05; **p ≤ 0.01), and square brackets 
indicate chi-squared comparisons (Raw data in Appendix 2: Tables S1-S2). 
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 To determine if YB-1 dephosphorylation had an additive effect on nuclear 
localisation, a serine-to-alanine 174-176 double -mutant was generated, transfected 
into HCT116 cells, and analysed by immunofluorescence (note: a Texas red® 
secondary antibody was used instead of Alexa Fluor® due to its availability at the 
time) (Fig.4.4). This double-mutant combination was selected due to the close 
proximity of both sites to the NLS compared to other mutants, and their strong 
observed individual effects on nuclear localisation. It allowed for the simultaneous 
absence of phosphorylation (i.e. dephosphorylation) at two proximal residues to be 
investigated. The experiment also included the three highest nuclear localisation-
inducing mutants (i.e. S167A-HA, S174A-HA, and S176A-HA) (see Fig.4.3).  
No additive effect was observed with the double-mutant (Fig.4.4). However, it 
did show the same levels of nuclear localisation as the other NLS-proximal mutants.  
All mutants were found to significantly increase the nuclear localisation of YB-1 (p < 
0.005), when compared to the wildtype YB-1-HA transfection in a chi-squared 
significance test (Fig.4.4).   
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d)    e)    f)    
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Fig.4.4. The NLS most proximal phosphorylation-defective mutants increase nuclear 
localisation, but not additively (S174-176A-HA). HA-tagged YB-1 and its serine-to-alanine 
mutants were transfected into HCT116 cells and probed using a primary rabbit anti-HA 
antibody and secondary Texas red® donkey anti-rabbit antibody. a-f) Displayed are examples 
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of S174-176A-HA transfected cells that were scored as either mainly cytoplasmic (a-c), or 
nuclear and cytoplasmic (d-f). All nuclei were stained with DAPI. g) The S167A-HA, S174A-
HA, S176A-HA, and the double S174-176A-HA mutant showed the highest levels of YB-1 
nuclear localisation. However, the double-mutant did not have an additive effect on YB-1 
nuclear localisation. Each transfection experiment was repeated three times (n=3), where 100 
transfected cells were analysed for each experiment. Distributions were compared between 
transfections using chi-squared tests (**p ≤ 0.01), and square brackets indicate chi-squared 
comparisons (Raw data in Appendix 2: Tables S3-S4). 
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 Finally, to confirm the results observed with the HCT116 cells, the 
immunofluorescence experiments were repeated with a select few mutants in A549 
cells, where the phosphorylation sites were originally identified (Fig.4.5 & 4.6). 
 The study was expanded to include a threonine-to-alanine phosphodeficient, 
and a threonine-to-glutamate phosphomimetic mutant of the threonine 271 residue 
(See Appendix 2 for details on mutagenesis). This phosphorylation residue was the 
only site found proximal to the CRS signal (Fig.3.12). Both recombinant YB-1-HA 
and mutants were observed as either mainly cytoplasmic, or cytoplasmic with an 
increased nuclear localisation (Fig.4.5 & 4.6). 
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Fig.4.5. Examples of immunofluorescent staining of HA-tagged YB-1 and its 
phosphorylation-defective mutants showing a mainly cytoplasmic localisation. HA-
tagged YB-1 and its serine-to-alanine mutants were transfected into A549 cells and probed 
using a primary rabbit anti-HA antibody and secondary Texas red® donkey anti-rabbit 
antibody. All cells, regardless of the transfected plasmid, showed some degree of nuclear 
localisation. a-c) YB-1-HA. d-f) S102A-HA mutant. g-i) S176A-HA. J-l) T271A-HA. m-o) 
T271E-HA. All nuclei were stained with DAPI. 
DAPI  YB-1-HA  YB-1-HA + DAPI 
S102A-HA DAPI  S102A-HA + DAPI 
 S176A-HA + DAPI S176A-HA DAPI 
 T271A-HA + DAPI T271A-HA DAPI 
 T271E-HA + DAPI T271E-HA DAPI 
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a)    b)    c)    
 
 
 
 
 
 
 
 
d)    e)    f)    
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Fig.4.6. Examples of immunofluorescent staining of HA-tagged YB-1 and its 
phosphorylation-defective mutants showing a dramatic increase in nuclear localisation 
(i.e. cytoplasmic and nuclear distribution). HA-tagged YB-1 and its serine-to-alanine 
mutants were transfected into A549 cells and probed using a primary rabbit anti-HA antibody 
and secondary Texas red® donkey anti-rabbit antibody. a-c) YB-1-HA. d-f) S102A-HA. g-i) 
S176A-HA. J-l) T271A-HA. m-o) T271E-HA. All nuclei were stained with DAPI. 
  
DAPI  YB-1-HA  YB-1-HA + DAPI 
S102A-HA DAPI  S102A-HA + DAPI 
 S176A-HA + DAPI S176A-HA DAPI 
 T271A-HA + DAPI T271A-HA DAPI 
 T271E-HA + DAPI T271E-HA DAPI 
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The YB-1-HA transfection showed a mainly cytoplasmic distribution, as did 
most of the other transfections (Fig.4.7). This was also observed with the S102A-HA 
mutant, which unlike in HCT116 cells, showed no significant shift in nuclear 
localisation when compared to wildtype YB-1-HA (p > 0.05), indicating possible cell-
specific phenotypes. Only the S176A-HA mutant transfection increased YB-1 nuclear 
localisation significantly (p < 0.05), in line with what was observed with the HCT116 
cells. On the other hand, the T271A-HA mutant’s increase in nuclear localisation was 
not significant (p > 0.05). The T271E-HA phosphomimetic mutant however, did 
decrease nuclear localisation significantly, relative to the phosphodeficient T271A-
HA mutant (p < 0.05), suggesting a reversal of nuclear localisation with 
phosphorylation at the CRS (Fig.4.7). However, this reduction in nuclear localisation 
was not substantial enough to significantly differ from the wildtype YB-1-HA 
transfection. 
 The immunofluorescence data in general also revealed a large proportion of 
condensed nuclei (the appearance of densely packed nuclear DNA) with some 
transfections (See section 4.2.0.). Therefore, the relationship between 
dephosphorylation and nuclear condensation was then explored and quantified. This is 
discussed in detail in the following section. 
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Fig.4.7. The S176A-HA phosphorylation-defective mutant increases YB-1 nuclear 
localisation. HA-tagged YB-1 and its serine-to-alanine mutants were transfected into A549 
cells and probed using a primary rabbit anti-HA antibody and secondary Texas red® donkey 
anti-rabbit secondary antibody. Cells were scored as either nuclear and cytoplasmic, or 
mainly cytoplasmic, with the S176A-HA mutants showing the highest increase of nuclear 
localisation. Each transfection experiment was repeated three times (n=3), where 100 
transfected cells were analysed for each experiment. Distributions were compared between 
transfections using chi-squared tests (*p < 0.05; **p ≤ 0.01), and square brackets indicate chi-
squared comparisons (Raw data in Appendix 2: Tables S5-S6). 
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4.2. Condensed nuclei and YB-1 expression 
Wildtype YB-1-HA and the HA-tagged S102A-HA, S165A-HA, S167A-HA, 
S174A-HA, and S176A-HA mutants were transfected into HCT116 cells as 
previously described. Transfected cells showed either normal or condensed nuclei, 
which appeared as dense areas of DAPI staining throughout the nucleus (Fig.4.8), 
suggesting tighter chromatin packaging of DNA. Occasionally, condensed nuclei 
were also observed with untransfected cells, however, these observations were very 
rare and attributed to natural phenomena. A disproportionate amount of cells 
exhibiting condensed nuclei were observed with all YB-1 transfections (wildtype and 
mutants), compared to the negative control transfection (Fig.4.9).  
a)     b)    c)	 
 
 
 
 
Fig.4.8. An example of a condensed nucleus observed after YB-1-HA transfection, 
compared to normal nuclei of a negative (empty vector) control transfection. a) YB-1-
HA surrounding the condensed nucleus. b) A condensed nucleus. c) Normal nuclei after 
negative control transfection.  
  
 YB-1-HA + DAPI 
Condensed 
DAPI (YB-1-HA) DAPI (Neg. ctrl) 
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c)             d)        
 
 
 
 
 
 
 
e)             f)       
 
 
 
 
 
 
 
g)             h)      
 
 
 
 
 
 
 
i)             j)      
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Fig.4.9. Examples of condensed nuclear chromatin observed after YB-1-HA and 
phosphorylation-defective mutant transfections. HA-tagged YB-1 and its serine-to-alanine 
mutants were transfected into HCT116 cells and probed using a primary rabbit anti-HA 
antibody and secondary 488nm Alexa Fluor® donkey anti-rabbit antibody. The panels on the 
left show the transfected cells, whereas the panels on the right show the DAPI stained 
condensed nuclei. a-b) YB-1-HA. c-d) S102A-HA. e-f) S165A-HA. g-h) S167A-HA. i-j) 
S174A-HA. k-l) S176A-HA. m) Negative (empty vector) control with normal nuclei. 
	
DAPI  YB-1-HA + DAPI 
DAPI 
 
 S102A-HA + DAPI 
 S165A-HA + DAPI DAPI 
 
 S167A-HA + DAPI DAPI 
 
 S174A-HA + DAPI DAPI 
 
 S176A-HA + DAPI DAPI 
 
Neg. ctrl + DAPI 
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The presence of condensed nuclei in transfected cells were quantified 
(Fig.4.10), and found to correlate with increased nuclear localisation (compare to 
Fig.4.3). The S102A-HA, S167A-HA, S174A-HA, and S176A-HA mutants all 
showed the highest frequency of condensed nuclei in HCT116 cells. However, all 
YB-1 transfections, whether wildtype or mutant, increased the frequency of 
condensed nuclei significantly (p < 0.05), when compared to the negative (empty 
vector) control transfection (Fig.4.10).  
When transfections were also compared to the wildtype YB-1-HA transfection 
(Fig.4.10), all phosphodeficient mutants except S165A-HA were found to increase the 
frequency of condensed nuclei significantly (p ≤ 0.01). The observed increase in 
condensed nuclei with S165A-HA was not found to be significant (Raw data in 
Appendix 2).   
  
		 157	
 
Fig.4.10. HA-tagged YB-1 and phosphorylation-defective mutant transfections increase 
nuclear chromatin condensation. HA-tagged YB-1 and its serine-to-alanine mutants were 
transfected into HCT116 cells and probed using a primary rabbit anti-HA antibody and 
secondary 488nm Alexa Fluor® donkey anti-rabbit antibody. All nuclei were stained with 
DAPI and transfected cells were scored as either condensed or normal, based on nuclei 
staining, with the S167A-HA, S174A-HA, and the S176A-HA, mutant showing the highest 
levels of condensed nuclei. Each transfection experiment was repeated three times (n=3), 
where 100 transfected cells were analysed for each experiment. Distributions were compared 
between transfections using chi-squared tests (*p < 0.05; **p ≤ 0.01), and square brackets 
indicate chi-squared comparisons (Raw data in Appendix 2: Tables S9-S12). 
 
Repeat experiments with a select few mutants (S167A-HA, S174A-HA, and 
S176A-HA) and the double-mutant (S174-176A-HA) showed similar results, with no 
additive effect observed with the double-mutant (Fig.4.11). As observed in previous 
experiments, all YB-1 transfections increased the frequency of condensed nuclei 
significantly (p ≤ 0.01; Fig.4.11). In addition, when compared to the wildtype YB-1-
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HA transfection, all four selected mutants increased the frequency of condensed 
nuclei significantly (p ≤ 0.01).   
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a)  
 
b)    c)     d)  
 
 
 
 
 
 
 
 
 
 
 
Fig.4.11. The HA-tagged NLS proximal phosphorylation-defective mutants and S174-
176A-HA double-mutant show similar increases in condensed nuclear chromatin. HA-
tagged YB-1 and its serine-to-alanine mutants were transfected into HCT116 cells and probed 
using a primary rabbit anti-HA antibody and secondary Texas red® donkey anti-rabbit 
antibody. a) All nuclei were stained with DAPI and transfected cells were scored as either 
condensed or normal, based on nuclear staining. Each transfection experiment was repeated 
three times (n=3), where 100 transfected cells were analysed for each experiment. 
Distributions were compared between transfections using chi-squared tests (*p < 0.05; **p ≤ 
0.01), and Square brackets indicate chi-squared comparisons (Raw data in Appendix 2: 
Tables S13-S16). All mutants showed high levels of condensed nuclei. b) The S174-176A-
HA mutant surrounding the condensed nuclei. c) An example of a condensed nucleus after the 
S174-176A-HA mutant transfection.  
0	
10	
20	
30	
40	
50	
60	
C
el
ls
 w
ith
 c
on
de
ns
ed
 c
hr
om
os
om
es
 (%
) 
Plasmid overexpression 
Condensed	chromosomes	
													**											**											**											**	
				**										**											**											**											**	
 YB-1-HA + DAPI 
Condensed 
DAPI (YB-1-HA) Neg. ctrl + DAPI 
		 160	
Finally, to confirm the observed results in A549 cells, where the phospho-sites 
were originally identified, the experiment was repeated with YB-1-HA and two 
mutants (S102A-HA, S176A-HA). This study additionally included the T271 
phosphodeficient and phosphomimetic mutants, given the identification of this 
phospho-site in A549 cells.  
As observed in HCT116 cells, both condensed and normal nuclei were 
observed after transfections (Fig.4.12). Confirming previous results, YB-1-HA, and 
the S102A-HA and S176A-HA mutants all significantly increased the frequency of 
condensed nuclei when compared to the control (empty vector) transfection (p < 0.05; 
Fig.4.13). The T271E-HA mutant was also found to significantly increase the 
frequency of condensed nuclei (p ≤ 0.01), but this was not the case with the T271A 
mutant. The T271A-HA mutant showed fewer condensed nuclei than the negative 
(empty vector) control, indicating an exception to the trend of the increasing 
frequency of condensed nuclei with dephosphorylation. 
When the mutants were compared to the wildtype YB-1-HA transfection, the 
S102A-HA and S176A-HA mutants, as observed with the HCT116 cells, increased 
the frequency of condensed nuclei significantly (p ≤ 0.01; Fig.4.13). On the other 
hand, the T271 mutants, both phospho-defective and phosphomimetic, showed no 
significant change from wildtype YB-1-HA (p > 0.05).  
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a)    b)    k)    
 
 
 
 
 
 
 
 
c)    d)     
 
 
 
 
 
 
 
 
e)    f)     
 
 
 
 
 
 
 
 
g)    h)     
 
 
 
 
 
 
 
 
i)    j)     
 
 
 
 
 
 
 
Fig.4.12. Examples of condensed nuclear chromatin observed with HA-tagged YB-1 and 
phosphorylation-defective mutant transfections. HA-tagged YB-1 and its serine-to-alanine 
mutants were transfected into A549 cells and probed using a primary rabbit anti-HA antibody 
and secondary Texas red® donkey anti-rabbit antibody. Displayed are examples of cells 
observed with condensed nuclei. Each row represents a plasmid transfection: a-b) YB-1-HA. 
c-d) S102A-HA mutant. e-f) S176A-HA. g-h) T271A-HA. i-j) T271E-HA. k) Negative 
(empty vector) control transfection (normal nuclei). All nuclei were stained with DAPI. 
DAPI  YB-1-HA + DAPI 
DAPI  S102A-HA + DAPI 
 S176A-HA + DAPI DAPI 
 T271A-HA + DAPI DAPI 
 T271E-HA + DAPI DAPI 
Neg. ctrl + DAPI 
		 162	
 
Fig.4.13. HA-tagged YB-1 and phosphorylation defective mutants, excluding the T271A-
HA mutant, increase nuclear chromatin condensation in A549 cells. HA-tagged YB-1 and 
its serine-to-alanine mutants were transfected into A549 cells and probed using a primary 
rabbit anti-HA antibody and secondary Texas red® donkey anti-rabbit secondary antibody. 
Nuclei were scored as either condensed or normal, with the S102A-HA and S176A-HA 
mutants showing the highest levels of condensed nuclei. Each transfection experiment was 
repeated three times (n=3), where 100 transfected cells were analysed for each experiment. 
Distributions were compared between transfections using chi-squared tests (*p < 0.05; **p ≤ 
0.01), and square brackets indicate chi-squared comparisons (Raw data in Appendix 2: Tables 
S17-S20). 
 
4.3. YB-1-HA and phosphorylation-defective mutants do not induce apoptosis 
Given the association of condensed nuclei with the early stages of apoptosis 
(Toné et al, 2009), it was hypothesised that the condensed nuclei observed upon YB-1 
transfection were due to the activation of apoptosis. To determine if this was indeed 
the case, an apoptosis assay was carried out on YB-1-HA and phospho-mutant 
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transfected HCT116 cells. The assay works by detecting caspase-3 activity, a 
hallmark of apoptosis (Gown and Willingham, 2001).  
Cells were stained with Nucview™ caspase-3 detection 488nm, a green dye 
attached to a caspase-3 substrate peptide sequence, which is activated upon cleavage 
by the key apoptosis effector caspase-3 (Lakhani et al, 2006). Cleavage of this 
substrate allows the green dye to translocate to the nucleus and stain apoptotic nuclei 
green (Biotium Incorporation, USA). However, in the present analysis, nuclei with 
activated caspase-3 were indicated with a turquoise colour, due to nuclear co-staining 
with DAPI (Fig.4.14.a). As in previous sections, to ensure only transfected cells were 
assessed, HA-tagged wildtype YB-1 and HA-tagged mutants were analysed with a 
primary rabbit anti-HA antibody and a Texas red® secondary donkey anti-rabbit 
antibody. Therefore, the analyses were conducted using a total of three fluorescent 
dyes (YB-1/mutant: red, DAPI = blue, Caspase-3 positive = green). No negative 
control was used for this experiment, as caspase-3 positive apoptosis was completely 
absent from all wildtype and mutant YB-1 transfections in a preliminary study. 
Accordingly, only a positive control was used to demonstrate the assay was 
functional. The positive control was treated with 30 µM of Mitmab to induce 
apoptosis, and resulted in a ~50% cell death rate. Mitmab works by Inhibiting 
Dynamin II, which is necessary for endocytosis, therefore resulting in apoptosis (Joshi 
et al, 2011). Almost no apoptotic cells were detected with all transfections relative to 
the positive apoptosis control. None of the YB-1-HA or phospho-mutants showed an 
apoptosis level higher than 2-3% (Fig.4.14.b), indicating that the cells displaying 
condensed nuclei were probably not undergoing apoptosis.  
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a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
 
Fig.4.14. HA-tagged YB-1 and its phosphorylation defective mutants do not induce 
caspase-3 dependent apoptosis. HA-tagged YB-1 and serine-to-alanine mutants 167, 174, 
176, and 174-176 were transfected into HCT116 cells and assessed for apoptosis using a 
caspase 3 assay. HA-tagged YB-1 and mutants were probed using a primary rabbit anti-HA 
antibody and secondary Texas red® donkey anti-rabbit antibody. Cells expressing YB-1-HA 
or mutants were then assessed for apoptosis by the presence of a green dye, activated by the 
cleavage from caspase 3. a) An example of one of the few caspase positive YB-1-HA cells, 
revealing a turquoise colour due to joint green (caspase positive) and DAPI co-staining. All 
cells were co-stained with DAPI. b) Caspase +/- cells were quantified, revealing almost no 
apoptotic cells after transfection. Each transfection experiment was repeated three times 
(n=3), where 100 transfected cells were analysed for each experiment.  
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The next step of this study was to explore the effects of these phospho-mutants 
on proliferation, a hallmark of cancer, given the original aims of this study of 
uncovering the effects of YB-1 phosphorylation on tumorigenesis. These experiments 
are still in the preliminary phase, and were reported to provide some insight into the 
involvement of YB-1 phosphorylation in cell proliferation. 
4.4. YB-1 dephosphorylation and proliferation 
Cancers are characterised by accelerated tumour cell growth and proliferation 
(reviewed by Fearnhead, 2002). Given the reported role of YB-1 in cell proliferation 
(as discussed in Chapter 1), the phospho-mutants were utilised to explore this role 
further. Wildtype YB-1-HA and several phosphorylation-defective HA-tagged YB-1 
mutants (S102A-HA, S165A-HA, S167A-HA, S174A-HA, S176A-HA, and S174-
176A-HA) were transfected into A549 cells. YB-1 plasmids were co-transfected with 
~10% pN1-mcherry plasmid to allow visualisation of transfected cells with live cell 
imaging 24 hours post transfection (1:10 µg ratio of mcherry plasmid to YB-1-
HA/mutant/control plasmids). The transfection ratio is indicated by a molar ratio, 
which was slightly under 10% (~1:8 pmoles). With this procedure, the mcherry-
positive cells were assumed to be carrying the 10-fold more abundant co-transfected 
plasmid of interest (indirect conservative scoring).  Cell proliferation was then 
observed over 72 hours with a Cell Voyager™ live imaging microscope (Yokogawa, 
Japan) at 10x magnification. Photographs of the live cells were recorded every hour, 
where each plasmid transfection had 5 different fields to be photographed hourly. All 
individual cells, expressing mcherry (exhibiting a red fluorescent colour), were then 
counted manually for each field, and the average number of cells for all 5 fields were 
calculated for each transfection (mcherry had a 3-5% transfection efficiency).  
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This experiment was repeated three times, but due to the variability in initial 
cell numbers between photographed fields in each experiment, they were graphed 
separately; albeit, with consistent patterns observed between experiments. A line of 
best fit was used to represent the proliferation of each plasmid transfection in order to 
allow transfections of differently observed initial cell numbers to be compared 
accurately, and without modifying the data (Fig.4.15). This method also allowed for 
proliferation gradients to be compared between transfections in order to rank 
proliferation rates accordingly (Table 4.1). For all three experiments, H-RAS was 
used as a positive control, which showed a dramatic increase in the rate of 
proliferation for all three experiments (Fig.’s 4.15, 4.16, and 4.17), indicating 
successful plasmid co-transfections. An empty vector plasmid was used as the 
negative control. 
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 a) 
 
 
b) 
 
Fig.4.15. Rate of proliferation experiment 1: YB-1 and phosphorylation-defective 
mutants have varying effects on the rate proliferation. HA-tagged YB-1 and its HA-
tagged serine-to-alanine mutant plasmids were co-transfected with an mcherry plasmid (ratio 
of 1:10 mcherry to YB-1-HA/mutant/control) into A549 cells, and observed for 72 hours 
under live cell imaging. A line of best fit was run through the observed data distribution for 
each transfection. Transfections were split into two graphs for clarity: a) Positive (H-RAS) 
and negative (empty vector) controls, YB-1-HA and the NLS most proximal mutant 
transfections showing varying rates of proliferation b) Positive (H-RAS) and negative (empty 
vector) controls, YB-1-HA, and the remaining mutant transfections showing varying rates of 
proliferation (the S167A-HA mutant was included for comparison). Proliferation distributions 
were compared between the negative control transfection and all other transfections using 
Mann-Whitney U tests (*p < 0.05; **p ≤ 0.01; Actual p-values in Appendix 2). 
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Table 4.1. Proliferation experiment 1: Rates of A549 cell proliferation. YB-1-
HA/phosphorylation-deficient mutant/or plasmid control transfections, ranked 
according to gradient slope of best-fit lines drawn through the proliferation 
distributions of each transfection (gradients dependent on proliferation rate from 
Fig.4.15). 
Transfection Slope formula Ranking according to slope 
S165A-HA y = 0.6235x - 1.7632 1 
Positive ctrl (Ras) y = 0.4736x + 1.4054 2 
S174-176A-HA y = 0.4384x - 1.3405 3 
S174A-HA y = 0.3832x + 0.2129 4 
S102A-HA y = 0.3758x - 1.7596 5 
Negative ctrl. y = 0.2602x - 0.9236 6 
S176A y = 0.2552x + 1.5985 7 
YB-1-HA y = 0.2177x + 6.036 8 
S167A-HA y = 0.0955x + 0.5187 9 
 
In experiment 1, wildtype YB-1-HA did not seem to boost proliferation, 
showing a rate of proliferation lower than that of the negative (empty vector) control 
(Fig.4.15; Table 4.1) The last two time points of YB-1-HA proliferation in this 
experiment were biased due to the culture reaching maximum confluency, and 
therefore artificially slowing down the rate of proliferation. Once corrected for these 
time points (i.e. cutoff of final two time points), wildtype YB-1-HA maintained an 
above negative (empty vector) control proliferation rate (Table 4.2), but still did not 
appear to have a dramatic effect on proliferation.   
The highest rates of cell proliferation were observed with the S165A-HA and 
S174-176A-HA double-mutant, whereas the lowest rates of proliferation were 
observed with the S167A-HA and S176A-HA mutants, which both showed 
proliferation rates lower than the negative (empty vector) control. 
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Table 4.2. Proliferation experiment 1 (corrected for confluent YB-1 time points): 
Rates of A549 cell proliferation. YB-1-HA/phosphorylation-deficient mutant/or 
plasmid control transfections, ranked according to gradient slope of best-fit lines 
drawn through the proliferation distributions of each transfection (gradients dependent 
on proliferation rate from Fig.4.15). 
Transfection Slope formula Ranking according to slope 
S165A-HA y = 0.6235x - 1.7632 1 
Positive ctrl (Ras) y = 0.4736x + 1.4054 2 
S174-176A-HA y = 0.4384x - 1.3405 3 
S174A-HA y = 0.3832x + 0.2129 4 
S102A-HA y = 0.3758x - 1.7596 5 
YB-1-HA y = 0.2869x + 4.8527 6 
Negative ctrl. y = 0.2602x - 0.9236 7 
S176A y = 0.2552x + 1.5985 8 
S167A-HA y = 0.0955x + 0.5187 9 
 
The second experiment also revealed that the S165A-HA and S174-176A-HA 
double-mutant transfection had the highest rates of proliferation, followed by 
wildtype YB-1-HA, whereas the NLS most proximal mutants S167A-HA, S174A-
HA, and S176A-HA had the lowest rates of proliferation (Fig.4.16; Table 3). 
However, only the S167A-HA mutant showed a proliferation rate below the negative 
(empty vector) control. It should be noted that there is a reasonable possibility that 
this experiment failed, as a very few cells were successfully transfected.  
Finally, experiment 3 showed that the S174-176A-HA double-mutant, 
wildtype YB-1-HA, and the S165A-HA mutant had the highest rates of proliferation, 
whereas the lowest rates of proliferation were all observed with the three NLS most 
proximal mutants, S167A-HA, S174A-HA, and S176A-HA, which all were below the 
negative (empty vector) control proliferation rate (Fig.4.17; Table 4).  
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a) 
 
 
b) 
 
Fig.4.16. Rate of proliferation experiment 2: YB-1 and phosphorylation-defective 
mutants have varying effects on the rate proliferation. HA-tagged YB-1 and its HA-
tagged serine-to-alanine mutant plasmids were co-transfected with an mcherry plasmid (ratio 
of 1:10 mcherry to YB-1-HA/mutant/control) into A549 cells, and observed for 72 hours 
under live cell imaging. A line of best fit was run through the observed data distribution for 
each transfection. Transfections were split into two graphs for clarity: a) Positive (H-RAS) 
and negative (empty vector) controls, YB-1-HA and the NLS most proximal mutant 
transfections showing varying rates of proliferation b) Positive (H-RAS) and negative (empty 
vector) controls, YB-1-HA, and the remaining mutant transfections showing varying rates of 
proliferation (the S167A-HA mutant was included for comparison). Proliferation distributions 
were compared between the negative control transfection and all other transfections using 
Mann-Whitney U tests (*p < 0.05; **p ≤ 0.01; Actual p-values in Appendix 2). 
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Table 4.3. Proliferation experiment 2: Rates of A549 cell proliferation. YB-1-
HA/phosphorylation-deficient mutant/or plasmid control transfections, ranked 
according to gradient slope of best-fit lines drawn through the proliferation 
distributions of each transfection (gradients dependent on proliferation rate from 
Fig.4.16). 
Transfection Slope formula Ranking according to slope 
Positive ctrl (Ras) y = 0.1221x + 0.4876 1st 
S174-176A-HA y = 0.0418x + 1.014 2nd 
S165A-HA y = 0.041x + 0.6615 3rd 
YB-1-HA y = 0.0322x + 1.3102 4th 
S102A-HA y = 0.0219x + 1.4282 5th 
S176A y = 0.0175x + 1.2617 6th 
S174A-HA y = 0.0153x + 1.6934 7th 
Negative ctrl. y = 0.014x + 1.9257 8th 
S167A-HA y = 0.0031x + 1.2839 9th 
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a)  
 
 
b) 
 
Fig.4.17. Rate of proliferation experiment 3: YB-1 and phosphorylation-defective 
mutants have varying effects on the rate proliferation. HA-tagged YB-1 and its HA-
tagged serine-to-alanine mutant plasmids were co-transfected with an mcherry plasmid (ratio 
of 1:10 mcherry to YB-1-HA/mutant/control) into A549 cells, and observed for 72 hours 
under live cell imaging. A line of best fit was run through the observed data distribution for 
each transfection. Transfections were split into two graphs for clarity: a) Positive (H-RAS) 
and negative (empty vector) controls, YB-1-HA and the NLS most proximal mutant 
transfections showing varying rates of proliferation b) Positive (H-RAS) and negative (empty 
vector) controls, YB-1-HA, and the remaining mutant transfections showing varying rates of 
proliferation (the S167A-HA mutant was included for comparison). Proliferation distributions 
were compared between the negative control transfection and all other transfections using 
Mann-Whitney U tests (*p < 0.05; **p ≤ 0.01; Actual p-values in Appendix 2). 
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Table 4.4. Proliferation experiment 3: Rates of A549 cell proliferation. YB-1-
HA/phosphorylation-deficient mutant/or plasmid control transfections, ranked 
according to gradient slope of best-fit lines drawn through the proliferation 
distributions of each transfection (gradients dependent on proliferation rate from 
Fig.4.17). 
Transfection Slope formula Ranking according to slope 
Ras y = 0.1545x + 0.6387 1st 
S174-176A-HA y = 0.1032x + 3.5618 2nd 
YB-1-HA y = 0.0939x + 0.8619 3rd 
S165A-HA y = 0.0919x + 1.153 4th 
Negative ctrl. y = 0.0702x + 2.9176 5th 
S102A-HA y = 0.0639x + 1.7867 6th 
S176A y = 0.0567x + 3.4737 7th 
S174A-HA y = 0.0543x + 1.5311 8th 
S167A-HA y = 0.044x + 1.0491 9th 
 
Mann-Whitney U tests were used to compare transfections to the negative 
(empty vector) control. The S165A-HA (Fig.4.15; experiment 1) and S174-176A-HA 
double-mutant (Fig.4.17; experiment 3) were both found to increase the rate of 
proliferation significantly (p < 0.05), whereas the NLS most proximal mutants, 
S167A-HA (Fig.4.16 & 4.17; experiments 2 & 3), S174A-HA (Fig.4.17; experiment 
3), S176A-HA (Fig.16; experiment 2) were found to decrease the rate of proliferation 
significantly (p < 0.05). Although these mutants did not significantly affect 
proliferation in every experiment (probably due to small sample sizes), trends did 
appear consistent amongst experiments. The S165A-HA and S174-176A-HA double-
mutant increased the rate of proliferation, whereas the NLS most proximal mutants 
appeared to have an anti-proliferative effect. This was especially evident with the 
S167A-HA mutant (Actual p-values in Appendix 2).  
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4.5. Discussion 
 YB-1 was found to be phosphorylated at various residues, with seven sites 
unequivocally identified by mass spectrometry (Fig.4.18). These phosphorylation 
sites were identified in both the nucleus and cytoplasm of A549 cells, with the T271 
site being the only exception, where it was identified twice only in the nucleus of 
untreated (no genotoxic stress) cells.   
 Immunofluorescence studies with the phosphorylation-defective mutants in 
HCT116 and A549 cells revealed that the S102A-HA, S165A-HA, S167A-HA, 
S174A-HA, S176A-HA, and S174-176A-HA mutants increased nuclear localisation 
significantly (p < 0.05; Fig.’s 4.3-4 & 7). The NLS most proximal, S167A-HA, 
S174A-HA, S176A-HA, and S174-176A-HA double-mutant showed the highest 
levels of nuclear localisation in these experiments. These studies also showed that 
phosphorylation at the T271-HA residue (i.e. T271E-HA phosphomimetic mutant) did 
not increase nuclear localisation significantly (p > 0.05; Fig.4.7), demonstrating an 
exception to the pattern observed in previous experiments of dephosphorylation 
increasing the nuclear localisation of YB-1. The immunofluorescence studies also 
revealed that YB-1-HA and the HA-tagged phosphorylation-defective mutants all 
induced a significantly higher frequency of condensed nuclei, with the T271A-HA 
mutant (phospho-defective) being the only exception (Fig.’s 4.10-11 & 13). 
Additionally, the data indicated that the NLS most proximal mutants, S167A-HA, 
S174A-HA, S176A-HA, and S174-176A-HA, showed the highest frequency of 
condensed nuclei, and were independent of apoptosis (Fig.4.14). 
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Fig.4.18. A linear representation of the YB-1 protein with identified phosphorylation 
sites accumulated from A549 cell lysates by mass spectrometry (LC-MS MS). YB-1 
antibody epitope a is indicated at the N-terminus of the protein. 
 
 Finally, the effects of YB-1-HA and the HA-tagged phosphorylation-defective 
mutants on proliferation were assessed showing varying results, with the NLS most 
proximal mutants, S167A-HA, S174A-HA, and S176A-HA all showing a significant 
antiproliferative effect (p < 0.05; Fig.’s 4.15-17). The S167A-HA mutant always 
showed the lowest levels of proliferation (Fig.’s 4.15-17; Tables 4.1-4), whereas only 
two amino acids away, the S165A-HA mutant significantly increased the rate of 
proliferation (p < 0.05; Fig.4.15). In addition, double mutations at the S174-176A-HA 
residues had a reverse effect on proliferation, compared to the single mutants, where it 
increased the rate of proliferation significantly (p  < 0.05; Fig.4.17).  
 The observed trends in this chapter are discussed in the following subsections. 
For a broader and deeper discussion of all results, refer to chapter 6. As stated in the 
results section, 
4.5.1. YB-1 immunofluorescence studies 
The number of cells with nuclear wildtype YB-1-HA varied between the 
HCT116 and A549 cell transfections. This is consistent with the literature, where 
distributions of nuclear and cytoplasmic YB-1 were reported to vary greatly according 
to cell type (reviewed by, Kosnopfel et al, 2014). For example, using a validated 
antibody against epitope a (Fig.4.18), nuclear YB-1 varied between 0-48%, and 
cytoplasmic between 76-100% of total cellular YB-1 in a variety of cancer cell lines, 
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with YB-1 observed as predominantly cytoplasmic in most studies, regardless of 
antibody type or epitope (Kosnopfel et al, 2014). Nevertheless, the levels of YB-1-HA 
observed in the nucleus of the A549 cells in this study were slightly elevated from 
previous experiments (Fig.4.7), which might be an artifact of overexpression, or 
possibly due to culturing conditions (cells grown to confluency repeatedly).  
When it comes to the S102A-HA mutant, the results were contrary to previous 
studies where phosphorylation, and not dephosphorylation at S102, was reported to be 
required for the nuclear localisation and transcriptional activity of YB-1 (Stratford et 
al, 2007; Sutherland et al, 2005). However, the S102A-HA defective mutant showed 
an increase in nuclear localisation in HCT116 cells  (Fig. 4.3). Phosphorylation at 
S102 may indeed be required for YB-1’s transcriptional activity; nevertheless, there 
have been reports of YB-1 translocating to the nucleus free of S102 phosphorylation 
(Bader and Vogt, 2008; Sinnberg et al, 2012). This suggests the involvement of 
additional factors, such as certain cell-specific binding partners that might affect YB-
1’s nuclear translocation, or the possible involvement of other residues (e.g. NLS 
proximal dephosphorylation).  
The phosphorylation-defective mutants most proximal to the NLS showed the 
highest levels of nuclear localisation in this study, which might suggest a dominant 
role for these residues in the nuclear localisation of YB-1 (Fig.’s 4.3-4 & 4.7).  In 
HCT116 cells the three most proximal mutants to the NLS (S167A-HA, S174A-HA, 
and S176A-HA) all showed the highest levels of nuclear localisation, with similar 
levels of nuclear localisation observed with the S174-176A-HA double-mutant 
(effects of double-mutant were not additive). Dephosphorylation at these residues 
might expose the NLS signal to proteins associated with nuclear transportation, thus 
effecting the nuclear translocation of YB-1. One of the NLS proximal mutants 
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selected for further studies with the A549 cells showed similar results (S176A-HA; 
Fig.4.7). Defective phosphorylation at the S176 site (i.e. S176A-HA) showed 
consistent results between the HCT116 and A4549 experiments, suggesting that at 
least when it comes to the NLS region, dephosphorylation drives YB-1’s nuclear 
translocation across different cell and tissue types. 
This was not the case with the S102A-HA and T271A-HA mutants that were 
observed in A549 cells (Fig.4.7). The S102A mutant did not show any significant 
increase in nuclear localisation when compared to the wildtype YB-1-HA 
transfection, in line with previous studies in the literature (Sutherland et al, 2005). 
However, YB-1-HA demonstrated an elevated nuclear localisation in these 
experiments, which might be masking any increases observed with the S102A-HA 
transfection (i.e. S102A-HA nuclear localisation was not significantly different from 
the YB-1-HA transfection). The T271A-HA mutant, on the other hand, was not 
expected to increase nuclear localisation like the other mutants, as the T271 
phosphopeptide was found to be exclusive to the nucleus in the mass spectrometry 
analysis (Fig.3.12). The exclusivity of the T271 phosphopeptide to the nucleus of 
untreated cells in the mass spectrometry analysis did not hold true when the T271E-
HA phosphomimetic mutant was probed in the A549 cells immunofluorescence 
studies. Phosphorylation at the T271 site (i.e. phosphomimetic mutation) showed a 
nuclear localisation frequency similar to that of the wildtype YB-1-HA transfections, 
and even showed significantly lower nuclear localisation than the T271A-HA mutant 
(p  < 0.05; Fig.4.7). The proximity of the T271 residue to the CRS might explain this 
phenomenon, as phosphorylation proximal to the CRS might induce interactions with 
proteins that increase cytoplasmic retention.  
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Although, these results rule out the involvement of T271 phosphorylation in 
the induction of YB-1 nuclear localisation, its involvement in drug-resistance in 
general remains to be explored. Some of the observed phenotypes of these mutants are 
discussed in the following subsections. 
4.5.2. YB-1 and chromatin modification  
YB-1 transfections increased the frequency of condensed nuclei in all 
experiments carried out in HCT116 and A549 cells, suggesting wildtype YB-1 plays a 
central role in chromatin condensation (Fig.’s 4.10-11. & 4.13.). Dephosphorylation 
had a positive effect on nuclear chromatin condensation, where all phosphorylation-
defective mutants in HCT116 colorectal cells increased the frequency of cells 
displaying chromatin condensation (Fig.’s 4.10-11). The results with the S102A-HA 
and S176A-HA mutants were confirmed in A549 cells (Fig.’s 4.13). However, the 
T271A-HA mutant was an exception, where phosphorylation (T271E-HA) and not 
dephosphorylation (T271A-HA) was found to increase the frequency of condensed 
nuclei. The T271E-HA mutant increased nuclear chromatin condensation significantly 
when compared to the negative (empty vector) control (p ≤ 0.01; Fig.4.13), but was 
not significantly different from the wildtype YB-1-HA transfections (p > 0.05), 
suggesting phosphorylation at T271 does not increase wildtype YB-1 driven 
chromatin condensation.  
The mostly cytoplasmic T271E-HA mutant and wildtype YB-1-HA 
transfections always significantly increased nuclear chromatin condensation when 
compared to the negative (empty vector) controls (p < 0.05; Fig.4.13), which might 
suggest that chromatin condensation is independent of nuclear localisation. However, 
the increase in chromatin condensation observed with the NLS most proximal mutants 
in HCT116 cells suggests otherwise, where chromatin condensation was found to 
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increase with mutants that showed an increased nuclear localisation (Fig.’s 4.3-4 & 
4.7). This was also observed with S176A-HA mutant in A549 cells (Fig.’s 4.7 & 
4.13).  
On the other hand, the S102A-HA transfections did not significantly increase 
the nuclear localisation of YB-1 in A549 cells (p > 0.05; Fig.4.13), yet these 
experiments did show elevated levels of nuclear localisation regardless of transfection 
type, which might account for the observed S102A-HA phenotype.  
The data suggests that the low level of T271E-HA and/or wildtype YB-1 
observed in the nucleus might be sufficient to induce chromatin condensation, and 
increases in nuclear localisation, as observed with the NLS most proximal mutants, 
would therefore result in an increased frequency of chromatin condensation. This 
increased frequency may in turn be inhibited or hindered by dephosphorylation at 
T271 (Fig.4.13); indicating selective and carefully regulated dephosphorylation within 
the CSD and NLS region may be required to increase the frequency of nuclear 
chromatin condensation. Consequently, dephosphorylation outside these regions 
might have the complete opposite effects and consequences. 
The caspase assay results (Fig.4.11) strengthen the argument that these 
mutants are directly driving chromatin condensation, and that the observed condensed 
nuclei are not a consequence of apoptosis. However, an extended caspase assay would 
be required to confirm this phenomenon (i.e. beyond 48 hours after transfection). 
Caspase-independent apoptosis, on the other hand, is unlikely as caspase-3 is 
indispensable for chromatin condensation during programmed cell death (Hirata et al, 
1998; Sahara et al, 1999; reviewed by, Porter and Janicke, 1999). Other natural 
processes such as mitosis are also associated with chromatin condensation (Fig.1.6). 
Nevertheless, mitosis being behind the observed chromatin condensation remains 
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unlikely, as the cell proliferation experiments (discussed in the following subsection) 
showed no correlation between chromatin condensation and cell proliferation, where 
most mutants that induced chromatin condensation did not promote cell proliferation 
(Fig.’s 4.15-17).  
These experiments implicate YB-1 directly in nuclear chromatin condensation, 
which may be attributed to its transcriptional activity (Astanehe et al, 2012). It 
remains plausible that YB-1-HA and mutants influence chromatin modeling through 
chromatin modification pathways (discussed in more detail in chapter six). YB-1 has 
been observed, through CHIP assays, to bind the promoters of several chromatin 
modeling and associated genes, including the promoters of several histone deacetylase 
and histone component genes (Astanehe et al, 2012). It has also been found to bind 
several chromatin modeling associated proteins such as CTCF (CCCTC-binding 
Factor) and NPM1 (NucleoPhosMin 1), all of which might contribute to the changes 
observed with chromatin modeling after YB-1 nuclear translocation (Chen et al, 2013; 
Chernukhin et al, 2000; Lindström, 2010; Philips and Corces, 2009; Young et al, 
2005) (further discussions in chapter six).  
4.5.3. YB-1 and tumour outgrowth and proliferation 
As stated in the results section, these experiments were still in the preliminary 
phase, and were reported to provide some insight into the involvement of YB-1 
phosphorylation in cell proliferation. Further more robust studies in a wide variety of 
cell lines would be needed to confirm any of the below discussed observations and 
conclusions. 
Given the reported proliferation enhancing properties of YB-1, the wildtype 
YB-1-HA transfection unexpectedly showed no significant increase in A549 cell 
proliferation (p > 0.05; Fig.’s 4.15-17). This might be due to the fact that A549 cells 
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already show an abnormally high rate of proliferation. However, small sample sizes 
might be another issue, since mcherry transfections were carried out at a ratio of 1:10 
(µg ratio of mcherry plasmid to YB-1-HA/mutant/control plasmids) to maximise the 
chances of counting YB-1-HA and mutant/control transfections during scoring (i.e. 
conservative scoring). This in turn may have resulted in smaller sample sizes for each 
transfection, and a lower overall number of cells counted. This is especially evident 
with experiment 2 (Fig.4.16), where there is a reasonable possibility that the 
experiment may have failed, due to the extremely low transfection efficiency. This 
experiment, although corroborating both experiments 2 & 3, demonstrated a much 
lower transection rate than the other experiments. Nevertheless, more robust 
experiments are required to make any final conclusions (discussed in chapter six). 
The NLS most proximal single mutants all showed significantly lower levels 
of cell proliferation (p  < 0.05; Fig.’s 4.15-17). This might be a possible consequence 
of the increased chromatin condensation observed with these mutants, as DAPI 
preferentially associates with heterochromatic A-T rich regions (Barros e Silva and 
Guerra, 2010), which might be suppressing cell proliferation genes (Fig.’s 4.10-11 & 
13) (Narita et al, 2003). It has certainly been observed that heterochromatin formation 
suppresses E2F target genes, which is a pathway directly regulated by YB-1 (Lasham 
et al, 2012; Narita et al, 2003). The proliferation assay results are consistent with this, 
where mutants that were the highest drivers of chromatin condensation (dense DAPI 
staining) showed significantly lower levels of cell proliferation, and were either no 
different (e.g. S102A-HA mutant; p > 0.05), or significantly lower in proliferation 
rate (NLS most proximal mutants; p  < 0.05), than the negative (empty vector) control 
transfections. Surprisingly however, the S174-176A-HA double-mutant, a likewise 
activator of chromatin condensation, overcomes this growth suppression/or basal level 
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of proliferation (Fig.4.17). The S165A-HA mutant, also a nearby residue, 
significantly increases chromatin condensation (p ≤ 0.01; Fig.4.10), and shows a 
significant increase in the rate of cell proliferation (p < 0.05; Fig.4.15). These results 
weaken the theory of chromatin condensation/gene silencing being behind the lower 
rates of proliferation, and suggest these effects are probably attributed to YB-1’s 
transcription factor activities in the nucleus.  
The complex nature of the observed phenotypes suggest that 
dephosphorylation proximal to the NLS might have strong implications on what 
protein binding partners can bind YB-1, and consequently which genes are activated 
or repressed (e.g. YB-1 target E2F genes-described by Lasham et al, 2012). The 
involvement of various binding partners and mechanisms of YB-1 regulation confer 
many of YB-1’s functions, and add to the complexity of the observed phenotypes. 
Potential binding partners and modes of regulation will be discussed further in 
the general discussion of chapter six.   
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Chapter Five: YB-1 dephosphorylation 
and cell migration 										
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5.0. Introduction 
Cancer cells require mesenchymal-like properties to become invasive and 
metastatic (Yilmaz and Christofori, 2009). Among these acquired properties is the 
increased ability to migrate and invade neighbouring tissues. Cell migration is 
important for embryonic development, immune surveillance, and wound repair 
(reviewed by, Binamé et al, 2010). It is also central to metastasis, a hallmark of 
cancer, as tumour cells need to migrate to invade neighbouring tissues and distant 
organs to form secondary tumours (Weinberg and Hanahan, 2011).  
YB-1 has been described in many studies as a driver of cell migration and 
invasion (Evdokimova et al, 2009; Schittek et al, 2007). More recent studies include a 
report that YB-1 and the GOLgi PHosphoprotein 3 (GOLPH3) protein were observed 
to be elevated in glioblastomas, where GOLPH3 increased cell migration and invasion 
via the mammalian Target Of Rapamycin (mTOR)-YB-1 pathway (Zhou et al, 2014). 
Another study revealed that siRNA knockdown of YB-1 in gastric cancer cells 
significantly inhibited migration and invasion in vitro (Guo et al, 2015).   
 
Fig.5.1. A schematic diagram of cancer cells migrating and invading surrounding tissue 
(WebMD, 2002).  
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Given the many pathways of YB-1 driven migration and invasion (see chapter 
one), it is plausible that some of the identified YB-1 phosphorylation sites (see 
chapter three) play a role in regulating its involvement with these pathways. To date, 
serine-102 (p-YB-1102) remains the only YB-1 phosphorylation site described to be 
involved with migration and invasion (Sinnberg et al, 2012). To explore the possible 
involvement of other phosphorylation sites in the regulation of YB-1 dependent cell 
migration, YB-1 phosphorylation-defective mutants were assessed in cell migration 
assays. Cell migration can be studied by measuring the cells’ velocity and directional 
persistence (Fig.5.2) (Gail et al, 1970). This relationship is explored through 
observing the YB-1/mutant influence on single cell migration speed and persistence. 
These experiments, as with the cell proliferation experiments, are still in the 
preliminary phase, and were reported to provide some insight into the involvement of 
YB-1 phosphorylation in single cell migration. Further more robust studies in a wide 
variety of cell lines would be needed to confirm the below discussed observations and 
conclusions. 
Wildtype YB-1-HA and the HA-tagged mutants S102A-HA, S165A-HA, 
S167A-HA, S174A-HA, S176A-HA, S174-176A-HA, T271A-HA, and T271E-HA 
were transfected into primary osteosarcoma derived Saos-2 cells, a cell-line 
previously optimised and used for migration experiments in the laboratory. Saos-2 
cells were found to migrate under confluent conditions (highly invasive), and were 
selected to fit the purpose of this study. Four-chambered 35 mm dishes were each 
seeded with 25,000 cells per chamber 24 hours prior to transfection, with each 
chamber then transfected with either YB-1-HA, a mutant, or control plasmid. These 
plasmids were also co-transfected with ~10% of pN1-mcherry plasmid to allow the 
visualisation of transfected cells under live cell imaging (1:10 ratio of mcherry 
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plasmid to YB-1-HA/mutant/control plasmids). The transfection ratio is indicated by 
a molar ratio, which was slightly under 10% (~1:8 pmoles).   
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Fig.5.2. Cell migration can be random or directed (persistent), depending on either 
intrinsic cell directionality or external regulation, respectively (reviewed by Petrie et al, 
2009). Directed migration plays an important role in metastasis, allowing cells to recognise 
and migrate towards an external stimulus (e.g. directed invasion to chemoattractant/gradient 
from surrounding tissue) (Anand-Apte et al, 1997, Petrie et al, 2009). 
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  The transfection ratio of 1:10 mcherry to YB-1-HA/mutant/control plasmid 
maximised the chances of selecting co-transfected YB-1-HA or mutant/control 
transfected cells during scoring (i.e. indirect conservative scoring), as mcherry-
positive cells were assumed to be carrying the much more abundant plasmid of 
interest (mcherry had a ~1% transfection efficiency). For all experiments, H-RAS was 
used as a positive control transfection to demonstrate increased migration (Shin et al, 
2005), whereas an empty vector plasmid was used as a negative control. 
Once confluent, 48 hours post-transfection, cell cultures were scratched with a 
pipette tip through the center of each chamber (creates a gradient for directed cell 
migration). Cell migration into the scratch “wound” was then observed over 48 hours 
with a Cell Voyager™ live imaging microscope (Yokogawa, Japan). Imaging was 
carried out at 10x magnification (5% CO2), where photographs of live cells were 
taken every 5 minutes. Each plasmid transfection within each chamber had 5 fixed 
fields to be photographed at every time point. All images were then imported into 
imageJ 1.46r (NIH) as an image sequence, and cells observed expressing mcherry	
(exhibiting red fluorescent dye) were tracked manually using an MTrackJ plugin 
(Fig.5.3).  
From the time-lapse images, single cell migrations were tracked manually 
(Fig.5.3), and the relative migration distance from the starting point over time, and 
migration direction were recorded. Migration speed (overall distance travelled [µm] 
/elapsed time [seconds]) and directional persistence (direct distance [µm] /overall 
distance travelled [µm]) were then calculated for each individually tracked cell 
(Fig.5.3.b). These experiments will be discussed in the following subsections. 
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a) 
 
b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.5.3. Overview of the single cell migration assay (“Scratch assay”). (a) Confluent cells 
were scratched with a p100 pipette tip, and the migration of single cells into the scratch 
“wound” (indicated by red arrows) was observed with live-cell imaging using a Cell Voyager 
microscope (10x magnification). The migration of YB-1-HA/mutant/control transfected cells 
were visualised by observing the red fluorescent dye of the pN1-mcherry co-transfected 
plasmid (1:10 mcherry plasmid to YB-1-HA/mutant/control plasmid). Images were exported 
as a sequence to ImageJ 1.46r (NIH), and mcherry-positive cells were tracked individually 
using an MTrackj plugin. Cells were tracked manually following the cell centroid (in red1), 
and the migration distance over time and direction were recorded. (b) Migration speed 
(overall distance travelled [µm]/elapsed time [seconds]) and persistence (direct distance 
[µm]/overall distance travelled [µm]) were calculated for each individually tracked cell (e.g. 
point A to B).  
Tracking migration with a co-transfected mcherry 
plasmid 
Migration 
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5.1. YB-1 and migration speed 
Saos-2 transfected cells were individually assessed for migration speed, 
calculated as the distance travelled by each cell (in µm) divided by the elapsed time in 
seconds (i.e. total migration of the tracked cells over time). The average speed of all 
tracked cells for each plasmid transfection was calculated and graphed in Figure 5.4. 
(Refer to Appendix 3 for information on data distributions for each transfection). The 
negative (empty vector) control transfected cells showed an average migration speed 
of 9.0 × 10-3 µm/s, which is between the ~8.0 × 10-3 - 1.0 × 10-2 µm/s range observed 
with most of the other transfections (Fig.5.4). The positive (H-RAS) control 
transfected cells, on the other hand, showed an increase in average migration speed 
(1.7 × 10-2 µm/s), almost double the migration speed observed with the negative 
(empty vector) control, YB-1-HA, and most of the other mutant transfections. This 
observation is consistent with work from others, wherein H-RAS was shown to 
approximately double migration speed in another cell line (Munever et al, 2001). This 
highlights the effectiveness of the positive (H-RAS) control. The YB-1-HA 
transfected cells and almost all other mutant transfections showed similar average 
migration speeds (S165A-HA, S167A-HA, S174A-HA, S176A-HA, and T271E-HA), 
comparable to that of the negative (empty vector) control cells. However, the S174-
176A-HA and T271A-HA mutants were observed to increase the average single cell 
migration speed to that above the range of 8.0 × 10-3 - 1.0 × 10-2 µm/s that was 
observed with all the other YB-1 transfections (Fig.5.4). 
For each transfection, depending on the nature of the overall data distribution 
(Appendix 3), the mean migration speed was compared to that of the negative (empty 
vector) control transfection by either a t-test or Mann Whitney-U test (Fig.5.4). A t-
test was used for comparisons between parametric distributions, whereas a Mann 
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Whitney-U was used for data exhibiting a non-parametric distribution (Lehmann, 
1999). All distributions were tested for normality using several statistical tests (refer 
to Appendix 3).  
The positive (H-RAS) control was found to be significantly different from the 
negative (empty vector) control transfection (p < 0.0001), which would be expected, 
given the two-fold increase in migration speed observed with the positive (H-RAS) 
control transfection (Fig.5.4). However, YB-1-HA and almost all the other mutants 
(S102A-HA, S165A-HA, S167A-HA, S174A-HA, S176A-HA, and T271E-HA) were 
found to not be significantly different from the negative (empty vector) control 
transfection (p > 0.05). The 174-176A-HA double-mutant however, increased average 
single cell migration speed significantly (p < 0.0001), despite the single serine-to-
alanine mutants at either the 174 or 176 residues, showing no significant difference 
from the negative (empty vector) control transfection (p > 0.05). The T271A-HA 
mutant was also found to significantly increase average migration speed when 
compared to the negative (empty vector) control transfection (p < 0.008). However, 
the phosphomimetic mutant of the same residue (T271E-HA) appeared to return YB-1 
average migration speed to a level comparable to the negative (empty vector) control 
(i.e. no significant difference; p > 0.05). 
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Fig.5.4. The S174-176A and T271A YB-1 mutants increase the average single cell 
migration speed of Saos-2 cells. Average single cell migration speed was compared between 
YB-1-HA, HA-tagged mutants, and control transfections of Saos-2 cells. All cells were 
tracked manually using ImageJ 1.46r with an MTrackJ plugin, and single cells from each 
transfection were assessed for migration speed (distance travelled [µm]/elapsed time 
[seconds]). Compiled from a total of two experiments, an average of 25 cells were assessed 
per transfection. Depending on the data distribution for each transfection, a two-tailed t-test or 
Mann-Whitney U test was used to compare average single cell migration speed of each 
transfection to the negative (empty vector) control (Data distributions in Appendix 3: Fig.’s 
S1-S11). 
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5.1.1. YB-1 knockdown and migration speed 
Since the increase in migration speed was observed with the double S174-
176A-HA mutant, but none of its corresponding single S174A-HA or S176A-HA 
mutants, it was hypothesised that the single-residue mutants might have been exerting 
a more subtle and hence undetected effect on migration speed that was being masked 
by endogenous YB-1 (i.e. hence the requirement of both mutations to observe the 
increased speed phenotype). To explore why the 174-176A double-mutant increased 
migration speed significantly (p < 0.0001; Fig.5.4), but neither of its corresponding 
single-residue mutants (S174A-HA and S176A-HA) appeared to do so, one of the 
single-residue mutants was selected for further studies in a reduced endogenous YB-1 
setting. For this experiment, the S176A-HA plasmid was transfected into Saos-2 cells 
after endogenous YB-1 knockdown (i.e. knockdown of cell’s wildtype YB-1). 
Recombinant wildtype YB-1 (YB-1-HA) was also included in this experiment for 
comparison, as well as the positive (H-RAS) and negative (empty vector) controls. 
The siRNA sequences used in this study target the genes’ 5’- or 3’- UnTranslated 
Regions (UTR), present exclusively in the mRNA of endogenous YB-1, and hence are 
designed to be specific to endogenous and not exogenous or mutant YB-1. The 
knockdown was previously optimised in A549 cells. These results are discussed 
below. 
To determine the most effective siRNA sequence for the endogenous YB-1 
knockdown, three siRNA sequences were optimised for knockdown in A549 cells 
(cell-line used in previous knockdown experiments). Optimisation experiments for 
this chapter were originally carried out in A549 cells, as all experiments were initially 
intended with this cell-line. However, A549 cells were not suitable for the ‘scratch 
assay’, as a highly invasive cell-line was essential for the required experimental 
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conditions (Fig.5.3).  Nevertheless, the tools optimised with A549 cells that are 
presented within this chapter (i.e. Fig.5.5 and 5.6) were then applied to the Saos-2 cell 
migration experiments. 
YB-1 was knocked down with siRNA-4, -7, and -8 for a duration of 4 days. 
The siRNA-4 sequence is specific to the 5’- UTR, whereas the siRNA-7 and -8 
sequences are 3’- UTR specific. Additionally, YB-1 was knocked down with both 5 
nM and 20 nM of siRNA, to determine an optimum RNA concentration for the 
knockdown. Following knockdown, cells were harvested and total cellular YB-1 was 
analysed by western with a validated rabbit anti-YB-1 antibody. YB-1 expression was 
then compared between the knockdowns and control (scrambled RNA) (Fig.5.5). Blot 
intensities for this western blot were assessed visually.  The siRNA-4 sequence 
showed the highest levels of YB-1 knockdown (visible without quantitation); 
however, increased siRNA concentrations did not appear to enhance the effectiveness 
of knockdown over and above 5nM.  
 Finally, to determine the minimum duration for optimal knockdown, 
endogenous YB-1 was knocked down for three, four, and five days with siRNA-4. 
The three-day knockdown was the most effective knockdown period, although the 
variation of the levels of knockdown between days was limited (Fig.5.6). 
Additionally, there might be some Lipofectamine® associated toxicity effects with a 
prolonged knockdown, as the protein blots appear to reduce in intensity beyond three 
days (i.e. less protein might indicate less viable cells). Although an equal amount of 
cells were harvested from each day for the western blot, the added stress from the 
harvest might have reduced protein yields further in the cells already stressed from the 
prolonged knockdown (i.e. more cell death). However, the toxicity does not appear to 
have any effect beyond the fourth day.  
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Fig.5.5. Endogenous YB-1 knockdown optimisation: siRNA-4 showed the highest levels 
of YB-1 knockdown. 5’- and 3’- UTR-specific YB-1 siRNA sequences were used to 
knockdown YB-1 in A459 cells in a four-day knockdown. YB-1 was targeted with three 
different siRNA sequences (Qiagen) at two concentrations (5 and 20 nM), and analysed by 
western blot. It was probed with a validated rabbit anti-YB-1 antibody, where expression was 
compared between YB-1 knockdowns and the control (scrambled RNA) knockdown (Ctrl) 
sample. Increased siRNA concentrations did not appear to have an effect on knockdown 
effectiveness. However, the siRNA-4 sequence did show the highest levels of YB-1 
knockdown. The ponceau-stained blot shows equal protein loading.  
   
	
50 
 
	
kDa 
 
	
siRNA-4 
siRNA-7 
siRNA-8 
      SiRNA: M    -4   -7   -8  Ctrl   -4     -7 -8 
	
40 
 
	
Ponceau-stained 
blot 
 
		 196	
a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.5.6. Knockdown period optimisation: YB-1 was knocked down with siRNA-4 for 
three, four, and five days in A549 cells at 5 nM. Samples were then analysed by western 
blot and YB-1 was probed with a validated rabbit anti-YB-1 antibody (C=control [scrambled 
RNA]; KD= knockdown). The ponceau-stained blot shows equal protein loading. b) Blots 
were later quantitated for intensity to determine the most effective knockdown period.  Blot 
intensities were quantified and standarised to their individual controls (Imagequant LAS 
4000®). The three-day knockdown period was the most effective YB-1 knockdown. 
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Upon determining the optimum conditions for the endogenous YB-1 specific 
knockdown, siRNA-4 was used to knockdown YB-1 in Saos-2 cells, before 
transfecting with either recombinant YB-1-HA, S176A-HA, or the positive (H-
RAS)/negative (empty vector) control plasmids 24 hours post-knockdown. Along 
with the required plasmid transfection (YB-1-HA/S176A-HA /controls), cells were 
co-transfected with ~10% of pN1-mcherry plasmid to allow visualisation with live 
cell imaging. An outline of these experiments is presented in Figure 5.7. 
Cells were seeded at day 0, in preparation for the siRNA knockdown. 
Endogenous YB-1 was then knocked down on day 2, followed by the plasmid 
transfections at day 3 (YB-1-HA, S176A-HA, control plasmids). Control (scrambled 
RNA) knockdowns were also set up for each transfection. At day 4, the cells from 
each transfection were then transferred into 35 mm four-chambered dishes, at 25,000 
cells per chamber. Confluent cells were then scratched once through the middle of 
each culture using a p100 pipette tip and analysed with live cell imaging, 48 hours 
post plasmid transfection (day 5). Cell migration into the scratch “wound” was 
immediately observed over 48 hours with a Cell Voyager live imaging microscope at 
10× magnification. Finally, upon completion of live imaging on day 7, the images 
were imported into ImageJ 1.46r as an image sequence, and single cell migration was 
tracked using an MTrackJ plugin.  
At the start of live imaging, cells that were treated with siRNA in parallel 
(under the same conditions), were harvested to confirm successful endogenous YB-1 
knockdown and plasmid expression. As observed from the western blot of the 
recombinant YB-1-HA transfection (Fig.5.8), endogenous YB-1 expression decreased 
in intensity with the endogenous YB-1 specific knockdown, whereas no decrease in 
expression was observed with recombinant YB-1-HA. As for the control (scrambled 
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RNA) knockdown, the lower observed intensity of the recombinant YB-1 (YB-1-HA) 
blot might be attributed to unequal protein loading (ponceau-stained blot shows more 
protein loaded onto the knockdown lane).   
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Fig.5.7. An overview of the migration experiment in the setting of reduced endogenous 
YB-1 expression. Cells were seeded at day 0, in preparation for the siRNA knockdown. YB-1 
was then knocked down on day 2, followed by the plasmid transfections at day 3 (YB-1-HA, 
S176A-HA, control plasmids). Control knockdowns were also set up for each transfection. At 
day 4, the cells from each transfection were then transferred into 35 mm four-chambered 
dishes, at 25,000 cells per chamber. Confluent cells were then “scratched” and analysed with 
live cell imaging, 48 hours post plasmid transfection (day 5). Live cell imaging was run for 48 
hours to day 7. Finally, upon completion of live imaging on day 7, the images were imported 
into ImageJ 1.46r as an image sequence, and single cell migration was tracked using an 
MTrackJ plugin. Cells were tracked manually following the cell centroid (in red1), and the 
migration distance and direction were recorded. The migration speed (overall distance 
travelled [µm]/elapsed time [seconds]) and persistence (direct distance [µm]/overall distance 
travelled [µm]) was then calculated for each tracked cell. 
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Fig.5.8. Endogenous YB-1 knockdown coupled with recombinant YB-1-HA transfection 
in Saos-2 cells. Endogenous YB-1 was knocked down in Saos-2 cells for three days with 
siRNA-4 at 5 nM. On day three of the knockdown, cells were then transfected with 
recombinant YB-1-HA. The cells were harvested 48 hours post-transfection and YB-1 was 
analysed by western blot. YB-1 was probed with a validated rabbit anti-YB-1 antibody, where 
expression was compared between the YB-1 knockdown (KD) and the control (scrambled 
RNA) knockdown (Ctrl) sample. As visible from the western blot, the endogenous YB-1 
expression decreased in intensity with knockdown (lower arrowß), whereas no decrease in 
expression was observed with the transfected recombinant YB-1-HA in the knockdown lane 
(upper arrow ß). This being the case despite the knockdown lane showing less protein 
loading on the ponceau-stained blot. 
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Following live cell imaging, cells were tracked using the same procedure 
explained in Figure 5.3, and the migration speed (overall distance travelled 
[µm]/elapsed time [seconds]) for each individually tracked cell was then calculated. 
The results from the migration speed analysis showed that the negative (empty vector) 
control transfection, in the context of reduced endogenous YB-1 expression, had an 
average migration speed of 9.6 × 10-3 µm/s (Fig.5.9). This value is between the 8.0 × 
10-3 - 1.0 × 10-2 µm/s range observed with all other transfections after YB-1 
knockdown, which includes the positive (H-RAS) control, YB-1-HA, and the S176A-
HA transfection. The lack of an apparent increase in migration speed with the S176A-
HA mutant transfection in the absence of endogenous YB-1 demonstrated that this 
mutant did not have an unrealised effect (boost) on migration speed that was being 
masked by endogenous YB-1. Therefore, phospho-defective mutations at both S174 
and S176 (i.e. S174-176A-HA) are probably required to increase migration speed 
significantly (Fig.5.4.).  
 In the presence of endogenous YB-1, all cells migrated at an average speed of 
between 1.0 - 1.2 × 10-2 µm/s. This was the case with all transfections from the 
negative (empty vector) and positive  (H-RAS) controls to YB-1-HA and the S176A-
HA mutant. The positive (H-RAS) control transfection showed a much more dramatic 
increase in average migration speed in the presence of endogenous YB-1 (control 
knockdown), where it was observed to increase to 1.2 × 10-2 µm/s, up from 8.4 × 10-3 
µm/s in a reduced endogenous YB-1 setting. This result suggests the importance of 
endogenous wildtype YB-1 in maintaining H-RAS driven migration (discussed in 
chapter six). 
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Fig.5.9. YB-1 knockdown decreases H-RAS driven migration speed dramatically. The 
average single cell migration speed was compared between YB-1-HA, S176A-HA, and 
control plasmid transfections in Saos-2 cells, in the presence of endogenous YB-1 or control 
knockdown. All cells were tracked manually using ImageJ 1.46r with an MTrackJ plugin, and 
single cells from each transfection were assessed for migration speed (distance travelled 
[µm]/elapsed time [seconds]). Compiled from a single experiment, an average of 67 cells 
were assessed per transfection (Data distributions in Appendix 3: Fig.’s S12-S19). 
  
0	
0.002	
0.004	
0.006	
0.008	
0.01	
0.012	
0.014	
Av
er
ag
e 
si
ng
le
 c
el
l m
ig
ra
tio
n 
sp
ee
d 
(µ
m
/s
) 
Plasmid overexpression 
		 203	
The average migration speed was compared between transfections using 
Mann-Whitney U tests, given the non-parametric distributions of the data (Appendix 
3). First, comparisons between all plasmid transfections and the negative (empty 
vector) controls were carried out, starting with the transfections under endogenous 
YB-1 knockdown (Table 5.1). Plasmid transfections YB-1-HA, S176A-HA, and the 
positive (H-RAS) control, under endogenous YB-1 knockdown were compared to the 
negative (empty vector) control transfection under endogenous YB-1 knockdown, 
revealing no significant differences in average migration speed (p > 0.05). However, 
when transfections were compared with the negative (empty vector) control in the 
presence of endogenous YB-1, the positive (H-RAS) control increased the rate of 
migration significantly (p < 0.01; Table 5.2). YB-1-HA and the S176A-HA mutant, 
on the other hand, did not show any significant change from the negative (empty 
vector) control in this setting (p > 0.05). The significant increase (p < 0.05) in H-RAS 
driven migration speed, only observed in the presence of endogenous YB-1, suggests 
H-RAS requires the presence of functional YB-1 (at adequate amounts) to maintain an 
elevated migration speed, despite YB-1-HA overexpression itself not showing any 
significant increase in migration speed (p > 0.05; Table 5.2). 
Table 5.1. Mann-Whitney U tests to compare average migration speed between 
the positive (H-RAS) control, YB-1, S176A transfections and the negative (empty 
vector) control transfection, in the presence of endogenous YB-1 knockdown. 
Plasmid overexpression with YB-1 knockdown Negative (empty vector) control plasmid 
with YB-1 knockdown 
p-score (two-tailed) 
Positive (H-RAS) control plasmid transfection  0.077 (Mann-Whitney U) 
YB-1-HA  0.707 (Mann-Whitney U) 
S176A-HA  0.732 (Mann-Whitney U) 		 	
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Table 5.2. Mann-Whitney U tests to compare average migration speed between 
positive (H-RAS) control, YB-1, S176A transfections, and the negative (empty 
vector) control transfection, in the presence of a control knockdown. 
Plasmid overexpression with control knockdown Negative (empty vector) control plasmid 
with control knockdown 
p-score (two-tailed) 
Positive (H-RAS) control plasmid transfection  0.011 (Mann-Whitney U) 
YB-1-HA  0.804 (Mann-Whitney U) 
S176A-HA  0.838 (Mann-Whitney U) 
 
Finally, the average migration speed was compared within each transfection 
(i.e. endogenous YB-1 knockdown vs. control knockdown for each transfection). 
Only the positive control showed a significant difference in migration speed between 
the endogenous YB-1 knockdown and control (scrambled RNA) knockdown, 
suggesting that H-RAS only increases migration speed in the presence of endogenous 
YB-1, where reducing endogenous YB-1 levels dampened the effects of H-RAS on 
cell migration speed (p < 0.0001; Table 5.3). This observation further strengthens the 
proposed role of YB-1 in maintaining H-RAS-dependent increases in migration speed 
(Evdokimova et al, 2009) (discussed in chapter six). Recombinant YB-1-HA and the 
S176A-HA plasmid transfections showed no significant difference in average 
migration speed, whether under endogenous YB-1 knockdown, or under control 
(scrambled RNA) knockdown (p > 0.05). 
Table 5.3. Mann-Whitney U tests to compare the average migration speed 
between YB-1 and control knockdowns within YB-1, positive (H-RAS) control, 
negative (empty vector) control, and S176A plasmid transfections. 
Plasmid overexpression p score (two-tailed) 
Positive (H-RAS) control plasmid transfection (YB-1 
knockdown vs Control knockdown)  
 < 0.0001 (Mann-Whitney U) 
Negative (empty vector) control plasmid transfection (YB-1 
knockdown vs Control knockdown) 
0.169 (Mann-Whitney U) 
 
YB-1-HA (YB-1 knockdown vs. Control knockdown) 0.313 (Mann-Whitney U) 
S176A-HA (YB-1 knockdown vs Control knockdown) 0.450 (Mann-Whitney U) 
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5.2. YB-1 and migration persistence  
From the migration speed experiment in section 5.1 (Fig.5.4) YB-1-HA, 
control, and mutant plasmids S102A-HA, S165A-HA, S167A-HA, S174A-HA, 
S176A-HA, S174-176A-HA, T271A-HA, and T271E-HA were then analysed for 
effects on migration persistence.  
Migration persistence is an estimate of a cells ability to migrate in a persistent 
direction, and is measured as the ratio of the direct distance between two points and 
the overall distance travelled between these two points by a migrating cell (Fig.5.10). 
The directional persistence (direct distance [µm]/overall distance travelled [µm]) was 
calculated for each individually tracked cell, with values closer to “0” indicating low 
persistence, and values approaching “1” indicating higher persistence. The negative 
(empty vector) control transfection had an average migration persistence value of 
0.21, which was lower than most transfections (Fig.5.10). The positive (H-RAS) 
control transfection, on the other hand, revealed a much higher value of 0.34. YB-1-
HA and the single S174A-HA and S176A-HA mutant transfections revealed 
persistence values closer to the negative (empty vector) control, which was observed 
to be within the range of ~ 0.2 - 0.25. The S102A-HA, S165A-HA, and double 174-
176A-HA mutant transfection revealed much higher persistence values, which were 
closer to the positive (H-RAS) control value (0.3 - 0.35 range). The S165A-HA and 
the S174-176A-HA double-mutant transfection even showed higher persistence 
values than the positive (H-RAS) control. Finally, the T271A/E-HA mutant 
transfections both showed the lowest values of migrational persistence. 
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a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
 
Fig.5.10. A comparison of the average persistence of single cell directional migration 
between YB-1, control, and mutant transfected Saos-2 cells. a) Single cells from each 
transfection were analysed for persistence in directional migration, where the persistence was 
calculated as the ratio of direct distance migration from start to finish (e.g. point A to B, 
indicated by the red arrow), to the overall migration distance (direct distance [µm]/overall 
migration distance [µm]). All cells were tracked manually using ImageJ 1.46r with an 
MTrackJ plugin. Compiled from a total of two migration experiments, an average of 25 cells 
were assessed per transfection. Depending on the data distribution for each transfection, a 
two-tailed t-test or Mann-Whitney U test was used to compare average single cell migration 
persistence of each transfection to the negative (empty vector) control. (Data distributions in 
Appendix 3: Fig.’s S20-S31).   
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  Mann-Whitney U tests were used to compare migration persistence values 
between transfections, as all the data showed non-parametric distributions (Appendix 
3). All directional persistence values, for each transfection, were compared to the 
negative (empty vector) control transfection (Fig.5.10). The positive (H-RAS) control 
transfection, as well as, S102A-HA, S165A-HA, S167A-HA, and the S174-176A-HA 
double-mutant transfection, all increased migration persistence significantly (p < 
0.05) when compared to the negative (empty vector) control. However, the YB-1-HA 
transfection, along with the S174A-HA and S176A-HA single mutants, as well as the 
T271A-HA and T271E-HA mutants, were not significantly different from the 
negative (empty vector) control (p > 0.05). 
Examples of single cell migration patterns are illustrated in Figure 5.11, where 
each figure represents three different cells of the transfection in question. Only the 
positive (H-RAS) and negative (empty vector) controls, and the transfection showing 
the highest significant increase (p < 0.05) in migration persistence are illustrated 
below (Fig.5.11). More examples of migration patterns for these transfections are 
illustrated in Appendix 3. Transfections showing no significant difference from the 
negative (empty vector) control, and all other transfections are also illustrated in 
Appendix 3.   
The negative (empty vector) control transfection clearly shows a dysregulated 
random migration pattern (Fig.5.11.a), centering around the same regional 
coordinates, as was also observed at varying degrees with the YB-1-HA, S174A-HA, 
S176A-HA, T271A & E -HA transfections (Appendix 3). The positive (H-RAS) 
control, S165A-HA mutant, and the double S174-176A-HA mutant (Fig.5.11) 
transfections all showed much more persistent migration patterns, in line with their 
observed persistence values (Fig.5.10). These transfections showed migration 
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spreading out much further over the two-dimensional plane, migrating away from the 
point of origin with less changes in direction. Similar migration patterns were also 
observed with the directionally persistent S102A-HA and S167A-HA mutant 
transfections (Appendix 3). 
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a) 
     
b) 
     
c) 
     
d) 
     
Fig.5.11. Random and persistent single-cell migration tracks in Saos-2 cells. Each of the 
four graphs represent the migration patterns of three cells of a single transfection. The Negative 
(empty vector) control transfection (a), illustrates random migration. Transfections of the 
Positive (H-RAS) control (b), S165A-HA (c), and S174-176A-HA (d), illustrate persistent 
migration. All cells were tracked individually using ImageJ 1.46r with an MTrackJ plugin.   
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5.2.1. YB-1 knockdown and migration persistence 
Since the increase in migration persistence was observed with the double 
S174-176A-HA mutant, but none of its corresponding single S174A-HA or S176A-
HA mutants, it was hypothesised that the single-residue mutants might have been 
exerting an undetected effect on migration persistence that was being masked by 
endogenous YB-1. To explore why the 174-176A-HA double-mutant increased 
migration persistence significantly (p < 0.005; Fig.5.10), but neither of its 
corresponding single-residue mutants (S174A-HA and S176A-HA) appeared to do so, 
one of the single-residue mutants was selected for further studies in a reduced 
endogenous YB-1 setting. From the migration speed experiment in section 5.1.1 
(Fig.5.9), the positive (H-RAS) control, negative (empty vector) control, YB-1-HA, 
and the S176A-HA mutant transfection were analysed for migration persistence. As 
outlined previously (in section 5.1.1), the optimised siRNA-4 sequence was used for a 
three-day endogenous YB-1 specific knockdown in Saos-2 cells. The cells were then 
transfected with the plasmids of interest (YB-1-HA/mutant/controls + ~10% mcherry 
plasmid), and analysed for migration speed (Fig.5.9) and persistence (Fig.5.12). 
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Fig.5.12. A Comparison of average single cell persistence of directional migration 
between YB-1 and mutant transfections of Saos-2 cells, in the presence or absence of 
endogenous YB-1 knockdown. Single cells from each transfection were assessed for the 
persistence of directional migration (direct distance [µm]/overall migration distance [µm]). 
All cells were tracked manually using ImageJ 1.46r with an MTrackJ plugin. Compiled from 
a single experiment, an average of 67 cells were assessed per transfection (Data distributions 
in Appendix 3: Fig.’s S32-S39). 
  
0	
0.05	
0.1	
0.15	
0.2	
0.25	
0.3	
0.35	
0.4	
0.45	
M
ig
ra
tio
n 
pe
rs
is
te
nc
e 
 
Plasmid overexpression 
		 212	
The migration persistence analysis revealed that the negative (empty vector) 
control plasmid transfections, both in the presence or absence (reduced) of 
endogenous YB-1, had a persistence value of ~ 0.27 (Fig.5.12). The positive (H-RAS) 
control transfections showed average migration persistence values of 0.28 in the 
presence of endogenous YB-1, and 0.31 in the absence of endogenous YB-1. On the 
other hand, the YB-1-HA plasmid transfection showed a slightly higher persistence 
value in the absence of endogenous YB-1 (0.37), and a persistence value of 0.31 in 
the presence of endogenous YB-1. Finally, the S176A-HA mutant transfections 
showed the lowest values for migration persistence, both in the presence (~ 0.26) or 
absence (~ 0.23) of endogenous YB-1.  
Mean persistence values in the absence of endogenous YB-1 were compared 
between all transfections and the negative (empty vector) control transfection, where 
no significant differences were found (p > 0.05; Table 5.4). This was also the case 
when transfections were compared to the negative (empty vector) control transfection 
in the presence of endogenous YB-1 (p > 0.05; Table 5.5). Comparisons of mean 
persistence values within each transfection also did not reveal any significant results 
(p > 0.05; Table 5.6).  
Table 5.4. Mann-Whitney U tests to compare average migration persistence 
between positive (H-RAS) control, YB-1, S176A transfections and the negative 
(empty vector) control transfection, in the presence of endogenous YB-1 
knockdown. 
Plasmid overexpression with YB-1 knockdown Negative control plasmid with 
YB-1 knockdown 
p-score (two-tailed) 
Positive (H-RAS) control plasmid transfection  0.337 
YB-1-HA  0.056 
S176A-HA  0.140 
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Table 5.5. Mann-Whitney U tests to compare average migration persistence 
between the positive (H-RAS) control, YB-1, S176A transfections and the 
negative (empty vector) control transfection, in the presence of a control 
knockdown. 
Plasmid overexpression with control knockdown Negative control plasmid with 
control knockdown 
p-score (two-tailed) 
Positive (H-RAS) control plasmid transfection  0.686 
YB-1-HA  0.538 
S176A-HA  0.309 
 
 
Table 5.6. Mann-Whitney U tests to compare the average migration persistence 
between YB-1 and control knockdowns within YB-1, positive (H-RAS) control, 
negative (empty vector) control, and S176A plasmid transfections. 
Plasmid overexpression p score (two-tailed) 
Positive (H-RAS) control plasmid transfection (YB-1 
knockdown vs Control knockdown)  
0.313 
Negative (empty vector) control plasmid transfection (YB-1 
knockdown vs Control knockdown) 
0.674 
YB-1-HA (YB-1 knockdown vs. Control knockdown) 0.148 
S176A-HA (YB-1 knockdown vs Control knockdown) 0.174 
 
This experiment, although showing a significantly upregulated migration 
speed with the positive (H-RAS) control transfection in the presence of endogenous 
YB-1 (Fig.5.9; Table 5.2), did not show any significant increase in migration 
persistence (Fig.5.12; Table 5.5). A lack of significant results might be a consequence 
of the elevated persistence values observed with the negative (empty vector) controls 
for this experiment, at least when comparisons to the negative (empty vector) control 
transfections are concerned (compare to previous persistence values in Fig.5.10).  
The data also highlights the fact that the single S176A-HA mutant transfection 
did not increase migration persistence, even though the double S174-176A-HA 
mutant was found to significantly elevate average single cell migration persistence 
(Fig.5.13).  
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a) 
 
b) 
 
c) 
 
d) 
 
 
Fig.5.13. An example of increased migration speed and persistence observed with S174-
176A transfected Saos-2 cells. The migration of YB-1-HA/mutant/control transfected cells 
were visualised by observing the red fluorescent dye of the pN1-mcherry co-transfected 
plasmid (1:10 mcherry plasmid to YB-1-HA/mutant/control plasmid). Images were exported 
as a sequence to ImageJ 1.46r, and mcherry-positive cells were tracked individually using an 
MTrackj plugin. Cells were tracked manually following the cell centroid (1,2), and the 
migration speed and persistence were calculated for each individually tracked cell. The image 
sequence from a-d shows two migrating cells from the S174-176A-HA transfection, both 
exhibiting mcherry expression. As observed from these images, both cells show a high degree 
of migration speed (distance travelled over recorded time) and persistence. 
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5.3. Discussion 
A compilation of the observed results for each YB-1-HA/mutant transfection 
from the Saos-2 single-cell migration experiments is presented in Table 5.7. The 
positive (H-RAS) control transfection significantly increased migration speed (p < 
0.0001; Fig.5.4 & p ≤ 0.01; Table 5.2), in both migration experiments (Fig’s 5.4 & 
5.9), indicating the effectiveness of H-RAS in upregulating the rate of migration. 
However, in the absence of endogenous YB-1 (Fig.5.9), H-RAS failed to boost 
average single-cell migration speed, highlighting the importance of YB-1 in the H-
RAS mediated upregulation of migration speed (discussed in chapter six). This is not 
unexpected, as H-RAS was reported to require the YB-1 pathway to upregulate cell 
migration (Evdokimova et al, 2009). Nonetheless, YB-1-HA transfected cells did not 
show any significant increase in average single cell migration speed (p > 0.05), nor 
did the partial YB-1 knockdown (siRNA-4 achieves ~60% knockdown) lower the 
YB-1-HA transfected cells speed of migration significantly (p > 0.05; Table 5.3). 
These results suggest the presence of a threshold-amount of wildtype YB-1 that is 
necessary for an H-RAS driven upregulation of migration speed, but may otherwise 
not be required for maintaining single cell migration speed. 
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Table 5.7. A summary of the average migration speed and persistence results 
reported in this chapter. 
Plasmid 
O/E 
Single cell migration 
Migration 
speed 
Migration 
speed 
(with/without 
endogenous 
YB-1 
knockdown) 
Migration 
persistence 
Migration 
persistence 
(with/without 
endogenous 
YB-
knockdown) 
Positive 
control (H-
RAS) 
Significantly 
increased speed 
Significantly 
increased 
speed in the 
absence of 
YB-1 
knockdown  
Significantly 
increased 
persistence 
Not sig. 
different from 
negative (empty 
vector) controls 
YB-1-HA Not sig. 
different from 
negative (empty 
vector) control 
Not sig. 
different from 
negative 
(empty vector) 
control 
Not sig. 
different from 
negative (empty 
vector) control 
Not sig. 
different from 
negative (empty 
vector) controls 
S102A-HA Not sig. 
different from 
negative (empty 
vector) control 
- Significantly 
increased 
persistence 
- 
S165A-HA Not sig. 
different from 
negative (empty 
vector) control 
- Significantly 
increased 
persistence 
- 
S167A-HA Not sig. 
different from 
negative (empty 
vector) control 
- Significantly 
increased 
persistence 
- 
S174A-HA Not sig. 
different from 
negative (empty 
vector) control 
- Not sig. 
different from 
negative (empty 
vector) control 
- 
S176A-HA Not sig. 
different from 
negative (empty 
vector) control 
Not sig. 
different from 
negative 
(empty vector) 
control 
Not sig. 
different from 
negative (empty 
vector) control 
Not sig. 
different from 
negative (empty 
vector) controls 
S174-
176A-HA 
Significantly 
increased speed 
- Significantly 
increased 
persistence 
- 
T271A-HA Significantly 
increased speed 
- Not sig. 
different from 
negative (empty 
vector) control 
- 
T271E-HA Not sig. 
different from 
negative (empty 
vector) control 
- Not sig. 
different from 
negative (empty 
vector) control 
- 
O/E: Overexpression 
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The S102A-HA and the NLS-proximal single mutants (S167A-HA, S174A-
HA, S176A-HA) did not have an observable effect on average single cell migration 
speed (Fig.5.4). However, the double S174-176A-HA mutant significantly increased 
average single cell migration speed (p < 0.0001), suggesting that dephosphorylation at 
both the S174 and 176 residues simultaneously might be required for YB-1 
upregulated cell migration speed. When the S176A-HA mutant was individually 
assessed for migration speed in a setting of reduced YB-1 expression (Fig.5.9), the 
experiment revealed that at least with the S176 residue, endogenous YB-1 does not 
mask any S176A-HA driven effects on migration speed. This suggests that the 
observed S174-176A-HA double-mutant upregulation of migration speed might be 
the result of a cooperative synergy between the S174A-HA and S176A-HA residues 
(i.e. S174A-HA and S176A-HA do not each individually exert a measured 
upregulation on migration speed). However, a similar experiment with the S174A-HA 
mutant, in a setting of reduced endogenous YB-1 expression, would be required to 
confirm that the single mutants alone cannot upregulate migration speed. It also 
remains possible that a 100% knockdown or knockout of endogenous YB-1 would be 
required to observe any effect from the single S174A-HA and S176A-HA mutants. 
 The T271A-HA phosphorylation-defective mutant also upregulated migration 
speed significantly (p < 0.008; Fig.5.4), whereas the phospho-mimetic mutant for that 
same residue appeared to return migration speed to a level that was indistinguishable 
from the negative (empty vector) control and wildtype YB-1-HA transfections (p > 
0.05). These results suggest phosphorylation at threonine 271 might reverse the 
T271A-HA induced increase in migration speed (i.e. phosphorylation might 
negatively regulate migration).  
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The data in general revealed the importance of dephosphorylation at specific 
residues (S174-176A-HA, T271A-HA) on migration speed, as not all mutants 
influenced migration. Dephosphorylation at these residues might therefore have 
implications on tumour invasion and metastasis (discussed in chapter six). 
All cells assessed for migration speed were also assessed for migration 
persistence (Fig’s 5.10 & 5.12). H-RAS increased migration persistence significantly 
in the presence of endogenous YB-1 (p < 0.01; Fig.5.10). The observed increase in 
migration persistence and speed corroborates the involvement of H-RAS in cell 
migration, which is also consistent with the literature (Munevar et al, 2001; 
Thevathasan et al, 2013). The YB-1-HA plasmid transfections, on the other hand, did 
not have any significant effect on migration persistence in both experiments (Fig.5.10 
& Fig.5.12). The S102A-HA, S165A-HA, and S167A-HA mutants increased 
migration persistence significantly, suggesting dephosphorylation at these residues 
increases directional migration (p < 0.05; Fig.5.10). Consistent with the migration 
speed analysis, the S174A-HA and S176A-HA single mutants had no effect on cell 
migration. The single mutants did not have a significant effect on migration 
persistence, even though the double S174-176A-HA mutant increased migration 
persistence significantly (p = 0.005; Fig.5.10). The S174-176A-HA mutant, as 
observed with H-RAS, increased both migration speed and persistence, validating the 
involvement of this mutant with cell migration.  
As stated in the results section, with the second migration persistence 
experiment, H-RAS in the presence of endogenous YB-1 did not show any significant 
increase in migration persistence when compare to the negative (empty vector) 
control transfection (Fig.5.12; Table 5.5). This being the case despite H-RAS 
significantly upregulating migration speed for the same experiment (Fig.5.9; Table 
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5.2). This is unexpected, and might be a consequence of the observed elevated 
persistence values with the negative (empty vector) controls for this experiment 
(compare to previous persistence values in Fig.5.10), making any compared increases 
in migration persistence insignificant. Cell migration is also a natural process that 
may have many lurking variables that can affect certain experiments, and more 
replicate experiments would be needed for any solid conclusions. Nevertheless, the 
results in general suggest that dephosphorylation at certain residues might increase 
directed migration to an external stimulus (i.e. gradient created from ‘scratch’), with 
possible implications on metastasis (see below). The implications of increased 
migration speed and persistence are discussed below. 
5.3.1. Implications of increased migration speed and persistence on cancer 
The S174-176A-HA and T271A-HA phosphorylation-defective mutants reveal 
the importance of dephosphorylation on migration speed (Fig.5.4), which might have 
implications on tumour invasion into surrounding tissues (a precursor to metastasis) 
(Chandrasekaran et al, 2015). An increase in migration speed, as observed with these 
mutants, suggests an increase the invasive potential of migrating cells, given the faster 
rate of cell dispersal from the original tumour (Chandrasekaran et al, 2015). 
Furthermore, in vivo cell migration, invasion, and dissemination were observed to be 
more efficient when cells were involved in directed migration (i.e. increased 
persistence) (Muller et al, 2001; Roussos et al, 2007). The results in this study 
implicate various phosphorylation-defective mutants (S102A-HA, S165A-HA, 
S167A-HA, and S174-176A-HA) in increased directional migration (Table 5.7), 
which might have important consequences in cancer (Martin-Villar et al, 2010). In 
particular, the YB-1 protein species dephosphorylated at both S174 and S176 is a 
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good candidate for further studies, as this mutant increased both cell migration speed 
and directed migration. 
The YB-1 protein has been reported to affect migration through a variety of 
mechanisms, given its established multifunctional properties (reviewed by Lasham et 
al, 2013). It can induce migration through its activities as both a transcription and 
translation factor (Evdokimova et al 2009; Mertens et al, 1998), with the observed 
results suggesting its dephosphorylation at certain residues is central to its activation 
or enhancement of cell migration (Table 5.7). There are several pathways associating 
YB-1 with cell migration, some of which are discussed briefly below.  
 YB-1 has been observed to activate the transcription of several genes 
implicated with cell migration and metastasis such as MMP-2, MMP-13, and CD44 
(Cheng et al, 2002; Hiraga et al, 2013; Samuel et al, 2007; Sarkar et al, 2004; To et al, 
2010). YB-1 is also involved in the translational upregulation of genes involved in 
EMT, a phenomenon which results in increased cell motility, and may play an 
important role in promoting metastasis (Evdokimova et al, 2009; Khan et al, 2014; 
Tsai et al, 2012). These different modes of regulation might potentially be behind the 
increased single cell migration speed observed with the S174-176A-HA and T271A-
HA YB-1 phosphorylation-defective mutants. Expression studies on mesenchymal 
markers would be required to determine if this is indeed the case. How YB-1 driven 
cell migration may be regulated/activated by dephosphorylation is discussed in 
chapter six. 
The YB-1 protein’s translational upregulation of EMT genes might also 
increase the directional persistence of migration by influencing integrin trafficking, a 
known driver of directional migration (Evdokimova et al, 2009; Khan et al, 2014; 
White et al, 2007). The CD44 gene is another YB-1 regulated cell surface gene that is 
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involved in directional migration, and could possibly play a role (Martín-Villar et al, 
2010). Another possible mode of increasing directional migration could be through 
YB-1’s proposed transcriptional upregulation of Wnt11 (non-canonical pathway), a 
known activator of the c-Jun N-terminal Kinase (JNK), which leads to the activation 
of key directional migration regulators (Rho-family GTPase activation), cell 
polarisation, cytoskeletal remodelling and cell migration (Nishita et al, 2006; 
reviewed by, Petrie et al, 2009). YB-1 might also affect migration persistence through 
its known interaction with actin (Ruzanov et al, 1999), given that the main factor that 
determines the orientation of migration being the frequency and direction of podial 
protrusions (Arrieumerlou and Meyer, 2005; Pankov et al, 2005; Petrie et al, 2009; 
Ruzanov et al, 1999). Actin cytoskeleton remodelling to create or stabilise protrusions 
(towards a certain stimulus) may contribute to YB-1 driven directional migration, at 
least when YB-1 is dephosphorylated at the S102, S165, S167, and S174-176 
residues. Preliminary experiments with HCT116 cells do in fact suggest the 
dephosphorylation of YB-1 at residues such as S102 may increase the number of 
polarised cells exhibiting lamellipodia towards a certain direction (preliminary data 
discussed in chapter 6). However, given the many potential pathways of action for 
YB-1 in migration, further studies will be needed to elucidate how the multiple 
functions of YB-1 could be affecting migration. Nonetheless, what is evident from 
these experiments is that YB-1 dephosphorylated at specific residues increases 
migration speed (T271A-HA), or persistence (S102A-HA, S165A-HA, S167A-HA), 
or both (S174-176A-HA), which would potentially have consequences on tumour 
invasion and even possibly, metastasis. 
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The results observed in this and previous chapters will be discussed together in 
the following chapter. YB-1 phosphorylation/dephosphorylation with regards to the 
wider scope of tumorigenesis will be discussed altogether. 
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Chapter Six: General discussion 										
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6.0. Introduction 
This project investigated the significance of phosphorylation on YB-1 
localisation and function. Central to any protein’s function is its localisation status, 
with S102 phosphorylation being the only post-translational modification reported to 
affect its intracellular localisation (Davies et al, 2014; Imada et al, 2013; Starford et 
al, 2007). The identification of a total of 7 phosphorylation sites provided more 
insight into the complexity of YB-1 regulation (Table 6.1 & 2), with the potential 
involvement of a number of these sites in YB-1’s subcellular localisation and specific 
functions. This study provides a first look at some of these identified phosphorylation 
sites, with much remaining to be uncovered (a summary of the findings is outlined in 
Table 6.2).  
For this study, only certain residues occurring within close proximity to the 
NLS and CRS were selected, given their proximity to regions of proposed relevance 
to YB-1 localisation and associated functions. The S102 residue was also selected, 
due to its reported importance in localisation, tumorigenesis, and malignancy (Bader 
and Vogt, 2004; Sutherland et al, 2005). These phosphorylation residues will first be 
discussed in detail concerning localisation, before their involvement in tumorigenesis 
is explored. The relevance of nuclear localisation to tumorigenesis and malignancy in 
particular will also be scrutinized. Moreover, the involvement of these 
phosphorylation sites with two major hallmarks of cancer, tumour proliferation and 
invasion/metastasis (migration) (Hanahan and Weinberg, 2011), will then be 
discussed in detail, before examining the potential pathways involved. Finally, 
limitations to the general approach of this study and potential future endeavors will be 
explored. 
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Table 6.1. A motif scanning prediction tool analysis of YB-1 indicating putative 
proteins that may phosphorylate/regulate YB-1 at key serine and threonine 
residues (Table modified from a previous review: Wu et al, 2007). 
YB-1 Residue Putative 
regulatory protein 
Pathways of regulatory 
protein 
Serine 167 ATM kinase DNA double-strand 
breaks (Stiff et al, 2004) 
Serine 176 14-3-3 
 
 
 
 
 
 
 
 
Casein Kinase 2 
Cell cycle, DNA damage 
checkpoints, mitogenic 
signaling, apoptosis, 
integrin signaling and 
cytoskeletal dynamics 
(Wilker and Yaffe, 
2004) 
 
Gene expression, protein 
synthesis, cell 
proliferation, apoptosis, 
and Wnt/β-catenin 
signaling (Gao and 
Wang, 2006) 
Threonine 271 DNA PK 
 
 
 
ATM kinase 
DNA double-strand 
breaks, recombination 
(Smith et al, 1999) 
 
DNA double-strand 
breaks (Stiff et al, 2004) 
Serine 314 Casein kinase 2 Gene expression, protein 
synthesis, cell 
proliferation, apoptosis, 
and Wnt/β-catenin 
signaling (Gao and 
Wang, 2006) 
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Table 6.2. A tabulated summary of some of the key findings of this thesis.  
Plasmid 
O/E 
Localisation 
distribution 
(significant increase 
in nuclear 
localisation?) 
 
Condensed 
nuclei 
Hallmarks or cancer 
Proliferation 
(A549 cells) 
Migration 
(Saos-2 cells) 
YB-1-HA HCT116: Mainly 
cytoplasmic (> 90%) 
 
A549: Mainly 
cytoplasmic (> 70%) 
HCT116: Yes 
 
 
A549: Yes 
Not significantly 
different from 
negative control 
Not sig. 
different from 
negative 
control 
S102A-HA HCT116: Significant 
increase in nuclear 
localisation 
 
A549: No significant 
increase in nuclear 
localisation 
HCT116: Yes 
 
 
 
A549: Yes 
Not significantly 
different from 
negative control 
Significantly 
increased 
precision 
S165A-HA HCT116: Significant 
increase in nuclear 
localisation 
 
HCT116: Yes 
 
 
A549: Yes 
Significantly 
increased 
proliferation 
Significantly 
increased 
precision 
S167A-HA HCT116: Significant 
increase in nuclear 
localisation 
 
HCT116: Yes 
 
 
A549: Yes 
Significantly 
suppressed 
proliferation 
Significantly 
increased 
precision 
S174A-HA HCT116: Significant 
increase in nuclear 
localisation 
HCT116: Yes 
 
 
A549: Yes 
Significantly 
suppressed 
proliferation 
Not sig. 
different from 
negative 
control 
S176A-HA HCT116: Significant 
increase in nuclear 
localisation 
 
A549: Significant 
increase in nuclear 
localisation 
HCT116: Yes 
 
 
 
A549: Yes 
Significantly 
suppressed 
proliferation 
Not sig. 
different from 
negative 
control 
S174-176A-
HA 
HCT116: Significant 
increase in nuclear 
localisation 
HCT116: Yes 
 
 
A549: Yes 
Significantly 
increased 
proliferation 
Significantly 
increased 
speed and 
precision 
T271A-HA A549: No significant 
increase in nuclear 
localisation 
A549: No No data Significantly 
increased 
speed 
T271E-HA A549: No significant 
increase in nuclear 
localisation 
A549: Yes No data Not sig. 
different from 
negative 
control 
O/E: Overexpression 
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6.1. Nuclear localisation and transcription: a phosphorylation-dependent 
mechanism? 
YB-1 has been reported to be phosphorylated by a number of kinases, 
including AKT and RSK 1/2 kinase at S102, which was described to be a requirement 
for the nuclear localisation and transcriptional activation of YB-1 (Coles et al, 2005; 
Shabkin et al, 2001; Stratford et al, 2008; Sutherland et al, 2005). As described in 
chapter four, contrary to these studies, the HCT116 localisation experiments revealed 
an increase, rather than a decrease in nuclear localisation with the S102A-HA 
phosphodeficient mutant (Table 6.2). Phosphorylation at S102 may indeed be required 
for YB-1’s transcriptional activity; however, there have been reports of YB-1 free of 
phosphorylation at S102 translocating to the nucleus (Bader and Vogt, 2008; Sinnberg 
et al, 2012). These findings suggest the involvement of additional factors, such as the 
possible dephosphorylation at other residues, or certain cell-specific binding partners 
that might induce YB-1’s nuclear translocation. 
Lyabin et al (2014) presented several points in their recent review that even 
disputed the role of YB-1 as a transcription factor. Firstly, they argue that increased 
levels of mRNA or proteins in response to YB-1, together with YB-1’s ability to 
interact with the Y-box in vitro, does not strictly mean that YB-1 is actively involved 
in transcription. These observations may be attributed to YB-1 being able to exert its 
effects through pre-mRNA processing and the stabilisation. They go on to argue that 
the interaction between YB-1 and active genes has not been proven either, and report 
of a homologue of YB-1 found to localise to the chromatin region of an actively 
transcribed gene, where it was revealed to be in fact bound to newly synthesised 
mRNA and not DNA. These chromatin interactions were easily disrupted by the 
addition of ribonuclease treatment (Soop et al, 2003).  They also presented the MDR1 
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gene as an example, where they point out that the affinity of YB-1 for the MDR1 
associated APE protein and the histonacetyltransferase p300 protein was higher than 
that of the MDR1 gene Y-box sequence, suggesting the YB-1 regulation of MDR1 
might only occur through interactions with proteins. They highlight a study where no 
change in P-glycoprotein, MDR1 mRNA, or drug sensitivity was observed with YB-1 
inhibition (Kaszubiak et al, 2007). Finally, they point out that no bioinformatics 
method was able to reveal YB-1’s specificity to the Y-box or any other DNA 
sequence. This might also explain why no unique phosphorylation residues were 
observed in A549 cells after genotoxic stress in this study (see chapter three), even 
with the putative DNA damage target phosphorylation residues (Table 6.1). However, 
the absence of the T271 phosphopeptide with genotoxic stress could be a potential 
lead for further studies (i.e. dephosphorylation at T271 with genotoxic stress). 
Although the proposal disputing YB-1 involvement in transcription is 
plausible, it remains unlikely, as YB-1 has been found to interact with many different 
transcription factors (Chernukhin et al, 2000; Okamoto et al, 2000; Mertens et al, 
1998), strengthening its role as a transcription co-factor. A more plausible 
explanation, also pointed out in this review (Lyabin et al, 2014), is that the role of 
YB-1 in transcription is probably confined to that of a transcriptional 
coactivator/corepressor, requiring the presence of certain binding partners to have an 
active role in transcription, which might be dependent on cell type or conditions. This 
might also be the case with the mechanism of nuclear localisation (i.e. requires certain 
binding partners and conditions), as seen with the immunofluorescence experiments, 
where the S102 mutant only increased the nuclear localisation of YB-1 in HCT116 
and not A549 cells (Table 6.2.). However, the localisation studies in A549 cells might 
need to be repeated with endogenous YB-1 to confirm this result, as the nuclear 
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localisation was unusually high with the wildtype YB-1 transfection, which might 
have skewed the significance results (i.e. mutants were compared to YB-1). 
In general, there remains a possibility that phosphorylation at S102 may 
indeed be responsible for YB-1’s transcriptional activity, but when it comes to YB-1 
nuclear localisation, dephosphorylation proximal to the NLS, appears to play a greater 
role, as evident with the phosphodeficient mutants.  
The three most proximal phosphorylation residues to the NLS showed the 
highest levels of nuclear localisation in HCT116 cells, which was again confirmed 
with the 176 mutant in the A549 cells (Table 6.2). The C-terminal domain, where the 
NLS sequence is present, has been reported to be important for protein-protein 
interactions (Sommerville and Ladomery, 1996; Wolffe et al, 1992; Wolffe, 1994). 
Phosphorylation or dephosphorylation at the identified C-terminal residues probably 
plays a role in influencing binding partners that might affect localisation status. There 
are several potential binding partners; two of which are discussed below. 
6.1.1. YB-1 and potential localisation influencing binding partners 
The phospho-serine/threonine interacting 14-3-3 proteins have been observed, 
among their many other functions, to be involved in the cytoplasmic retention of 
proteins (reviewed by Fu et al, 2000). The YB-1 S176 residue has been identified as a 
predicted motif for the 14-3-3 proteins (Wu et al, 2007). Therefore, dephosphorylation 
at serine 176 might inhibit the interaction of 14-3-3 proteins with YB-1. The release 
of YB-1 from bound 14-3-3 proteins might then free YB-1 to translocate to the 
nucleus.  
Another possible interaction that might be influenced by dephosphorylation 
could be YB-1’s reported interaction with the DACHshund homolog 1 (DACH1) 
protein (Wu et al, 2014). DACH1 was observed to bind the C-terminus of YB-1, 
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driving its nuclear localisation, and inhibiting proliferation and EMT at the same time 
(Wu et al, 2014). It remains conceivable that the dephosphorylation of YB-1 within 
the C-terminus, allows for increased interactions between the YB-1 protein and 
DACH1, as the S167A-HA, S174A-HA, and S176A-HA mutants all increased 
nuclear localisation, and reduced cell proliferation. Additionally, these mutants did 
not increase cell migration speed in Saos-2 cells (i.e. no increase in EMT) (Table 6.2). 
However, this process is probably much more complicated, involving multiple 
binding partners, as the double S174-176A-HA mutant, despite showing increased 
levels of nuclear localisation, overcomes this inhibited or basal level of cell 
proliferation, observed with the S174A-HA and S176A-HA single mutants in A549 
cells, and increases migration speed in Saos-2 cells (Table 6.2.). Further biochemical 
and molecular studies would be required to elucidate these observed results.  
6.2. Is YB-1 nuclear localisation relevant to tumorigenesis? 
Early reports of nuclear YB-1 being a marker for poor patient outcome and 
prognosis have been blurred by the revelation of cross-reactivity between many 
commercial anti-YB-1 antibodies and the hnRNPA1 protein (see chapter three) 
(Cohen et al, 2010). Therefore, many previous studies that demonstrated the value of 
nuclear YB-1 as a prognostic marker remain unclear. These ambiguities led to the 
question of whether there is in fact a nuclear form of YB-1 that can act as a prognostic 
indicator. Even with a validated anti-YB-1 antibody (against epitope a; Fig.4.18), 
results remain inconclusive and confusing. One study showed that breast tumours 
with nuclear YB-1 had high levels of P-glycoprotein and decreased chemosensitivity 
(Bargou et al, 1997). Conversely, another study also conducted in breast cancers, with 
antibodies against the same epitope, revealed that total cellular YB-1 levels, and not 
specifically nuclear YB-1 was associated with decreased chemosensitivity and 
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disease-free patient survival (Janz et al, 2002). Another study with the same epitope in 
non-Hodgkin lymphomas had similar results, where it was reported that cytoplasmic, 
but not nuclear YB-1, was found to be associated with the decreased progression free 
survival of patients (Szczuraszek et al, 2011). On the other hand, in non-small cell 
lung cancers, when YB-1 was probed with antibodies against both epitope a and 
another validated target (epitope c), it was nuclear YB-1 that was found to be 
associated with decreased overall patient survival (Gessner et al, 2004; Shibhara et al, 
2001). This result was also observed in synovial sarcomas with epitope c specific 
antibodies (Izumi et al, 2001; Oda et al, 2003; Schittek et al, 2007). In ovarian 
cancers, with the same antibody (epitope c specific), it was again observed that 
nuclear YB-1 was associated with decreased disease-free and overall patient survival  
(Kamura et al, 1999; Oda et al, 2007). This result was also confirmed in another study 
with ovarian cancers, using anti-YB-1S102 specific antibodies (Kang et al, 2013). 
However, in Head and Neck Squamous Cell Carcinomas (HNSCC), studies with 
epitope c specific antibodies showed decreased overall survival of patients was 
associated with both nuclear and cytoplasmic YB-1 (Kolk et al, 2011). Nonetheless 
this study also showed that the majority of YB-1 was nuclear in these cancers. In 
contrast, in breast cancer, several studies with the same antibody showed that it was 
cytoplasmic, rather than nuclear YB-1 that was associated with decreased disease-free 
and overall patient survival (Gluz et al, 2009; Habibi et al, 2008; Wu et al, 2006). This 
result was also observed in gastric cancers with epitope c specific antibodies, where 
cytoplasmic YB-1 was reported to be associated with disease-free patient survival 
(Wu et al, 2012).  
These studies collectively indicate that the nuclear localisation of YB-1 
probably contributes partially to its overall oncogenic activities, either through its 
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known distinct nuclear specific functions (e.g. transcription), or through its nuclear 
and cytoplasmic specific functions (mRNA stability and translation) (Wu et al, 2007). 
However, as evident in the literature, cell/tissue specific conditions (e.g. binding 
partners and regulators) probably dictate these functions to drive tumorigenesis and 
malignancy (reviewed by, Kosnopfel et al, 2014).   
In this project, the nuclear localisation of YB-1 appeared to coincide with 
several cellular events relevant to tumorigenesis (Table 6.2) (Lasham et al, 2014; Wu 
et al, 2007). In the immunofluorescence studies, the 167, 174, and 176, serine-to-
alanine mutants all showed the highest levels of nuclear localisation, and the highest 
frequency of condensed nuclei (see chapter four). These mutants appeared to have an 
anti-oncogenic effect on A549 cells, suppressing cell proliferation, with mutants like 
the S167A-HA significantly suppressing proliferation (Table 6.2). This is in line with 
what has been reported of the YB-1 C-terminus being involved in the transcriptional 
repression of proliferation (Shi et al, 2013). 
6.2.1. YB-1 induced chromatin condensation and cell proliferation 
The increased frequency of condensed chromatin observed with these mutants 
(e.g. S167A-HA, S174A-HA, and S176A-HA) is probably associated with chromatin 
inactivation and gene silencing, which might also play a role in the observed 
inhibition of proliferation (Robertson, 2002; Vaissière et al, 2008). These results 
suggest a YB-1 driven, chromatin-induced inhibition of access to proliferation-
associated gene promoters, therefore hindering transcriptional access to promoters. 
However, the S174-176A-HA mutant, which also increases nuclear localisation and 
the frequency condensed nuclei, overcomes this suppressed proliferation.  This 
indicates that the inhibited proliferation might alternatively be through a separate 
mechanism, not associated with chromatin condensation. Another possibility would 
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be a dephosphorylation driven change in potential binding partners or regulators, 
given the importance of the C-terminus in protein-protein interactions (see following 
section). This was also evident with the S165A-HA mutant, which although increased 
nuclear localisation and the frequency of condensed nuclei (to a lower degree), still 
significantly upregulated cell proliferation compared to the other transfections (Table 
6.2). This would suggest an alternative theory, where the increased YB-1 nuclear 
localisation results in increased interactions with different protein effectors, therefore 
resulting in the observed increased frequency of chromatin condensation, and 
inhibited/increased proliferation, based on cell type and binding partners.  However, 
more robust experiments would be needed to make any conclusions. 
6.2.2. Nuclear vs. cytoplasmic YB-1 and tumour malignancy 
The S174-176A-HA and T271A-HA mutants both showed an increased 
migration speed and nuclear localisation. However, only the S174-176A-HA double-
mutant significantly increased nuclear localisation and the frequency of condensed 
nuclei significantly (Fig.6.1.), suggesting the involvement of a separate mechanism, 
other than chromatin mediated gene inactivation or silencing, in the drive of 
tumorigenesis (e.g. alternative splicing, transcription, or even translation). There have 
been reports of YB-1 and the Protein Phosphatase 2 Cγ (PP2Cγ) being involved in 
the alternative splicing of genes to variants that increase tumour invasion (Stickeler et 
al, 2001; Zen et al, 2008).  
What is evident from the literature and further supported by this thesis, is that 
nuclear and cytoplasmic YB-1 both have a prognostic value in cancer (i.e. total YB-
1). YB-1 interacts transcriptionally with several proliferation and migration-
associated genes in the nucleus, including the EGFR, ERBB2, MMP-2, MMP-12, and 
MMP-13 (Mertens et al, 1997; Sakura et al, 1988; Samuel et al, 2007; Shapiro, 1999; 
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Shibata et al, 2013; Stratford et al, 2007). In the cytoplasm YB-1 has been reported to 
increase the production of proteins regulating cell proliferation and oncogenic 
transformation, after its phosphorylation at S102, which also inhibited YB-1 mediated 
5’ cap-dependent translational repression (Evdokimova et al, 2006). It has also been 
observed to participate in the translation of the c-MYC proto-oncogene, which is 
capable of stimulating proliferation (Cobbold et al, 2008). Moreover, YB-1 has also 
been shown to influence migration through its activity as a translation factor and 
driver of EMT (Evdokimova et al, 2009; Khan et al, 2014). It’s involved in the 
translational regulation of several EMT associated genes, where it was found to 
downregulate epithelial cell markers such as E-cadherin, Zona Occludens 1 (ZO-1), 
CytoKeratin 18 (CK18), and MUCin 1 (MUC1), and upregulate mesenchymal 
markers such as fibronectin, vimentin, α-Smooth Muscle Actin (SMA), CytoKeratin 
14 (CK14), and tumour protein p63 (Evdokimova et al, 2009; Khan et al, 2014). YB-1 
was also found to translationally upregulate several EMT promoting genes including 
SNAIL1, Twist-1, and Hypoxia-Inducible Factor 1-alpha (HIF1α) (Evdokimova et al, 
2009). Additionally, it interacts with a variety of proteins, which probably contributes 
to its functions along with localisation, with the C-terminus undoubtedly playing a 
significant role, given its importance in protein-protein interactions and dimerisation 
(Sorokin et al, 2005; Wu et al, 2014). Could YB-1 functions or protein-protein 
interactions be driven at least partly by dephosphorylation at certain residues? The 
data suggest so (see following section below).  
To explore the prognostic value of nuclear or cytoplasmic YB-1 in tumour 
malignancy, its phosphorylation and dephosphorylation need to be studied further, 
taking into account the many different complexes that YB-1 may possibly form, and 
the ability of certain antibodies to detect or miss these complexes (Woolley et al, 
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2011). The S174-176A-HA mutant is a good candidate for further studies, with its 
observed effects on localisation, chromatin modeling, cell proliferation, migration 
speed, and persistence, all of which are relevant to tumour progression and 
malignancy (Fig.6.1). It is however noteworthy that total YB-1 mRNA alone has been 
shown to be prognostic (Lasham et al, 2012), and future proteomic studies should 
therefore also include mRNA expression studies. 
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Fig.6.1. A speculative schematic diagram of some proposed nuclear specific tumour 
driving properties of the YB-1 protein after serine 174 and 176 dephosphorylation.  
Double dephosphorylation at both serine 174 and 176 results in an increase in YB-1 nuclear 
localisation, followed by the transcription and alternative splicing of some YB-1 target genes. 
Given the unique properties of the S174-176A-HA mutant, it is assumed these target genes 
would be activated based on unique YB-1 binding partners, as a result of the double 
dephosphorylation. YB-1 driven chromatin remodelling, on the other hand, would result in 
the repression of other genes (e.g. tumour suppressors). Any suppression of oncogenes 
through chromatin condensation would be overcome by the transcription and alternative 
splicing of other YB-1 target genes. The overall result would be an upregulation of cell 
proliferation and migration, therefore further driving tumour progression. 
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6.3. Dephosphorylation: a driver of cell migration? 
YB-1 has been reported to be associated with several different phosphatases 
including, Protein-Tyrosine Phosphatase 1 B (PTP1B), Protein Phosphatase 2 B 
(PP2B), and Protein Phosphatase 2 Cγ (PP2Cγ) (Alidousty et al, 2014; Allemand et 
al, 2007; Fukada and Tonks, 2003). The PTP1B protein, a tyrosine phosphatase, is 
unlikely to be the activator or enhancer of YB-1 migration observed in these 
experiments, as none of the targets found to increase migration speed are tyrosine 
residues. Additionally, no phospho-tyrosine residues were identified on YB-1 (see 
chapter 4). The PP2B protein has been reported to dephosphorylate YB-1 at the Serine 
102 residue within the CSD, which is not within the range of most of the 
phosphorylation residues (e.g. S165 and S174-176 are within the C-terminal domain) 
(Alidousty et al, 2014). However, this does not rule out its activity beyond the CSD 
(Fig.6.2.). The PP2Cγ phosphatase, on the other hand, has been found to directly 
interact with YB-1’s C-terminal domain, which would cover the region of the double 
S174-176A-HA mutant and the single T271A-HA mutant (Allemand et al, 2007). The 
PP2Cγ Acidic Domain (AD) was reported to be activated after phosphorylation, 
where it then interacts with YB-1’s C-terminal domain, and acts as a non-essential 
functional translation co-factor in alternative mRNA splicing (Allemand et al, 2007). 
This is a possible mode of action for YB-1 dephosphorylation to drive cell migration 
and proliferation, as for example, YB-1 was found to promote the alternative splicing 
of the CD44 gene to include exon 4, which promotes cancer cell invasion 
(Spiegelberg et al, 2014; Stickeler et al, 2001; Zen et al, 2008). The same CD44v4 
variant has also been implicated with increased cell proliferation (Spiegelberg et al, 
2014). The involvement of RAS in the alternative splicing of CD44 gene variants 
might also explain why the knockdown of YB-1 (Table 6.2.), a downstream effector 
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in the RAS pathway (see section below), reduced migration speed (i.e. 
reduced/inhibited alternative CD44 gene splicing) (Cheng et al 2006; Cheng and 
Sharp 2006; Rall and Rustgi, 1995).  However, whether this role of RAS involves the 
activation of PP2Cγ, possibly though phosphorylation of the AD domain remains to 
be seen (Allemand et al, 2007). 
There remain many other possibilities behind YB-1 driven migration. The 
phosphorylation of YB-1 at S102 was described to promote tumour invasion 
(Astanehe et al, 2009), yet it was its dephosphorylation (i.e. phosphorylation-defective 
mutant) that was found to increase migration persistence (Table 6.2). This possibly 
might be attributed to the actin binding/stabilising properties of YB-1 (through 
dephosphorylation?), given the main factor that determines the orientation of 
migration being the frequency and direction of lamellipodial protrusions 
(Arrieumerlou and Meyer, 2005; Pankov et al, 2005; Petrie et al, 2009; Ruzanov et al, 
1999). YB-1 has been reported to interact with and stabilise G- and F-actin (Ruzanov 
et al, 1999). In addition, preliminary experiments with HCT116 cells revealed that 
S102A-HA transfected cells showed significantly increased (Appendix 3: p < 0.05; 
Tables S42-43) lamellipodia-like structures (polarised towards a single direction), 
when compared to wildtype YB-1-HA transfected cells (Appendix 3: Fig.S51). These 
S102A-HA transfected cells also significantly increased migration persistence 
(Appendix 3: p < 0.05; Table S44), when compared to YB-1-HA transfected HCT116 
cells (Appendix 3: Fig.S52), confirming what was observed in experiments with Saos-
2 cells (Table 6.2). Actin cytoskeleton remodelling to create or stabilise protrusions 
(towards a certain stimulus) are therefore likely to contribute to YB-1-driven 
directional migration. It remains a possibility that dephosphorylation may potentially 
increase YB-1’s overall affinity and stabilisation of actin in the lamella, and 
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consequently increase migration persistence. However, further studies would be 
required to substantiate such a hypothesis.  
The increased migration speed only observed only with the S174-176A-HA 
and T271A-HA mutants suggests YB-1 dephosphorylation at these residues may 
increase migration in a different manner than that observed with the mutants that 
increased directional migration. This could be through increased EMT, which would 
result in increased cell migration (Evdokimova et al, 2009), or through other 
pathways, such as the RAS-RAF pathway, since YB-1 knockdown resulted in 
significantly reduced H-RAS driven migration speed (p < 0.05; Table 6.2). This 
observed increase in migration speed would in turn be inhibited by T271 
phosphorylation, as the T271E-HA phospho-mimetic mutant showed migration 
speeds that were indistinguishable from the negative control transfections (Table 
6.2.).  
The S174-176A-HA mutant also increased directed migration, along with 
migration speed, which would make this double-mutant a potential contributor to 
tumour invasion and possibly metastasis (Table 6.2). Increases in directed migration 
allows tumours to migrate directly to sources of stimuli (chemoattractant), potentially 
increasing chances of metastasis (Bravo-Cordero et al, 2012). It should be noted that 
the S176 phosphorylation residue of YB-1 is proposed to interact with the 14-3-3 
proteins (Table 6.1), which are also involved in integrin signaling and cytoskeletal 
dynamics (Wilker and Yaffe, 2004).  
These results in general reveal the complexity of YB-1 regulation, and confirm 
the involvement of many different pathways. The Ras-Raf-MEK-ERK pathway and 
its involvement with YB-1 is discussed below.  
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Fig.6.2. A schematic diagram of plausible YB-1 pathways activated by 
dephosphorylation through putative YB-1 targeting phosphatases. The dephosphorylation 
of YB-1 at certain residues (e.g. S174-176), results in the nuclear localisation of YB-1, and 
subsequent increase in transcription and alternative splicing of target genes. On the other 
hand, dephosphorylation might also be behind YB-1’s functions as a translation factor and 
actin stabiliser in the cytoplasm. All these mechanisms have the potential to drive tumour 
progression further.  
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6.4. A web of pathways: RAS and YB-1  
The multifunctional properties of YB-1 suggest the involvement of various 
and interconnected pathways influencing its regulation (reviewed by, Lasham et al, 
2013). The predicted involvement of certain kinases such as the DNA-dependent 
Protein Kinase (DNA PK) and ATM kinase in the phosphorylation of YB-1 at T271, 
or ATM kinase at S167, suggest the involvement of those residues in YB-1’s reported 
DNA repair activities (de Souza-Pinto et al, 2009; Gaudreault et al, 2009; Wu et al, 
2007). Phosphorylation of these residues might be important in maintaining overall 
genomic integrity, and may contribute to preventing genomic instability, a pre-
requisite of cancer (Beckman and Loeb, 2005). YB-1 has also been suggested to be 
regulated via S102 phosphorylation, by the PI3K-AKT-mTOR and RAS-RAF-MEK-
ERK signaling pathways, upregulating processes such as proliferation (e.g. E2F 
upregulation) and migration (MMP protein upregulation) (Lasham et al, 2013; 
Sinnberg et al, 2012; Stratford et al, 2008). 
The endogenous YB-1 knockdown/migration experiments revealed the 
importance of the YB-1 protein in the RAS-RAF-MEK-ERK pathway (see chapter 
five). The positive H-RAS control transfection, after endogenous YB-1 knockdown, 
showed a more dramatic reduction in migration speed than other transfections, where 
H-RAS driven migration was no longer significantly different from the control 
knockdown transfection (Fig.5.9). These results reveal the interdependence of the 
YB-1 and RAS pathways in migration. In line with the literature, YB-1’s involvement 
in the RAS-ERK pathway has been well documented (reviewed by, Lasham et al, 
2013).  The phosphorylation of YB-1 after IR stress was also observed to be induced 
by oncogenic K-RAS, enhancing its DNA double strand break repair and post-
irradiation survival via ERB1, and downstream of the PI3K-AKT and MAPK-ERK 
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signaling pathways (Toulany et al, 2011). Moreover, YB-1 has been reported to 
regulate EGFR and ERBB2, and many of the MEK/ERK kinase targets 
transcriptionally (Sakura et al, 1988; Shibata et al, 2013; Stratford et al, 2007).  
The involvement of YB-1 in the RAS-ERK pathway is not only one-
directional, as MEK inhibitors were observed to reduce YB-1 protein abundance (van 
Roeyen et al, 2005). The EGF protein ligand was also found to upregulate p-YB01102, 
whereas MEK inhibitors decreased p-YB01102 (Imada et al, 2013). Additionally, the 
silencing of YB-1 using siRNA decreased the expression of ERK 2 and 
phosphorylated MEK, ERK 1/2, and RSK, and was found to regulate the expression 
of the downstream RAS activated protein RAF-1 (Imada et al, 2013). YB-1 and RAS-
ERK signaling were both also reported to be required for the induction of EMT and 
cell migration (Evdokimova et al, 2009). Inhibition of RAS-ERK signaling in this 
study was observed to completely abolish the formation of cord-like structures in YB-
1 transfected malignant mammary epithelial MCF10AT cells. Moreover, RAS-ERK, 
but not PI3K-AKT signaling were found to be crucial for the observed YB-1 mediated 
phenotypic effects in these cells.  
The observed effects of inhibited proliferation with S167A-HA, S174A-HA, 
and S176A-HA phosphorylation defective mutants might involve the RAS-ERK 
pathway (Table 6.2.). An increased expression of YB-1 in premalignant mammary 
epithelial cells, with elevated RAS-ERK signaling, was found to block proliferation 
(Evdokimova et al, 2009). Additionally, this increased expression was observed to 
disrupt mammary morphogenesis and promote invasive properties and cell 
dissemination, implicating this pathway in migration. Finally, the condensed nuclei 
observed with most of the YB-1 mutants (Table 6.2.) might also involve this pathway, 
as MYC, a downstream target of RAS, is also a master regulator of chromatin 
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condensation (Knoepfler et al, 2006). To further elucidate the involvement of YB-1 
phosphorylation/dephosphorylation in the RAS pathway, further molecular studies 
would be needed. 
Some of the limitations of this project in general are discussed below. 
6.5. Scope of thesis and future studies 
The general aims of this study were all completed successfully. Nuclear and 
cytoplasmic YB-1 were purified using a validated antibody and identified using mass 
spectrometry (chapter three). The phosphorylation sites of YB-1 were also 
characterised under both normal conditions and under genotoxic stress. Finally, 
through experiments with the various phosphorylation mutants in chapter four and 
five, the importance of phosphorylation in YB-1 localisation, and its impact on two 
hallmarks of cancer, proliferation and metastasis, were explored. However, there were 
some limitations to this project in general, some of which are discussed briefly below.  
The mass spectrometry analysis was limited to a qualitative rather than 
quantitative analysis, which therefore lacks any information on the abundance of 
phosphopeptides within the nucleus and cytoplasm. As a result, changes in the 
balance of phosphopeptides in each compartment would remain undetected in a 
qualitative analysis. The functional studies also lacked any phosphomimetic mutants 
for each phospho-site (excluding the T271 mutants), which would be required for a 
clearer and more conclusive understanding of the significance of 
phosphorylation/dephosphorylation on YB-1 functions.  
The study as a whole was initially intended in A549 cells to allow data from 
the mass spectrometry analyses and functional studies to be easily compared, with 
parallel functional studies in other cell lines to observe any cell type specific effects of 
YB-1. However, due to time constraints, an extremely low transfection efficiency of 
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the mutant plasmid constructs (especially evident in A549 cells), and a lack of 
compatibility of A549 cells with the single cell migration assay, Saos-2 cells were 
eventually utilised for the final results chapter (see chapter five). Nevertheless, this 
approach did allow for the best “fit for purpose” cell line to be utilised for the single 
cell migration experiments.  	 Further molecular studies would be needed to solidify the above-discussed 
conclusions and hypotheses, as some functional studies were preliminary. These 
studies would require a variety of cell lines to get a clearer overall picture of the 
functions of YB-1 across different cell and tissue types. Stable rather than transient 
transfections would also greatly benefit any future studies to overcome any issues 
with transfection efficiency. Nevertheless, what is evident from this study is that the 
S174-176 doubly-dephosphorylated form of YB-1 is a clear candidate for further 
studies of YB-1 function and its potential application as a prognostic indicator for 
cancer. 
  
		 245	
7.0. References 
Abraham, A. G. and O'Neill, E. (2014) 'PI3K/Akt-mediated regulation of p53 in 
cancer', Biochem Soc Trans, 42(4), pp. 798-803. 
Agarwal, M. L., Agarwal, A., Taylor, W. R. and Stark, G. R. (1995) 'p53 controls 
both the G2/M and the G1 cell cycle checkpoints and mediates reversible 
growth arrest in human fibroblasts.', Proceedings of the National Academy of 
Sciences of the United States of America, 92(18), pp. 8493-8497. 
Alidousty, C., Rauen, T., Hanssen, L., Wang, Q., Alampour-Rajabi, S., Mertens, P. 
R., Bernhagen, J., Floege, J., Ostendorf, T. and Raffetseder, U. (2014) 
'Calcineurin-mediated YB-1 dephosphorylation regulates CCL5 expression 
during monocyte differentiation', J Biol Chem, 289(31), pp. 21401-12. 
Allemand, E., Hastings, M. L., Murray, M. V., Myers, M. P. and Krainer, A. R. 
(2007) 'Alternative splicing regulation by interaction of phosphatase 
PP2Cgamma with nucleic acid-binding protein YB-1', Nat Struct Mol Biol, 
14(7), pp. 630-8. 
Amon, A. (1999) 'The spindle checkpoint', Current Opinion in Genetics  &  
Development, 9(1), pp. 69-75. 
An, H. J., Lee, Y. H., Cho, N. H., Shim, J. Y., Kim, J. Y., Lee, C. and Kim, S. J. 
(2002) 'Alteration of PTEN expression in endometrial carcinoma is associated 
with down-regulation of cyclin-dependent kinase inhibitor, p27', 
Histopathology, 41(5), pp. 437-445. 
Anand-Apte, B. and Zetter, B. (1997) 'Signaling mechanisms in growth factor-
stimulated cell motility', Stem Cells, 15(4), pp. 259-67. 
Andl, C. D., Mizushima, T., Nakagawa, H., Oyama, K., Harada, H., Chruma, K., 
Herlyn, M. and Rustgi, A. K. (2003) 'Epidermal growth factor receptor 
mediates increased cell proliferation, migration, and aggregation in esophageal 
keratinocytes in vitro and in vivo', J Biol Chem, 278(3), pp. 1824-30. 
Ansari, S. A., Safak, M., Gallia, G. L., Sawaya, B. E., Amini, S. and Khalili, K. 
(1999) 'Interaction of YB-1 with human immunodeficiency virus type 1 Tat 
and TAR RNA modulates viral promoter activity', J Gen Virol, 80 ( Pt 10), pp. 
2629-38. 
Arrieumerlou, C. and Meyer, T. (2005) 'A local coupling model and compass 
parameter for eukaryotic chemotaxis', Dev Cell, 8(2), pp. 215-27. 
Asakuno, K., Kohno, K., Uchiumi, T., Kubo, T., Sato, S., Isono, M. and Kuwano, M. 
(1994) 'Involvement of a DNA-binding protein, MDR-NF1/YB-1, in human 
MDR1 gene-expression by actinomycin-D', Biochemical and Biophysical 
Research Communications, 199(3), pp. 1428-1435. 
Ashizuka, M., Fukuda, T., Nakamura, T., Shirasuna, K., Iwai, K., Izumi, H., Kohno, 
K., Kuwano, M. and Uchiumi, T. (2002) 'Novel translational control through 
an iron-responsive element by interaction of multifunctional protein YB-1 and 
IRP2', Molecular and Cellular Biology, 22(18), pp. 6375-6383. 
Astanehe, A., Finkbeiner, M. R., Hojabrpour, P., To, K., Fotovati, A., Shadeo, A., 
Stratford, A. L., Lam, W. L., Berquin, I. M., Duronio, V. and Dunn, S. E. 
(2009) 'The transcriptional induction of PIK3CA in tumor cells is dependent 
on the oncoprotein Y-box binding protein-1', Oncogene, 28(25), pp. 2406-18. 
Astanehe, A., Finkbeiner, M. R., Krzywinski, M., Fotovati, A., Dhillon, J., Berquin, I. 
M., Mills, G. B., Marra, M. A. and Dunn, S. E. (2012) 'MKNK1 is a YB-1 
target gene responsible for imparting trastuzumab resistance and can be 
blocked by RSK inhibition', Oncogene, 31(41), pp. 4434-46. 
		 246	
Bader, A. G., Feits, K. A., Jiang, N., Chang, H. W. and Vogt, P. K. (2003) 'Y box-
binding protein 1 induces resistance to oncogenic transformation by the 
phosphatidylinositol 3-kinase pathway', Proceedings of the National Academy 
of Sciences of the United States of America, 100(21), pp. 12384-12389. 
Bader, A. G. and Vogt, P. K. (2005) 'Inhibition of protein synthesis by Y box-binding 
protein 1 blocks oncogenic cell transformation', Molecular and Cellular 
Biology, 25(6), pp. 2095-2106. 
Bader, A. G. and Vogt, P. K. (2008) 'Phosphorylation by Akt disables the anti-
oncogenic activity of YB-1', Oncogene, 27(8), pp. 1179-1182. 
Baldin, V., Lukas, J., Marcote, M. J., Pagano, M. and Draetta, G. (1993) 'Cyclin D1 is 
a nuclear protein required for cell cycle progression in G1', Genes Dev, 7(5), 
pp. 812-21. 
Bandyopadhyay, S., Pai, S. K., Gross, S. C., Hirota, S., Hosobe, S., Miura, K., Saito, 
K., Commes, T., Hayashi, S., Watabe, M. and Watabe, K. (2003) 'The Drg-1 
gene suppresses tumor metastasis in prostate cancer.', Cancer Res, 63(8), pp. 
1731-6. 
Banin, S., Moyal, L., Shieh, S. Y., Taya, Y., Anderson, C. W., Chessa, L., 
Smorodinsky, N. I., Prives, C., Reiss, Y., Shiloh, Y. and Ziv, Y. (1998) 
'Enhanced phosphorylation of p53 by ATM in response to DNA damage', 
Science, 281(5383), pp. 1674-1677. 
Barbash, O., Zamfirova, P., Lin, D. I., Chen, X., Yang, K., Nakagawa, H., Lu, F., 
Rustgi, A. K. and Diehl, J. A. (2008) 'Mutations in Fbx4 inhibit dimerization 
of the SCF(Fbx4) ligase and contribute to cyclin D1 overexpression in human 
cancer', Cancer Cell, 14(1), pp. 68-78. 
Bargou, R. C., Jurchott, K., Wagener, C., Bergmann, S., Metzner, S., Bommert, K., 
Mapara, M. Y., Winzer, K. J., Dietel, M., Dorken, B. and Royer, H. D. (1997) 
'Nuclear localization and increased levels of transcription factor YB-1 in 
primary human breast cancers are associated with intrinsic MDR1 gene 
expression', Nature Medicine, 3(4), pp. 447-450. 
Baric, R. S., Carlin, L. J. and Johnston, R. E. (1983) 'Requirement for host 
transcription in the replication of Sindbis virus', J Virol, 45(1), pp. 200-5. 
Barros e Silva, A. E. and Guerra, M. (2010) 'The meaning of DAPI bands observed 
after C-banding and FISH procedures', Biotech Histochem, 85(2), pp. 115-25. 
Bartek, J. and Lukas, J. (2003) 'Chk1 and Chk2 kinases in checkpoint control and 
cancer', Cancer Cell, 3(5), pp. 421-9. 
Basaki, Y., Hosoi, F., Oda, Y., Fotovati, A., Maruyama, Y., Oie, S., Ono, M., Izumi, 
H., Kohno, K., Sakai, K., Shimoyama, T., Nishio, K. and Kuwano, M. (2007) 
'Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition 
of malignant characteristics by human ovarian cancer cells', Oncogene, 
26(19), pp. 2736-2746. 
Basaki, Y., Taguchi, K., Izumi, H., Murakami, Y., Kubo, T., Hosoi, F., Watari, K., 
Nakano, K., Kawaguchi, H., Ohno, S., Kohno, K., Ono, M. and Kuwano, M. 
(2010) 'Y-box binding protein-1 (YB-1) promotes cell cycle progression 
through CDC6-dependent pathway in human cancer cells', Eur J Cancer, 
46(5), pp. 954-65. 
Beausoleil, S. A., Villén, J., Gerber, S. A., Rush, J. and Gygi, S. P. (2006) 'A 
probability-based approach for high-throughput protein phosphorylation 
analysis and site localization', Nat Biotechnol, 24(10), pp. 1285-92. 
Beckman, R. A. and Loeb, L. A. (2005) 'Genetic instability in cancer: theory and 
experiment', Semin Cancer Biol, 15(6), pp. 423-35. 
		 247	
Ben-Porath, I. and Weinberg, R. A. (2005) 'The signals and pathways activating 
cellular senescence', Int J Biochem Cell Biol, 37(5), pp. 961-76. 
Bennett, M. R., Macdonald, K., Chan, S. W., Boyle, J. J. and Weissberg, P. L. (1998) 
'Cooperative interactions between RB and p53 regulate cell proliferation, cell 
senescence, and apoptosis in human vascular smooth muscle cells from 
atherosclerotic plaques', Circulation Research, 82(6), pp. 704-712. 
Benzeno, S., Lu, F., Guo, M., Barbash, O., Zhang, F., Herman, J. G., Klein, P. S., 
Rustgi, A. and Diehl, J. A. (2006) 'Identification of mutations that disrupt 
phosphorylation-dependent nuclear export of cyclin D1', Oncogene, 25(47), 
pp. 6291-303. 
Bergmann, S., Royer-Pokora, B., Fietze, E., Jurchott, K., Hildebrandt, B., Trost, D., 
Leenders, F., Claude, J. C., Theuring, F., Bargou, R., Dietel, M. and Royer, H. 
D. (2005) 'YB-1 provokes breast cancer through the induction of chromosomal 
instability that emerges from mitotic failure and centrosome amplification', 
Cancer Research, 65(10), pp. 4078-4087. 
Berquin, I. M., Pang, B., Dziubinski, M. L., Scott, L. M., Chen, Y. Q., Nolan, G. P. 
and Ethier, S. P. (2005) 'Y-box-binding protein 1 confers EGF independence 
to human mammary epithelial cells', Oncogene, 24(19), pp. 3177-3186. 
Biggins, S., Severin, F. F., Bhalla, N., Sassoon, I., Hyman, A. A. and Murray, A. W. 
(1999) 'The conserved protein kinase Ipl1 regulates microtubule binding to 
kinetochores in budding yeast', Genes  &  Development, 13(5), pp. 532-544. 
Binamé, F., Pawlak, G., Roux, P. and Hibner, U. (2010) 'What makes cells move: 
requirements and obstacles for spontaneous cell motility', Mol Biosyst, 6(4), 
pp. 648-61. 
Boukamp, P., Popp, S. and Krunic, D. (2005) 'Telomere-dependent chromosomal 
instability', Journal of Investigative Dermatology Symposium Proceedings, 
10(2), pp. 89-94. 
Bowtell, D., Fu, P., Simon, M. and Senior, P. (1992) 'Identification of murine 
homologues of the Drosophila son of sevenless gene: potential activators of 
ras', Proc Natl Acad Sci U S A, 89(14), pp. 6511-5. 
Bowen, D. T., Frew, M. E., Hills, R., Gale, R. E., Wheatley, K., Groves, M. J., 
Langabeer, S. E., Kottaridis, P. D., Moorman, A. V., Burnett, A. K. and Linch, 
D. C. (2005) 'RAS mutation in acute myeloid leukemia is associated with 
distinct cytogenetic subgroups but does not influence outcome in patients 
younger than 60 years', Blood, 106(6), pp. 2113-2119. 
Brady, C. A. and Attardi, L. D. (2010) 'p53 at a glance', J Cell Sci, 123(Pt 15), pp. 
2527-32. 
Brady, D. M. and Hardwick, K. G. (2000) 'Complex formation between Mad1p, 
Bub1p and Bub3p is crucial for spindle checkpoint function', Current Biology, 
10(11), pp. 675-678. 
Bravo-Cordero, J. J., Hodgson, L. and Condeelis, J. (2012) 'Directed cell invasion and 
migration during metastasis', Curr Opin Cell Biol, 24(2), pp. 277-83. 
Brondello, J. M., Boddy, M. N., Furnari, B. and Russell, P. (1999) 'Basis for the 
checkpoint signal specificity that regulates Chk1 and Cds1 protein kinases', 
Molecular and Cellular Biology, 19(6), pp. 4262-4269. 
Brown, E. J. and Baltimore, D. (2000) 'ATR disruption leads to chromosomal 
fragmentation and early embryonic lethality', Genes  &  Development, 14(4), 
pp. 397-402. 
Buckley, M. F., Sweeney, K. J., Hamilton, J. A., Sini, R. L., Manning, D. L., 
Nicholson, R. I., deFazio, A., Watts, C. K., Musgrove, E. A. and Sutherland, 
		 248	
R. L. (1993) 'Expression and amplification of cyclin genes in human breast 
cancer', Oncogene, 8(8), pp. 2127-33. 
Buday, L. and Downward, J. (1993) 'Epidermal growth factor regulates p21ras 
through the formation of a complex of receptor, Grb2 adapter protein, and Sos 
nucleotide exchange factor', Cell, 73(3), pp. 611-20. 
Buday, L., Egan, S. E., Viciana, P. R., Cantrell, D. A. and Downward, J. (1994) 'A 
complex of GRB2 adapter protein, sos exchange factor, and a 36-kda 
membrane-bound tyrosine phosphoprotein is implicated in ras activation in T-
cells ', Journal of Biological Chemistry, 269(12), pp. 9019-9023. 
Buffart, T. E., Carvalho, B., Mons, T., Reis, R. M., Moutinho, C., Silva, P., van 
Grieken, N. C., Vieth, M., Stolte, M., Van De Velde, C. J., Schrock, E., 
Matthaei, A., Ylstra, B., Carneiro, F. and Meijer, G. A. (2007) 'DNA copy 
number profiles of gastric cancer precursor lesions', Bmc Genomics, 8(345). 
Burma, S., Chen, B. P., Murphy, M., Kurimasa, A. and Chen, D. J. (2001) 'ATM 
phosphorylates histone H2AX in response to DNA double-strand breaks', 
Journal of Biological Chemistry, 276(45), pp. 42462-42467. 
Byers, T., Levin, B., Rothenberger, D., Dodd, G. D. and Smith, R. A. (1997) 
'American Cancer Society guidelines for screening and surveillance for early 
detection of colorectal polyps and cancer: Update 1997', Ca-a Cancer Journal 
for Clinicians, 47(3), pp. 154-60. 
Campbell, P. M., Groehler, A. L., Lee, K. M., Ouellette, M. M., Khazak, V. and Der, 
C. J. (2007) 'K-Ras promotes growth transformation and invasion of 
immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase 
signaling', Cancer Res, 67(5), pp. 2098-106. 
Canman, C. E., Wolff, A. C., Chen, C. Y., Fornace, A. J. and Kastan, M. B. (1994) 
'The p53-depentent G(1) cell-cycle checkpoint pathway and ataxia-
telangiectasia', Cancer Research, 54(19), pp. 5054-5058. 
Cardoso, J., Molenaar, L., de Menezes, R. X., van Leerdam, M., Rosenberg, C., 
Moslein, G., Sampson, J., Morreau, H., Boer, J. M. and Fodde, R. (2006) 
'Chromosomal instability in MYH- and APC-mutant adenomatous polyps', 
Cancer Research, 66(5), pp. 2514-2519. 
Casper, A. M., Nghiem, P., Arlt, M. F. and Glover, T. W. (2002) 'ATR is responsible 
for genome stability at fragile sites', American Journal of Human Genetics, 
71(4), pp. 183-183. 
Castaneda, C. A., Andrés, E., Barcena, C., Gómez, H. L., Cortés-Funés, H. and 
Ciruelos, E. (2012) 'Behaviour of breast cancer molecular subtypes through 
tumour progression.', Clin Transl Oncol, 14(6), pp. 481-5. 
Castillo, A. R., Meehl, J. B., Morgan, G., Schutz-Geschwender, A. and Winey, M. 
(2002) 'The yeast protein kinase Mps1p is required for assembly of the 
integral spindle pole body component Spc42p', Journal of Cell Biology, 
156(3), pp. 453-465. 
Cesare, A. J. and Reddel, R. R. (2010) 'Alternative lengthening of telomeres: models, 
mechanisms and implications', Nature Reviews Genetics, 11(5), pp. 319-330. 
Chandrasekaran, S., Deng, H. and Fang, Y. (2015) 'PTEN deletion potentiates 
invasion of colorectal cancer spheroidal cells through 3D Matrigel', Integr Biol 
(Camb), 7(3), pp. 324-34. 
Chansky, H. A., Hu, M., Hickstein, D. D. and Yang, L. (2001) 'Oncogenic TLS/ERG 
and EWS/Fli-1 fusion proteins inhibit RNA splicing mediated by YB-1 
protein', Cancer Research, 61(9), pp. 3586-3590. 
		 249	
Chatterjee, M., Rancso, C., Stuhmer, T., Eckstein, N., AndruliS, M., Gerecke, C., 
Lorentz, H., Royer, H. D. and Bargoul, R. C. (2008) 'The Y-box binding 
protein YB-1 is associated with progressive disease and mediates survival and 
drug resistance in multiple myeloma', Blood, 111(7), pp. 3714-3722. 
Chen, C. R., Wang, W. X., Rogoff, H. A., Li, X. T., Mang, W. and Li, C. J. (2005) 
'Dual induction of apoptosis and senescence in cancer cells by Chk2 
activation: Checkpoint activation as a strategy against cancer', Cancer 
Research, 65(14), pp. 6017-6021. 
Chen, H. P., Li, Y. Y. and Tollefsbol, T. O. (2009) 'Strategies Targeting Telomerase 
Inhibition', Molecular Biotechnology, 41(2), pp. 194-199. 
Chen, R. H. (2007) 'Dual inhibition of Cdc20 by the spindle checkpoint', Journal of 
Biomedical Science, 14(4), pp. 475-479. 
Chen, R. H., Brady, D. M., Smith, D., Murray, A. W. and Hardwick, K. G. (1999) 
'The spindle checkpoint of budding yeast depends on a tight complex between 
the Mad1 and Mad2 proteins', Molecular Biology of the Cell, 10(8), pp. 2607-
2618. 
Chen, R. H., Shevchenko, A., Mann, M. and Murray, A. W. (1998) 'Spindle 
checkpoint protein Xmad1 recruits Xmad2 to unattached kinetochores', 
Journal of Cell Biology, 143(2), pp. 283-295. 
Cheng, C. and Sharp, P. A. (2006) 'Regulation of CD44 alternative splicing by 
SRm160 and its potential role in tumor cell invasion', Mol Cell Biol, 26(1), pp. 
362-70. 
Cheng, C., Yaffe, M. B. and Sharp, P. A. (2006) 'A positive feedback loop couples 
Ras activation and CD44 alternative splicing', Genes Dev, 20(13), pp. 1715-
20. 
Cheng, S. F., Alfonso-Jaume, M. A., Mertens, P. R. and Lovett, D. H. (2002) 'Tumour 
metastasis suppressor, nm23-beta, inhibits gelatinase A transcription by 
interference with transactivator Y-box protein-1 (YB-1)', Biochemical 
Journal, 366, pp. 807-816. 
Chernov, K. G., Mechulam, A., Popova, N. V., Pastre, D., Nadezhdina, E. S., 
Skabkina, O. V., Shanina, N. A., Vasiliev, V. D., Tarrade, A., Melki, J., Joshi, 
V., Baconnais, S., Toma, F., Ovchinnikov, L. P. and Curmi, P. A. (2008) 'YB-
1 promotes microtubule assembly in vitro through interaction with tubulin and 
microtubules', BMC Biochem, 9, pp. 23. 
Chernukhin, I. V., Shamsuddin, S., Robinson, A. F., Carne, A. F., Paul, A., El-Kady, 
A. I., Lobanenkov, V. V. and Klenova, E. M. (2000) 'Physical and functional 
interaction between two pluripotent proteins, the Y-box DNA/RNA-binding 
factor, YB-1, and the multivalent zinc finger factor, CTCF', Journal of 
Biological Chemistry, 275(38), pp. 29915-29921. 
Chiang, M. F., Chang, C. N., Chen, M. F. and Ho, Y. S. (1998) 'Nuclear 
multiparameter flow cytometric DNA analysis of human brain tumors: 
Correlation of DNA content with tumor histology and clinical behavior', 
Surgical Neurology, 50(1), pp. 65-72. 
Chibi, M., Meyer, M., Skepu, A., Rees, D. J. G., Moolman-Smook, J. C. and Pugh, D. 
J. R. (2008) 'RBBP6 Interacts with Multifunctional Protein YB-1 through Its 
RING Finger Domain, Leading to Ubiquitination and Proteosomal 
Degradation of YB-1', Journal of Molecular Biology, 384(4), pp. 908-916. 
Chipuk, J. E., Kuwana, T., Bouchier-Hayes, L., Droin, N. M., Newmeyer, D., Schuler, 
M. and Green, D. R. (2004) 'Direct activation of Bax by p53 mediates 
		 250	
mitochondrial membrane permeabilization and apoptosis', Science, 303(5660), 
pp. 1010-1014. 
Cho, H. J., Baek, K. E., Park, S. M., Kim, I. K., Choi, Y. L., Nam, I. K., Hwang, E. 
M., Park, J. Y., Han, J. Y., Kang, S. S., Kim, D. C., Lee, W. S., Lee, M. N., 
Oh, G. T., Kim, J. W., Lee, C. W. and Yoo, J. (2009) 'RhoGDI2 expression is 
associated with tumor growth and malignant progression of gastric cancer.', 
Clin Cancer Res, 15(8), pp. 2612-9. 
Christophorou, M. A., Martin-Zanca, D., Soucek, L., Lawlor, E. R., Brown-Swigart, 
L., Verschuren, E. W. and Evan, G. I. (2005) 'Temporal dissection of p53 
function in vitro and in vivo', Nat Genet, 37(7), pp. 718-26. 
Chung, E. N. and Chen, R. H. (2003) 'Phosphorylation of Cdc20 is required for its 
inhibition by the spindle checkpoint', Nature Cell Biology, 5(8), pp. 748-753. 
Cobbold, L. C., Wilson, L. A., Sawicka, K., King, H. A., Kondrashov, A. V., Spriggs, 
K. A., Bushell, M. and Willis, A. E. (2010) 'Upregulated c-myc expression in 
multiple myeloma by internal ribosome entry results from increased 
interactions with and expression of PTB-1 and YB-1', Oncogene, 29(19), pp. 
2884-91. 
Cohen, S. B., Graham, M. E., Lovrecz, G. O., Bache, N., Robinson, P. J. and Reddel, 
R. R. (2007) 'Protein composition of catalytically active human telomerase 
from immortal cells', Science, 315(5820), pp. 1850-1853. 
Cohen, S. B., Ma, W., Valova, V. A., Algie, M., Harfoot, R., Woolley, A. G., 
Robinson, P. J. and Braithwaite, A. W. (2010) 'Genotoxic stress-induced 
nuclear localization of oncoprotein YB-1 in the absence of proteolytic 
processing', Oncogene, 29(3), pp. 403-410. 
Coles, L. S., Lambrusco, L., Burrows, J., Hunter, J., Diamond, P., Bert, A. G., Vadas, 
M. A. and Goodall, G. J. (2005) 'Phosphorylation of cold shock domain/Y-box 
proteins by ERK2 and GSK3beta and repression of the human VEGF 
promoter', FEBS Lett, 579(24), pp. 5372-8. 
Cooper, S. (2003) 'Reappraisal of serum starvation, the restriction point, G0, and G1 
phase arrest points', Faseb Journal, 17(3), pp. 333-340. 
Cortez, D., Wang, Y., Qin, J. and Elledge, S. J. (1999) 'Requirement of ATM-
dependent phosphorylation of BRCA1 in the DNA damage response to 
double-strand breaks', Science, 286(5442), pp. 1162-1166. 
Cortot, A. B., Italiano, A., Burel-Vandenbos, F., Martel-Planche, G. and Hainaut, P. 
(2010) 'KRAS Mutation Status in Primary Nonsmall Cell Lung Cancer and 
Matched Metastases', Cancer, 116(11), pp. 2682-2687. 
Cosme-Blanco, W., Shen, M. F., Lazar, A. J. F., Pathak, S., Lozano, G., Multani, A. 
S. and Chang, S. (2007) 'Telomere dysfunction suppresses spontaneous 
tumorigenesis in vivo by initiating p53-dependent cellular senescence', Embo 
Reports, 8(5), pp. 497-503. 
Coverley, D., Pelizon, C., Trewick, S. and Laskey, R. A. (2000) 'Chromatin-bound 
Cdc6 persists in S and G2 phases in human cells, while soluble Cdc6 is 
destroyed in a cyclin A-cdk2 dependent process', J Cell Sci, 113 ( Pt 11), pp. 
1929-38. 
Croce, C. M. (2008) 'Molecular origins of cancer: Oncogenes and cancer', New 
England Journal of Medicine, 358(5), pp. 502-511. 
Dahl, E., En-Nia, A., Wiesmann, F., Krings, R., Djudjaj, S., Breuer, E., Fuchs, T., 
Wild, P. J., Hartmann, A., Dunn, S. E. and Mertens, P. R. (2009) 'Nuclear 
detection of Y-box protein-1 (YB-1) closely associates with progesterone 
		 251	
receptor negativity and is a strong adverse survival factor in human breast 
cancer', Bmc Cancer, 9(410). 
Dang, C. V., O'Donnell, K. A., Zeller, K. I., Nguyen, T., Osthus, R. C. and Li, F. 
(2006) 'The c-Myc target gene network', Seminars in Cancer Biology, 16(4), 
pp. 253-264. 
Davies, A. H., Barrett, I., Pambid, M. R., Hu, K., Stratford, A. L., Freeman, S., 
Berquin, I. M., Pelech, S., Hieter, P., Maxwell, C. and Dunn, S. E. (2011) 'YB-
1 evokes susceptibility to cancer through cytokinesis failure, mitotic 
dysfunction and HER2 amplification', Oncogene, 30(34), pp. 3649-60. 
Davies, A. H., Reipas, K. M., Pambid, M. R., Berns, R., Stratford, A. L., Fotovati, A., 
Firmino, N., Astanehe, A., Hu, K., Maxwell, C., Mills, G. B. and Dunn, S. E. 
(2014) 'YB-1 transforms human mammary epithelial cells through chromatin 
remodeling leading to the development of basal-like breast cancer', Stem Cells, 
32(6), pp. 1437-50. 
de Klein, A., Muijtjens, M., van Os, R., Verhoeven, Y., Smit, B., Carr, A. M., 
Lehmann, A. R. and Hoeijmakers, J. H. J. (2000) 'Targeted disruption of the 
cell-cycle checkpoint gene ATR leads to early embryonic lethality in mice', 
Current Biology, 10(8), pp. 479-482. 
de Souza-Pinto, N. C., Mason, P. A., Hashiguchi, K., Weissman, L., Tian, J. Y., 
Guay, D., Lebel, M., Stevnsner, T. V., Rasmussen, L. J. and Bohr, V. A. 
(2009) 'Novel DNA mismatch-repair activity involving YB-1 in human 
mitochondria', DNA Repair, 8(6), pp. 704-719. 
Delom, F. and Chevet, E. (2006) 'Phosphoprotein analysis: from proteins to 
proteomes', Proteome Sci, 4, pp. 15. 
Dhillon, J., Astanehe, A., Lee, C., Fotovati, A., Hu, K. and Dunn, S. E. (2010) 'The 
expression of activated Y-box binding protein-1 serine 102 mediates 
trastuzumab resistance in breast cancer cells by increasing CD44+ cells', 
Oncogene, 29(47), pp. 6294-300. 
Didier, D. K., Schiffenbauer, J., Woulfe, S. L., Zacheis, M. and Schwartz, B. D. 
(1988) 'Characterization of the CDNA-encoding a protein-binding to the major 
histocompatibility complex class-II Y-box', Proceedings of the National 
Academy of Sciences of the United States of America, 85(19), pp. 7322-7326. 
Dix, D. (1989) 'The role of aging in cancer incidence - An epidemiological-study', 
Journals of Gerontology, 44(6), pp. 10-18. 
Doherty, S. C., McKeown, S. R., McKelvey-Martin, V., Downes, C. S., Atala, A., 
Yoo, J. J., Simpson, D. A. and Kaufmann, W. K. (2003) 'Cell cycle checkpoint 
function in bladder cancer', Journal of the National Cancer Institute, 95(24), 
pp. 1859-1868. 
Dohner, H., Fischer, K., Bentz, M., Hansen, K., Benner, A., Cabot, G., Diehl, D., 
Schlenk, R., Coy, J., Stilgenbauer, S., Volkmann, M., Galle, P. R., Poustka, 
A., Hunstein, W. and Lichter, P. (1995) 'P53 gene deletion predicts for poor 
survival and nonresponse to therapy with purine analogs in chronic B-cell 
leukemias', Blood, 85(6), pp. 1580-1589. 
Dominguez, I., Marshall, M. S., Gibbs, J. B., Deherreros, A. G., Cornet, M. E., 
Graziani, G., Diazmeco, M. T., Johansen, T., McCormick, F. and Moscat, J. 
(1991) ' Role of gtpase activating protein in mitogenic signaling through 
Phosphatidylcholine-Hydrolyzing Phospholipase-C ', Embo Journal, 10(11), 
pp. 3215-3220. 
Duesberg, P., Li, R. H., Rasnick, D., Rausch, C., Willer, A., Kraemer, A., Yerganian, 
G. and Hehlmann, R. (2000) 'Aneuploidy precedes and segregates with 
		 252	
chemical carcinogenesis', Cancer Genetics and Cytogenetics, 119(2), pp. 83-
93. 
Ehlers, J. P., Worley, L., Onken, M. D. and Harbour, J. W. (2008) 'Integrative 
genomic analysis of aneuploidy in uveal melanoma', Clinical Cancer 
Research, 14(1), pp. 115-122. Eliseeva,	 I.	 A.,	 Kim,	 E.	 R.,	 Guryanov,	 S.	 G.,	 Ovchinnikov,	 L.	 P.	 and	 Lyabin,	 D.	 N.	(2011)	 'Y-box-binding	 protein	 1	 (YB-1)	 and	 its	 functions',	 Biochemistry	
(Mosc),	76(13),	pp.	1402-33.	
Ellegren, H. (2004) 'Microsatellites: simple sequences with complex evolution', Nat 
Rev Genet, 5(6), pp. 435-45. 
El-Naggar, A. M., Veinotte, C. J., Cheng, H., Grunewald, T. G., Negri, G. L., 
Somasekharan, S. P., Corkery, D. P., Tirode, F., Mathers, J., Khan, D., Kyle, 
A. H., Baker, J. H., LePard, N. E., McKinney, S., Hajee, S., Bosiljcic, M., 
Leprivier, G., Tognon, C. E., Minchinton, A. I., Bennewith, K. L., Delattre, 
O., Wang, Y., Dellaire, G., Berman, J. N. and Sorensen, P. H. (2015) 
'Translational Activation of HIF1α by YB-1 Promotes Sarcoma Metastasis', 
Cancer Cell, 27(5), pp. 682-97. 
En-Nia, A., Yilmaz, E., Klinge, U., Lovett, D. H., Stefanidis, I. and Mertens, P. R. 
(2005) 'Transcription factor YB-1 mediates DNA polymerase alpha gene 
expression', Journal of Biological Chemistry, 280(9), pp. 7702-7711. 
Encalada, S. E., Willis, J., Lyczak, R. and Bowerman, B. (2005) 'A spindle 
checkpoint functions during mitosis in the early Caenorhabditis elegans 
embryo', Molecular Biology of the Cell, 16(3), pp. 1056-1070. 
Esteller, M., Sparks, A., Toyota, M., Sanchez-Cespedes, M., Capella, G., Peinado, M. 
A., Gonzalez, S., Tarafa, G., Sidransky, D., Meltzer, S. J., Baylin, S. B. and 
Herman, J. G. (2000) 'Analysis of Adenomatous Polyposis Coli promoter 
hypermethylation in human cancer', Cancer Research, 60(16), pp. 4366-4371. 
Etzioni, R., Urban, N., Ramsey, S., McIntosh, M., Schwartz, S., Reid, B., Radich, J., 
Anderson, G. and Hartwell, L. (2003) 'The case for early detection', Nature 
Reviews Cancer, 3(4), pp. 243-252. 
Everett, R. D. (1984) 'Trans activation of transcription by herpes virus products: 
requirement for two HSV-1 immediate-early polypeptides for maximum 
activity', EMBO J, 3(13), pp. 3135-41. 
Evdokimova, V., Ovchinnikov, L. P. and Sorensen, P. H. (2006) 'Y-box binding 
protein 1: providing a new angle on translational regulation', Cell Cycle, 5(11), 
pp. 1143-7. 
Evdokimova, V., Ruzanov, P., Imataka, H., Raught, B., Svitkin, Y., Ovchinnikov, L. 
P. and Sonenberg, N. (2001) 'The major mRNA-associated protein YBA is a 
potent 5 ' cap-dependent mRNA stabilizer', Embo Journal, 20(19), pp. 5491-
5502. 
Evdokimova, V., Tognon, C., Ng, T., Ruzanov, P., Melnyk, N., Fink, D., Sorokin, A., 
Ovchinnikov, L. P., Davicioni, E., Triche, T. J. and Sorensen, P. H. B. (2009) 
'Translational Activation of Snail1 and Other Developmentally Regulated 
Transcription Factors by YB-1 Promotes an Epithelial-Mesenchymal 
Transition', Cancer Cell, 15(5), pp. 402-415. 
Fearnhead, N. S., Wilding, J. L. and Bodmer, W. F. (2002) 'Genetics of colorectal 
cancer: hereditary aspects and overview of colorectal tumorigenesis', British 
Medical Bulletin, 64, pp. 27-43. 
Feldser, D. M. and Greider, C. W. (2007) 'Short telomeres limit tumor progression in 
vivo by inducing senescence', Cancer Cell, 11(5), pp. 461-469. 
		 253	
Fig 5.1. “A schematic diagram of cancer cells migrating and invading surrounding 
tissue" (2002) [online] At: http//www.webmd.com  (Accessed on 1.10.14). 
Finkbeiner, M. R., Astanehe, A., To, K., Fotovati, A., Davies, A. H., Zhao, Y., Jiang, 
H., Stratford, A. L., Shadeo, A., Boccaccio, C., Comoglio, P., Mertens, P. R., 
Eirew, P., Raouf, A., Eaves, C. J. and Dunn, S. E. (2009) 'Profiling YB-1 
target genes uncovers a new mechanism for MET receptor regulation in 
normal and malignant human mammary cells', Oncogene, 28(11), pp. 1421-
1431. 
Finlay, C. A., Hinds, P. W. and Levine, A. J. (1989) 'The p53 proto-oncogene can act 
as a suppressor of transformation', Cell, 57(7), pp. 1083-1093. 
Flores, E. R., Tsai, K. Y., Crowley, D., Sengupta, S., Yang, A., McKeon, F. and 
Jacks, T. (2002) 'p63 and p73 are required for p53-dependent apoptosis in 
response to DNA damage', Nature, 416(6880), pp. 560-4. 
Foster, F. M., Traer, C. J., Abraham, S. M. and Fry, M. J. (2003) 'The 
phosphoinositide (PI) 3-kinase family', Journal of Cell Science, 116(15), pp. 
3037-3040. 
Francisco, L., Wang, W. F. and Chan, C. S. M. (1994) 'Type 1 protein phosphatase 
acts in opposition to IpL1 protein kinase in regulating yeast chromosome 
segregation.', Molecular and Cellular Biology, 14(7), pp. 4731-4740. 
Fraser, D. J., Phillips, A. O., Zhang, X., van Roeyen, C. R., Muehlenberg, P., En-Nia, 
A. and Mertens, P. R. (2008) 'Y-box protein-1 controls transforming growth 
factor-beta1 translation in proximal tubular cells', Kidney Int, 73(6), pp. 724-
32. 
Freedman, D. A. and Levine, A. J. (1999) 'Regulation of the p53 protein by the 
MDM2 oncoprotein--thirty-eighth G.H.A. Clowes Memorial Award Lecture', 
Cancer Res, 59(1), pp. 1-7. 
Frye, B. C., Halfter, S., Djudjaj, S., Muehlenberg, P., Weber, S., Raffetseder, U., En-
Nia, A., Knott, H., Baron, J. M., Dooley, S., Bernhagen, J. and Mertens, P. R. 
(2009) 'Y-box protein-1 is actively secreted through a non-classical pathway 
and acts as an extracellular mitogen', Embo Reports, 10(7), pp. 783-789. 
Fu, H., Subramanian, R. R. and Masters, S. C. (2000) '14-3-3 proteins: structure, 
function, and regulation', Annu Rev Pharmacol Toxicol, 40, pp. 617-47. 
Fu, M., Wang, C., Li, Z., Sakamaki, T. and Pestell, R. G. (2004) 'Minireview: Cyclin 
D1: normal and abnormal functions', Endocrinology, 145(12), pp. 5439-47. 
Fujita, T., Ito, K. I., Izumi, H., Kimura, M., Sano, M., Nakagomi, H., Maeno, K., 
Hama, Y., Shingu, K., Tsuchiya, S. I., Kohno, K. and Fujimori, M. (2005) 
'Increased nuclear localization of transcription factor Y-box binding protein 1 
accompanied by up-regulation of P-glycoprotein in breast cancer pretreated 
with paclitaxel', Clinical Cancer Research, 11(24), pp. 8837-8844. 
Fukada, T. and Tonks, N. K. (2003) 'Identification of YB-1 as a regulator of PTP1B 
expression: implications for regulation of insulin and cytokine signaling', 
Embo Journal, 22(3), pp. 479-493. 
Funakoshi, T., Kobayashi, S., Ohashi, S., Sato, T. A. and Anzai, K. (2003) 'Isolation 
and characterization of brain Y-box protein: developmentally regulated 
expression, polyribosomal association and dendritic localization', Molecular 
Brain Research, 118(1-2), pp. 1-9. 
Furuno, N., den Elzen, N. and Pines, J. (1999) 'Human cyclin A is required for mitosis 
until mid prophase', J Cell Biol, 147(2), pp. 295-306. 
Gail, M. H. and Boone, C. W. (1970) 'The locomotion of mouse fibroblasts in tissue 
culture', Biophys J, 10(10), pp. 980-93. 
		 254	
Gao, Y., Fotovati, A., Lee, C., Wang, M., Cote, G., Guns, E., Toyota, B., Faury, D., 
Jabado, N. and Dunn, S. E. (2009) 'Inhibition of Y-box binding protein-1 
slows the growth of glioblastoma multiforme and sensitizes to temozolomide 
independent O6-methylguanine-DNA methyltransferase', Mol Cancer Ther, 
8(12), pp. 3276-84. 
Gao, Y. and Wang, H. Y. (2006) 'Casein kinase 2 Is activated and essential for 
Wnt/beta-catenin signaling', J Biol Chem, 281(27), pp. 18394-400. 
Gardner, R. D. and Burke, D. J. (2000) 'The spindle checkpoint: two transitions, two 
pathways', Trends in Cell Biology, 10(4), pp. 154-158. 
Gatz, S. A. and Wiesmuller, L. (2006) 'p53 in recombination and repair', Cell Death 
and Differentiation, 13(6), pp. 1003-1016. 
Gaudreault, I., Guay, D. and Lebel, M. (2004) 'YB-1 promotes strand separation in 
vitro of duplex DNA containing either mispaired bases or cisplatin 
modifications, exhibits endonucleolytic activities and binds several DNA 
repair proteins', Nucleic Acids Research, 32(1), pp. 316-327. 
Gavory, G., Farrow, M. and Balasubramanian, S. (2002) 'Minimum length 
requirement of the alignment domain of human telomerase RNA to sustain 
catalytic activity in vitro', Nucleic Acids Research, 30(20), pp. 4470-4480. 
Gavet, O. and Pines, J. (2010) 'Activation of cyclin B1-Cdk1 synchronizes events in 
the nucleus and the cytoplasm at mitosis', J Cell Biol, 189(2), pp. 247-59. 
Gessner, C., Woischwill, C., Schumacher, A., Liebers, U., Kuhn, H., Stiehl, P., 
Jürchott, K., Royer, H. D., Witt, C. and Wolff, G. (2004) 'Nuclear YB-1 
expression as a negative prognostic marker in nonsmall cell lung cancer', Eur 
Respir J, 23(1), pp. 14-9. 
Giménez-Bonafé, P., Fedoruk, M. N., Whitmore, T. G., Akbari, M., Ralph, J. L., 
Ettinger, S., Gleave, M. E. and Nelson, C. C. (2004) 'YB-1 is upregulated 
during prostate cancer tumor progression and increases P-glycoprotein 
activity', Prostate, 59(3), pp. 337-49. 
Rubin, R., Strayer, D. S. and Rubin, E. (2008) Rubin's Pathology : clinicopathologic 
foundations of medicine. 5th edn. Philadelphia: Wolters Kluwer 
Health/Lippincott Williams  &  Wilkins. 
Gale, M., Tan, S. L. and Katze, M. G. (2000) 'Translational control of viral gene 
expression in eukaryotes', Microbiol Mol Biol Rev, 64(2), pp. 239-80. 
Glover, D. M., Leibowitz, M. H., McLean, D. A. and Parry, H. (1995) 'Mutations in 
aurora prevent centrosome separation leading to the formation of monopolar 
spindles', Cell, 81(1), pp. 95-105. 
Gluz, O., Mengele, K., Schmitt, M., Kates, R., Diallo-Danebrock, R., Neff, F., Royer, 
H. D., Eckstein, N., Mohrmann, S., Ting, E., Kiechle, M., Poremba, C., Nitz, 
U. and Harbeck, N. (2009) 'Y-Box-Binding Protein YB-1 Identifies High-Risk 
Patients With Primary Breast Cancer Benefiting From Rapidly Cycled 
Tandem High-Dose Adjuvant Chemotherapy', Journal of Clinical Oncology, 
27(36), pp. 6144-6151. 
Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., 
Chen, F., Duh, F. M., Lubensky, I., Duan, D. R., Florence, C., Pozzatti, R., 
Walther, M. M., Bander, N. H., Grossman, H. B., Brauch, H., Pomer, S., 
Brooks, J. D., Isaacs, W. B., Lerman, M. I., Zbar, B. and Linehan, W. M. 
(1994) 'Mutations of the VHL tumor-suppressor gene in renal-carinoma.', 
Nature Genetics, 7(1), pp. 85-90. 
		 255	
Gollin, S. M. (2001) 'Chromosomal alterations in squamous cell carcinomas of the 
head and neck: Window to the biology of disease', Head and Neck-Journal for 
the Sciences and Specialties of the Head and Neck, 23(3), pp. 238-253. 
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., 
Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., Bloomfield, C. D. 
and Lander, E. S. (1999) 'Molecular classification of cancer: Class discovery 
and class prediction by gene expression monitoring', Science, 286(5439), pp. 
531-537. 
Gorski, B., Debniak, T., Masoic, B., Mierzejewski, M., Medrek, K., Cybulski, C., 
Jakubowska, A., Kurzawski, G., Chosia, M., Scott, R. and Lubinski, J. (2003) 
'Germline 657del5 mutation in the NBS1 gene in breast cancer patients', 
International Journal of Cancer, 106(3), pp. 379-381. 
Gown, A. M. and Willingham, M. C. (2002) 'Improved detection of apoptotic cells in 
archival paraffin sections: immunohistochemistry using antibodies to cleaved 
caspase 3', J Histochem Cytochem, 50(4), pp. 449-54. 
Gradilone, A., Gazzaniga, P., Silvestri, I., Gandini, O., Trasatti, L., Lauro, S., Frati, L. 
and Agliano, A. M. (2003) 'Detection of CK19, CK20 and EGFR mRNAs in 
peripheral blood of carcinoma patients: Correlation with clinical stage of 
disease', Oncology Reports, 10(1), pp. 217-222. 
Greider, C. W. and Blackburn, E. H. (1985) 'Identification of a specific telomere 
terminal transferase-activity in Terahymena extracts', Cell, 43(2), pp. 405-413. 
Gu, W. and Roeder, R. G. (1997) 'Activation of p53 sequence-specific DNA binding 
by acetylation of the p53 C-terminal domain', Cell, 90(4), pp. 595-606. 
Guo, T., Yu, Y., Yip, G. W., Baeg, G. H., Thike, A. A., Lim, T. K., Tan, P. H., 
Matsumoto, K. and Bay, B. H. (2015) 'Y-box binding protein 1 is correlated 
with lymph node metastasis in intestinal-type gastric cancer', Histopathology, 
66(4), pp. 491-9. 
Guo, T. T., Yu, Y. N., Yip, G. W., Matsumoto, K. and Bay, B. H. (2013) 'Silencing 
the YB-1 gene inhibits cell migration in gastric cancer in vitro', Anat Rec 
(Hoboken), 296(6), pp. 891-8. 
Habibi, G., Leung, S., Law, J. H., Gelmon, K., Masoudi, H., Turbin, D., Pollak, M., 
Nielsen, T. O., Huntsman, D. and Dunn, S. E. (2008) 'Redefining prognostic 
factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-
specific survival than estrogen receptor or HER-2 across all tumor subtypes', 
Breast Cancer Research, 10(5), pp. R86. 
Hamad, N. M., Banik, S. S. R. and Counter, C. M. (2002) 'Mutational analysis defines 
a minimum level of telomerase activity required for tumourigenic growth of 
human cells', Oncogene, 21(46), pp. 7121-7125. 
Hanahan, D. and Weinberg, R. A. (2011) 'Hallmarks of cancer: the next generation', 
Cell, 144(5), pp. 646-74. 
Harada, M., Kotake, Y., Ohhata, T., Kitagawa, K., Niida, H., Matsuura, S., Funai, K., 
Sugimura, H., Suda, T. and Kitagawa, M. (2014) 'YB-1 promotes transcription 
of cyclin D1 in human non-small-cell lung cancers', Genes Cells, 19(6), pp. 
504-16. 
Harbour, J. W., Luo, R. X., Dei Santi, A., Postigo, A. A. and Dean, D. C. (1999) 'Cdk 
phosphorylation triggers sequential intramolecular interactions that 
progressively block Rb functions as cells move through G1', Cell, 98(6), pp. 
859-69. 
Harley, C. B., Futcher, A. B. and Greider, C. W. (1990) 'Telomeres shorten during 
aging of human fibroblasts', Nature, 345(6274), pp. 458-460. 
		 256	
Hartman, A. R. and Ford, J. M. (2002) 'BRCA1 induces DNA damage recognition 
factors and enhances nucleotide excision repair', Nature Genetics, 32(1), pp. 
180-184. 
Hass, H. G., Schmidt, A., Nehls, O. and Kaiser, S. (2008) 'DNA ploidy, proliferative 
capacity and intratumoral heterogeneity in primary and recurrent head and 
neck squamous cell carcinomas (HNSCC) - Potential implications for clinical 
management and treatment decisions', Oral Oncology, 44(1), pp. 78-85. 
Haupt, Y., Maya, R., Kazaz, A. and Oren, M. (1997) 'Mdm2 promotes the rapid 
degradation of p53', Nature, 387(6630), pp. 296-299. 
Hawksworth, D., Ravindranath, L., Chen, Y., Furusato, B., Sesterhenn, I. A., 
McLeod, D. G., Srivastava, S. and Petrovics, G. (2010) 'Overexpression of C-
MYC oncogene in prostate cancer predicts biochemical recurrence', Prostate 
Cancer and Prostatic Diseases, 13(4), pp. 311-315. 
Hay, E. D. (1995) 'An overview of epithelio-mesenchymal transformation', Acta Anat 
(Basel), 154(1), pp. 8-20. 
Henson, J. D., Hannay, J. A., McCarthy, S. W., Royds, J. A., Yeager, T. R., 
Robinson, R. A., Wharton, S. B., Jellinek, D. A., Arbuckle, S. M., Yoo, J. Y., 
Robinson, B. G., Learoyd, D. L., Stalley, P. D., Bonar, S. F., Yu, D. H., 
Pollock, R. E. and Reddel, R. R. (2005) 'A robust assay for alternative 
lengthening of telomeres in tumors shows the significance of alternative 
lengthening of telomeres in sarcomas and astrocytomas', Clinical Cancer 
Research, 11(1), pp. 217-225. 
Herman, J. G., Latif, F., Weng, Y. K., Lerman, M. I., Zbar, B., Liu, S., Samid, D., 
Duan, D. S. R., Gnarra, J. R., Linehan, W. M. and Baylin, S. B. (1994) '	
Silencing of the VHL tumor-suppressor gene by DNA methylation in renal-
carcinoma ', Proceedings of the National Academy of Sciences of the United 
States of America, 91(21), pp. 9700-9704. 
Hess, R., Plaumann, B., Lutum, A. S., Haessler, C., Heinz, B., Fritsche, M. and 
Brandner, G. (1994) 'Nuclear accumulation of p53 in response to treatment 
with DNA-damaging agents', Toxicology Letters, 72(1-3), pp. 43-52. 
Higashi, K., Inagaki, Y., Fujimori, K., Nakao, A., Kaneko, H. and Nakatsuka, I. 
(2003) 'Interferon-gamma interferes with transforming growth factor-beta 
signaling through direct interaction of YB-1 with Smad3', Journal of 
Biological Chemistry, 278(44), pp. 43470-43479. 
Hinds, P. W., Dowdy, S. F., Eaton, E. N., Arnold, A. and Weinberg, R. A. (1994) 
'Function of a human cyclin gene as an oncogene', Proc Natl Acad Sci U S A, 
91(2), pp. 709-13. 
Hipfel, R., Schittek, B., Bodingbauer, Y. and Garbe, C. (2000) 'Specifically regulated 
genes in malignant melanoma tissues identified by subtractive hybridization', 
Br J Cancer, 82(6), pp. 1149-57. 
Hiraga, T., Ito, S. and Nakamura, H. (2013) 'Cancer stem-like cell marker CD44 
promotes bone metastases by enhancing tumorigenicity, cell motility, and 
hyaluronan production', Cancer Res, 73(13), pp. 4112-22. 
Hirao, A., Kong, Y. Y., Matsuoka, S., Wakeham, A., Ruland, J., Yoshida, H., Liu, D., 
Elledge, S. J. and Mak, T. W. (2000) 'DNA damage-induced activation of p53 
by the checkpoint kinase Chk2', Science, 287(5459), pp. 1824-1827. 
Hirata, H., Takahashi, A., Kobayashi, S., Yonehara, S., Sawai, H., Okazaki, 
T.,Yamamoto, K., and Sasada, M., (1998) 'Caspases are activated in a 
branched protease cascade and control distinct downstream processes in Fas-
induced apoptosis', J Exp Med, 187(4), pp. 587-600. 
		 257	
Hockenbery, D., Nuñez, G., Milliman, C., Schreiber, R. D. and Korsmeyer, S. J. 
(1990) 'Bcl-2 is an inner mitochondrial membrane protein that blocks 
programmed cell death', Nature, 348(6299), pp. 334-6. 
Hollstein, M., Sidransky, D., Vogelstein, B. and Harris, C. C. (1991) 'P53 mutations 
in human cancers', Science, 253(5015), pp. 49-53. 
Holmberg Olausson, K., Nistér, M. and Lindström, M. S. (2012) 'p53 -Dependent and 
-Independent Nucleolar Stress Responses', Cells, 1(4), pp. 774-98. 
Homer, C., Knight, D. A., Hananeia, L., Sheard, P., Risk, J., Lasham, A., Royds, J. A. 
and Braithwaite, A. W. (2005) 'Y-box factor YB1 controls p53 apoptotic 
function', Oncogene, 24(56), pp. 8314-8325. 
Honda, R., Tanaka, H. and Yasuda, H. (1997) 'Oncoprotein MDM2 is a ubiquitin 
ligase E3 for tumor suppressor p53', Febs Letters, 420(1), pp. 25-27. 
Honda, R. and Yasuda, H. (1999) 'Association of p19(ARF) with Mdm2 inhibits 
ubiquitin ligase activity of Mdm2 for tumor suppressor p53', Embo Journal, 
18(1), pp. 22-27. 
Hoogwater, F. J., Nijkamp, M. W., Smakman, N., Steller, E. J., Emmink, B. L., 
Westendorp, B. F., Raats, D. A., Sprick, M. R., Schaefer, U., Van Houdt, W. 
J., De Bruijn, M. T., Schackmann, R. C., Derksen, P. W., Medema, J. P., 
Walczak, H., Borel Rinkes, I. H. and Kranenburg, O. (2010) 'Oncogenic K-
Ras turns death receptors into metastasis-promoting receptors in human and 
mouse colorectal cancer cells', Gastroenterology, 138(7), pp. 2357-67. 
Hoque, M. T. and Ishikawa, F. (2002) 'Cohesin defects lead to premature sister 
chromatid separation, kinetochore dysfunction, and spindle-assembly 
checkpoint activation', Journal of Biological Chemistry, 277(44), pp. 42306-
42314. 
Hoyt, M. A., Totis, L. and Roberts, B. T. (1991) 'Saccharomyces-cerevisiae genes 
required for cell cycle arrest in response to loss of microtubule function.', Cell, 
66(3), pp. 507-517. 
Huang, J. X., Tan, P. H., Li, K. B., Matsumoto, K., Tsujimoto, M. and Bay, B. H. 
(2005) 'Y-box binding protein, YB-1, as a marker of tumor aggressiveness and 
response to a adjuvant chemotherapy in breast cancer', International Journal 
of Oncology, 26(3), pp. 607-613. 
Hur, K., Han, T. S., Jung, E. J., Yu, J., Lee, H. J., Kim, W. H., Goel, A. and Yang, H. 
K. (2012) 'Up-regulated expression of sulfatases (SULF1 and SULF2) as 
prognostic and metastasis predictive markers in human gastric cancer.', J 
Pathol, 228(1), pp. 88-98. 
Imada, K., Shiota, M., Kohashi, K., Kuroiwa, K., Song, Y., Sugimoto, M., Naito, S. 
and Oda, Y. (2013) 'Mutual regulation between Raf/MEK/ERK signaling and 
Y-box-binding protein-1 promotes prostate cancer progression', Clin Cancer 
Res, 19(17), pp. 4638-50. 
International Agency for Research on Cancer (2015) , Available 
at: http://www.iarc.fr/(Accessed: December 2014). 
Irigaray, P., Newby, J. A., Clapp, R., Hardell, L., Howard, V., Montagnier, L., 
Epstein, S. and Belpomme, D. (2007) 'Lifestyle-related factors and 
environmental agents causing cancer: An overview', Biomedicine  &  
Pharmacotherapy, 61(10), pp. 640-658. 
Iritani, B. M. and Eisenman, R. N. (1999) 'c-Myc enhances protein synthesis and cell 
size during B lymphocyte development', Proceedings of the National Academy 
of Sciences of the United States of America, 96(23), pp. 13180-13185. 
		 258	
Isaacs, J. S., Chiao, C., Merrick, B. A., Selkirk, J. K., Barrett, J. C. and Weissman, B. 
E. (1997) 'p53-dependent p21 induction following gamma-irradiation without 
concomitant p53 induction in a human peripheral neuroepithelioma cell-line', 
Cancer Research, 57(14), pp. 2986-2992. 
Ise, T., Nagatani, G., Imamura, T., Kato, K., Takano, H., Nomoto, M., Izumi, H., 
Ohmori, H., Okamoto, T., Ohga, T., Uchiumi, T., Kuwano, M. and Kohno, K. 
(1999) 'Transcription factor Y-box binding protein 1 binds preferentially to 
cisplatin-modified DNA and interacts with proliferating cell nuclear antigen', 
Cancer Research, 59(2), pp. 342-346. 
Ito, Y., Yoshida, H., Shibahara, K., Uruno, T., Nakano, K., Takamura, Y., Miya, A., 
Kobayashi, K., Yokozawa, T., Matsuzuka, F., Uchimi, T., Kuwano, M., 
Miyoshi, E., Matsuura, N., Kuma, K. and Miyauchi, A. (2003) 'Y-box binding 
protein expression in thyroid neoplasms: Its linkage with anaplastic 
transformation', Pathology International, 53(7), pp. 429-433. 
Izumi, H., Imamura, T., Nagatani, G., Ise, T., Murakami, T., Uramoto, H., Torigoe, 
T., Ishiguchi, H., Yoshida, Y., Nomoto, M., Okamoto, T., Uchiumi, T., 
Kuwano, M., Funa, K. and Kohno, K. (2001) 'Y box-binding protein-1 binds 
preferentially to single-stranded nucleic acids and exhibits 3 '-> 5 ' 
exonuclease activity', Nucleic Acids Research, 29(5), pp. 1200-1207. 
James, G. T. (1978) 'Inactivation of the protease inhibitor phenylmethylsulfonyl 
fluoride in buffers', Anal Biochem, 86(2), pp. 574-9. 
Janda, M. and Ahlquist, P. (1993) 'RNA-dependent replication, transcription, and 
persistence of brome mosaic virus RNA replicons in S. cerevisiae', Cell, 72(6), 
pp. 961-70. 
Janz, M., Harbeck, N., Dettmar, P., Berger, U., Schmidt, A., Jurchott, K., Schmitt, M. 
and Royer, H. D. (2002) 'Y-box factor YB-1 predicts drug resistance and 
patient outcome in breast cancer independent of clinically relevant tumor 
biologic factors HER2, uPA and PAI-1', International Journal of Cancer, 
97(3), pp. 278-282. 
Jardim, M. J., Wang, Q. H., Furumai, R., Wakeman, T., Goodman, B. K. and Wang, 
X. F. (2009) 'Reduced ATR or Chk1 Expression Leads to Chromosome 
Instability and Chemosensitization of Mismatch Repair-deficient Colorectal 
Cancer Cells', Molecular Biology of the Cell, 20(17), pp. 3801-3809. 
Jelinek, T., Dent, P., Sturgill, T. W. and Weber, M. J. (1996) 'Ras-induced activation 
of Raf-1 is dependent on tyrosine phosphorylation', Molecular and Cellular 
Biology, 16(3), pp. 1027-1034. 
Jiang, F., Caraway, N. P., Sabichi, A. L., Zhang, H. Z., Ruitrok, A., Grossman, H. B., 
Gu, J., Lerner, S. P., Lippman, S. and Katz, R. L. (2003) 'Centrosomal 
abnormality is common in and a potential biomarker for bladder cancer', 
International Journal of Cancer, 106(5), pp. 661-665. 
Jiang, W., Kahn, S. M., Tomita, N., Zhang, Y. J., Lu, S. H. and Weinstein, I. B. 
(1992) 'Amplification and expression of the human cyclin D gene in 
esophageal cancer', Cancer Res, 52(10), pp. 2980-3. 
Jiang, X. R., Jimenez, G., Chang, E., Frolkis, M., Kusler, B., Sage, M., Beeche, M., 
Bodnar, A. G., Wahl, G. M., Tlsty, T. D. and Chiu, C. P. (1999) 'Telomerase 
expression in human somatic cells does not induce changes associated with a 
transformed phenotype', Nature Genetics, 21(1), pp. 111-114. 
Joshi, S., Braithwaite, A. W., Robinson, P. J. and Chircop, M. (2011) 'Dynamin 
inhibitors induce caspase-mediated apoptosis following cytokinesis failure in 
		 259	
human cancer cells and this is blocked by Bcl-2 overexpression', Mol Cancer, 
10, pp. 78. 
Jurchott, K., Bergmann, S., Stein, U., Walther, W., Janz, M., Manni, I., Piaggio, G., 
Fietze, E., Dietel, M. and Royer, H. D. (2003) 'YB-1 as a cell cycle-regulated 
transcription factor facilitating cyclin A and cyclin B1 gene expression', 
Journal of Biological Chemistry, 278(30), pp. 27988-27996. 
Kamura, T., Yahata, H., Amada, S., Ogawa, S., Sonoda, T., Kobayashi, H., 
Mitsumoto, M., Kohno, K., Kuwano, M. and Nakano, H. (1999) 'Is nuclear 
expression of Y box-binding protein-1 a new prognostic factor in ovarian 
serous adenocarcinoma?', Cancer, 85(11), pp. 2450-2454. 
Kandel, R., Li, S. Q., Ozcelik, H. and Rohan, T. (2000) 'p53 protein accumulation and 
mutations in normal and benign breast tissue', International Journal of 
Cancer, 87(1), pp. 73-78. 
Kang, Y., Hu, W., Ivan, C., Dalton, H. J., Miyake, T., Pecot, C. V., Zand, B., Liu, T., 
Huang, J., Jennings, N. B., Rupaimoole, R., Taylor, M., Pradeep, S., Wu, S. 
Y., Lu, C., Wen, Y., Liu, J. and Sood, A. K. (2013) 'Role of focal adhesion 
kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer', J 
Natl Cancer Inst, 105(19), pp. 1485-95. 
Kang, Y. H., Park, J. E., Yu, L. R., Soung, N. K., Yun, S. M., Bang, J. K., Seong, Y. 
S., Yu, H. T., Garfield, S., Veenstra, T. D. and Lee, K. S. (2006) 'Self-
regulated Plk1 recruitment to kinetochores by the Plk1-PBIP1 interaction is 
critical for proper chromosome segregation', Molecular Cell, 24(3), pp. 409-
422. 
Kastan, M. B. and Bartek, J. (2004) 'Cell-cycle checkpoints and cancer', Nature, 
432(7015), pp. 316-323. 
Kaszubiak, A., Holm, P. S. and Lage, H. (2007) 'Overcoming the classical multidrug 
resistance phenotype by adenoviral delivery of anti-MDR1 short hairpin 
RNAs and ribozymes', Int J Oncol, 31(2), pp. 419-30. 
Khan, M. I., Adhami, V. M., Lall, R. K., Sechi, M., Joshi, D. C., Haidar, O. M., Syed, 
D. N., Siddiqui, I. A., Chiu, S. Y. and Mukhtar, H. (2014) 'YB-1 expression 
promotes epithelial-to-mesenchymal transition in prostate cancer that is 
inhibited by a small molecule fisetin', Oncotarget, 5(9), pp. 2462-74. 
Kim, J. K. and Diehl, J. A. (2009) 'Nuclear cyclin D1: an oncogenic driver in human 
cancer', J Cell Physiol, 220(2), pp. 292-6. 
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. 
C., Coviello, G. M., Wright, W. E., Weinrich, S. L. and Shay, J. W. (1994) 
'Specific association of human telomerase activity with immortal cells and 
cancer', Science, 266(5193), pp. 2011-2015. 
Kim, S., Mohapatra, G. and Haber, D. A. (2008) 'In vitro phosphorylation of BRCA2 
by the checkpoint kinase CHEK2', British Journal of Cancer, 99(8), pp. 1302-
1306. 
Kloks, C., Spronk, C., Lasonder, E., Hoffmann, A., Vuister, G. W., Grzesiek, S. and 
Hilbers, C. W. (2002) 'The solution structure and DNA-binding properties of 
the cold-shock domain of the human Y-box protein YB-1', Journal of 
Molecular Biology, 316(2), pp. 317-326. 
Kohno, K., Izumi, H., Uchiumi, T., Ashizuka, M. and Kuwano, M. (2003) 'The 
pleiotropic functions of the Y-box-binding protein, YB-1', Bioessays, 25(7), 
pp. 691-698. 
		 260	
Koike, K., Uchiumi, T., Ohga, T., Toh, S., Wada, M., Kohno, K. and Kuwano, M. 
(1997) 'Nuclear translocation of the Y-box binding protein by ultraviolet 
irradiation', Febs Letters, 417(3), pp. 390-394. 
Kojic, S., Medeot, E., Guccione, E., Krmac, H., Zara, I., Martinelli, V., Valle, G. and 
Faulkner, G. (2004) 'The Ankrd2 protein, a link between the sarcomere and 
the nucleus in skeletal muscle', Journal of Molecular Biology, 339(2), pp. 313-
325. 
Kolk, A., Jubitz, N., Mengele, K., Mantwill, K., Bissinger, O., Schmitt, M., Kremer, 
M. and Holm, P. S. (2011) 'Expression of Y-box-binding protein YB-1 allows 
stratification into long- and short-term survivors of head and neck cancer 
patients', Br J Cancer, 105(12), pp. 1864-73. 
Kopnin, B. P. (2000) 'Targets of oncogenes and tumor suppressors: key for 
understanding basic mechanisms of carcinogenesis', Biochemistry (Mosc), 
65(1), pp. 2-27. 
Kosaka, T., Yatabe, Y., Onozato, R., Kuwano, H. and Mitsudomi, T. (2009) 
'Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a 
Large Cohort of Japanese Patients with Surgically Treated Lung 
Adenocarcinoma', Journal of Thoracic Oncology, 4(1), pp. 22-29. 
Kosnopfel, C., Sinnberg, T. and Schittek, B. (2014) 'Y-box binding protein 1--a 
prognostic marker and target in tumour therapy', Eur J Cell Biol, 93(1-2), pp. 
61-70. 
Kudo-Saito, C., Shirako, H., Takeuchi, T. and Kawakami, Y. (2009) 'Cancer 
metastasis is accelerated through immunosuppression during Snail-induced 
EMT of cancer cells', Cancer Cell, 15(3), pp. 195-206. 
Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V. and Kastan, M. B. (1992) 'Wild-type 
p53 is a cell-cycle checkpoint determinant following irradiation', Proceedings 
of the National Academy of Sciences of the United States of America, 89(16), 
pp. 7491-7495. 
Lakhani, S. A., Masud, A., Kuida, K., Porter, G. A., Booth, C. J., Mehal, W. Z., 
Inayat, I. and Flavell, R. A. (2006) 'Caspases 3 and 7: key mediators of 
mitochondrial events of apoptosis', Science, 311(5762), pp. 847-51. 
Lamouille, S., Xu, J. and Derynck, R. (2014) 'Molecular mechanisms of epithelial-
mesenchymal transition', Nat Rev Mol Cell Biol, 15(3), pp. 178-96. 
Lane, D. P. and Crawford, L. V. (1979) 'T-antigen is bound to a host protein in SV40-
transformed cells', Nature, 278(5701), pp. 261-263. 
Lasham, A., Lindridge, E., Rudert, F., Onrust, R. and Watson, J. (2000) 'Regulation of 
the human fas promoter by YB-1, Pur alpha and AP-1 transcription factors', 
Gene, 252(1-2), pp. 1-13. 
Lasham, A., Moloney, S., Hale, T., Homer, C., Zhang, Y. F., Murison, J. G., 
Braithwaite, A. W. and Watson, J. (2003) 'The Y-box-binding protein, YB1, is 
a potential negative regulator of the p53 tumor suppressor', J Biol Chem, 
278(37), pp. 35516-23. 
Lasham, A., Print, C. G., Woolley, A. G., Dunn, S. E. and Braithwaite, A. W. (2013) 
'YB-1: oncoprotein, prognostic marker and therapeutic target?', Biochem J, 
449(1), pp. 11-23. 
Lasham, A., Samuel, W., Cao, H., Patel, R., Mehta, R., Stern, J. L., Reid, G., 
Woolley, A. G., Miller, L. D., Black, M. A., Shelling, A. N., Print, C. G. and 
Braithwaite, A. W. (2012) 'YB-1, the E2F pathway, and regulation of tumor 
cell growth', J Natl Cancer Inst, 104(2), pp. 133-46. 
		 261	
Lazebnik, Y. (2010) 'What are the hallmarks of cancer?', Nat Rev Cancer, 10(4), pp. 
232-3. 
Lee, C., Dhillon, J., Wang, M. Y., Gao, Y., Hu, K., Park, E., Astanehe, A., Hung, M. 
C., Eirew, P., Eaves, C. J. and Dunn, S. E. (2008) 'Targeting YB-1 in HER-2 
overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 
pathway and suppresses tumor growth in mice', Cancer Res, 68(21), pp. 8661-
6. 
Lee, J. H. and Paull, T. T. (2004) 'Direct activation of the ATM protein kinase by the 
Mre11/Rad50/Nbs1 complex', Science, 304(5667), pp. 93-96. 
Leeper, T. C. and Varani, G. (2005) 'The structure of an enzyme-activating fragment 
of human telomerase RNA', Rna-a Publication of the Rna Society, 11(4), pp. 
394-403. 
Lees, E. (1995) 'Cyclin-dependent kinase regulation', Current Opinion in Cell 
Biology, 7(6), pp. 773-780. 
Lehmann, E. L. (1999) Elements of Large-Sample Theory. 1st edn.: Springer-Verlag 
New York, p. 632. 
Lengauer, C., Kinzler, K. W. and Vogelstein, B. (1997) 'Genetic instability in 
colorectal cancers', Nature, 386(6625), pp. 623-627. 
Leu, J. I. J., Dumont, P., Hafey, M., Murphy, M. E. and George, D. L. (2004) 
'Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 
complex', Nature Cell Biology, 6(5), pp. 443-450. 
Levine, A. J. (1997) 'p53, the cellular gatekeeper for growth and division', Cell, 88(3), 
pp. 323-331. 
Levy, M. Z., Allsopp, R. C., Futcher, A. B., Greider, C. W. and Harley, C. B. (1992) 
'Telomere end-replication problem and cell aging', Journal of Molecular 
Biology, 225(4), pp. 951-960. 
Li, R. and Murray, A. W. (1991) 'Feedback control of mitosis in budding yeast.', Cell, 
66(3), pp. 519-531. 
Lin, J., Xie, Z., Zhu, H. and Qian, J. (2010) 'Understanding protein phosphorylation 
on a systems level', Brief Funct Genomics, 9(1), pp. 32-42. 
Lindqvist, A., van Zon, W., Karlsson Rosenthal, C. and Wolthuis, R. M. (2007) 
'Cyclin B1-Cdk1 activation continues after centrosome separation to control 
mitotic progression', PLoS Biol, 5(5), pp. e123. 
Lindström, M. S. (2011) 'NPM1/B23: A Multifunctional Chaperone in Ribosome 
Biogenesis and Chromatin Remodeling', Biochem Res Int, 2011, pp. 195209. 
Liu, C. G., Zhang, H., Shuang, C., Lu, Y., Jin, F., Xu, H. M. and Lu, P. (2010) 
'Alternations of ER, PR, HER-2/neu, and P53 protein expression in ductal 
breast carcinomas and clinical implications', Medical Oncology, 27(3), pp. 
747-752. 
Liu, Q. H., Guntuku, S., Cui, X. S., Matsuoka, S., Cortez, D., Tamai, K., Luo, G. B., 
Carattini-Rivera, S., DeMayo, F., Bradley, A., Donehower, L. A. and Elledge, 
S. J. (2000) 'Chk1 is an essential kinase that is regulated by Atr and required 
for the G(2)/M DNA damage checkpoint', Genes  &  Development, 14(12), pp. 
1448-1459. 
Lowenstein, E. J., Daly, R. J., Batzer, A. G., Li, W., Margolis, B., Lammers, R., 
Ullrich, A., Skolnik, E. Y., Bar-Sagi, D. and Schlessinger, J. (1992) 'The SH2 
and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to 
ras signaling', Cell, 70(3), pp. 431-42. 
		 262	
Lu, P., Takai, K., Weaver, V. M. and Werb, Z. (2011) 'Extracellular matrix 
degradation and remodeling in development and disease', Cold Spring Harb 
Perspect Biol, 3(12), pp. a005058. 
Lu, X. and Lane, D. P. (1993) 'Differential induction of transcriptionally active p53 
following UV  or ionizing radiation: defects in chromosome instability 
syndromes?', Cell, 75(4), pp. 765-778. 
Luo, H., Li, C., O'Neal, J., Kreisel, F., Le Beau, M. M. and Tomasson, M. H. (2005) 
'c-Myc rapidly induces acute myeloid leukemia in mice without evidence of 
lymphoma-associated antiapoptotic mutations', Blood, 106(7), pp. 2452-2461. 
Luqmani, Y. A. (2005) 'Mechanisms of Drug Resistance in Cancer Chemotherapy', 
Medical Principles and Practice, 14, pp. 35-48. 
Lyabin, D. N., Eliseeva, I. A. and Ovchinnikov, L. P. (2014) 'YB-1 protein: functions 
and regulation', Wiley Interdiscip Rev RNA, 5(1), pp. 95-110. 
Ma, L., Teruya-Feldstein, J. and Weinberg, R. A. (2007) 'Tumour invasion and 
metastasis initiated by microRNA-10b in breast cancer.', Nature, 449(7163), 
pp. 682-8. 
Mahimainathan, L., Ghosh-Choudhury, N., Venkatesan, B. A., Danda, R. S. and 
Choudhury, G. G. (2005) 'EGF stimulates mesangial cell mitogenesis via PI3-
kinase-mediated MAPK-dependent and AKT kinase-independent manner: 
involvement of c-fos and p27(Kip1)', American Journal of Physiology-Renal 
Physiology, 289(1), pp. F72-F82. 
Manfe, V., Biskup, E., Johansen, P., Kamstrup, M. R., Krejsgaard, T. F., Morling, N., 
Wulf, H. C. and Gniadecki, R. (2012) 'MDM2 Inhibitor Nutlin-3a Induces 
Apoptosis and Senescence in Cutaneous T-Cell Lymphoma: Role of p53', 
Journal of Investigative Dermatology, 132(5), pp. 1487-1496. 
Marchetti, A. and Gasparini, G. (2009) 'K-ras Mutations and Cetuximab in Colorectal 
Cancer', New England Journal of Medicine, 360(8), pp. 833-834. 
Marenstein, D. R., Ocampo, M. T. A., Chan, M. K., Altamirano, A., Basu, A. K., 
Boorstein, R. J., Cunningham, R. P. and Teebor, G. W. (2001) 'Stimulation of 
human endonuclease III by Y box-binding protein 1 (DNA-binding protein B) 
- Interaction between a base excision repair enzyme and a transcription factor', 
Journal of Biological Chemistry, 276(24), pp. 21242-21249. 
Martín-Villar, E., Fernández-Muñoz, B., Parsons, M., Yurrita, M. M., Megías, D., 
Pérez-Gómez, E., Jones, G. E. and Quintanilla, M. (2010) 'Podoplanin 
associates with CD44 to promote directional cell migration', Mol Biol Cell, 
21(24), pp. 4387-99. 
Marx, A. H., Zielinski, M., Kowitz, C. M., Dancau, A. M., Thieltges, S., Simon, R., 
Choschzick, M., Yekebas, E., Kaifi, J. T., Mirlacher, M., Atanackovic, D., 
Brummendorf, T. H., Fiedler, W., Bokemeyer, C., Izbicki, J. R. and Sauter, G. 
(2010) 'Homogeneous EGFR amplification defines a subset of aggressive 
Barrett's adenocarcinomas with poor prognosis', Histopathology, 57(3), pp. 
418-426. 
Matheu, A., Maraver, A., Klatt, P., Flores, I., Garcia-Cao, I., Borras, C., Flores, J. M., 
Vina, J., Blasco, M. A. and Serrano, M. (2007) 'Delayed ageing through 
damage protection by the Arf/p53 pathway', Nature, 448(7151), pp. 375-U14. 
Matsumoto, K., Tanaka, K. J. and Tsujimoto, M. (2005) 'An acidic protein, YBAP1, 
mediates the release of YB-1 from mRNA and relieves the translational 
repression activity of YB-1', Molecular and Cellular Biology, 25(5), pp. 1779-
1792. 
		 263	
Matsuoka, S., Rotman, G., Ogawa, A., Shiloh, Y., Tamai, K. and Elledge, S. J. (2000) 
'Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro', 
Proceedings of the National Academy of Sciences of the United States of 
America, 97(19), pp. 10389-10394. 
Matsushime, H., Roussel, M. F., Ashmun, R. A. and Sherr, C. J. (1991) 'Colony-
stimulating factor 1 regulates novel cyclins during the G1 phase of the cell 
cycle', Cell, 65(4), pp. 701-13. 
Maya, R., Balass, M., Kim, S. T., Shkedy, D., Leal, J. F. M., Shifman, O., Moas, M., 
Buschmann, T., Ronai, Z., Shiloh, Y., Kastan, M. B., Katzir, E. and Oren, M. 
(2001) 'ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 
activation by DNA damage', Genes  &  Development, 15(9), pp. 1067-1077. 
Mayya, V., Lundgren, D. H., Hwang, S. I., Rezaul, K., Wu, L., Eng, J. K., Rodionov, 
V. and Han, D. K. (2009) 'Quantitative phosphoproteomic analysis of T cell 
receptor signaling reveals system-wide modulation of protein-protein 
interactions', Sci Signal, 2(84), pp. ra46. 
McDonnell, T. J., Troncoso, P., Brisbay, S. M., Logothetis, C., Chung, L. W., Hsieh, 
J. T., Tu, S. M. and Campbell, M. L. (1992) 'Expression of the protooncogene 
bcl-2 in the prostate and its association with emergence of androgen-
independent prostate cancer', Cancer Res, 52(24), pp. 6940-4. 
Mehta, V. B. and Besner, G. E. (2007) 'HB-EGF promotes angiogenesis in endothelial 
cells via PI3-kinase and MAPK signaling pathways', Growth Factors, 25(4), 
pp. 253-263. 
Menendez, D., Inga, A. and Resnick, M. A. (2009) 'The expanding universe of p53 
targets', Nature Reviews Cancer, 9(10), pp. 724-737. 
Mertens, P. R., Alfonso-Jaume, M. A., Steinmann, K. and Lovett, D. H. (1998) 'A 
synergistic interaction of transcription factors AP2 and YB-1 regulates 
gelatinase A enhancer-dependent transcription', Journal of Biological 
Chemistry, 273(49), pp. 32957-32965. 
Mertens, P. R., Alfonso-Jaume, M. A., Steinmann, K. and Lovett, D. H. (1999) 'YB-1 
regulation of the human and rat gelatinase A genes via similar enhancer 
elements', Journal of the American Society of Nephrology, 10(12), pp. 2480-
2487. 
Mertens, P. R., Fodor, E. and Lovett, D. H. (1997a) 'A double-stranded (AP-2) and 
single-stranded (YB-1) transcription factor synergistically regulate gelatinase 
a transcription', Journal of the American Society of Nephrology, 8, pp. A2426-
A2426. 
Mertens, P. R., Harendza, S., Pollock, A. S. and Lovett, D. H. (1997b) 'Glomerular 
mesangial cell-specific transactivation of matrix metalloproteinase 2 
transcription is mediated by YB-1', Journal of Biological Chemistry, 272(36), 
pp. 22905-22912. 
Mihara, M., Erster, S., Zaika, A., Petrenko, O., Chittenden, T., Pancoska, P. and Moll, 
U. M. (2003) 'p53 has a direct apoptogenic role at the mitochondria', 
Molecular Cell, 11(3), pp. 577-590. 
Minamida, S., Iwamura, M., Kodera, Y., Kawashima, Y., Tabata, K., Matsumoto, K., 
Fujita, T., Satoh, T., Maeda, T. and Baba, S. (2011) '14-3-3 protein beta/alpha 
as a urinary biomarker for renal cell carcinoma: proteomic analysis of cyst 
fluid.', Anal Bioanal Chem, 401(1), pp. 245-52. 
Minich, W. B., Maidebura, I. P. and Ovchinnikov, L. P. (1993) 'Purification and 
characterization of the major 50-KDa repressor Protein from cytoplasmic 
		 264	
mRNP of rabbit reticulocytes', European Journal of Biochemistry, 212(3), pp. 
633-638. 
Miyaki, M., Konishi, M., Kikuchiyanoshita, R., Enomoto, M., Igari, T., Tanaka, K., 
Muraoka, M., Takahashi, H., Amada, Y., Fukayama, M., Maeda, Y., Iwama, 
T., Mishima, Y., Mori, T. and Koike, M. (1994) '	Characteristics of somatic 
mutation of the adenomatous polyposis-coli gene in colorectal tumors ', 
Cancer Research, 54(11), pp. 3011-3020. 
Miyanaga, T., Hirato, J. and Nakazato, Y. (2008) 'Amplification of the epidermal 
growth factor receptor gene in glioblastoma: An analysis of the relationship 
between genotype and phenotype by CISH method', Neuropathology, 28(2), 
pp. 116-126. 
Moll, U. M., Wolff, S., Speidel, D. and Deppert, W. (2005) 'Transcription-
independent pro-apoptotic functions of p53', Current Opinion in Cell Biology, 
17(6), pp. 631-636. 
Monteiro, L. S., Diniz-Freitas, M., Garcia-Caballero, T., Warnakulasuriya, S., 
Forteza, J. and Fraga, M. (2012) 'Combined cytoplasmic and membranous 
EGFR and p53 overexpression is a poor prognostic marker in early stage oral 
squamous cell carcinoma.', J Oral Pathol Med, 41(7), pp. 559-67. 
Mora, N., Rosales, R. and Rosales, C. (2007) 'R-Ras promotes metastasis of cervical 
cancer epithelial cells', Cancer Immunol Immunother, 56(4), pp. 535-44. 
Moraleda, G. and Taylor, J. (2001) 'Host RNA polymerase requirements for 
transcription of the human hepatitis delta virus genome', J Virol, 75(21), pp. 
10161-9. 
Morgan, D. O. (1995) 'Principles of CDK regulation', Nature, 374(6518), pp. 131-
134. 
Moro, F., Ottaggio, L., Bonatti, S., Simili, M., Miele, M., Bozzo, S. and 
Abbondandolo, A. (1995) 'p53 expression in normal versus transformed 
mammalian-cells', Carcinogenesis, 16(10), pp. 2435-2440. 
Morrish, F., Isern, N., Sadilek, M., Jeffrey, M. and Hockenbery, D. M. (2009) 'c-Myc 
activates multiple metabolic networks to generate substrates for cell-cycle 
entry', Oncogene, 28(27), pp. 2485-2491. 
Moynahan, M. E., Chiu, J. W., Koller, B. H. and Jasin, M. (1999) 'Brca1 controls 
homology-directed DNA repair', Molecular Cell, 4(4), pp. 511-518. 
Moyzis, R. K., Buckingham, J. M., Cram, L. S., Dani, M., Deaven, L. L., Jones, M. 
D., Meyne, J., Ratliff, R. L. and Wu, J. R. (1988) 'A highly conserved 
repetitive DNA-sequence, (TTAGGG)n, present at the telomeres of human 
chromosomes', Proceedings of the National Academy of Sciences of the United 
States of America, 85(18), pp. 6622-6626. 
Mulholland, D. J., Kobayashi, N., Ruscetti, M., Zhi, A., Tran, L. M., Huang, J., 
Gleave, M. and Wu, H. (2012) 'Pten loss and RAS/MAPK activation 
cooperate to promote EMT and metastasis initiated from prostate cancer 
stem/progenitor cells', Cancer Res, 72(7), pp. 1878-89. 
Murakami, T., Cardones, A. R. and Hwang, S. T. (2004) 'Chemokine receptors and 
melanoma metastasis', J Dermatol Sci, 36(2), pp. 71-8. 
Myers, J. S. and Cortez, D. (2006) 'Rapid activation of ATR by ionizing radiation 
requires ATM and Mre11', Journal of Biological Chemistry, 281(14), pp. 
9346-9350. 
Munevar, S., Wang, Y. and Dembo, M. (2001) 'Traction force microscopy of 
migrating normal and H-ras transformed 3T3 fibroblasts', Biophys J, 80(4), pp. 
1744-57. 
		 265	
Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, 
T., Murphy, E., Yuan, W., Wagner, S. N., Barrera, J. L., Mohar, A., 
Verástegui, E. and Zlotnik, A. (2001) 'Involvement of chemokine receptors in 
breast cancer metastasis', Nature, 410(6824), pp. 50-6. 
Nadal, A., Campo, E., Pinto, J., Mallofre, C., Palacin, A., Arias, C., Traserra, J. and 
Cardesa, A. (1995) 'p53 expression in normal, dysplastic, and neoplastic 
laryngeal epithelium. Absence of a correlation with prognostic factors', 
Journal of Pathology, 175(2), pp. 181-188. 
Narita, M., Nũnez, S., Heard, E., Lin, A. W., Hearn, S. A., Spector, D. L., Hannon, G. 
J. and Lowe, S. W. (2003) 'Rb-mediated heterochromatin formation and 
silencing of E2F target genes during cellular senescence', Cell, 113(6), pp. 
703-16. 
National Cancer Institute, the National Institutes of Health (2015) Tumour 
markers,Available at: www.cancer.gov (Accessed: December 2013). 
Nasrin, F., Rahman, M. A., Masuda, A., Ohe, K., Takeda, J. and Ohno, K. (2014) 
'HnRNP C, YB-1 and hnRNP L coordinately enhance skipping of human 
MUSK exon 10 to generate a Wnt-insensitive MuSK isoform', Sci Rep, 4, pp. 
6841. 
Ngan, B. Y., Chen-Levy, Z., Weiss, L. M., Warnke, R. A. and Cleary, M. L. (1988) 
'Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with 
the t(14;18) chromosomal translocation', N Engl J Med, 318(25), pp. 1638-44. 
Nghiem, P., Park, P., Kim, Y., Vaziri, C. and Schreiber, S. (2001) 'ATR is required 
for a mitotic entry checkpoint that prevents premature chromatin condensation 
after UV exposure', Journal of Investigative Dermatology, 117(2), pp. 489-
489. 
Nghiem, P., Park, P. K., Kim, Y. S., Desai, B. N. and Schreiber, S. L. (2002) 'ATR is 
not required for p53 activation but synergizes with p53 in the replication 
check-point', Journal of Biological Chemistry, 277(6), pp. 4428-4434. 
Nicolson, G. L., Nawa, A., Toh, Y., Taniguchi, S., Nishimori, K. and Moustafa, A. 
(2003) 'Tumor metastasis-associated human MTA1 gene and its MTA1 
protein product: Role in epithelial cancer cell invasion, proliferation and 
nuclear regulation', Clinical  &  Experimental Metastasis, 20(1), pp. 19-24. 
Niture, S. K. and Jaiswal, A. K. (2012) 'Nrf2 protein up-regulates antiapoptotic 
protein Bcl-2 and prevents cellular apoptosis', J Biol Chem, 287(13), pp. 9873-
86. 
Nowak, M. A., Komarova, N. L., Sengupta, A., Jallepalli, P. V., Shih, I. M., 
Vogelstein, B. and Lengauer, C. (2002) 'The role of chromosomal instability 
in tumor initiation', Proceedings of the National Academy of Sciences of the 
United States of America, 99(25), pp. 16226-16231. 
O'Connell, C. B. and Khodjakov, A. L. (2007) 'Cooperative mechanisms of mitotic 
spindle formation', J Cell Sci, 120(Pt 10), pp. 1717-22. 
Ocaña, O. H., Córcoles, R., Fabra, A., Moreno-Bueno, G., Acloque, H., Vega, S., 
Barrallo-Gimeno, A., Cano, A. and Nieto, M. A. (2012) 'Metastatic 
colonization requires the repression of the epithelial-mesenchymal transition 
inducer Prrx1', Cancer Cell, 22(6), pp. 709-24. 
Oda, K., Matsuoka, Y., Funahashi, A. and Kitano, H. (2005) 'A comprehensive 
pathway map of epidermal growth factor receptor signaling', Molecular 
Systems Biology, 1(2005), pp. 2005.0010. 
Oda, Y., Ohishi, Y., Saito, T., Hinoshita, E., Uchiumi, T., Kinukawa, N., Iwamoto, 
Y., Kohno, K., Kuwano, M. and Tsuneyoshi, M. (2003) 'Nuclear expression of 
		 266	
Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase II 
alpha expression, and with poor prognosis in synovial sarcoma', Journal of 
Pathology, 199(2), pp. 251-258. 
Oda, Y., Sakamoto, A., Shinohara, N., Ohga, T., Uchiumi, T., Kohno, K., Tsuneyoshi, 
M., Kuwano, M. and Iwamoto, Y. (1998) 'Nuclear expression of YB-1 protein 
correlates with P-glycoprotein expression in human osteosarcoma', Clinical 
Cancer Research, 4(9), pp. 2273-2277. 
Ogden, G. R., Kiddie, R. A., Lunny, D. P. and Lane, D. P. (1992) 'Assessment of p53 
protein expression in normal, benign, and malignant oral-mucosa', Journal of 
Pathology, 166(4), pp. 389-394. 
Ohbayashi, T., Oikawa, K., Yamada, K., Nishida-Umehara, C., Matsuda, Y., Satoh, 
H., Mukai, H., Mukai, K. and Kuroda, M. (2007) 'Unscheduled overexpression 
of human WAPL promotes chromosomal instability', Biochemical and 
Biophysical Research Communications, 356(3), pp. 699-704. 
Ohga, T., Koike, K., Ono, M., Makino, Y., Itagaki, Y., Tanimoto, M., Kuwano, M. 
and Kohno, K. (1996) 'Role of the human Y box-binding protein YB-1 in 
cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and 
ultraviolet light', Cancer Research, 56(18), pp. 4224-4228. 
Okamoto, T., Izumi, H., Imamura, T., Takano, H., Ise, T., Uchiumi, T., Kuwano, M. 
and Kohno, K. (2000) 'Direct interaction of p53 with the Y-box binding 
protein, YB-1: a mechanism for regulation of human gene expression', 
Oncogene, 19(54), pp. 6194-6202. 
Oki, E., Oda, S., Maehara, Y. and Sugimachi, K. (1999) 'Mutated gene-specific 
phenotypes of dinucleotide repeat instability in human colorectal carcinoma 
cell-lines deficient in DNA mismatch repair', Oncogene, 18(12), pp. 2143-
2147. 
Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W. and 
Vogelstein, B. (1993) 'Oncoprotein MDM2 conceals the activation domain of 
tumour suppressor p53', Nature, 362(6423), pp. 857-60. 
Oliver, B. L., Shaafi, R. I. and Hajjar, J. J. (1995) 'Transforming Growth-Factor-
Alpha and Epidermal Growth-Factor activate Mitogen-Activated Protein-
Kinase and its substrates in intestinal epithelial-cells', Proceedings of the 
Society for Experimental Biology and Medicine, 210(2), pp. 162-170. 
Olsen, J. V., Vermeulen, M., Santamaria, A., Kumar, C., Miller, M. L., Jensen, L. J., 
Gnad, F., Cox, J., Jensen, T. S., Nigg, E. A., Brunak, S. and Mann, M. (2010) 
'Quantitative phosphoproteomics reveals widespread full phosphorylation site 
occupancy during mitosis', Sci Signal, 3(104), pp. ra3. 
Ou, Y. H., Chung, P. H., Sun, T. P. and Shieh, S. Y. (2005) 'P53C-terminal 
phosphorylation by CHM and CHK2 participates in the regulation of DNA-
Damage-induced C-terminal acetylation', Molecular Biology of the Cell, 16(4), 
pp. 1684-1695. 
Pabla, N., Ma, Z., McIlhatton, M. A., Fishel, R. and Dong, Z. (2011) 'hMSH2 
Recruits ATR to DNA Damage Sites for Activation during DNA Damage-
induced Apoptosis', Journal of Biological Chemistry, 286(12), pp. 10411-
10418. 
Padrón, J. M., van der Wilt, C. L., Smid, K., Smitskamp-Wilms, E., Backus, H. H., 
Pizao, P. E., Giaccone, G. and Peters, G. J. (2000) 'The multilayered 
postconfluent cell culture as a model for drug screening', Crit Rev Oncol 
Hematol, 36(2-3), pp. 141-57. 
		 267	
Palomba, G., Loi, A., Uras, A., Fancello, P., Piras, G., Gabbas, A., Cossu, A., 
Budroni, M., Contu, A., Tanda, F., Farris, A., Orru, S., Floris, C., Pisano, M., 
Lovicu, M., Santona, M. C., Landriscina, G., Crisponi, L., Palmieri, G. and 
Monne, M. (2009) 'A role of BRCA1 and BRCA2 germline mutations in 
breast cancer susceptibility within Sardinian population', Bmc Cancer, 20(9), 
pp. 245. 
Pan, W., Cox, S., Hoess, R. H. and Grafström, R. H. (2001) 'A cyclin D1/cyclin-
dependent kinase 4 binding site within the C domain of the retinoblastoma 
protein', Cancer Res, 61(7), pp. 2885-91. 
Pankov, R., Endo, Y., Even-Ram, S., Araki, M., Clark, K., Cukierman, E., 
Matsumoto, K. and Yamada, K. M. (2005) 'A Rac switch regulates random 
versus directionally persistent cell migration', J Cell Biol, 170(5), pp. 793-802. 
Pardee, A. B. (1974) 'Restriction Point for control of normal animal-cell proliferation', 
Proceedings of the National Academy of Sciences of the United States of 
America, 71(4), pp. 1286-1290. 
Park, B. S., Song, Y. S., Yee, S. B., Lee, B. G., Seo, S. Y., Park, Y. C., Kim, J. M., 
Kim, H. M. and Yoo, Y. H. (2005) 'Phospho-ser 15-p53 translocates into 
mitochondria and interacts with Bcl-2 and Bcl-xL in eugenol-induced 
apoptosis', Apoptosis, 10(1), pp. 193-200. 
Parry, D., Bates, S., Mann, D. J. and Peters, G. (1995) 'Lack of cyclin D-Cdk 
complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 
tumour suppressor gene product', EMBO J, 14(3), pp. 503-11. 
Paull, T. T., Rogakou, E. P., Yamazaki, V., Kirchgessner, C. U., Gellert, M. and 
Bonner, W. M. (2000) 'A critical role for histone H2AX in recruitment of 
repair factors to nuclear foci after DNA damage', Current Biology, 10(15), pp. 
886-895. 
Perez de Castro, I., de Carcer, G. and Malumbres, M. (2007) 'A census of mitotic 
cancer genes: new insights into tumor cell biology and cancer therapy', 
Carcinogenesis, 28(5), pp. 899-912. 
Peters, J. M. (2006) 'The anaphase promoting complex/cyclosome: a machine 
designed to destroy', Nature Reviews Molecular Cell Biology, 7(9), pp. 644-
656. 
Petersen, B. O., Lukas, J., Sørensen, C. S., Bartek, J. and Helin, K. (1999) 
'Phosphorylation of mammalian CDC6 by cyclin A/CDK2 regulates its 
subcellular localization', EMBO J, 18(2), pp. 396-410. 
Petrie, R. J., Doyle, A. D. and Yamada, K. M. (2009) 'Random versus directionally 
persistent cell migration', Nat Rev Mol Cell Biol, 10(8), pp. 538-49. 
Phillips, J. E. and Corces, V. G. (2009) 'CTCF: master weaver of the genome', Cell, 
137(7), pp. 1194-211. 
Phillips, R. M. and Clayton, M. R. (1997) 'Plateau-phase cultures: an experimental 
model for identifying drugs which are bioactivated within the 
microenvironment of solid tumours', Br J Cancer, 75(2), pp. 196-201. 
Placzek, W. J., Wei, J., Kitada, S., Zhai, D., Reed, J. C. and Pellecchia, M. (2010) 'A 
survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types 
provides a platform to predict the efficacy of Bcl-2 antagonists in cancer 
therapy', Cell Death Dis, 1, pp. e40. 
Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W. and Vogelstein, B. (1997) 'A model 
for p53-induced apoptosis', Nature, 389(6648), pp. 300-305. 
Porter, A. G., and Janicke, R. U. (1999) 'Emerging roles of caspase-3 in apoptosis', 
Cell Death Differ, 6(2), pp 99–104. 
		 268	
Prior, I. A., Lewis, P. D. and Mattos, C. (2012) 'A Comprehensive Survey of Ras 
Mutations in Cancer', Cancer Research, 72(10), pp. 2457-2467. 
Prochazka, L., Tesarik, R. and Turanek, J. (2014) 'Regulation of alternative splicing 
of CD44 in cancer', Cell Signal, 26(10), pp. 2234-9. 
Raffetseder, U., Frye, B., Rauen, T., Jurchott, K., Royer, H. D., Jansen, P. L. and 
Mertens, P. R. (2003) 'Splicing factor SRp30c interaction with Y-box protein-
1 confers nuclear YB-1 shuttling and alternative splice site selection', Journal 
of Biological Chemistry, 278(20), pp. 18241-18248. 
Rajasekharan, S. K. and Raman, T. (2013) 'Ras and Ras mutations in cancer', Central 
European Journal of Biology, 8(7), pp. 609-624. 
Raj, G. V., Safak, M., MacDonald, G. H. and Khalili, K. (1996) 'Transcriptional 
regulation of human polyomavirus JC: Evidence for a functional interaction 
between RelA (p65) and the Y-box-binding protein, YB-1', Journal of 
Virology, 70(9), pp. 5944-5953. 
Rall, C. J. and Rustgi, A. K. (1995) 'CD44 isoform expression in primary and 
metastatic pancreatic adenocarcinoma', Cancer Res, 55(9), pp. 1831-5. 
Rapp, T. B., Yang, L., Conrad, E. U., Mandahl, N. and Chansky, H. A. (2002) 'RNA 
splicing mediated by YB-1 is inhibited by TLS/CHOP in human myxoid 
liposarcoma cells', Journal of Orthopaedic Research, 20(4), pp. 723-729. 
Rapp, U. R., Korn, C., Ceteci, F., Karreman, C., Luetkenhaus, K., Serafin, V., 
Zanucco, E., Castro, I. and Potapenko, T. (2009) 'MYC is a metastasis gene 
for non-small-cell lung cancer', PLoS One, 4(6), pp. e6029. 
Reddy, S. K., Rape, M., Margansky, W. A. and Kirschner, M. W. (2007) 
'Ubiquitination by the anaphase-promoting complex drives spindle checkpoint 
inactivation', Nature, 446(7138), pp. 921-925. 
Rego, R. L., Foster, N. R., Smyrk, T. C., Le, M., O'Connell, M. J., Sargent, D. J., 
Windschitl, H. and Sinicrope, F. A. (2010) 'Prognostic effect of activated 
EGFR expression in human colon carcinomas: comparison with EGFR status', 
British Journal of Cancer, 102(1), pp. 165-172. 
Reif, K., Buday, L., Downward, J. and Cantrell, D. A. (1994) 'SH3 domains of the 
adapter molecule GRB2 complex with 2 proteins in T-cells - the guanine-
nucleotide exchange protein SOS and a 75-kda protein that is a substrate for 
T-cell antigen receptor-activated tyrosine kinases', Journal of Biological 
Chemistry, 269(19), pp. 14081-14087. 
Rieder, C. L. and Khodjakov, A. (2003) 'Mitosis through the microscope: Advances in 
seeing inside live dividing cells', Science, 300(5616), pp. 91-96. 
Rigbolt, K. T., Prokhorova, T. A., Akimov, V., Henningsen, J., Johansen, P. T., 
Kratchmarova, I., Kassem, M., Mann, M., Olsen, J. V. and Blagoev, B. (2011) 
'System-wide temporal characterization of the proteome and phosphoproteome 
of human embryonic stem cell differentiation', Sci Signal, 4(164), pp. rs3. 
Roberts, N. J., Jiao, Y. C., Yu, J., Kopelovich, L., Petersen, G. M., Bondy, M. L., 
Gallinger, S., Schwartz, A. G., Syngal, S., Cote, M. L., Axilbund, J., Schulick, 
R., Ali, S. Z., Eshleman, J. R., Velculescu, V. E., Goggins, M., Vogelstein, B., 
Papadopoulos, N., Hruban, R. H., Kinzler, K. W. and Klein, A. P. (2012) 
'ATM Mutations in Patients with Hereditary Pancreatic Cancer', Cancer 
Discovery, 2(1), pp. 41-46. 
Robertson, K. D. (2002) 'DNA methylation and chromatin - unraveling the tangled 
web', Oncogene, 21(35), pp. 5361-79. 
		 269	
Roe, J. S., Kim, H., Lee, S. M., Kim, S. T., Cho, E. J. and Youn, H. D. (2006) 'p53 
stabilization and transactivation by a von Hippel-Lindau protein', Mol Cell, 
22(3), pp. 395-405. 
Rush, J., Moritz, A., Lee, K. A., Guo, A., Goss, V. L., Spek, E. J., Zhang, H., Zha, X. 
M., Polakiewicz, R. D. and Comb, M. J. (2005) 'Immunoaffinity profiling of 
tyrosine phosphorylation in cancer cells', Nat Biotechnol, 23(1), pp. 94-101. 
Russell, P. (1998) 'Checkpoints on the road to mitosis', Trends in Biochemical 
Sciences, 23(10), pp. 399-402. 
Ruzanov, P. V., Evdokimova, V. M., Korneeva, N. L., Hershey, J. W. B. and 
Ovchinnikov, L. P. (1999) 'Interaction of the universal mRNA-binding 
protein, p50, with actin: a possible link between mRNA and microfilaments', 
Journal of Cell Science, 112(20), pp. 3487-3496. 
Sablina, A. A., Budanov, A. V., Ilyinskaya, G. V., Agapova, L. S., Kravchenko, J. E. 
and Chumakov, P. M. (2005) 'The antioxidant function of the p53 tumor 
suppressor', Nature Medicine, 11(12), pp. 1306-1313. Safak,	M.,	Gallia,	G.	L.,	Ansari,	S.	A.	and	Khalili,	K.	(1999)	'Physical	and	functional	interaction	 between	 the	 Y-box	 binding	 protein	 YB-1	 and	 human	polyomavirus	JC	virus	large	T	antigen',	J	Virol,	73(12),	pp.	10146-57.	
Safak, M., Sadowska, B., Barrucco, R. and Khalili, K. (2002) 'Functional interaction 
between JC virus late regulatory agnoprotein and cellular Y-box binding 
transcription factor, YB-1', Journal of Virology, 76(8), pp. 3828-3838. 
Sahara, S., Aoto, M., Eguchi, Y., Imamoto, N., Yoneda, Y., Tsujimoto, Y. (1999) 
‘Acinus is a caspase-3-activated protein required for apoptotic chromatin 
condensation’, Nature, 401(6749), pp. 168–173. 
Sakura, H., Maekawa, T., Imamoto, F., Yasuda, K. and Ishii, S. (1988) 'Two human 
genes isolated by a novel method encode DNA-binding proteins containing a 
common region of homology', Gene, 73(2), pp. 499-507. 
Sambrook, J. and Russel, D. W. 2001. Molecular cloning: A laboratory manual in 
Molecular cloning. Cold Spring Harbor Laboratory Press. 
Samuel, S., Beifuss, K. K. and Bernstein, L. R. (2007) 'YB-1 binds to the MMP-13 
promoter sequence and represses MMP-13 transactivation via the AP-1 site', 
Biochim Biophys Acta, 1769(9-10), pp. 525-31. 
Santarius, T., Shipley, J., Brewer, D., Stratton, M. R. and Cooper, C. S. (2010) 'A 
census of amplified and overexpressed human cancer genes', Nat Rev Cancer, 
10(1), pp. 59-64. 
Sarkar, R., Lee, J., Mahimkar, R. and Lovett, D. (2004) 'P53, YB-1 and the AP-1 
family of transcription factors mediate MMP-2 transcription induced by 
skeletal muscle ischemia', Journal of the American College of Surgeons, 
199(3, Supplement), pp. 103. 
Satyanarayana, A. and Kaldis, P. (2009) 'Mammalian cell-cycle regulation: several 
Cdks, numerous cyclins and diverse compensatory mechanisms', Oncogene, 
28(33), pp. 2925-39. 
Sermeus, A. and Michiels, C. (2011) 'Reciprocal influence of the p53 and the hypoxic 
pathways', Cell Death Dis, 2, pp. e164. 
Schittek, B., Psenner, K., Sauer, B., Meier, F., Iftner, T. and Garbe, C. (2007) 'The 
increased expression of Y box-binding protein 1 in melanoma stimulates 
proliferation and tumor invasion, antagonizes apoptosis and enhances 
chemoresistance', International Journal of Cancer, 120(10), pp. 2110-2118. 
		 270	
Schmitt, C. A., Fridman, J. S., Yang, M., Baranov, E., Hoffman, R. M. and Lowe, S. 
W. (2002) 'Dissecting p53 tumor suppressor functions in vivo', Cancer Cell, 
1(3), pp. 289-98. 
Schubbert, S., Shannon, K. and Bollag, G. (2007) 'Hyperactive Ras in developmental 
disorders and cancer', Nature Reviews Cancer, 7(7), pp. 295-308. 
Sears, R., Nuckolls, F., Haura, E., Taya, Y., Tamai, K. and Nevins, J. R. (2000) 
'Multiple Ras-dependent phosphorylation pathways regulate Myc protein 
stability', Genes  &  Development, 14(19), pp. 2501-2514. 
Shapiro, S. D. (1999) 'Diverse roles of macrophage matrix metalloproteinases in 
tissue destruction and tumor growth', Thromb Haemost, 82(2), pp. 846-9. 
Shay, J. W. and Bacchetti, S. (1997) 'A survey of telomerase activity in human 
cancer', European Journal of Cancer, 33(5), pp. 787-791. 
Shell, S. M., Li, Z., Shkriabai, N., Kvaratskhelia, M., Brosey, C., Serrano, M. A., 
Chazin, W. J., Musich, P. R. and Zou, Y. (2009) 'Checkpoint Kinase ATR 
Promotes Nucleotide Excision Repair of UV-induced DNA Damage via 
Physical Interaction with Xeroderma Pigmentosum Group A', Journal of 
Biological Chemistry, 284(36), pp. 24213-24222. 
Shen, Q. C., Wu, R., Leonard, J. L. and Newburger, P. E. (1998) 'Identification and 
molecular cloning of a human selenocysteine insertion sequence-binding 
protein - A bifunctional role for DNA-binding protein B', Journal of 
Biological Chemistry, 273(10), pp. 5443-5446. 
Shi, J. H., Zheng, B., Li, Y. H., Sun, Y., Han, A. L., Zhang, X. H., Lv, X. R., Chen, S. 
and Wen, J. K. (2013) 'Novel insight into Y-box binding protein 1 in the 
regulation of vascular smooth muscle cell proliferation through targeting GC 
box-dependent genes', FEBS Lett, 587(9), pp. 1326-32. 
Shibahara, K., Sugio, K., Osaki, T., Uchiumi, T., Maehara, Y., Kohno, K., Yasumoto, 
K., Sugimachi, K. and Kuwano, M. (2001) 'Nuclear expression of the Y-box 
binding protein, YB-1, as a novel marker of disease progression in non-small 
cell lung cancer', Clinical Cancer Research, 7(10), pp. 3151-3155. 
Shibata, T., Kan, H., Murakami, Y., Ureshino, H., Watari, K., Kawahara, A., Kage, 
M., Hattori, S., Ono, M. and Kuwano, M. (2013) 'Y-box binding protein-1 
contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human 
gastric cancer cells', Mol Cancer Ther, 12(5), pp. 737-46. 
Shieh, S. Y., Ahn, J., Tamai, K., Taya, Y. and Prives, C. (2000) 'The human homologs 
of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple 
DNA damage-inducible sites', Genes  &  Development, 14(3), pp. 289-300. 
Shieh, S. Y., Ikeda, M., Taya, Y. and Prives, C. (1997) 'DNA damage-induced 
phosphorylation of p53 alleviates inhibition by MDM2', Cell, 91(3), pp. 325-
334. 
Shin, I., Kim, S., Song, H., Kim, H. R. and Moon, A. (2005) 'H-Ras-specific 
activation of Rac-MKK3/6-p38 pathway: its critical role in invasion and 
migration of breast epithelial cells', J Biol Chem, 280(15), pp. 14675-83. 
Shin, M. H., Yuan, M., Zhang, H., Margolick, J. B. and Kai, M. (2012) 'ATM-
dependent phosphorylation of the checkpoint clamp regulates repair pathways 
and maintains genomic stability', Cell Cycle, 11(9), pp. 1796-1803. 
Shinozaki, T., Nota, A., Taya, Y. and Okamoto, K. (2003) 'Functional role of Mdm2 
phosphorylation by ATR in attenuation of p53 nuclear export', Oncogene, 
22(55), pp. 8870-8880. 
		 271	
Shiota, M., Izumi, H., Onitsuka, T., Miyamoto, N., Kashiwagi, E., Kidani, A., 
Yokomizo, A., Naito, S. and Kohno, K. (2008) 'Twist promotes tumor cell 
growth through YB-1 expression', Cancer Res, 68(1), pp. 98-105. 
Shiota, M., Yokomizo, A., Itsumi, M., Uchiumi, T., Tada, Y., Song, Y., Kashiwagi, 
E., Masubuchi, D. and Naito, S. (2011) 'Twist1 and Y-box-binding protein-1 
promote malignant potential in bladder cancer cells', BJU Int, 108(2 Pt 2), pp. 
E142-9. 
Shiota, M., Yokomizo, A., Tada, Y., Uchiumi, T., Inokuchi, J., Tatsugami, K., 
Kuroiwa, K., Yamamoto, K., Seki, N. and Naito, S. (2010) 'P300/CBP-
associated factor regulates Y-box binding protein-1 expression and promotes 
cancer cell growth, cancer invasion and drug resistance', Cancer Sci, 101(8), 
pp. 1797-806. 
Shnyreva, M., Schullery, D. S., Suzuki, H., Higaki, F. and Bomsztyk, K. (2000) 
'Interaction of two multifunctional proteins - Heterogeneous nuclear 
ribonucleoprotein K and Y-box-binding protein', Journal of Biological 
Chemistry, 275(20), pp. 15498-15503. 
Sigal, B. M., Munoz, D. F., Kurian, A. W. and Plevritis, S. K. (2012) 'A Simulation 
Model to Predict the Impact of Prophylactic Surgery and Screening on the Life 
Expectancy of BRCA1 and BRCA2 Mutation Carriers.', Cancer Epidemiol 
Biomarkers Prev, 21(7), pp. 1066-77. 
Singh, R. and Saini, N. (2012) 'Downregulation of BCL2 by miRNAs augments drug-
induced apoptosis--a combined computational and experimental approach', J 
Cell Sci, 125(Pt 6), pp. 1568-78. 
Sinicrope, F. A., Ruan, S. B., Cleary, K. R., Stephens, L. C., Lee, J. J. and Levin, B. 
(1995) 'bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis', 
Cancer Res, 55(2), pp. 237-41. 
Simon, R. and Roychowdhury, S. (2013) 'Implementing personalized cancer 
genomics in clinical trials', Nat Rev Drug Discov, 12(5), pp. 358-69. 
Sinnberg, T., Sauer, B., Holm, P., Spangler, B., Kuphal, S., Bosserhoff, A. and 
Schittek, B. (2012) 'MAPK and PI3K/AKT mediated YB-1 activation 
promotes melanoma cell proliferation which is counteracted by an 
autoregulatory loop', Exp Dermatol, 21(4), pp. 265-70. 
Skabkin, M. A., Evdokimova, V., Thomas, A. A. and Ovchinnikov, L. P. (2001) 'The 
major messenger ribonucleoprotein particle protein p50 (YB-1) promotes 
nucleic acid strand annealing', J Biol Chem, 276(48), pp. 44841-7. 
Skabkina, O. V., Lyabin, D. N., Skabkin, M. A. and Ovchinnikov, L. P. (2005) 'YB-1 
autoregulates translation of its own mRNA at or prior to the step of 40S 
ribosomal subunit joining', Mol Cell Biol, 25(8), pp. 3317-23. 
Smith, R. A., Cokkinides, V., Brooks, D., Saslow, D. and Brawley, O. W. (2010) 
'Cancer screening in the United States, 2010: a review of current American 
Cancer Society guidelines and issues in cancer screening.', CA Cancer J Clin, 
60(2), pp. 99-119. 
Soler, D., Genesca, A., Arnedo, G., Egozcue, J. and Tusell, L. (2005) 'Telomere 
dysfunction drives chromosomal instability in human mammary epithelial 
cells', Genes Chromosomes  &  Cancer, 44(4), pp. 339-350. 
Sommerville, J. and Ladomery, M. (1996) 'Transcription and masking of mRNA in 
germ cells: involvement of Y-box proteins', Chromosoma, 104(7), pp. 469-78. 
Soreide, K., Janssen, E. A. M., Soiland, H., Korner, H. and Baak, J. P. A. (2006) 
'Microsatellite instability in colorectal cancer', British Journal of Surgery, 
93(4), pp. 395-406. 
		 272	
Sorokin, A. V., Selyutina, A. A., Skabkin, M. A., Guryanov, S. G., Nazimov, I. V., 
Richard, C., Th'ng, J., Yau, J., Sorensen, P. H. B., Ovchinnikov, L. P. and 
Evdokimova, V. (2005) 'Proteasome-mediated cleavage of the Y-box-binding 
protein 1 is linked to DNA-damage stress response', Embo Journal, 24(20), 
pp. 3602-3612. 
Spiegelberg, D., Kuku, G., Selvaraju, R. and Nestor, M. (2014) 'Characterization of 
CD44 variant expression in head and neck squamous cell carcinomas', Tumour 
Biol, 35(3), pp. 2053-62. 
Srivastava, R. K., Sasaki, C. Y., Hardwick, J. M. and Longo, D. L. (1999) 'Bcl-2-
mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of 
activated T lymphocytes (NFAT)-induced Fas ligand transcription', J Exp 
Med, 190(2), pp. 253-65. 
Steczkiewicz, K., Zimmermann, M. T., Kurcinski, M., Lewis, B. A., Dobbs, D., 
Kloczkowski, A., Jernigan, R. L., Kolinski, A. and Ginalski, K. (2011) 
'Human telomerase model shows the role of the TEN domain in advancing the 
double helix for the next polymerization step', Proceedings of the National 
Academy of Sciences of the United States of America, 108(23), pp. 9443-9448. 
Stein, U., Jürchott, K., Walther, W., Bergmann, S., Schlag, P. M. and Royer, H. D. 
(2001) 'Hyperthermia-induced nuclear translocation of transcription factor 
YB-1 leads to enhanced expression of multidrug resistance-related ABC 
transporters', J Biol Chem, 276(30), pp. 28562-9. 
Stenina, O. I., Poptic, E. J. and DiCorleto, P. E. (2000) 'Thrombin activates a Y box-
binding protein (DNA-binding protein B) in endothelial', Journal of Clinical 
Investigation, 106(4), pp. 579-587. 
Stickeler, E., Fraser, S. D., Honig, A., Chen, A. L., Berget, S. M. and Cooper, T. A. 
(2001) 'The RNA binding protein YB-1 binds A/C-rich exon enhancers and 
stimulates splicing of the CD44 alternative exon v4', Embo Journal, 20(14), 
pp. 3821-3830. 
Stiff, T., O'Driscoll, M., Rief, N., Iwabuchi, K., Löbrich, M. and Jeggo, P. A. (2004) 
'ATM and DNA-PK function redundantly to phosphorylate H2AX after 
exposure to ionizing radiation', Cancer Res, 64(7), pp. 2390-6. 
Stiff, T., Walker, S. A., Cerosaletti, K., Goodarzi, A. A., Petermann, E., Concannon, 
P., O'Driscoll, M. and Jeggo, P. A. (2006) 'ATR-dependent phosphorylation 
and activation of ATM in response to UV treatment or replication fork 
stalling', Embo Journal, 25(24), pp. 5775-5782. 
Stratford, A. L., Fry, C. J., Desilets, C., Davies, A. H., Cho, Y. Y., Li, Y., Dong, Z. 
G., Berquin, I. M., Roux, P. P. and Dunn, S. E. (2008) 'Y-box binding protein-
1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like 
breast cancer cells', Breast Cancer Research, 10(6), pp. R99. 
Stratford, A. L., Habibi, G., Astanehe, A., Jiang, H., Hu, K., Park, E., Shadeo, A., 
Buys, T. P., Lam, W., Pugh, T., Marra, M., Nielsen, T. O., Klinge, U., 
Mertens, P. R., Aparicio, S. and Dunn, S. E. (2007) 'Epidermal growth factor 
receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 
(YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a 
potential target for therapy', Breast Cancer Res, 9(5), pp. R61. 
Streuli, C. H. (2002) 'Maspin is a tumour suppressor that inhibits breast cancer tumour 
metastasis in vivo', Breast Cancer Research, 4(4), pp. 137-140. 
Subik, K., Lee, J. F., Baxter, L., Strzepek, T., Costello, D., Crowley, P., Xing, L., 
Hung, M. C., Bonfiglio, T., Hicks, D. G. and Tang, P. (2010) 'The Expression 
Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by 
		 273	
Immunohistochemical Analysis in Breast Cancer Cell-lines', Breast Cancer 
(Auckl), 4, pp. 35-41. 
Sugrue, M. M., Shin, D. Y., Lee, S. W. and Aaronson, S. A. (1997) 'Wild-type p53 
triggers a rapid senescence program in human tumor cells lacking functional 
p53', Proceedings of the National Academy of Sciences of the United States of 
America, 94(18), pp. 9648-9653. 
Sutherland, B. W., Kucab, J., Wu, J., Lee, C., Cheang, M. C. U., Yorida, E., Turbin, 
D., Dedhar, S., Nelson, C., Pollak, M., Grimes, H. L., Miller, K., Badve, S., 
Huntsman, D., Blake-Gilks, C., Chen, M., Pallen, C. J. and Dunn, S. E. (2005) 
'Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold 
shock domain and affects the anchorage-independent growth of breast cancer 
cells', Oncogene, 24(26), pp. 4281-4292. 
Szczuraszek, K., Halon, A., Materna, V., Mazur, G., Wrobel, T., Kuliczkowski, K., 
Donizy, P., Holm, P. S., Lage, H. and Surowiak, P. (2011) 'Elevated YB-1 
expression is a new unfavorable prognostic factor in non-Hodgkin's 
lymphomas', Anticancer Res, 31(9), pp. 2963-70. 
Thevathasan, J. V., Tan, E., Zheng, H., Lin, Y. C., Li, Y., Inoue, T. and Fivaz, M. 
(2013) 'The small GTPase HRas shapes local PI3K signals through positive 
feedback and regulates persistent membrane extension in migrating 
fibroblasts', Mol Biol Cell, 24(14), pp. 2228-37. 
Thirthagiri, E., Robinson, C. M., Huntley, S., Davies, M., Yap, L. F., Prime, S. S. and 
Paterson, I. C. (2007) 'Spindle assembly checkpoint and centrosome 
abnormalities in oral cancer', Cancer Letters, 258(2), pp. 276-285. 
Tibbetts, R. S., Cortez, D., Brumbaugh, K. M., Scully, R., Livingston, D., Elledge, S. 
J. and Abraham, R. T. (2000) 'Functional interactions between BRCA1 and the 
checkpoint kinase ATR during genotoxic stress', Genes  &  Development, 
14(23), pp. 2989-3002. 
To, K., Fotovati, A., Reipas, K. M., Law, J. H., Hu, K., Wang, J., Astanehe, A., 
Davies, A. H., Lee, L., Stratford, A. L., Raouf, A., Johnson, P., Berquin, I. M., 
Royer, H. D., Eaves, C. J. and Dunn, S. E. (2010) 'Y-box binding protein-1 
induces the expression of CD44 and CD49f leading to enhanced self-renewal, 
mammosphere growth, and drug resistance', Cancer Res, 70(7), pp. 2840-51. 
Toledo, F. and Wahl, G. M. (2006) 'Regulating the p53 pathway: in vitro hypotheses, 
in vivo veritas', Nature Reviews Cancer, 6(12), pp. 909-923. 
Toné, S., Sugimoto, K., Tanda, K., Suda, T., Uehira, K., Kanouchi, H., Samejima, K., 
Minatogawa, Y. and Earnshaw, W. C. (2007) 'Three distinct stages of 
apoptotic nuclear condensation revealed by time-lapse imaging, biochemical 
and electron microscopy analysis of cell-free apoptosis', Exp Cell Res, 
313(16), pp. 3635-44. 
Toulany, M., Schickfluss, T. A., Eicheler, W., Kehlbach, R., Schittek, B. and 
Rodemann, H. P. (2011) 'Impact of oncogenic K-RAS on YB-1 
phosphorylation induced by ionizing radiation', Breast Cancer Res, 13(2), pp. 
R28. 
Tsai, J. H., Donaher, J. L., Murphy, D. A., Chau, S. and Yang, J. (2012) 
'Spatiotemporal regulation of epithelial-mesenchymal transition is essential for 
squamous cell carcinoma metastasis', Cancer Cell, 22(6), pp. 725-36. 
Tsujimoto, Y., Finger, L. R., Yunis, J., Nowell, P. C. and Croce, C. M. (1984) 
'Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) 
chromosome translocation', Science, 226(4678), pp. 1097-9. 
		 274	
Tuan, T. F., Chung, C. T., Tsou, H. H., Chen, F. W., Lin, H. L., Lai, Y. K., Lee, W. 
S., Chao, Y. S., Hwang, L. L. and Chen, C. T. (2012) 'Putative tumor 
metastasis-associated genes in human gastric cancer.', Int J Oncol, 41(3), pp. 
1068-64. 
Uekita, T., Fujii, S., Miyazawa, Y., Iwakawa, R., Narisawa-Saito, M., Nakashima, K., 
Tsuta, K., Tsuda, H., Kiyono, T., Yokota, J. and Sakai, R. (2014) 'Oncogenic 
Ras/ERK signaling activates CDCP1 to promote tumor invasion and 
metastasis', Mol Cancer Res, 12(10), pp. 1449-59. 
Uhlmann, F., Lottspeich, F. and Nasmyth, K. (1999) 'Sister-chromatid separation at 
anaphase onset is promoted by cleavage of the cohesin subunit Scc1', Nature, 
400(6739), pp. 37-42. 
Vaissière, T., Sawan, C. and Herceg, Z. (2008) 'Epigenetic interplay between histone 
modifications and DNA methylation in gene silencing', Mutat Res, 659(1-2), 
pp. 40-8. 
van Montfort, R. L. M. and Workman, P. (2009) 'Structure-based design of molecular 
cancer therapeutics', Trends in Biotechnology, 27(5), pp. 315-328. 
van Roeyen, C. R. C., Eitner, F., Martinkus, S., Thieltges, S. R., Ostendorf, T., 
Bokemeyer, D., Luscher, B., Luscher-Firzlaff, J. M., Floege, J. and Mertens, 
P. R. (2005) 'Y-box protein 1 mediates PDGF-B effects in 
mesangioproliferative glomerular disease', Journal of the American Society of 
Nephrology, 16(10), pp. 2985-2996. 
van Zijl, F., Krupitza, G. and Mikulits, W. (2011) 'Initial steps of metastasis: cell 
invasion and endothelial transmigration', Mutat Res, 728(1-2), pp. 23-34. 
Vaux, D. L., Cory, S. and Adams, J. M. (1988) 'Bcl-2 gene promotes haemopoietic 
cell survival and cooperates with c-myc to immortalize pre-B cells', Nature, 
335(6189), pp. 440-2. 
Veiga-Fernandes, H. and Rocha, B. (2004) 'High expression of active CDK6 in the 
cytoplasm of CD8 memory cells favors rapid division', Nat Immunol, 5(1), pp. 
31-7. 
Vennstrom, B., Sheiness, D., Zabielski, J. and Bishop, J. M. (1982) 'Isolation and 
characterization of c-MYC, a cellular homolog of the oncogene (v-MYC) of 
avian myelocytomatosis virus strain-29', Journal of Virology, 42(3), pp. 773-
779. 
Verde, F., Labbe, J. C., Doree, M. and Karsenti, E. (1990) 'Regulation of microtubule 
dynamics by cdc2 protein kinase in cell-free extracts of Xenopus eggs.', 
Nature, 343(6255), pp. 233-238. 
Villalonga-Planells, R., Coll-Mulet, L., Martinez-Soler, F., Castano, E., Acebes, J. J., 
Gimenez-Bonafe, P., Gil, J. and Tortosa, A. (2011) 'Activation of p53 by 
Nutlin-3a Induces Apoptosis and Cellular Senescence in Human Glioblastoma 
Multiforme', Plos One, 6(4), pp. e18588. 
Vogel, H., Lim, D. S., Karsenty, G., Finegold, M. and Hasty, P. (1999) 'Deletion of 
Ku86 causes early onset of senescence in mice', Proceedings of the National 
Academy of Sciences of the United States of America, 96(19), pp. 10770-
10775. 
Vogelstein, B. and Kinzler, K. W. (2004) 'Cancer genes and the pathways they 
control', Nature Medicine, 10(8), pp. 789-799. 
Wachowiak, R., Thieltges, S., Rawnaq, T., Kaifi, J. T., Fiegel, H., Metzger, R., 
Quaas, A., Mertens, P. R., Till, H. and Izbicki, J. R. (2010) 'Y-Box-binding 
Protein-1 is a Potential Novel Tumour Marker for Neuroblastoma', Anticancer 
Research, 30(4), pp. 1239-1242. 
		 275	
Wang, Y., Chen, Y., Geng, H., Qi, C., Liu, Y. and Yue, D. (2015) 'Overexpression of 
YB1 and EZH2 are associated with cancer metastasis and poor prognosis in 
renal cell carcinomas', Tumour Biol, 36(9), pp. 7159-66. 
Ward, I. M. and Chen, J. J. (2001) 'Histone H2AX is phosphorylated in an ATR-
dependent manner in response to replicational stress', Journal of Biological 
Chemistry, 276(51), pp. 47759-47762. 
Wei, W. J., Mu, S. R., Heiner, M., Fu, X., Cao, L. J., Gong, X. F., Bindereif, A. and 
Hui, J. (2012) 'YB-1 binds to CAUC motifs and stimulates exon inclusion by 
enhancing the recruitment of U2AF to weak polypyrimidine tracts', Nucleic 
Acids Res, 40(17), pp. 8622-36. 
Weigelt, B., Peterse, J. L. and van 't Veer, L. J. (2005) 'Breast cancer metastasis: 
markers and models', Nat Rev Cancer, 5(8), pp. 591-602. 
Wenner, T., Roth, V., Fischer, G., Fourrier, C., Aigle, B., Decaris, B. and Leblond, P. 
(2003) 'End-to-end fusion of linear deleted chromosomes initiates a cycle of 
genome instability in Streptomyces ambofaciens', Molecular Microbiology, 
50(2), pp. 411-425. 
Whang, Y. E., Wu, X. Y., Suzuki, H., Reiter, R. E., Tran, C., Vessella, R. L., Said, J. 
W., Isaacs, W. B. and Sawyers, C. L. (1998) 'Inactivation of the tumor 
suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of 
expression', Proceedings of the National Academy of Sciences of the United 
States of America, 95(9), pp. 5246-5250. 
White, D. P., Caswell, P. T. and Norman, J. C. (2007) 'alpha v beta3 and alpha5beta1 
integrin recycling pathways dictate downstream Rho kinase signaling to 
regulate persistent cell migration', J Cell Biol, 177(3), pp. 515-25. 
Wilkens, L., Flemming, P., Gebel, M., Bleck, J., Terkamp, C., Wingen, L., Kreipe, H. 
and Schlegelberger, B. (2004) 'Induction of aneuploidy by increasing 
chromosomal instability during dedifferentiation of hepatocellular carcinoma', 
Proceedings of the National Academy of Sciences of the United States of 
America, 101(5), pp. 1309-1314. 
Wilker, E. and Yaffe, M. B. (2004) '14-3-3 Proteins--a focus on cancer and human 
disease', J Mol Cell Cardiol, 37(3), pp. 633-42. 
Williams, N. G., Roberts, T. M. and Li, P. (1992) 'Both p21ras and pp60v-src are 
required, but neither alone is sufficient, to activate the Raf-1 kinase', Proc Natl 
Acad Sci U S A, 89(7), pp. 2922-6. 
Wolfer, A. and Ramaswamy, S. (2011) 'MYC and metastasis', Cancer Res, 71(6), pp. 
2034-7. 
Wolffe, A. P. (1994) 'Structural and functional-properties of the evolutionarily ancient 
Y-box family of nucleic-acid binding-proteins', Bioessays, 16(4), pp. 245-251. 
Wolffe, A. P., Tafuri, S., Ranjan, M. and Familari, M. (1992) 'The Y-box factors: a 
family of nucleic acid binding proteins conserved from Escherichia coli to 
man', New Biol, 4(4), pp. 290-8. 
Woolley, A. G., Algie, M., Samuel, W., Harfoot, R., Wiles, A., Hung, N. A., Tan, P. 
H., Hains, P., Valova, V. A., Huschtscha, L., Royds, J. A., Perez, D., Yoon, H. 
S., Cohen, S. B., Robinson, P. J., Bay, B. H., Lasham, A. and Braithwaite, A. 
W. (2011) 'Prognostic association of YB-1 expression in breast cancers: a 
matter of antibody', PLoS One, 6(6), pp. e20603. 
Wright, K. (1989) 'Antibodies a laboratory manual: By E Harlow and D Lane. pp 726. 
Cold Spring Harbor Laboratory. 1988. $50 ISBN 0-87969-314-2', Biochemical 
Education, 17(4), pp. 220--220. 
		 276	
Wu, J., Lee, C., Yokom, D., Jiang, H., Cheang, M. C., Yorida, E., Turbin, D., 
Berquin, I. M., Mertens, P. R., Iftner, T., Gilks, C. B. and Dunn, S. E. (2006) 
'Disruption of the Y-box binding protein-1 results in suppression of the 
epidermal growth factor receptor and HER-2', Cancer Res, 66(9), pp. 4872-9. 
Wu, J., Stratford, A. L., Astanehe, A. and Dunn, S. E. (2007) 'YB-1 is a 
Transcription/Translation Factor that Orchestrates the Oncogenome by 
Hardwiring Signal Transduction to Gene Expression', 11(2), pp. 49-65. 
Wu, K., Chen, K., Wang, C., Jiao, X., Wang, L., Zhou, J., Wang, J., Li, Z., Addya, S., 
Sorensen, P. H., Lisanti, M. P., Quong, A., Ertel, A. and Pestell, R. G. (2014) 
'Cell fate factor DACH1 represses YB-1-mediated oncogenic transcription and 
translation', Cancer Res, 74(3), pp. 829-39. 
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, 
R. H., Eshleman, J. R., Nowak, M. A., Velculescu, V. E., Kinzler, K. W., 
Vogelstein, B. and Iacobuzio-Donahue, C. A. (2010) 'Distant metastasis 
occurs late during the genetic evolution of pancreatic cancer', Nature, 
467(7319), pp. 1114-7. 
Yahata, H., Kobayashi, H., Toshiharu, K., Amada, S., Hirakawa, T., Kohno, K. and 
Kuwano, M. (2002) 'Increased nuclear localization of transcription factor YB-
1 in acquired cisplatin-resistant ovarian cancer', Journal of Cancer Research 
and Clinical Oncology, 128(11), pp. 621-626. 
Yang, M. H. and Wu, K. J. (2008) 'TWIST activation by hypoxia inducible factor-1 
(HIF-1): implications in metastasis and development', Cell Cycle, 7(14), pp. 
2090-6. 
Yang, M. H., Wu, M. Z., Chiou, S. H., Chen, P. M., Chang, S. Y., Liu, C. J., Teng, S. 
C. and Wu, K. J. (2008) 'Direct regulation of TWIST by HIF-1alpha promotes 
metastasis', Nat Cell Biol, 10(3), pp. 295-305. 
Yao, G., Lee, T. J., Mori, S., Nevins, J. R. and You, L. (2008) 'A bistable Rb-E2F 
switch underlies the restriction point', Nat Cell Biol, 10(4), pp. 476-82. 
Yarden, Y. and Schlessinger, J. (1987a) 'Epidermal growth factor induces rapid, 
reversible aggregation of the purified epidermal growth factor receptor', 
Biochemistry, 26(5), pp. 1443-51. 
Yarden, Y. and Schlessinger, J. (1987b) 'Self-phosphorylation of epidermal growth 
factor receptor: evidence for a model of intermolecular allosteric activation', 
Biochemistry, 26(5), pp. 1434-42. 
Yi, Y., Shepard, A., Kittrell, F., Mulac-Jericevic, B., Medina, D. and Said, T. K. 
(2004) 'p19ARF determines the balance between normal cell proliferation rate 
and apoptosis during mammary gland development', Mol Biol Cell, 15(5), pp. 
2302-11. 
Yilmaz, M. and Christofori, G. (2009) 'EMT, the cytoskeleton, and cancer cell 
invasion', Cancer Metastasis Rev, 28(1-2), pp. 15-33. 
Yoshimatsu, T., Uramoto, H., Oyama, T., Yashima, Y., Gu, C. D., Morita, M., Sugio, 
K., Kohno, K. and Yasumoto, K. (2005) 'Y-box-binding protein-1 expression 
is not correlated with p53 expression but with proliferating cell nuclear 
antigen expression in non-small cell lung cancer', Anticancer Research, 25(5), 
pp. 3437-3443. 
Young, J. I., Hong, E. P., Castle, J. C., Crespo-Barreto, J., Bowman, A. B., Rose, M. 
F., Kang, D., Richman, R., Johnson, J. M., Berget, S. and Zoghbi, H. Y. 
(2005) 'Regulation of RNA splicing by the methylation-dependent 
transcriptional repressor methyl-CpG binding protein 2', Proc Natl Acad Sci U 
S A, 102(49), pp. 17551-8. 
		 277	
Yu, G. L. and Blackburn, E. H. (1991) 'Developmentally programmed healing of 
chromosomes by telomerase in Tetrahymena', Cell, 67(4), pp. 823-832. 
Bowtell, D., Fu, P., Simon, M. and Senior, P. (1992) 'Identification of murine 
homologues of the Drosophila son of sevenless gene: potential activators of 
ras', Proc Natl Acad Sci U S A, 89(14), pp. 6511-5. 
Buday, L. and Downward, J. (1993) 'Epidermal growth factor regulates p21ras 
through the formation of a complex of receptor, Grb2 adapter protein, and Sos 
nucleotide exchange factor', Cell, 73(3), pp. 611-20. 
Buday, L., Egan, S. E., Viciana, P. R., Cantrell, D. A. and Downward, J. (1994) 'A 
complex of GRB2 adapter protein, sos exchange factor, and a 36-kda 
membrane-bound tyrosine phosphoprotein is implicated in ras activation in T-
cells ', Journal of Biological Chemistry, 269(12), pp. 9019-9023. 
Dominguez, I., Marshall, M. S., Gibbs, J. B., Deherreros, A. G., Cornet, M. E., 
Graziani, G., Diazmeco, M. T., Johansen, T., McCormick, F. and Moscat, J. 
(1991) ' Role of gtpase activating protein in mitogenic signaling through 
Phosphatidylcholine-Hydrolyzing Phospholipase-C ', Embo Journal, 10(11), 
pp. 3215-3220. 
Jelinek, T., Dent, P., Sturgill, T. W. and Weber, M. J. (1996) 'Ras-induced activation 
of Raf-1 is dependent on tyrosine phosphorylation', Molecular and Cellular 
Biology, 16(3), pp. 1027-1034. 
Lowenstein, E. J., Daly, R. J., Batzer, A. G., Li, W., Margolis, B., Lammers, R., 
Ullrich, A., Skolnik, E. Y., Bar-Sagi, D. and Schlessinger, J. (1992) 'The SH2 
and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to 
ras signaling', Cell, 70(3), pp. 431-42. 
Prior, I. A., Lewis, P. D. and Mattos, C. (2012) 'A Comprehensive Survey of Ras 
Mutations in Cancer', Cancer Research, 72(10), pp. 2457-2467. 
Raffetseder, U., Frye, B., Rauen, T., Jurchott, K., Royer, H. D., Jansen, P. L. and 
Mertens, P. R. (2003) 'Splicing factor SRp30c interaction with Y-box protein-
1 confers nuclear YB-1 shuttling and alternative splice site selection', Journal 
of Biological Chemistry, 278(20), pp. 18241-18248. 
Rajasekharan, S. K. and Raman, T. (2013) 'Ras and Ras mutations in cancer', Central 
European Journal of Biology, 8(7), pp. 609-624. 
Reif, K., Buday, L., Downward, J. and Cantrell, D. A. (1994) 'SH3 domains of the 
adapter molecule GRB2 complex with 2 proteins in T-cells - the guanine-
nucleotide exchange protein SOS and a 75-kda protein that is a substrate for 
T-cell antigen receptor-activated tyrosine kinases', Journal of Biological 
Chemistry, 269(19), pp. 14081-14087. 
Williams, N. G., Roberts, T. M. and Li, P. (1992) 'Both p21ras and pp60v-src are 
required, but neither alone is sufficient, to activate the Raf-1 kinase', Proc Natl 
Acad Sci U S A, 89(7), pp. 2922-6. 
Yarden, Y. and Schlessinger, J. (1987a) 'Epidermal growth factor induces rapid, 
reversible aggregation of the purified epidermal growth factor receptor', 
Biochemistry, 26(5), pp. 1443-51. 
Yarden, Y. and Schlessinger, J. (1987b) 'Self-phosphorylation of epidermal growth 
factor receptor: evidence for a model of intermolecular allosteric activation', 
Biochemistry, 26(5), pp. 1434-42. 
Yu, X. C., Sharma, K. D., Takahashi, T., Iwamoto, R. and Mekada, E. (2002) 'Ligand-
independent dimer formation of epidermal growth factor receptor (EGFR) is a 
step separable from ligand-induced EGFR signaling', Molecular Biology of the 
Cell, 13(7), pp. 2547-2557. 
		 278	
Zen, K., Liu, D. Q., Guo, Y. L., Wang, C., Shan, J., Fang, M., Zhang, C. Y. and Liu, 
Y. (2008) 'CD44v4 is a major E-selectin ligand that mediates breast cancer 
cell transendothelial migration', PLoS One, 3(3), pp. e1826. 
Zetterberg, A., Larsson, O. and Wiman, K. G. (1995) 'What is the restriction point?', 
Current Opinion in Cell Biology, 7(6), pp. 835-842. 
Zhang, P. L., Bhakta, K. S., Puri, P. L., Newbury, R. O., Feramisco, J. R. and Wang, 
J. Y. (2003a) 'Association of ataxia telangiectasia mutated (ATM) gene 
mutation/deletion with rhabdomyosarcoma', Cancer Biology  &  Therapy, 
2(1), pp. 87-91. 
Zhang, Y. F., Homer, C., Edwards, S. J., Hananeia, L., Lasham, A., Royds, J., Sheard, 
P. and Braithwaite, A. W. (2003b) 'Nuclear localization of Y-box factor YB1 
requires wild-type p53', Oncogene, 22(18), pp. 2782-94. 
Zhou, S. F. (2008) 'Structure, function and regulation of P-glycoprotein and its 
clinical relevance in drug disposition', Xenobiotica, 38(7-8), pp. 802-832. 
Zia, M. K., Rmali, K. A., Watkins, G., Mansel, R. E. and Jiang, W. G. (2007) 'The 
expression of the von Hippel-Lindau gene product and its impact on 
invasiveness of human breast cancer cells', International Journal of Molecular 
Medicine, 20(4), pp. 605-611. 
Zilfou, J. T. and Lowe, S. W. (2009) 'Tumor suppressive functions of p53', Cold 
Spring Harb Perspect Biol, 1(5), pp. a001883. 
  
		 279	
																				
Appendix 1 										
	  
		 280	
 
Fig.S1. Preparation of A549 cell nuclear and cytoplasmic extracts with a Dounce 
homogeniser. A Western blot of ß-tubulin, a cytoplasmic marker, detected in the nuclear 
fraction in this case. ß-tubulin acts as an indicator of the purity and lack of contamination of 
the nuclear fraction with cytoplasmic contaminants. This blot reveals some contamination in 
the nuclear fraction. 
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Fig.S2. LC-MS MS mass spectrum showing mass to charge ratio (x-axis) and relative 
intensity (y-axis) for the identified S102 phosphopeptide. 	 	
		 282	
	
Fig.S3. LC-MS MS mass spectrum showing mass to charge ratio (x-axis) and relative 
intensity (y-axis) for the identified S165 phosphopeptide. 	 	
		 283	
	
Fig.S4. LC-MS MS mass spectrum showing mass to charge ratio (x-axis) and relative 
intensity (y-axis) for the identified S176 phosphopeptide. 
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Fig.S5. LC-MS MS mass spectrum showing mass to charge ratio (x-axis) and relative 
intensity (y-axis) for the identified S314 phosphopeptide. 		 	
		 285	
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Fig.S1. An outline of the mutagenesis approach utilised for this study. (a) All 
phosphorylation sites from the CSD to the NLS were individually PCR mutated for this study. 
Later studies were expanded to include the threonine 271 residue, to explore the observed 
phosphorylated threonine’s exclusivity to the nuclei of unstressed A549 cells, and its 
proximity to the CRS. (b) Serine-to-alanine mutations result in the biomimicry of 
unphosphorylated serine residues (CH3 substitutes for the –OH group), therefore mimicking a 
constant unphosphorylated state. This also holds true for the threonine to alanine mutant (c). 
(d) To mimic phosphorylated residues, the threonine 271 amino acid was PCR mutated to 
glutamate, allowing the exposed COO- group to act as a substitute for PO-4, thus mimicking a 
constant state of phosphorylation.  
a) 
 
 
	
b) 
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c) 
	
d) 
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Table S1. Average tallies of the observed localisation status for each transfection 
compared to the wildtype YB-1 transfection (expected). 
 Nuclear and Cytoplasmic 
 
Cytoplamic 
 
 Observed (%) Expected (%) Observed (%) Expected (%) 
YB-1-HA 10.3 89.3 
S102A-HA 25 10.3 74.7 89.3 
S165A-HA 17.7 10.3 82.3 89.3 
S167A-HA 35.7 10.3 64.3 89.3 
S174A-HA 37.7 10.3 61.7 89.3 
S176A-HA 33.3 10.3 66.7 89.3 
 
 
Table S2. Chi-squared significance to compare the localisation distribution 
between the expected HA-tagged YB-1 transfection and the observed YB-1 
mutants (raw data in Table S1). 
 
Nuclear and 
cytoplasmic 
(Chi-squared 
value) 
Cytoplasmic 
 (Chi-
squared 
value) 
Chi-squared 
value (sum) 
Critical 
value (df = 
1) 
Statistical 
significance 
YB-1-HA SET AS REFERENCE (EXPECTED) 
S102A-HA 21 2.4 23.4 3.841 p < 0.005 
S165A-HA 5.3 0.5 5.8 3.841 p < 0.025 
S167A-HA 62.5 7 69.5 3.841 p < 0.005 
S174A-HA 72.7 8.6 81.3 3.841 p < 0.005 
S176A-HA 51.5 5.7 57.3 3.841 p < 0.005 
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Table S3. Average tallies of the observed localisation status for each transfection 
compared to the wildtype YB-1 transfection (expected). 
 Nuclear and Cytoplasmic 
 
Cytoplamic 
 
 Observed (%) Expected (%) Observed (%) Expected (%) 
YB-1-HA 5.3 94.7 
S167A-HA 37.7 5 62.3 95 
S174A-HA 32 5 68 95 
S176A-HA 35.3 5 64.7 95 
S174-176A-
HA 32 5 68 95 
 
 
Table S4. Chi-squared significance test to compare the localisation distribution 
between the expected HA-tagged YB-1 transfection and the observed YB-1 
mutants (raw data in Table S3). 
 
Nuclear and 
cytoplasmic 
(Chi-squared 
value) 
Cytoplasmic 
 (Chi-
squared 
value) 
Chi-squared 
value (sum) 
Critical 
value (df 
= 1) 
Statistical 
significance 
YB-1-HA SET AS REFERENCE (EXPECTED) 
S167A-HA 213.4 11.2 224.7 3.841 p < 0.005 
S174A-HA 145.8 7.7 153.5 3.841 p < 0.005 
S176A-HA 184 9.7 193.7 3.841 p < 0.005 
S174-
176A-HA 145.8 7.7 153.5 3.841 p < 0.005 
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Table S5. Average tallies of the observed localisation status for each transfection 
compared to the wildtype YB-1 transfection (expected). 
 Nuclear and Cytoplasmic 
 
Cytoplamic 
 
 Observed (%) Expected (%) Observed (%) Expected (%) 
YB-1-HA 26.9 73.1 
S102A-HA 27.1 26.9 72.9 73.1 
S176A-HA 42.5 26.9 57.5 73.1 
T271A-HA 34.8 26.9 65.2 73.1 
T271E-HA 24.9 26.9 75.1 73.1 
 
 
Table S6. Chi-squared significance test to compare the localisation distribution 
between the expected HA-tagged YB-1 transfection and the observed YB-1 
mutants (raw data in Table S5). 
 
Nuclear and 
cytoplasmic 
(Chi-squared 
value) 
Cytoplasmic 
 (Chi-
squared 
value) 
Chi-squared 
value (sum) 
Critical 
value 
(df = 1) 
Statistical 
significance 
YB-1-HA SET AS REFERENCE (EXPECTED) 
S102A-HA 0.002 0.0007 0.003 3.841 p > 0.05 
S176A-HA 9.1 3.3 12.4 3.841 p < 0.05 
T271A-HA 2.3 0.9 3.2 3.841 p > 0.05 
T271E-HA 0.1 0.06 0.2 3.841 p > 0.05 
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Table S7. Average tally of the observed localisation status for the T271E-HA 
mutant transfection compared to the the T271A mutant (expected). 
 Nuclear and Cytoplasmic 
 
Cytoplamic 
 
 Observed (%) Expected (%) Observed (%) Expected (%) 
T271A-HA 34.8 65.2 
T271E-HA 24.9 34.8 75.1 65.2 
 
 
Table S8. Chi-squared significance test to compare the localisation distribution 
between the T271A-HA mutant transfection and the T271E mutant (raw data in 
Table S7). 
 
Nuclear and 
cytoplasmic 
(Chi-squared 
value) 
Cytoplasmic 
 (Chi-
squared 
value) 
Chi-squared 
value (sum) 
Critical 
value 
(df = 1) 
Statistical 
significance 
T271A-HA SET AS REFERENCE (EXPECTED) 
T271E-HA 2.8 1.5 4.3 3.841 p < 0.05 
 
 
Table S9. Average tallies of the observed condensed or normal nuclei for each 
transfection compared to the wildtype YB-1 transfection (expected). 
 Condensed Normal 
 
 Observed (%) Expected (%) Observed (%) Expected (%) 
Neg. ctrl. 
transfection 5.3 94.7 
YB-1-HA 10.7 5.3 89.3 94.7 
S102A-HA 23.7 5.3 76.3 94.7 
S165A-HA 14 5.3 86 94.7 
S167A-HA 20.7 5.3 79.3 94.7 
S174A-HA 33.7 5.3 66.3 94.7 
S176A-HA 32 5.3 68 94.7 
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Table S10. Chi-squared significance test to compare chromatin condensation 
between the negative control transfection and the observed YB-1/mutant 
transfections (raw data in Table S9). 
 
 
 
 
Condensed 
(Chi-squared 
value) 
 
 
 
Normal 
(Chi-squared 
value) 
Chi-squared 
value (sum) 
Critical 
value 
(df = 1) 
Statistical 
significance 
Neg. ctrl. 
transfection SET AS REFERENCE (EXPECTED) 
YB-1-HA 5.3 0.3 5.6 3.841 p < 0.05 
S102A-HA 63 3.6 66.6 3.841 p < 0.005 
S165A-HA 14.1 0.8 14.9 3.841 p < 0.005 
S167A-HA 44.1 2.5 46.6 3.841 p < 0.005 
S174A-HA 150.5 8.5 159 3.841 p < 0.005 
S176A-HA 133.3 7.5 140.8 3.841 p < 0.005 
 
 
Table S11. Average tallies of the observed condensed or normal nuclei for each 
transfection compared to the wildtype YB-1 transfection (expected). 
 Condensed Normal 
 
 Observed (%) Expected (%) Observed (%) Expected (%) 
YB-1-HA 10.7 89.3 
S102A-HA 23.7 10.7 76.3 89.3 
S165A-HA 14 10.7 86 89.3 
S167A-HA 20.7 10.7 79.3 89.3 
S174A-HA 33.7 10.7 66.3 89.3 
S176A-HA 32 10.7 68 89.3 
Neg. ctrl. 
transfection 5.3 10.7 94.7 89.3 
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Table S12. Chi-squared significance test to compare chromatin condensation 
between expected HA-tagged YB-1 transfection and the observed YB-1 mutants 
(raw data in Table S11). 
 
 
 
 
Condensed 
(Chi-squared 
value) 
 
 
 
Normal 
(Chi-squared 
value) 
Chi-squared 
value (sum) 
Critical 
value 
(df = 1) 
Statistical 
significance 
YB-1-HA SET AS REFERENCE (EXPECTED) 
S102A-HA 15.8 1.9 17.7 3.841 p < 0.005 
S165A-HA 1 0.1 1.2 3.841 p > 0.05 
S167A-HA 9.4 1.1 10.5 3.841 p < 0.005 
S174A-HA 49.6 5.9 55.5 3.841 p < 0.005 
S176A-HA 42.7 5.1 47.8 3.841 p < 0.005 
Neg. ctrl. 
transfection 2.7 0.3 3 3.841 p > 0.05 
 
 
Table S13. Average tallies of the observed condensed or normal nuclei for each 
transfection compared to the wildtype YB-1 transfection (expected). 
 Condensed Normal 
 
 Observed (%) Expected (%) Observed (%) Expected (%) 
Neg. ctrl. 
transfection 2 98 
YB-1-HA 7 2 93 98 
S167A-HA 30.3 2 69.7 98 
S174A-HA 40.7 2 59.3 98 
S176A-HA 39.7 2 60.3 98 
S174-176A-HA 40 2 60 98 
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Table S14. Chi-squared significance test to compare chromatin condensation 
between the negative control transfection and the observed YB-1/mutant 
transfections (raw data in Table S13). 
 
 
 
 
Condensed 
(Chi-squared 
value) 
 
 
 
Normal 
(Chi-squared 
value) 
Chi-squared 
value (sum) 
Critical 
value 
(df = 1) 
Statistical 
significance 
Neg. ctrl. 
transfection SET AS REFERENCE (EXPECTED) 
YB-1-HA 12.5 0.3 12.8 3.841 p < 0.005 
S167A-HA 401.4 8.2 409.6 3.841 p < 0.005 
S174A-HA 747.6 15.3 762.8 3.841 p < 0.005 
S176A-HA 709.4 14.5 723.9 3.841 p < 0.005 
S174-176A-HA 722 14.7 736.7 3.841 p < 0.005 
 
 
Table S15. Average tallies of the observed condensed or normal nuclei for each 
transfection compared to the wildtype YB-1 transfection (expected). 
 Condensed Normal 
 
 Observed (%) Expected (%) Observed (%) Expected (%) 
YB-1-HA 7 93 
S167A-HA 30.3 7 69.7 93 
S174A-HA 40.7 7 59.3 93 
S176A-HA 39.7 7 60.3 93 
S174-176A-HA 40 7 60 93 
Neg. ctrl. 
transfection 2 7 98 93 
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Table S16. Chi-squared significance test to compare chromatin condensation 
between the expected HA-tagged YB-1 transfection and the observed YB-1 
mutants (raw data in Table S15). 
 
 
 
 
Condensed 
(Chi-
squared 
value) 
 
 
 
Normal 
(Chi-squared 
value) Chi-squared 
value (sum) 
Critical 
value 
(df = 1) 
Statistical 
significance 
YB-1-HA SET AS REFERENCE (EXPECTED) 
S167A-HA 77.8 5.9 83.6 3.841 p < 0.005 
S174A-HA 161.9 12.2 174.1 3.841 p < 0.005 
S176A-HA 152.4 11.5 163.9 3.841 p < 0.005 
S174-176A-HA 155.6 11.7 167.3 3.841 p < 0.005 
Neg. ctrl. 
transfection 3.6 0.3 3.840 3.841 p > 0.05 
 
 
Table S17. Average tallies of the observed condensed or normal nuclei for each 
transfection compared to the wildtype YB-1 transfection (expected). 
 Condensed Normal 
 
 Observed (%) Expected (%) Observed (%) Expected (%) 
Neg. ctrl. 
transfection 3.3 96.7 
YB-1-HA 6.9 3.3 93.1 96.7 
S102A-HA 15.3 3.3 84.7 96.7 
S176A-HA 28.6 3.3 71.4 96.7 
T271A-HA 3 3.3 97 96.7 
T271E-HA 9.8 3.3 90.2 96.7 
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Table S18. Chi-squared significance test to compare chromatin condensation 
between the negative control transfection and the observed YB-1/mutant 
transfections (raw data in Table S17). 
 
 
 
 
Condensed 
(Chi-squared 
value) 
 
 
 
Normal 
(Chi-squared 
value) 
Chi-squared 
value (sum) 
Critical 
value 
(df = 1) 
Statistical 
significance 
Neg. ctrl. 
transfection SET AS REFERENCE (EXPECTED) 
YB-1-HA 3.8 0.1 3.9 3.841 p < 0.05 
S102A-HA 43 1.5 44.5 3.841 p < 0.005 
S176A-HA 192 6.6 198.6 3.841 p < 0.005 
T271A-HA 0.03 0.001 0.03 3.841 p > 0.05 
T271E-HA 12.6 0.4 13 3.841 p < 0.005 	
 
Table S19. Average tallies of the observed condensed or normal nuclei for each 
transfection compared to the wildtype YB-1 transfection (expected). 
 Condensed Normal 
 
 Observed (%) Expected (%) Observed (%) Expected (%) 
YB-1-HA 6.9 93.1 
S102A-HA 15.3 6.9 84.7 93.1 
S176A-HA 28.6 6.9 71.4 93.1 
T271A-HA 3 6.9 97 93.1 
T271E-HA 9.8 6.9 90.2 93.1 
Neg. ctrl. 
transfection 3.3 6.9 96.7 93.1 
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Table S20. Chi-squared significance test to compare chromatin condensation 
between the expected HA-tagged YB-1 transfection and the observed YB-1 
mutants (raw data in Table S19) 
 
 
 
 
Condensed 
(Chi-squared 
value) 
 
 
 
Normal 
(Chi-squared 
value) 
Chi-squared 
value (sum) 
Critical 
value 
(df = 1) 
Statistical 
significance 
YB-1-HA SET AS REFERENCE (EXPECTED) 
S102A-HA 10.3 0.8 11 3.841 p < 0.005 
S176A-HA 68.6 5.1 73.7 3.841 p < 0.005 
T271A-HA 2.2 0.2 2.4 3.841 p > 0.05 
T271E-HA 1.2 0.09 1.3 3.841 p > 0.05 
Neg. ctrl. 
transfection 1.8 0.1 2 3.841 p > 0.05 	  
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Fig.S2. Compiled proliferation experiment 1: YB-1 and phosphorylation-defective 
mutants have varying effects on the rate proliferation. HA-tagged YB-1 and its serine-to-
alanine mutant plasmids were co-transfected with an mcherry plasmid (ratio of 1:10 mcherry 
to YB-1/mutant/control) into A549 cells, and observed for 72 hours under live cell imaging. 
A line of best fit was run through the observed data distribution for each transfection. The 
transfections: Positive and negative controls, YB-1-HA and YB-1 mutants showing varying 
effects on proliferation. 
 
 
Fig.S3. Compiled proliferation experiment 1 (Corrected for confluency): YB-1 and 
phosphorylation-defective mutants have varying effects on the rate proliferation. HA-
tagged YB-1 and its serine-to-alanine mutant plasmids were co-transfected with an mcherry 
plasmid (ratio of 1:10 mcherry to YB-1/mutant/control) into A549 cells, and observed for 72 
hours under live cell imaging. A line of best fit was run through the observed data distribution 
for each transfection. The transfections: Positive and negative controls, YB-1-HA and YB-1 
mutants showing varying effects on proliferation. 
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Fig.S4. Compiled proliferation experiment 2: YB-1 and phosphorylation-defective 
mutants have varying effects on the rate proliferation. HA-tagged YB-1 and its serine-to-
alanine mutant plasmids were co-transfected with an mcherry plasmid (ratio of 1:10 mcherry 
to YB-1/mutant/control) into A549 cells, and observed for 72 hours under live cell imaging. 
A line of best fit was run through the observed data distribution for each transfection. The 
transfections: Positive and negative controls, YB-1-HA and YB-1 mutants showing varying 
effects on proliferation. 
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Fig.S5. Compiled proliferation experiment 3: YB-1 and phosphorylation-defective 
mutants have varying effects on the rate proliferation. HA-tagged YB-1 and its serine-to-
alanine mutant plasmids were co-transfected with an mcherry plasmid (ratio of 1:10 mcherry 
to YB-1/mutant/control) into A549 cells, and observed for 72 hours under live cell imaging. 
A line of best fit was run through the observed data distribution for each transfection. The 
transfections: Positive and negative controls, YB-1-HA and YB-1 mutants showing varying 
effects on proliferation. 	  
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Table S21. Proliferation experiment 1: Mann-Whitney U test results for each 
plasmid transfection compared to the negative control transfection. 
Plasmid O/E vs Negative control plasmid 
transfection 
Mann-Whitney U  (p-score) 
 
Positive control plasmid transfection 0.026 
YB-1-HA  0.685 
YB-1-HA (modified) 0.352 
S102A-HA 0.470 
S165A-HA 0.046 
S167A-HA 0.094 
S174A-HA 0.106 
S176A-HA 0.402 
S174-176A-HA 0.149 
O/E: Overexpression 
Table S22. Proliferation experiment 2: Mann-Whitney U test results for each 
plasmid transfection compared to the negative control transfection. 
Plasmid O/E vs Negative control plasmid 
transfection 
Mann-Whitney U  (p-score) 
 
Positive control plasmid transfection 0.077 
YB-1-HA  0.685 
S102A-HA 0.416 
S165A-HA 0.772 
S167A-HA  < 0.0001 
S174A-HA 0.308 
S176A-HA 0.039 
S174-176A-HA 0.750 
O/E: Overexpression 
Table S23. Proliferation experiment 3: Mann-Whitney U test results for each 
plasmid transfection compared to the negative control transfection. 
Plasmid O/E vs Negative control plasmid 
transfection 
Mann-Whitney U  (p-score) 
 
Positive control plasmid transfection 0.418 
YB-1-HA  0.184 
S102A-HA 0.125 
S165A-HA 0.488 
S167A-HA 0.001 
S174A-HA 0.008 
S176A-HA 0.977 
S174-176A-HA 0.037 
O/E: Overexpression 
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Cell proliferation experiments: XLSTAT® analysis output (Mann-Whitney U 
tests) 
 
Proliferation experiment 1 
 
Positive control plasmid transfection vs Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 111.000 
 Expected value 72.000 
 Variance (U) 300.000 
 p-value (Two-tailed) 0.026 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
   
As the computed p-value is lower than the significance level alpha=0.05, one should  
reject the null hypothesis H0, and accept the alternative hypothesis Ha. 
The risk to reject the null hypothesis H0 while it is true is lower than 2.62%. 
    
 
YB-1-HA vs Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 64.500 
 Expected value 72.000 
 Variance (U) 296.870 
 p-value (Two-tailed) 0.685 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05, one cannot  
reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 68.45%. 
    
         Ties have been detected in the data and the appropriate corrections have been applied. 
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YB-1-HA (modified) vs Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 53.500 
 Expected value 42.000 
 Variance (U) 139.877 
 p-value (Two-tailed) 0.352 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05, one cannot  
reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 35.23%. 
    
         Ties have been detected in the data and the appropriate corrections have been applied. 
   
 
S102A-HA vs Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 85.000 
 Expected value 72.000 
 Variance (U) 299.609 
 p-value (Two-tailed) 0.470 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05, one cannot  
reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 47.02%. 
    
         Ties have been detected in the data and the appropriate corrections have been applied. 
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165A-HA vs Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 107.000 
 Expected value 72.000 
 Variance (U) 299.739 
 p-value (Two-tailed) 0.046 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
  Ha: The difference of location between the samples is different from 0. 
   
As the computed p-value is lower than the significance level alpha=0.05, one should  
reject the null hypothesis H0, and accept the alternative hypothesis Ha. 
The risk to reject the null hypothesis H0 while it is true is lower than 4.63%. 
   
         Ties have been detected in the data and the appropriate corrections have been applied. 
   
 
S167-HA modified vs Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 42.500 
 Expected value 72.000 
 Variance (U) 299.348 
 p-value (Two-tailed) 0.094 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05, one cannot  
reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 9.37%. 
    
         Ties have been detected in the data and the appropriate corrections have been applied. 
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S174A-HA vs Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 100.500 
 Expected value 72.000 
 Variance (U) 299.609 
 p-value (Two-tailed) 0.106 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
    
   Test interpretation: 
 H0: The difference of location between the samples is equal to 0. 
    Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05, one cannot  
reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 10.57%. 
    
         Ties have been detected in the data and the appropriate corrections have been applied. 
   
 
S176-HA modified vs Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 87.000 
 Expected value 72.000 
 Variance (U) 299.739 
 p-value (Two-tailed) 0.402 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05, one cannot  
reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 40.23%. 
    
         Ties have been detected in the data and the appropriate corrections have been applied. 
   
  
		 306	
S174-176A-HA vs Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 97.500 
 Expected value 72.000 
 Variance (U) 299.870 
 p-value (Two-tailed) 0.149 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05, one cannot  
reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 14.88%. 
    
         Ties have been detected in the data and the appropriate corrections have been applied. 
   
 
Proliferation experiment 2 
 
Positive control plasmid transfection vs Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 103.000 
 Expected value 72.000 
 Variance (U) 297.783 
 p-value (Two-tailed) 0.077 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05, one cannot  
reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 7.72%. 
    
         Ties have been detected in the data and the appropriate corrections have been applied. 
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YB-1-HA vs Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 64.500 
 Expected value 72.000 
 Variance (U) 296.870 
 p-value (Two-tailed) 0.685 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05, one cannot  
reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 68.45%. 
    
         Ties have been detected in the data and the appropriate corrections have been applied. 
   
 
S102A-HA vs Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 57.500 
 Expected value 72.000 
 Variance (U) 296.348 
 p-value (Two-tailed) 0.416 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05, one cannot  
reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 41.61%. 
    
         Ties have been detected in the data and the appropriate corrections have been applied. 
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S165A-HA vs Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 66.500 
 Expected value 72.000 
 Variance (U) 297.913 
 p-value (Two-tailed) 0.772 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05, one cannot  
reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 77.21%. 
    
         Ties have been detected in the data and the appropriate corrections have been applied. 
   
 
S167-HA modified vs Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 3.000 
 Expected value 72.000 
 Variance (U) 295.826 
 p-value (Two-tailed)  < 0.0001 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
   
As the computed p-value is lower than the significance level alpha=0.05, one should  
reject the null hypothesis H0, and accept the alternative hypothesis Ha. 
The risk to reject the null hypothesis H0 while it is true is lower than 0.01%. 
   
         Ties have been detected in the data and the appropriate corrections have been applied. 
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S174A-HA vs Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 54.000 
 Expected value 72.000 
 Variance (U) 294.783 
 p-value (Two-tailed) 0.308 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05, one cannot  
reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 30.81%. 
    
         Ties have been detected in the data and the appropriate corrections have been applied. 
   
 
S176-HA modified vs Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 36.000 
 Expected value 72.000 
 Variance (U) 296.478 
 p-value (Two-tailed) 0.039 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
   
As the computed p-value is lower than the significance level alpha=0.05, one should  
reject the null hypothesis H0, and accept the alternative hypothesis Ha. 
The risk to reject the null hypothesis H0 while it is true is lower than 3.92%. 
   
         Ties have been detected in the data and the appropriate corrections have been applied. 
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S174-176A-HA vs Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 78.000 
 Expected value 72.000 
 Variance (U) 297.783 
 p-value (Two-tailed) 0.750 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05, one cannot  
reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 74.99%. 
    
         Ties have been detected in the data and the appropriate corrections have been applied. 
   
 
Proliferation experiment 3 
 
Positive control plasmid transfection vs Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 86.500 
 Expected value 72.000 
 Variance (U) 299.217 
 p-value (Two-tailed) 0.418 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
    Test interpretation: 
  H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 41.83%. 
    
         Ties have been detected in the data and the appropriate corrections have been  
applied. 
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YB-1-HA vs Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 48.500 
 Expected value 72.000 
 Variance (U) 299.478 
 p-value (Two-tailed) 0.184 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
    Test interpretation: 
  H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 18.38%. 
    
         Ties have been detected in the data and the appropriate corrections have been  
applied. 
   
 
S102A-HA vs Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 45.000 
 Expected value 72.000 
 Variance (U) 298.696 
 p-value (Two-tailed) 0.125 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
   Test interpretation: 
 H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 12.52%. 
    
         Ties have been detected in the data and the appropriate corrections have been  
applied. 
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S165A-HA vs Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 59.500 
 Expected value 72.000 
 Variance (U) 299.217 
 p-value (Two-tailed) 0.488 
 alpha 0.05 
   An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 48.79%. 
   
        Ties have been detected in the data and the appropriate corrections have been  
applied. 
   
 
S167-HA modified vs Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 12.500 
 Expected value 72.000 
 Variance (U) 299.087 
 p-value (Two-tailed) 0.001 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is lower than the significance level alpha=0.05,  
one should reject the null hypothesis H0, and accept the alternative hypothesis  
Ha. 
The risk to reject the null hypothesis H0 while it is true is lower than 0.06%. 
      Ties have been detected in the data and the appropriate corrections have been  
applied. 
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S174A-HA vs Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 26.000 
 Expected value 72.000 
 Variance (U) 298.565 
 p-value (Two-tailed) 0.008 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is lower than the significance level alpha=0.05,  
one should reject the null hypothesis H0, and accept the alternative hypothesis  
Ha. 
The risk to reject the null hypothesis H0 while it is true is lower than 0.85%. 
   
         Ties have been detected in the data and the appropriate corrections have been  
applied. 
   
 
S176-HA modified vs Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 73.000 
 Expected value 72.000 
 Variance (U) 294.913 
 p-value (Two-tailed) 0.977 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
 Ha: The difference of location between the samples is different from 0. 
  As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 97.68%. 
     Ties have been detected in the data and the appropriate corrections have been  
applied. 
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S174-176A-HA vs Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 108.500 
 Expected value 72.000 
 Variance (U) 298.565 
 p-value (Two-tailed) 0.037 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is lower than the significance level alpha=0.05,  
one should reject the null hypothesis H0, and accept the alternative hypothesis  
Ha. 
The risk to reject the null hypothesis H0 while it is true is lower than 3.72%. 
      Ties have been detected in the data and the appropriate corrections have been  
applied. 
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Migration speed data distributions 
 
Experiment 1 
 
Table S1. Various parametric tests applied to the distribution of migration speed 
for the negative control transfection. 
Shapiro-Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
0.986 0.985 0.961 0.844 
 
0.997 
Distribution: parametric 
 
Fig.S1. Negative control plasmid distribution compared to a normal distribution. 
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Table S2. Various parametric tests applied to the distribution of migration speed 
for the positive control transfection. 
Shapiro-
Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
0.035 0.043 0.131 0.092 
 
0.550 
Distribution: non-parametric 
 
Fig.S2. Positive control plasmid distribution compared to a normal distribution. 
  
		 318	
Table S3. Various parametric tests applied to the distribution of migration speed 
for the YB-1-HA transfection. 
Shapiro-Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
0.161 0.285 0.224 0.138 
 
0.661 
Distribution: parametric 
 
Fig.S3. YB-1-HA plasmid distribution compared to a normal distribution. 
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Table S4. Various parametric tests applied to the distribution of migration speed 
for the S102A-HA transfection. 
Shapiro-
Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
0.043 0.169 0.479 0.011 
 
0.854 
Distribution: non-parametric 
 
Fig.S4. S102A-HA plasmid distribution compared to a normal distribution. 
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Table S5. Various parametric tests applied to the distribution of migration speed 
for the S165A-HA transfection. 
Shapiro-
Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
0.001 0.002 0.007  < 0.0001 
 
0.221 
Distribution: non-parametric 
 
Fig.S5. S165A-HA plasmid distribution compared to a normal distribution. 
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Table S6. Various parametric tests applied to the distribution of migration speed 
for the S167A-HA transfection. 
Shapiro-Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
0.086 0.105 0.018 0.373 
 
0.280 
Distribution: non-parametric 
 
Fig.S6. S167A-HA plasmid distribution compared to a normal distribution. 
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Table S7. Various parametric tests applied to the distribution of migration speed 
for the S174A-HA transfection. 
Shapiro-Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
0.284 0.197 0.429 0.432 
 
0.817 
Distribution: parametric 
 
Fig.S7. S174A-HA plasmid distribution compared to a normal distribution. 
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Table S8. Various parametric tests applied to the distribution of migration speed 
for the S176A-HA transfection. 
Shapiro-Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
0.209 0.180 0.115 0.467 
 
0.532 
Distribution: parametric 
 
Fig.S8. S176A-HA plasmid distribution compared to a normal distribution. 
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Table S9. Various parametric tests applied to the distribution of migration speed 
for the S174-176A-HA transfection. 
Shapiro-Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
0.164 0.177 0.141 0.481 
 
0.578 
Distribution: parametric 
 
Fig.S9. S174-176A-HA plasmid distribution compared to a normal distribution. 
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Table S10. Various parametric tests applied to the distribution of migration 
speed for the T271A-HA transfection. 
Shapiro-Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
0.496 0.412 0.531 0.413 
 
0.882 
Distribution: parametric 
 
Fig.S10. T271A-HA plasmid distribution compared to a normal distribution. 
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Table S11. Various parametric tests applied to the distribution of migration 
speed for the T271E-HA transfection. 
Shapiro-Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
0.602 0.613 0.681 0.490 
 
0.973 
Distribution: parametric 
 
Fig.S11. T271E-HA plasmid distribution compared to a normal distribution. 
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Migration speed experiment 1: XLSTAT® analysis output  
 
 
Table S12. A Comparison of the average single cell migration speed of the 
negative (empty vector) control transfection and all other transfections using a 
two-tailed t-test or Mann-Whitney U test, depending on the data distribution (i.e. 
parametric vs. non-parametric) 
Plasmid overexpression Negative (empty vector) control plasmid 
p score (two-tailed) 
Positive (H-RAS) control plasmid transfection  0.0001 (Mann-Whitney U) 
YB-1-HA 0.970 (t-test) 
S102A-HA 0.768 (Mann-Whitney U) 
S165A-HA 0.514 (Mann-Whitney U) 
S167A-HA 0.581 (t-test) 0.731 (Mann-Whitney U) 
S174A-HA 0.444 (t-test) 
S176A-HA 0.377 (t-test) 
S174-176-HA 0.0001 (t-test) 
T271A-HA 0.008 (t-test) 
T271E-HA 0.227 (t-test) 
 
 
Positive control plasmid transfection vs Negative control plasmid transfection 	
Mann-Whitney test / Two-tailed test: 
   U 860.000 
 Expected value 551.000 
 Variance (U) 6244.667 
 p-value (Two-tailed)  < 0.0001 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
    
   Test interpretation: 
 H0: The difference of location between the samples is equal to 0. 
    Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is lower than the significance level alpha=0.05,  
one should reject the null hypothesis H0, and accept the alternative hypothesis  
Ha. 
The risk to reject the null hypothesis H0 while it is true is lower than 0.01%. 
 
YB-1-HA vs Negative control plasmid transfection 
 
t-test for two independent samples / Two-tailed test: 
 
  Difference 0.000 
t (Observed 
value) -0.038 
|t| (Critical value) 1.995 
DF 68 
p-value (Two-
tailed) 0.970 
alpha 0.05 
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  Test interpretation: 
H0: The difference between the means is equal to 0. 
Ha: The difference between the means is different from 0. 
As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 97.01%. 
 
 
 
S102A-HA vs. Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 247.000 
 Expected value 261.000 
 Variance (U) 2088.000 
 p-value (Two-tailed) 0.768 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 76.77%. 
     
 
S165A-HA vs Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 260.000 
 Expected value 232.000 
 Variance (U) 1778.667 
 p-value (Two-tailed) 0.514 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 51.44%. 
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S167A-HA vs. Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 428.000 
 Expected value 406.000 
 Variance (U) 3924.667 
 p-value (Two-tailed) 0.731 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 73.15%. 
     
 
S167A-HA vs. Negative control plasmid transfection 
 
t-test for two independent samples / Two-tailed test: 
     95% confidence interval on the difference between the means: 
] -0.001 , 0.002 [ 
   
     Difference 0.001 
   t (Observed value) 0.651 
   |t| (Critical value) 2.004 
   DF 55 
   p-value (Two-tailed) 0.518 
   alpha 0.05 
   
     Test interpretation: 
   H0: The difference between the means is equal to 0. 
Ha: The difference between the means is different from 0. 
As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 51.79%. 
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S174A-HA vs Negative control plasmid transfection 
 
t-test for two independent samples / Two-tailed test: 
   Difference 0.001 
 t (Observed value) 0.770 
 |t| (Critical value) 2.000 
 DF 60 
 p-value (Two-
tailed) 0.444 
 alpha 0.05 
 
   Test interpretation: 
 H0: The difference between the means is equal to 0. 
    Ha: The difference between the means is different from 0. 
    As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 44.41%. 
     
 
S176A-HA vs Negative control plasmid transfection 
 
t-test for two independent samples / Two-tailed test: 
 
Difference 0.001 
 t (Observed value) 0.892 
 |t| (Critical value) 2.008 
 DF 51 
 p-value (Two-
tailed) 0.377 
 alpha 0.05 
 
   Test interpretation: 
 H0: The difference between the means is equal to 0. 
    Ha: The difference between the means is different from 0. 
    As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 37.68%. 
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S174-176A-HA vs. Negative control plasmid transfection 
 
t-test for two independent samples / Two-tailed test: 
 
Difference 0.005 
t (Observed value) 4.841 
|t| (Critical value) 2.013 
DF 46 
p-value (Two-
tailed)  < 0.0001 
alpha 0.05 
  Test interpretation: 
  H0: The difference between the means is equal to 0. 
    Ha: The difference between the means is different from 0. 
    As the computed p-value is lower than the significance level alpha=0.05,  
one should reject the null hypothesis H0, and accept the alternative hypothesis  
Ha. 
The risk to reject the null hypothesis H0 while it is true is lower than 0.01%. 
    
 
T271A-HA vs. Negative control plasmid transfection 
 
t-test for two independent samples / Two-tailed test: 
 
Difference 0.003 
t (Observed value) 2.805 
|t| (Critical value) 2.018 
DF 42 
p-value (Two-
tailed) 0.008 
alpha 0.05 
  Test interpretation: 
  H0: The difference between the means is equal to 0. 
    Ha: The difference between the means is different from 0. 
    As the computed p-value is lower than the significance level alpha=0.05,  
one should reject the null hypothesis H0, and accept the alternative hypothesis Ha. 
The risk to reject the null hypothesis H0 while it is true is lower than 0.76%. 
    
 
    
  
		 332	
T271E-HA vs. Negative control plasmid transfection 
 
t-test for two independent samples / Two-tailed test: 
 
Difference 0.001 
t (Observed value) 1.225 
|t| (Critical value) 2.015 
DF 44 
p-value (Two-
tailed) 0.227 
alpha 0.05 
  Test interpretation: 
  H0: The difference between the means is equal to 0. 
    Ha: The difference between the means is different from 0. 
    As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 22.72%. 
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Migration speed data distributions (with endogenous YB-1 knockdown) 
 
Experiment 2 
 
Table S13. Various parametric tests applied to the distribution of migration 
speed for the negative control transfection (YB-1 knockdown). 
Shapiro-Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
0.121 0.209 0.148 0.233 
 
0.572 
Distribution: parametric 
 
Fig.S12. Negative control plasmid distribution (with YB-1 knockdown) compared to a 
normal distribution. 
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Table S14. Various parametric tests applied to the distribution of migration 
speed for the positive control transfection (with YB-1 knockdown). 
Shapiro-Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
0.081 0.121 0.271 0.141 
 
0.705 
Distribution: parametric 
 
Fig.S13. Positive control plasmid distribution (with YB-1 knockdown) compared to a 
normal distribution. 
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Table S15. Various parametric tests applied to the distribution of migration 
speed for the YB-1-HA transfection (with YB-1 knockdown). 
Shapiro-Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
0.102 0.057 0.043 0.179 
 
0.380 
Distribution: non-parametric 
 
Fig.S14. YB-1-HA plasmid distribution (with YB-1 knockdown) compared to a normal 
distribution. 
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Table S16. Various parametric tests applied to the distribution of migration 
speed for the S176A-HA transfection (with YB-1 knockdown). 
Shapiro-
Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
0.002 0.004 0.027 0.008 
 
0.320 
Distribution: non-parametric 
 
Fig.S15. S176A-HA plasmid distribution (with YB-1 knockdown) compared to a normal 
distribution. 
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Table S17. Various parametric tests applied to the distribution of migration 
speed for the negative control transfection (with control knockdown). 
Shapiro-
Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
 < 0.0001  < 0.0001  < 0.0001  < 0.0001 
 
0.042 
Distribution: non-parametric 
 
Fig.S16. Negative control plasmid distribution (with control knockdown) compared to a 
normal distribution 
.
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Table S18. Various parametric tests applied to the distribution of migration 
speed for the positive control transfection (with control knockdown). 
Shapiro-
Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
 < 0.0001 0.000 0.063  < 0.0001 
 
0.426 
Distribution: non-parametric 
 
Fig.S17. Positive control plasmid distribution (with control knockdown) compared to a 
normal distribution. 
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Table S19. Various parametric tests applied to the distribution of migration 
speed for the YB-1-HA transfection (with control knockdown). 
Shapiro-
Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
 < 0.0001  < 0.0001 0.000  < 0.0001 
 
0.050 
Distribution: non-parametric 
 
Fig.S18. YB-1-HA plasmid distribution (with control knockdown) compared to a normal 
distribution. 
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Table S20. Various parametric tests applied to the distribution of migration 
speed for the S176-HA transfection (with control knockdown). 
Shapiro-
Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
 < 0.0001  < 0.0001 0.029  < 0.0001 
 
0.323 
Distribution: non-parametric 
 
Fig.S19. S176A-HA plasmid distribution (with control knockdown) compared to a 
normal distribution. 
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Migration speed experiment 2 (with YB-1 knockdown): XLSTAT® analysis 
output  
 
Positive control plasmid transfection (YB-1 knockdown) vs. Negative control 
plasmid transfection (YB-1 knockdown) 
 
Mann-Whitney test / Two-tailed test: 
   U 771.000 
 Expected value 988.000 
 Variance (U) 14984.667 
 p-value (Two-tailed) 0.077 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 7.70%. 
 
 
YB-1-HA (YB-1 knockdown) vs. Negative control plasmid transfection (YB-1 
knockdown) 
 
Mann-Whitney test / Two-tailed test: 
   U 712.000 
 Expected value 676.000 
 Variance (U) 8900.667 
 p-value (Two-tailed) 0.707 
 alpha 0.05 
   An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
 Ha: The difference of location between the samples is different from 0. 
  As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 70.67%. 
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S176A-HA (YB-1 knockdown) vs. Negative control plasmid transfection (YB-1 
knockdown) 
 
Mann-Whitney test / Two-tailed test: 
   U 1030.500 
 Expected value 988.000 
 Variance (U) 14984.543 
 p-value (Two-tailed) 0.732 
 alpha 0.05 
   An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
 As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 73.15%. 
  
       Ties have been detected in the data and the appropriate corrections have been  
applied. 
 
 
Positive control plasmid transfection (control knockdown) vs. Negative control 
plasmid transfection (control knockdown) 
 
Mann-Whitney test / Two-tailed test: 
   U 6331.000 
 Expected value 5251.000 
 Variance (U) 182034.297 
 p-value (Two-tailed) 0.011 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
 As the computed p-value is lower than the significance level alpha=0.05, one should  
reject the null hypothesis H0, and accept the alternative hypothesis Ha. 
The risk to reject the null hypothesis H0 while it is true is lower than 1.14%. 
 
       Ties have been detected in the data and the appropriate corrections have been  
applied. 
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YB-1-HA (control knockdown) vs. Negative control plasmid transfection (control 
knockdown) 
 
Mann-Whitney test / Two-tailed test: 
   U 4699.000 
 Expected value 4602.000 
 Variance (U) 151098.639 
 p-value (Two-tailed) 0.804 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
 As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 80.39%. 
  
       Ties have been detected in the data and the appropriate corrections have been  
applied. 
 
 
S176A-HA (control knockdown) vs. Negative control plasmid transfection 
(control knockdown) 
 
Mann-Whitney test / Two-tailed test: 
   U 3607.000 
 Expected value 3540.000 
 Variance (U) 105608.989 
 p-value (Two-tailed) 0.838 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
 As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 83.79%. 
  
       Ties have been detected in the data and the appropriate corrections have been  
applied. 
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Positive control plasmid transfection (YB-1 knockdown vs. control knockdown) 
 
Mann-Whitney test / Two-tailed test: 
   U 813.000 
 Expected value 1691.000 
 Variance (U) 36074.667 
 p-value (Two-tailed)  < 0.0001 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is lower than the significance level alpha=0.05,  
one should reject the null hypothesis H0, and accept the alternative hypothesis  
Ha. 
The risk to reject the null hypothesis H0 while it is true is lower than 0.01%. 
    
 
Negative control plasmid transfection (YB-1 knockdown vs. control knockdown) 
 
Mann-Whitney test / Two-tailed test: 
   U 2661.000 
 Expected value 3068.000 
 Variance (U) 87437.680 
 p-value (Two-tailed) 0.169 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 16.92%. 
    
         Ties have been detected in the data and the appropriate corrections have been  
applied. 
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YB-1-HA (YB-1 knockdown vs. control knockdown) 
 
Mann-Whitney test / Two-tailed test: 
   U 879.000 
 Expected value 1014.000 
 Variance (U) 17745.000 
 p-value (Two-tailed) 0.313 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 31.26%. 
     
 
S176-HA (YB-1 knockdown vs. control knockdown) 
 
Mann-Whitney test / Two-tailed test: 
   U 1036.000 
 Expected value 1140.000 
 Variance (U) 18809.880 
 p-value (Two-tailed) 0.450 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 45.05%. 
    
         Ties have been detected in the data and the appropriate corrections have been  
applied. 
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Migration persistence data distributions: 
 
 
Experiment 1 
 
 
Table S21. Various parametric tests applied to the distribution of migration 
persistence for the negative control transfection. 
Shapiro-
Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
0.020 0.029 0.206 0.271 
 
0.647 
Distribution: non-parametric 
 
Fig.S20. Negative control plasmid distribution compared to a normal distribution. 
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Table S22. Various parametric tests applied to the distribution of migration 
persistence for the negative control transfection. 
Shapiro-
Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
0.020 0.029 0.206 0.271 
 
0.647 
Distribution: non-parametric 
 
Fig.S21. Negative control plasmid distribution compared to a normal distribution. 
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Table S23. Various parametric tests applied to the distribution of migration 
persistence for the positive control transfection. 
Shapiro-Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
0.249 0.435 0.460 0.553 0.834 
Distribution: parametric 
 
Fig.S22. Positive control plasmid distribution compared to a normal distribution. 
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Table S24. Various parametric tests applied to the distribution of migration 
persistence for the YB-1-HA transfection. 
Shapiro-
Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
 < 0.0001  < 0.0001 0.000  < 0.0001 
 
0.057 
Distribution: non-parametric 
 
Fig.S23. YB-1-HA plasmid distribution compared to a normal distribution. 
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Table S25. Various parametric tests applied to the distribution of migration 
persistence for the S102A-HA transfection. 
Shapiro-Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
0.429 0.415 0.209 0.611 
 
0.661 
Distribution: parametric 
 
Fig.S24. S102A-HA plasmid distribution compared to a normal distribution. 
 
		 351	
Table S26. Various parametric tests applied to the distribution of migration 
persistence for the S165A-HA transfection. 
Shapiro-
Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
0.025 0.020 0.083 0.212 
 
0.491 
Distribution: non-parametric 
 
Fig.S25. S165A-HA plasmid distribution compared to a normal distribution. 
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Table S27. Various parametric tests applied to the distribution of migration 
persistence for the S167A-HA transfection. 
Shapiro-
Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
0.002 0.001 0.001 0.135 
 
0.112 
Distribution: non-parametric 
 
Fig.S26. S167A-HA plasmid distribution compared to a normal distribution. 
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Table S28. Various parametric tests applied to the distribution of migration 
persistence for the S174A-HA transfection. 
Shapiro-
Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
0.003 0.008 0.195 0.005 
 
0.634 
Distribution: non-parametric 
 
Fig.S27. S174A-HA plasmid distribution compared to a normal distribution. 
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Table S29. Various parametric tests applied to the distribution of migration 
persistence for the S176A-HA transfection. 
Shapiro-
Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
0.004 0.003 0.014 0.185 
 
0.262 
Distribution: non-parametric 
 
Fig.S28. S176A-HA plasmid distribution compared to a normal distribution. 
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Table S30. Various parametric tests applied to the distribution of migration 
persistence for the S174-176A-HA transfection. 
Shapiro-Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
0.624 0.735 0.807 0.651 
 
0.971 
Distribution: parametric 
 
Fig.S29. S174-176A-HA plasmid distribution compared to a normal distribution. 
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Table S31. Various parametric tests applied to the distribution of migration 
persistence for the T271A-HA transfection. 
Shapiro-Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
0.631 0.555 0.340 0.669 
 
0.776 
Distribution: parametric 
 
Fig.S30. T271A-HA plasmid distribution compared to a normal distribution. 
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Table S32. Various parametric tests applied to the distribution of migration 
persistence for the T271E-HA transfection. 
Shapiro-Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
0.317 0.439 0.698 0.552 
 
0.943 
Distribution: parametric 
 
Fig.S31. T271E -HA plasmid distribution compared to a normal distribution. 
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Migration persistence experiment 1: XLSTAT® analysis output  
 
 
Table S33. Mann-Whitney U tests to compare migration persistence between 
YB-1, mutant, and the negative (empty vector) control transfection. 
Plasmid overexpression Negative control plasmid 
p score (two-tailed) 
Positive (H-RAS) control plasmid transfection  0.012 
YB-1-HA 0.411 
S102A-HA 0.028 
S165A-HA 0.025 
S167A-HA 0.034 
S174A-HA 0.592 
S176A-HA 0.339 
S174-176-HA 0.005 
T271A-HA 0.862 
T271E-HA 0.682 
 
 
Positive control plasmid transfection vs. Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 749.000 
 Expected value 551.000 
 Variance (U) 6244.667 
 p-value (Two-tailed) 0.012 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
As the computed p-value is lower than the significance level alpha=0.05,  
one should reject the null hypothesis H0, and accept the alternative hypothesis Ha. 
The risk to reject the null hypothesis H0 while it is true is lower than 1.24%. 
 
 
YB-1-HA vs. Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 664.000 
 Expected value 594.500 
 Variance (U) 7034.917 
 p-value (Two-tailed) 0.411 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
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S102A-HA vs. Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 362.000 
 Expected value 261.000 
 Variance (U) 2088.000 
 p-value (Two-tailed) 0.028 
 alpha 0.05 
    An approximation has been used to compute the p-value. 
    
         Test interpretation: 
       H0: The difference of location between the samples is equal to 0. 
    Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is lower than the significance level alpha=0.05,  
one should reject the null hypothesis H0, and accept the alternative hypothesis Ha. 
The risk to reject the null hypothesis H0 while it is true is lower than 2.79%. 
    
 
S165A-HA vs. Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 327.000 
 Expected value 232.000 
 Variance (U) 1778.667 
 p-value (Two-tailed) 0.025 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
    
         Test interpretation: 
       H0: The difference of location between the samples is equal to 0. 
    Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is lower than the significance level alpha=0.05,  
one should reject the null hypothesis H0, and accept the alternative hypothesis Ha. 
The risk to reject the null hypothesis H0 while it is true is lower than 2.50%. 
    
 
    
  
H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 41.07%. 
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S167A-HA vs. Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 539.000 
 Expected value 406.000 
 Variance (U) 3924.667 
 p-value (Two-tailed) 0.034 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
    
         Test interpretation: 
       H0: The difference of location between the samples is equal to 0. 
    Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is lower than the significance level alpha=0.05,  
one should reject the null hypothesis H0, and accept the alternative hypothesis Ha. 
The risk to reject the null hypothesis H0 while it is true is lower than 3.44%. 
    
 
S174A-HA vs. Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 517.000 
 Expected value 478.500 
 Variance (U) 5024.250 
 p-value (Two-tailed) 0.592 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
    
         Test interpretation: 
       H0: The difference of location between the samples is equal to 0. 
    Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 59.19%. 
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S176A-HA vs. Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 402.000 
 Expected value 348.000 
 Variance (U) 3132.000 
 p-value (Two-tailed) 0.339 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
    
         Test interpretation: 
       H0: The difference of location between the samples is equal to 0. 
    Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 33.91%. 
     
 
S174-176A-HA vs. Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 409.000 
 Expected value 275.500 
 Variance (U) 2249.917 
 p-value (Two-tailed) 0.005 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
    
         Test interpretation: 
       H0: The difference of location between the samples is equal to 0. 
    Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is lower than the significance level alpha=0.05,  
one should reject the null hypothesis H0, and accept the alternative hypothesis Ha. 
The risk to reject the null hypothesis H0 while it is true is lower than 0.50%. 
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T271A-HA vs. Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 225.000 
 Expected value 217.500 
 Variance (U) 1631.250 
 p-value (Two-tailed) 0.862 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
    
         Test interpretation: 
       H0: The difference of location between the samples is equal to 0. 
    Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 86.24%. 
     
 
T271E-HA vs. Negative control plasmid transfection 
 
Mann-Whitney test / Two-tailed test: 
   U 228.000 
 Expected value 246.500 
 Variance (U) 1930.917 
 p-value (Two-tailed) 0.682 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
    
         Test interpretation: 
       H0: The difference of location between the samples is equal to 0. 
    Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 68.21%. 
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Migration persistence data distributions (with endogenous YB-1 knockdown) 
 
Experiment 2 
 
Table S34. Various parametric tests applied to the distribution of migration 
persistence for the negative control transfection (with YB-1 knockdown). 
Shapiro-
Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
0.001 0.008 0.123  < 0.0001 
 
0.572 
Distribution: non-parametric 
 
Fig.S32. Negative control plasmid distribution (with YB-1 knockdown) compared to a 
normal distribution. 
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Table S35. Various parametric tests applied to the distribution of migration 
persistence for the positive control transfection (with YB-1 knockdown). 
Shapiro-Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
0.081 0.169 0.253 0.161 
 
0.689 
Distribution: parametric 
 
Fig.S33. Positive control plasmid distribution (with YB-1 knockdown) compared to a 
normal distribution. 
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Table S36. Various parametric tests applied to the distribution of migration 
speed for the YB-1-HA transfection (with YB-1 knockdown). 
Shapiro-Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
0.232 0.189 0.156 0.564 
 
0.591 
Distribution: parametric 
 
Fig.S34. YB-1-HA plasmid distribution (with YB-1 knockdown) compared to a normal 
distribution. 
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Table S37. Various parametric tests applied to the distribution of migration 
speed for the S176A-HA transfection (with YB-1 knockdown). 
Shapiro-
Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
 < 0.0001  < 0.0001 0.001 0.000 
 
0.086 
Distribution: non-parametric 
 
Fig.S35. S176A-HA plasmid distribution (with YB-1 knockdown) compared to a normal 
distribution. 
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Table S38. Various parametric tests applied to the distribution of migration 
speed for the negative control transfection (with control knockdown). 
Shapiro-
Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
0.001 0.008 0.123  < 0.0001 
 
0.535 
Distribution: non-parametric 
 
Fig.S36. Negative control plasmid distribution (with control knockdown) compared to a 
normal distribution 
.
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Table S39. Various parametric tests applied to the distribution of migration 
speed for the positive control transfection (with control knockdown). 
Shapiro-
Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
0.000  < 0.0001 0.001 0.018 
 
0.112 
Distribution: non-parametric 
 
Fig.S37. Positive control plasmid distribution (with control knockdown) compared to a 
normal distribution. 
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Table S40. Various parametric tests applied to the distribution of migration 
speed for the YB-1-HA transfection (with control knockdown). 
Shapiro-
Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
0.002 0.001 0.001 0.027 
 
0.102 
Distribution: non-parametric 
 
Fig.S38. YB-1-HA plasmid distribution (with control knockdown) compared to a normal 
distribution. 
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Table S41. Various parametric tests applied to the distribution of migration 
speed for the S176-HA transfection (with control knockdown). 
Shapiro-
Wilk 
Anderson-
Darling Lilliefors 
Jarque-
Bera 
Kolmogorov-
Smirnov 
0.000 0.007 0.089  < 0.0001 
 
0.485 
Distribution: non-parametric 
 
Fig.S39. S176A-HA plasmid distribution (with control knockdown) compared to a 
normal distribution. 
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Migration persistence experiment 2 (with YB-1 knockdown): XLSTAT® analysis 
output  
 
Positive control plasmid transfection (YB-1 knockdown) vs. Negative control 
plasmid transfection (YB-1 knockdown) 
 
Mann-Whitney test / Two-tailed test: 
   U 1106.000 
 Expected value 988.000 
 Variance (U) 14984.667 
 p-value (Two-tailed) 0.337 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
    
         Test interpretation: 
       H0: The difference of location between the samples is equal to 0. 
    Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 33.71%. 
     
 
YB-1-HA YB-1 (knockdown) vs. Negative control plasmid transfection (YB-1 
knockdown) 
 
Mann-Whitney test / Two-tailed test: 
   U 857.000 
 Expected value 676.000 
 Variance (U) 8900.667 
 p-value (Two-tailed) 0.056 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
    
         Test interpretation: 
       H0: The difference of location between the samples is equal to 0. 
    Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 5.57%. 
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S176A-HA YB-1 (knockdown) vs. Negative control plasmid transfection (YB-1 
knockdown) 
 
Mann-Whitney test / Two-tailed test: 
   U 807.000 
 Expected value 988.000 
 Variance (U) 14984.667 
 p-value (Two-tailed) 0.140 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 14.03%. 
  
 
Positive control plasmid transfection (control knockdown) vs. Negative control 
plasmid transfection (control knockdown) 
 
Mann-Whitney test / Two-tailed test: 
   U 5078.000 
 Expected value 5251.000 
 Variance (U) 182034.544 
 p-value (Two-tailed) 0.686 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
     Test interpretation: 
   H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 68.60%. 
     Ties have been detected in the data and the appropriate corrections have been  
applied. 
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YB-1-HA (control knockdown) vs. Negative control plasmid transfection (control 
knockdown) 
 
Mann-Whitney test / Two-tailed test: 
   U 4842.000 
 Expected value 4602.000 
 Variance (U) 151098.880 
 p-value (Two-tailed) 0.538 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
    
         Test interpretation: 
       H0: The difference of location between the samples is equal to 0. 
    Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05, one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 53.78%. 
    
         Ties have been detected in the data and the appropriate corrections have been applied. 
   
 
S176A-HA (control knockdown) vs. Negative control plasmid transfection 
(control knockdown) 
 
Mann-Whitney test / Two-tailed test: 
   U 3209.000 
 Expected value 3540.000 
 Variance (U) 105609.888 
 p-value (Two-tailed) 0.309 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
    
         Test interpretation: 
       H0: The difference of location between the samples is equal to 0. 
    Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 30.92%. 
    
         Ties have been detected in the data and the appropriate corrections have been  
applied. 
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Positive control plasmid transfection (YB-1 knockdown vs control knockdown) 
 
Mann-Whitney test / Two-tailed test: 
   U 1883.000 
 Expected value 1691.000 
 Variance (U) 36074.667 
 p-value (Two-tailed) 0.313 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
    
         Test interpretation: 
       H0: The difference of location between the samples is equal to 0. 
    Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 31.33%. 
     
 
Negative control plasmid transfection (YB-1 knockdown vs control knockdown) 
 
Mann-Whitney test / Two-tailed test: 
   U 2943.000 
 Expected value 3068.000 
 Variance (U) 87437.893 
 p-value (Two-tailed) 0.674 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
    
         Test interpretation: 
       H0: The difference of location between the samples is equal to 0. 
    Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 67.37%. 
    
         Ties have been detected in the data and the appropriate corrections have been  
applied. 
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YB-1-HA (YB-1 knockdown vs control knockdown) 
 
Mann-Whitney test / Two-tailed test: 
   U 1207.000 
 Expected value 1014.000 
 Variance (U) 17745.000 
 p-value (Two-tailed) 0.148 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
    
         Test interpretation: 
       H0: The difference of location between the samples is equal to 0. 
    Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 14.84%. 
     
 
S176-HA (YB-1 knockdown vs control knockdown) 
 
Mann-Whitney test / Two-tailed test: 
   U 953.000 
 Expected value 1140.000 
 Variance (U) 18810.000 
 p-value (Two-tailed) 0.174 
 alpha 0.05 
 An approximation has been used to compute the p-value. 
    
         Test interpretation: 
       H0: The difference of location between the samples is equal to 0. 
    Ha: The difference of location between the samples is different from 0. 
   As the computed p-value is greater than the significance level alpha=0.05,  
one cannot reject the null hypothesis H0. 
The risk to reject the null hypothesis H0 while it is true is 17.39%. 
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Migration persistence patterns 
 
a) 
 
 
 
b) 
 
 
Fig.S40. Single-cell migration tracks of the negative control transfection of Saos-2 cells. 
Each of the two graphs, (a) and (b), represent the migration patterns of three negative (empty 
vector) control transfected Saos-2 cells, tracked individually using ImageJ 1.46r with an 
MTrackJ plugin. 
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a) 
 
 
 
b) 
 
 
Fig.S41. Single-cell migration tracks of the positive control transfection of Saos-2 cells. 
Each of the two graphs, (a) and (b), represent the migration patterns of three positive control 
transfected Saos-2 cells, tracked individually using ImageJ 1.46r with an MTrackJ plugin. 
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a) 
 
 
 
b) 
 
 
 
c) 
 
 
Fig.S42. Single-cell migration tracks of the YB-1-HA transfection of Saos-2 cells. Each of 
the three graphs, (a), (b), and (c), represent the migration patterns of three YB-1 transfected 
Saos-2 cells, tracked individually using ImageJ 1.46r with an MTrackJ plugin. 
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a) 
 
 
 
b) 
 
 
 
c) 
 
 
Fig.S43. Single-cell migration tracks of the S102A-HA transfection of Saos-2 cells. Each 
of the three graphs, (a), (b), and (c), represent the migration patterns of three S102A 
transfected Saos-2 cells, tracked individually using ImageJ 1.46r with an MTrackJ plugin. 
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a)	
 
 
 
b) 
 
 
Fig.S44. Single-cell migration tracks of the S165A-HA transfection of Saos-2 cells. Each 
of the two graphs, (a) and (b), represent the migration patterns of three S165A transfected 
Saos-2 cells, tracked individually using ImageJ 1.46r with an MTrackJ plugin. 
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Fig.S45. Single-cell migration tracks of the S167A-HA transfection of Saos-2 cells. Each 
of the three graphs, (a), (b), and (c), represent the migration patterns of three S167A 
transfected Saos-2 cells, tracked individually using ImageJ 1.46r with an MTrackJ plugin. 
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Fig.S46. Single-cell migration tracks of the S174A-HA transfection of Saos-2 cells. Each 
of the three graphs, (a), (b), and (c), represent the migration patterns of three S174A 
transfected Saos-2 cells, tracked individually using ImageJ 1.46r with an MTrackJ plugin. 
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a) 
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Fig.S47. Single-cell migration tracks of the S176A-HA transfection of Saos-2 cells. Each 
of the three graphs, (a), (b), and (c), represent the migration patterns of three S174A 
transfected Saos-2 cells, tracked individually using ImageJ 1.46r with an MTrackJ plugin. 
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a) 
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Fig.S48. Single-cell migration tracks of the S174-176A transfection of Saos-2 cells. Each 
of the two graphs, (a) and (b), represent the migration patterns of three S174-176A transfected 
Saos-2 cells, tracked individually using ImageJ 1.46r with an MTrackJ plugin. 
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Fig.S49. Single-cell migration tracks of the T271A-HA transfection of Saos-2 cells. Each 
of the three graphs, (a), (b), and (c), represent the migration patterns of three T271A 
transfected Saos-2 cells, tracked individually using ImageJ 1.46r with an MTrackJ plugin. 
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a) 
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Fig.S50. Single cell migration tracks of the T271E-HA transfection of Saos-2 cells. Each 
of the three graphs, (a), (b), and (c), represent the migration patterns of three T271E-HA 
transfected Saos-2 cells, tracked individually using ImageJ 1.46r with an MTrackJ plugin. 
  
-40	-20	
0	20	
40	60	
80	
-60	 -40	 -20	 0	 20	 40	 60	 80	 100	
-60	-40	
-20	0	
20	40	
60	80	
100	120	
-40	 -20	 0	 20	 40	 60	
-20	0	
20	40	
60	80	
-80	 -60	 -40	 -20	 0	 20	 40	 60	 80	
		 387	
Preliminary migration persistence experiments in HCT116 cells 
YB-1-HA, S102A-HA, S165A-HA, and S167A-HA HCT116 transfected cells 
were assessed for the presence of lamellipodia-like structures under a Cell Voyager 
confocal microscope at 40x magnification (Fig.S46.). The S102A mutant significantly 
increased (p < 0.001) the percentage of cells exhibiting lamellipodia-like structures 
(Tables S40-41.). 
The YB-1-HA, S102A-HA, and negative control transfected HCT116 cells 
were also assessed for the persistence of directional migration in HCT116 cells 
(Fig.S47.), where the S102A mutant significantly increased migration persistence (p < 
0.05; Table S42.) 
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a) 
 
 
 
b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.S51. Quantification of lamellipodia-like structures in HCT116 cells: S102A 
transfected cells show increased lamellipodia-like structures. HA-tagged YB-1 and a 
select of serine-to-alanine mutants were transfected into HCT116 cells and probed using a 
primary rabbit anti-HA antibody and secondary 488nm Alexa Fluor® donkey anti-rabbit 
antibody. a) Cells expressing either YB-1-HA, S102A-HA, S165A-HA, or S167A-HA were 
scored for lamellipodia (percent of cells showing lamellipodia). Each transfection experiment 
was repeated three times (n=3). b) An example of a YB-1-HA mutant cell exhibiting a 
lamellipodia-like extension. 
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Table S42. Average percentage of cells observed with lamellipodia-like structures 
for each transfection compared to the wildtype YB-1 transfection (expected). 
 Lamellipodia 
 
No Lamellipodia 
 
 SET AS REFERENCE (EXPECTED) 
 Observed (%) Expected (%) Observed (%) Expected (%) 
YB-1-HA 12.3 87.7 
S102A-
HA 28.7 12.3 71.3 87.7 
S165A-
HA 18 12.3 82 87.7 
S167A-
HA 14 12.3 86 87.7 
 
 
Table S43. Chi-squared significance test between the expected YB-1 transfection 
and the observed YB-1 mutants. 
 
 
 
 
Lamellipodia 
 
 
 
No 
Lamellipodia Chi-squared 
value 
Critical 
value 
(df = 1) 
Statistical 
significance 
YB-1-HA SET AS REFERENCE (EXPECTED) 
S102A-
HA 21.7 3 24.7 3.841 p < 0.001 
S165A-
HA 2.7 0.4 3 3.841 p > 0.05 
S167A-
HA 0.2 0.03 0.3 3.841 p > 0.05 
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Fig.S52. S102A transfected HCT116 cells dramatically increase migration persistence. 
Comparison of average single cell directional migration persistence between YB-1, S102A 
mutant, and negative control plasmid transfected HCT116 cells. Single cells from each 
transfection were assessed for the persistence of directional migration (direct distance 
[µm]/overall migration distance [µm]). All cells were tracked manually using ImageJ 1.46r 
with an MTrackJ plugin. 
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Table S44. Mann-Whitney U test to compare migration persistence between YB-
1-HA, the S102A-HA mutant and the negative control transfection. 
Plasmid overexpression Negative control plasmid 
p score (two-tailed) 
YB-1-HA 0.296 
S102A-HA 0.037 
 
 
Preliminary migration persistence experiment: XLSTAT® analysis output 
 
Mann-Whitney test / Two-tailed test: 
    U 2.000 
  Expected value 12.500 
  Variance (U) 22.917 
  p-value (Two-tailed) 0.037 
  alpha 0.05 
  An approximation has been used to compute the p-value. 
      Test interpretation: 
    H0: The difference of location between the samples is equal to 0. 
Ha: The difference of location between the samples is different from 0. 
  As the computed p-value is lower than the significance level alpha=0.05, one should  
reject the null hypothesis H0, and accept the alternative hypothesis Ha. 
The risk to reject the null hypothesis H0 while it is true is lower than 3.67%. 
   
 	
 
